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Abstract 
Historically, empyema thoracis has been a major cause of morbidity and mortality in children. It 
became the focus of considerable attention following its resurgence globally in the 1990’s.  The 
factors driving this change remain uncertain. In addition, there remains significant controversy over 
the best method of management of the condition.  
 
This thesis aimed to define the epidemiology of paediatric empyema thoracis, to understand the 
factors contributing to the rise in the incidence of the disease. Secondary aims included investigation 
of the impact of the pneumococcal conjugate vaccine on paediatric empyema and evaluation of the 
effectiveness of different treatment methodologies in the condition. 
 
A progressive framework of multivariate time series models and wavelet analysis was used to 
investigate relationships between empyema and pneumonia, activity of Streptococcus pneumoniae, 
Staphylococcus aureus, Streptococcus pyogenes and Mycoplasma pneumoniae and time. The spatial 
epidemiology of the both conditions in North East England was defined and the impact of the 
introduction of routine pneumococcal vaccination investigated using an interrupted time series 
analysis. Multivariate survival models were used to investigate outcomes following different 
treatment methods.  
 
Hospitalisations due to empyema increased significantly in England between 1997 and 2006, 
underpinned by an increase in bacterial pneumonia. Isolations of S. pneumoniae and S. pyogenes were 
positive predictors of empyema nationally. No spatial variation in the risk of empyema was detected. 
Introduction of pneumococcal vaccination did not decrease empyema hospitalisations. Children who 
underwent primary surgical treatment for their empyema had a 40% reduction in hospital stay and a 
lower risk of readmission or of any complication.   
 
The increase in the incidence of paediatric empyema in England was driven predominantly by an 
increase in pneumococcal and streptococcal pneumonia. Primary surgery in empyema allowed earlier 
discharge, but further research is needed to establish which outcomes are most acceptable to patients 
and their families.     
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Glossary 
Autocorrelation – statistical property of time and spatial data due to serial dependency often inherent 
in this form of data. This leads to violation of the assumption of independence required in standard 
statistical approaches. 
Autoregressive model – statistical model containing specific function designed to balance presence of 
serial dependency within the residuals and which models the residual at time s as a function of 
residual of time s – 1. 
Auto-regressive moving average model – similar to autoregressive model except that the function to 
model serial dependency is more complex. The residuals are modelled as a function of the p previous 
time points and white noise.  
Conditional autoregressive models (CAR) – form of Bayesian statistical modelling that allows for 
both spatial heterogeneity and serial dependency to accurately estimate differences between different 
spatial areas.  
Generalised linear models – generic term for a large group of statistical methods that are flexible 
extensions of standard linear regression.   
Generalised least squares model – group of statistical models developed for analysis of time series 
data.  
Homeoscedasity – all variables or observations have equal variance.  
Periodicity – biological variability based on a cyclical pattern occurring out with normal seasonal 
patterns. 
Seasonality – biological variability based on a seasonal (within year) pattern.  
State-space models – stochastic models which can be used to represent time series with multiple 
processes contained within them. 
Survival analysis – specific group of techniques for analysing data with censored end-points.  
Wavelet analysis – Statistical techniques based on transformation of the signal of a time series into a 
series of functions (wavelets) that represent both the frequency and time-scale within that signal 
allowing assessment of the presence of different periods or cycles within data and associations 
between time series. 
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1 Introduction and scientific background 
 
“So much has been written about acute empyema in the recent literature, that one wonders what there 
is left to say about it.” G Heuer, 1932 
 
1.1 Definitions and epidemiology 
 
1.1.1 Definitions 
 
An empyema is a collection of pus within a naturally occurring anatomical space. The term itself is a 
compound Greek word consisting of the prefix ‘en’ meaning ‘in’ or ‘within’ and the stem ‘pyema’ 
meaning accumulation of pus (Christopoulou-Aletra and Papavramidou, 2008).  Empyema thoracis 
refers to infection and pus formation within the pleural space (the space between the parietal and 
visceral pleura) in the thorax. Other common forms of empyema include subdural empyema and 
empyema within the uterus known as pyometra. For simplicity throughout this thesis, empyema refers 
to empyema thoracis. This is in line with common medical usage where empyema is used almost 
exclusively to mean empyema thoracis and other forms are referred to by their longer form including 
their precise anatomical location.    
 
1.1.2 Historical perspectives on epidemiology of empyema 
 
Empyema is an old and historically important condition that has been recognised and treated for 
millennia. The Hippocratic physicians recorded its management in significant detail (Christopoulou-
Aletra and Papavramidou, 2008). Ancient Egyptian artefacts also refer to the occurrence of empyema 
(Cole, 1937).  
 
While tracking the evolution of the management of empyema in children through time is relatively 
straightforward, doing the same for the epidemiology of empyema is more problematic. Major 
advances in the identification of pathogens, variation in diagnostic classifications and a paucity of 
attention to epidemiology, relative to treatment, make establishing historical trends more challenging. 
However, a number of aspects are clear.  
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OT Clagett, an author who published on the epidemiology of empyema both before and after the 
introduction of antibiotics, estimated the incidence of empyema at around 10% of those with 
pneumonia in the pre-antibiotic era (Clagett, 1943; Clagett, 1973). He cited a number of large series in 
support of this, including Penberthy and Benson’s (1936) series of 5,868 children with pneumonia in 
Detroit, Michigan who reported a rate of 7%. Clagett reported that there was no apparent difference in 
the empyema rate between adults and children but did comment on the phenomenon of annual 
fluctuations in incidence. Other researchers in the early 20
th
 Century such as Heuer (1932) and 
Graham (1933) recognised this propensity for sudden increases in the incidence of empyema through 
examination of the annual variations in mortality and linked it to changes in virulence of the different 
strains of pathogens causing pneumonia. 
 
Mortality from this condition at that time was much greater than it is now, with rates as high as 50% 
during the first world war, although some of this mortality was iatrogenic because of the dangerous 
methods of pleural drainage employed (Graham and Berck, 1933). It is difficult to exclude this 
iatrogenic component from the historical estimates. Perhaps the most accurate estimate comes from 
Lionakis et al (1958) study, which covered the period after changes in the management of empyema 
resulted in a significant reduction in iatrogenic deaths but before the widespread introduction of 
antibiotics and reported a mortality of 17% in children treated. The most recent available estimate of 
mortality in children is <0.5% (Williams et al., 2011).   
 
Heuer (1932) was the first author to describe trends in mortality in empyema by age and co-morbidity. 
He found that mortality rates were much greater at the extremes of age than in late childhood and 
adolescence (>40% in the <2 years and 51-70 year age groups; 2%-10% in the 5 to 10 years and 11 to 
20 years age groups).   
 
As well as being associated with high levels of mortality, empyema has been historically associated 
with significant morbidity. Hospital stay was often prolonged (Heuer (1932), 39 days; Penberthy and 
Benson (1936), 48.6 days and Lionakis et al (1958), 48.5 days). The longest stay in the survey of 
Lionakis et al (1958) survey was 212 days. Interestingly, the length of hospital stay did not decrease 
significantly following the introduction of antibiotics.  
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Following the adoption of antibiotics in around 1947 there was a substantial reduction in the incidence 
of empyema. In a 25 year study of empyema in children from 1932 to 1956 in Atlanta, cases almost 
ceased in the eight years following the introduction of antibiotics (4 cases 1948-1956 (0.5 cases/yr), 
129 cases 1932-1947 (8.5 cases/yr). The reduction was so profound it led the authors to conclude that 
unless new, resistant bacterial strains were to develop faster than new antibiotics it seemed probable 
that empyema would no longer be an important thoracic disease (Lionakis et al., 1958). This, coupled 
with their finding of no decrease in hospital stay following the arrival of antibiotics, led them to 
speculate that antibiotics do not necessarily alter the clinical course of empyema, but do prevent it 
arising from pneumonia. Decreases of a similar magnitude were reported by other authors in the early 
years following the introduction of antibiotics (Schwartz et al., 1939; Thompson et al., 1940).  
 
However this decrease appeared short-lived with a significant peak in the incidence empyema 
reported in the late 1950’s and early 1960’s. Studies from five large American centres – Pittsburgh 
(Kiesewetter WB et al., 1959), Harriet Lane, Baltimore (Ravitch MM and Fein R, 1961), St Louis 
(Middelkamp JN et al., 1964), Washington (Groff DB et al., 1966) and Duke University, North 
Carolina (Wolfe WG et al., 1968) highlighted a change in the incidence of empyema at approximately 
contemporaneous times. For example cases in Baltimore increased from 6 cases/yr in the years 1951-4 
to 38 in 1955-58 (Ravitch MM and Fein R, 1961). In contrast to the pre-antibiotic era where 
pneumococci and streptococci were most frequent, the predominant organism was Staphylococcus 
aureus. Isolates of Staphylococcus aureus from children with empyema during this period were 
frequently multi-drug resistant, leading to speculation that the increase in staphylococcal empyema 
was related to the introduction of antibiotics (Ravitch MM and Fein R, 1961; Geha AS, 1970). 
Furthermore, certain phage types or strains of S. aureus were more commonly isolated e.g. in the St 
Louis series, phage type 80/81 accounted for over 80% of S. aureus isolates from pleural fluid 
(Middelkamp JN et al., 1964), suggesting that particular strains that had been circulating may have 
had a predisposition towards causing empyema.  
 
In the decades following this rise in the incidence of empyema, interest in the condition appeared to 
wane and only a handful of studies addressing the epidemiology of the condition were published. 
Fajardo and Chang (1987) recovered Haemophilus influenzae from pleural fluid in 15% of children 
with empyema presenting to American military hospitals between 1978 and 1982, a greater proportion 
than had been previously reported. However, the widespread introduction of vaccination against H. 
influenzae type B shortly afterwards led to a significant decline in invasive disease due to this 
pathogen (Lewis and Feigin, 2002). Brook’s series of 93 cases of empyema (1990) highlighted the 
role of anaerobic bacteria in empyema, particularly in association with aspiration pneumonia. No 
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other significant changes in the epidemiology of the condition were reported until the current interest 
in empyema began in 1997 in the UK (Playfor et al., 1997; Rees et al., 1997).  
 
1.1.3 Current epidemiology of empyema 
 
In the middle of the 1990’s there were several reports noting a rise in incidence of empyema in UK 
children (Playfor et al., 1997; Rees et al., 1997). Similar rises were noted in a range of countries 
around the world and are illustrated in Figure 1.1. 
 
 
Figure 1.1 Map of countries where an increase in the incidence of paediatric empyema has been 
reported. Countries with significant increases in incidence shaded in red (Grijalva et al 2010; 
Hardie et al., 1996; Thompson et al., 1999; Byington et al., 2002b; Hsieh et al., 2004; Deiros Bronte 
et al., 2006; Spencer et al., 2006b; Wexler et al., 2006; Bekri et al., 2007; Finley et al., 2008; Obando 
et al., 2008; Proesmans and De Boeck, 2009; Strachan and Jaffe, 2009).  
 
No hypothesis has been universally accepted for these changes in incidence, although a number have 
been proposed. These include: an increase in the underlying incidence of pneumonia (Roxburgh et al., 
2008); a change in circulating pneumococcal serotypes or increasing pathogen virulence (Byington et 
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al., 2002b; Wexler et al., 2006); a change in causative organism (Schultz et al., 2004) and a change in 
community antibiotic prescribing (Strachan and Jaffé, 2009). 
 
Empyema is a seasonal condition with peaks in incidence between November and March in the 
northern hemisphere (Hardie et al., 1996). There has been some suggestion that there are bimodal 
peaks within the winter season with one in December and a further peak in early spring, although this 
has not been widely investigated (Spencer et al., 2006a). Three large studies have measured the 
incidence of empyema in the UK and all have used hospital coding data. Roxburgh et al (2008) 
reported 37 cases of empyema per million in Scotland in 2005. Gupta and Crowley (2006) reported an 
incidence 26 cases per million in England in 2002/3. Most recently Koshy et al (2010) reported a 
change from 4.7 to a peak of 17.5 per million children and a subsequent fall to 13.7 by 2008. Koshy et 
al acknowledge that their estimates of empyema incidence are lower than those of other studies and 
cite their usage of more specific diagnostic codes as a potential explanation for the difference. 
 
Empyema occurs at all ages but the natural history of the disease and outcomes vary significantly 
between adults and children. In childhood, empyema most often occurs in previously healthy children 
and is associated with very low mortality (<0.5%) in developed countries (Balfour-Lynn et al., 2005; 
Williams et al., 2011). In contrast in adults, patients frequently have several co-morbidities and 
mortality in the UK was estimated at 15 % in 2005, with the highest death rate occurring in the elderly 
(Maskell et al., 2005).  
 
The average length of hospital stay has substantially reduced compared to historical figures (Heuer 
(1932), 39 days; Penberthy and Benson (1936), 48.6 days and Lionakis et al (1958), 48.5 days), with 
the median between four to seven days post treatment (Balfour-Lynn et al., 2005; Sonnappa et al., 
2006; Li and Gates, 2008). 
 
1.2 Microbiology of empyema 
 
The Hippocratic physicians recognised that empyema may have different causes, appearing to 
differentiate between cases caused by anaerobes and other causes by their relative mortality, and the 
constitution and smell of the fluid drained from the pleural cavity (Odell, 1994). Within the literature 
a wide range of bacteria, fungi and viruses have been reported as causes but, non-tuberculous bacteria 
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are the predominant cause (Chernick et al., 2006). Historically, three species account for the 
overwhelming majority of cases. These are S. pneumoniae, S. aureus, and S. pyogenes. S. pneumoniae, 
S. aureus and S. pyogenes are all colonisers of the human nasopharynx and are, arguably, the leading 
causes of bacterial pneumonia in children worldwide. The relative contribution of S. pneumoniae, S. 
pyogenes and S. aureus to empyema in children in published series from 1950 onwards is shown in 
Figure 1.2.  
 
 
Figure 1.2 Summary of the major bacteriological causes of empyema in children from published 
series from 1950 onwards. All pathogens were identified by pleural fluid or blood culture.  
 
Overall, S. pneumoniae was the leading cause of empyema, accounting for approximately 40% of 
cases where a pathogen was identified (296 of 757 cases). Staphylococcal empyema was the next 
most prevalent accounting for 30% of cases (229 cases). S. pyogenes was associated with 
approximately 10% (72 cases). Staphylococcal empyema was predominant in the majority of studies 
from the 1960’s, illustrating staphylococcal dominance at this time. The five studies from 2000 
onwards consistently found that the majority of cases were culture negative, but that pneumococcal 
infection was the dominant organism found. Similarly, the two earliest studies included, Lionakis et al 
(1958) and Ravitch MM and Fein R (1961), found high proportions of pneumococcal disease.    
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There has been a substantial increase in the proportion of culture-negative disease over time or to put 
it alternately, empyema where no causative pathogen is isolated using standard culture techniques. 
Early surveys such as Lionakis et al (1958) reported virtually no culture negative cases. In contrast, 
between 42% and 75% of cases had no identifiable cause in studies published after 2000. This 
increase in the frequency of culture negative disease has been presumed to be as a consequence of 
antibiotic treatment prior to sampling (Balfour-Lynn et al., 2005). 
 
A number of studies have used molecular diagnostic techniques in order to address this problem 
(Boersma et al., 1993; Menezes-Martins et al., 2005; Saglani et al., 2005; Lahti et al., 2006; Le 
Monnier et al., 2006; Strachan and Jaffé, 2009). These generally utilise PCR for the detection of 
specific DNA products from bacteria and have been shown to substantially increase the rate of 
attribution of a definitive cause in empyema. Both broad spectrum techniques such as 16S and single 
organism specific PCR’s such as pneumolysin specific PCR for S. pneumoniae have been used. Table 
1.1 illustrates the improvement in detection seen in the two studies that have used 16S in empyema 
(Saglani et al., 2005; Le Monnier et al., 2006). 
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Study Le Monnier (2006) 
Result Culture (%) 16S PCR (%) % Change 
S. pneumoniae 30 47 +18 
S. pyogenes 5 9 +4 
S. aureus 6 7 +1 
Other 8 8 0 
Culture negative disease 51 28 -23 
Study Saglani (2005) 
Result Culture (%) 16S PCR (%) % Change 
S. pneumoniae 3 41 +38 
S. pyogenes 3 9 +6 
S. aureus 9 16 +7 
Other 3 9 +6 
Culture negative disease 81 34 -56 
 
Table 1.1 Improvement in detection of a pathogen in studies using 16S molecular diagnostics in 
empyema 
 
Studies using molecular techniques have universally attributed the bulk of culture negative disease to 
S. pneumoniae, but there is a potential reporting bias within this. As all these studies have included 
assays to detect S. pneumoniae, but have not always included assays specific for other pathogens. For 
example Strachan et al (2009) used specific PCR’s for S. pneumoniae, S. aureus, Haemophilus 
influenzae, Mycoplasma pneumoniae and Chlamydia pneumoniae, but not for S. pyogenes. Studies 
using broad range detection including Le Monnier et al (2006) and Saglani et al (2005) confirm that 
the bulk of culture negative disease is due to S. pneumoniae.   
 
Brook’s (1990) series highlighted the role of anaerobes within paediatric empyema. He detected 
anaerobic bacteria in 33% of the 72 cases reported and attributed them as the sole cause in 24% of 
patients. Bacteriodes species were the most common anaerobic isolates. No other studies have 
30 
 
reported this level of anaerobic infection and Brook only included cases where a definite cause was 
identified, potentially biasing the results towards this group. Anaerobic infections are more likely in 
children who are at risk of aspiration pneumonia, such as those with chronic neurodevelopmental 
problems and immunocompromised children  (Chernick et al., 2006).   
 
Viruses, in particular enteroviruses can be associated with the formation of pleural effusions, but they 
are only very rarely associated with the development of empyema (Lewis and Feigin, 2002; Chernick 
et al., 2006). However, there are well-recognised associations between primary viral infection and 
subsequent bacterial pneumonia and empyema, a classic example of this being the association of the 
1918 influenza epidemic and empyema (Dunham et al., 1918).   
 
Fungi are a well recognised cause of empyema, especially in immunocompromised individuals, but as 
a group they are a much rarer cause in previously healthy individuals. Ko et al (2000) studied fungal 
empyema in 67 adults, Candida spp was the most common isolated species, accounting for over 60% 
of isolates and 85% had some form of predisposing condition. As well as immunocompromise or 
immunosuppression, abdominal perforation may be significant risk factor for fungal empyema 
(Ishiguro et al., 2010).   
 
Primary pulmonary tuberculosis (TB) in children is associated with pleural effusion in 2-38% of cases, 
with the association being greatest in older children and adolescents (Merino et al., 1999). Pleural 
effusion in TB can look very similar to empyema, particularly as it is commonly associated with 
consolidation of the underlying lung parenchyma and it is listed as a cause of empyema (Merino et al., 
1999; Balfour-Lynn et al., 2005). However, the pathophysiology is different in TB infection and is 
typically characterised by granulomatous inflammation in contrast to the classical neutrophil led 
inflammation seen in empyema (Merino et al., 1999). As a consequence, most researchers separate 
the two conditions by referring to tuberculous and non-tuberculous empyema.  
 
The microbiology of empyema in adults is different to that of children. S. milleri spp were the 
commonest cause of culture positive empyema in adults in the UK accounting for 11% of cases in the 
largest and best conducted survey yet published (Maskell et al., 2005). The Streptococcus milleri 
group comprises S. mitis, S. viridans, S. mutans, S. oralis, S. sanguinis and S. sobrinis. They are 
oropharyngeal commensals and facultive anaerobes. They can cause a range of rare, but serious, 
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diseases including infective endocarditis, liver abscess and brain abscess (Ruoff, 1988). Their 
contribution in paediatric empyema is much smaller and they occur only infrequently within 
published series. Isolation of S. milleri spp in paediatric patients is usually confined to children in 
whom aspiration of food contents is a problem, such as children with severe cerebral palsy.     
 
1.2.1 Pneumococcal serotypes, pneumococcal vaccines and paediatric empyema 
 
S. pneumoniae is not only the leading cause of paediatric empyema, but is also the leading cause of 
bacterial pneumonia in children (van der Poll and Opal, 2011). It is an obligate human pathogen but 
frequently exists as a commensal in the nasopharynx in a state referred to as carriage (Lipsitch, 1999). 
It is a genotypically diverse organism and over 90 different serotypes or groups are recognised 
(Lipsitch, 1999). Serotyping is based on recognition of the polysaccharide capsule expressed by the 
organism (Lipsitch, 1999). The capsule is also the most potent virulence factor expressed by S. 
pneumoniae and significant differences in the invasiveness, severity of disease caused and 
nasopharyngeal carriage are reported between serotypes (van der Poll and Opal, 2011).  
 
Only a small minority of serotypes have been detected in children with empyema. Pneumococcal 
serotype 1 was the most frequently recovered serotype in the majority of series (Eltringham et al., 
2003; Byington et al., 2006). In the most recent data published in the UK, serotype 1 accounted for 
47.5 % of cases (n=223), serotype 3 24%, 7F/A 5.4%, 5 4.5% and 19A 4% of children with empyema 
and culture negative pleural fluid (Sheppard et al., 2011).    
 
Pneumococcal vaccines based on capsular polysaccharides were initially developed in 1945 but did 
not reach widespread use until the 1970’s (MacLeod et al., 1945; Austrian R et al., 1976). Purely 
polysaccharide based vaccines are poorly immunogenic in young children, however conjugation, a 
process whereby capsular polysaccharides are linked to a more immunogenic protein, alleviates this 
problem (Eskola J and Anittila, 1999). A negative feature of conjugation is that the number of specific 
polysaccharides that can be incorporated onto the vaccine and hence the serotypes protected against 
are limited. The first commercially available pneumococcal vaccine (PCV-7) stimulated immunity 
against only seven serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F). It was introduced into the 
routine immunisation schedule for infants in the USA in 2000 and in the UK in 2006. It was replaced 
in the UK by an expanded valency vaccine (PCV-13) in 2010, providing additional protection against 
serotypes 1, 3, 5, 6A, 19A and 7F.  
32 
 
 
The projected impact of PCV-7 on paediatric empyema, extrapolated from the two studies of the 
pneumococcal serotype distribution carried out pre-vaccine introduction, was of a modest 20% 
reduction (Eltringham et al., 2003; Fletcher et al., 2006). The only UK data published after the 
introduction of PCV-7 demonstrated a reduction in incidence of approximately this magnitude (Koshy 
et al., 2010). This is in contrast to the experience elsewhere. In the USA, where the longest time has 
elapsed since the introduction of PCV-7, the incidence of paediatric empyema increased substantially 
in the years following the introduction of PCV-7 (Grijalva et al., 2010; Lee et al., 2010; Li and 
Tancredi, 2010).   
 
Pneumococcal conjugate vaccines are highly effective in preventing invasive pneumococcal disease 
caused by serotypes contained within the vaccine. However, concerns have been raised about the 
possibility of serotype replacement disease. Serotype replacement disease is the process of removal of 
vaccine serotypes from their ecological niche by vaccination coupled to an expansion of non-vaccine 
serotypes and concomitant increase in disease due to non-vaccine serotypes. This phenomenon has 
been observed in both overall invasive pneumococcal disease in England and Wales and in empyema 
in the USA (Byington et al., 2006; Miller et al., 2011). While serotype replacement disease cannot be 
responsible for the increase in empyema within the UK, as the increase began around a decade prior 
to the introduction of PCV-7, its impact on empyema in the UK is likely to be of significance.  
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1.3 Anatomy and physiology of the pleura and the pathophysiology of empyema  
 
1.3.1 Anatomy and physiology of the pleura  
 
In gross anatomical terms, the pleura consist of two mesothelial layers covered by differing amounts 
of connective tissue and separated by approximately 10 - 24 µm (Chernick et al., 2006). Within the 
potential space between the pleura, there is a small volume of fluid. The inner layer is the visceral 
pleura and the outer layer the parietal pleura. The visceral pleura extend over the entire surface of the 
lung and the parietal pleura the inner surface of the thoracic cage, mediastinum, and diaphragm 
(Wang, 1985). The extent of pleura is shown in Figure 1.3. The left and right pleural cavities are 
completely separate, although may be adherent to each other on the anterior and posterior surfaces of 
the heart (Wang, 1985).   
   
 
 
Figure 1.3 The anatomy of the pleura as illustrated in Grey’s Anatomy (1918) 
Embryologically, the pleura are mesodermal structures that arise in concert with the pericardium and 
peritoneum from the coloem (Davila and Crouch, 1995). By the seventh week of gestation the 
developing pleura have been separated from the pericardium by the pleuropericardial membrane and 
from the peritoneum by the pleuropertioneal membrane (Davila and Crouch, 1995). Mesothelial cells 
begin to line both the visceral and parietal pleura from around fifth week of gestation as the lung buds 
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begin to form. As embryogenesis proceeds layers of connective tissue divide and proliferate around 
the mesothelium, until the pleura are fully formed (Wang, 1985).  
 
There are significant structural differences between the visceral and parietal pleura. The parietal 
pleura is smooth whereas the visceral pleura is indurated as it adheres too tightly to the surface of the 
lung, including in the intralobular fissures. The parietal pleura is perfused by the intercostal arteries 
and pericardiophrenic branch of the internal mammary arteries (Davila and Crouch, 1995). In contrast, 
the visceral pleura appear to be supplied by both the branches of the bronchial arteries and in some 
areas the pulmonary arteries (Harley, 1987). There are also differences in the lymphatic drainage 
between the visceral and parietal pleura. The visceral pleura drains largely to the pulmonary hilum 
and into the hilar nodes. The parietal pleura drains into the intercostal system anteriorly and into the 
retroperitoneal system posteriorly (Harley, 1987). There is also differential innervation of the pleura. 
The innervation of the parietal pleura arises from the intercostal nerves, in a manner similar to that of 
the lympyhatics. The visceral pleura is supplied by the vagus nerve and by the sympathetic trunks, but 
is not innervated by pain nerves (Harley, 1987).  
 
At a micro-anatomical level there are further differences between the pleura. The most important is 
the presence of stomata on the parietal pleura which form an important mechanism in the homeo-
static regulation of the pleural space (Wang, 1985). There are differences in the density of microvilli 
and elastic fibres between the pleura and also between different regions of the pleura (Wang, 1985). 
  
The physiological function of the pleura is to reduce the work of breathing by reducing the friction 
between the thoracic cage and the lungs and is an adaptation to life on land. All land mammals have a 
similar anatomical arrangement, except the Asian elephant (Elepheas maximus) and African elephant 
(Loxodonta africana) in whom the pleural space is filled with fibrous connective tissue.    
 
The surface area of the pleura is approximate to 4000 cm
2
 in a 70 kg man and the estimated volume of 
pleural fluid in health is 18 mL (equivalent to 0.26 mL/kg) (Zocchi, 2002). Pleural fluid has a low 
concentration of protein and contains approximately 1700 cells/mm
3 
(Zocchi, 2002). The cellular 
composition is 75% macrophages, 23% lymphocytes and 1% mesothelial cells (Zocchi, 2002).    
 
35 
 
In order to maintain the function of pleura, the volume and composition of the pleural fluid are under 
tight homeo-static control (Zocchi, 2002). Three mechanisms are recognised to be important Figure 
1.4: 
 
1. Starling forces (providing filtration through parietal and absorption through visceral 
mesothelium) 
2. Lymphatic drainage through parietal pleural stomata  
3. Electrolyte coupled liquid absorption through mesothelium of both sides and transcytosis   
 
 
Figure 1.4 Recognised mechanisms for regulation of fluid volume within the pleural space. Blue 
arrows indicate direction of filtration gradient driven by differences in oncotic pressure 
(Starling forces) on either side of parietal and visceral pleura. The red arrow indicates 
reabsorption of fluid into the lymphatic system through the lymphatic stomata of the parietal 
pleura. Green arrows indicate direct cell transport of liquids and solutes including through 
transcytosis, which also prevents accumulation of pleural fluid (adapted from Zocchi, 2002). 
 
1.3.2 Pathophysiology of empyema 
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In up to 95% of cases, the first step in development of an empyema is the development of pneumonia 
in lung parenchyma adjacent to the pleura (Hamm and Light, 1997). The remaining cases result from 
direct inoculation of pathogens as a result of penetrating chest trauma or as a complication of thoracic 
surgery. Once inflammation and infection are established in the pleural space, the subsequent 
pathophysiological processes appear to be consistent regardless of the initiating event (Hamm and 
Light, 1997). The development of an empyema can be broken down into four stages which are well 
described in the literature (Hamm and Light, 1997; Zocchi, 2002; Antony, 2003; Brims et al., 2010).  
 
The initial or reactive phase, begins with the spread of inflammatory mediators and a protein rich 
inflammatory fluid to the extracellular fluid of the sub-mesothelial connective tissue from the infected 
sub-pleural lung parenchyma. This leads to a reversal of oncotic pressure gradient across the pleural 
space and the visceral pleura facilitating the accumulation of a transudate-like effusion within the 
pleural space.  
 
During the exudative phase the influx of inflammatory cells and mediators interact with the 
mesothelial cells, triggering a local pleural immune response with the further release of inflammatory 
mediators and migration of neutrophils. This immunological activation of the mesothelial monolayer 
leads to changes in its permeability to both proteins and cells leading to the accumulation of a small 
neutrophil dominated sterile exudative effusion within the pleural space.  
 
The fibrinopurulent phase is catalysed by secondary bacterial invasion of the pleural space. This 
causes further mesothelial immunological activation, aggravation of mesothelial cell injury and 
neutrophil migration into the pleural space. The resultant inflammatory milieu creates a relatively pro-
fibrinogenic and anti-fibrinolytic environment. As a consequence, the coagulation cascade is triggered 
and fibrin is deposited on both pleural surfaces. The deposition of fibrin exacerbates the accumulation 
of fluid within the pleural space by blocking the stomata of the parietal pleura. At the end of the 
fibrinopurulent phase, frank pus is present within the pleural space. 
 
The organisational phase is characterised by the development of dense fibrinous septations between 
the pleura leading to separate pockets of loculated pus within the pleural space. As part of the healing 
process, fibroblasts invade the pleural space leading to further fibrosis of the pleural space and 
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ultimately to the development of a fibrothorax if no intervention occurs. These stages are illustrated in 
Figure 1.5. 
   
 
 
Figure 1.5 Pathophysiological development of an empyema (adapted from illustration of normal 
physiological regulation of the pleural space, Zocchi, 2002). 1.) Reactive phase 2.) Exudative 
phase 3.) Fibrinopurulent phase 4.) Organisational phase.  
 
The macroscopic pathological changes in empyema are shown in Figure 1.6.  
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Figure 1.6 A pathology specimen demonstrating an extensive left -sided pleural empyema 
encasing the left lower lobe, lingular and extending into the left upper lobe. The white debris 
seen is fibrin deposition and pus formation. The specimen illustrates how an empyema restricts 
the normal expansion of the lung. Also demonstrated is, the huge expansion in the pleural space 
illustrated by the contrast between the normal pleura on the right and the left pleura containing 
the empyema. (Author – Yale Rosen, Source 
http://www.flickr.com/photos/pulmonary_pathology/3704699031/)   
 
1.4 Clinical features & management of empyema 
 
1.4.1 Clinical features 
 
Symptoms of empyema are similar to those of pneumonia and include cough, fever, dyspnoea and 
chest pain. Dyspnoea, pleuritic and abdominal pain may be more prominent than in pneumonia 
(Balfour-Lynn et al., 2005). Physical signs seen on examination include reduced chest movement, 
stony dullness to percussion, reduced breath sounds and a pleural rub (Balfour-Lynn et al., 2005). 
Compensatory scoliosis may be present. 
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1.4.2 Investigations 
 
In routine practice, the diagnosis is usually made by plain film chest radiography, although definitive 
confirmation requires examination of pleural fluid. The presence of significant fluid results in 
obliteration of the costophrenic or cardiophrenic angles and a meniscus or visible fluid level visible on 
the radiograph, as shown in Figure 1.7. Larger effusions cause mediastinal deviation and compression 
of the contralateral lung. Thoracic ultrasound is a useful investigation which is able to detect even 
small volumes of pleural fluid, loculation and abscess cavities without use of ionising radiation 
(Calder and Owens, 2009). Thoracic computerised tomography (CT) is only required to assess more 
complicated disease or when conditions such as malignancy are suspected.  
 
 
 
Figure 1.7 Plain radiograph showing pleural empyema in a teenager. Note the obliteration of 
the cardiophrenic and costophrenic angles in the left hemithorax. A chest drain has been placed 
for pleural drainage. 
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In UK patients pleural fluid is usually culture negative using routine bacterial culture, presumably 
because the majority of patients have received antibiotics prior to sampling (Balfour-Lynn et al., 
2005). Advanced molecular techniques including 16S ribosomal gene sequencing, antigen-specific 
polymerase chain reaction (PCR) based assays and sequential multiplex PCR capable of 
differentiating between serotypes are increasingly used to identify causative organisms (Saglani et al., 
2005; Le Monnier et al., 2006). Raised white cell count, increased protein, reduced glucose and 
increased lactate dehydrogenase in pleural fluid indicate an exudative fluid within the pleural cavity 
consistent with empyema (Light et al., 1972).   
 
1.4.3 Historical perspectives on treatment 
 
Treatment of empyema by the Ancient Greeks’ can be divided into two stages; initial “conservative” 
management with medicaments followed by surgery for those not improving (Christopoulou-Aletra 
and Papavramidou, 2008). Surgery consisted of opening of the chest and direct drainage of the pus. 
The importance of prompt diagnosis and leaving a hollow read as a form of chest drain in situ was 
recognised (Odell, 1994). These principles still underpin the treatment of empyema (Balfour-Lynn et 
al., 2005). 
 
Treatment of empyema remained largely unchanged until it became the focus of significant interest 
following the influenza pandemic of 1918 (Peters, 1989). During the pandemic, exceptionally high 
mortality of healthy young recruits due to empyema was observed in US army camps (Dunham et al., 
1918). The management techniques at the time were mainly focused on open drainage, with an 
inaccurate understanding of pleural physiology leading to high risk of pneumothorax and unsuccessful 
re-inflation of infected areas of the lung (Odell, 1994). These inappropriate procedures were 
undertaken despite the fact that effective closed drainage techniques had been described over forty 
years previously (Hewett, 1876). The establishment of the US Army Empyema Commission headed 
by the thoracic surgeon Evarts Graham, recognised these short-comings and proposed a series of 
recommendations (1) careful avoidance of open pneumothorax during the acute stage (2) prevention 
of a chronic empyema by rapid sterilisation and obliteration of the infected cavity; and (3) careful 
attention to the nutrition of the patient (Dunham et al., 1918; Odell, 1994). The adoption of these 
recommendations drastically reduced mortality from an average of 30.2% (although in some centres 
using open drainage upwards of 70%) to 3.4% (Odell, 1994).  
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The next major advance in the management of empyema was the introduction of antibiotics. One of 
the first reports of the successful use of penicillin in the USA included eight patients with empyema in 
1944 (Tillet et al., 1944). A case series by Lionakis et al (1958) suggests that the use of antibiotics 
became routine around 1947.  
 
Despite the advent of antibiotics, surgical pleural drainage remained a key component of empyema 
treatment. Building on the insights of Graham’s Empyema Commission, different strategies have 
emerged to achieve this which have varied in favour over time (Samson, 1971; Molnar et al., 2004). 
They have included:  
 
- Thoracentesis  
- Intercostal tube drainage  
- Rib-resection tube drainage  
- Open flap drainage 
- Decortication 
- ‘Empyemectomies’ 
- Sterilization of the pleural cavity 
- Thoracoplasty (Samson, 1971) 
 
Of these, thoracentesis, intercostal tube drainage and a modified form of decortication are in usage in 
modern paediatric care (Balfour-Lynn et al., 2005). Video-assisted thoracoscopic surgery, known as 
VATS began to be employed to drain the pleural cavity as part of the wider trend towards minimally 
invasive surgery in the 1990’s. Kern and Rodgers are recognised as the pioneers of this technique, 
first publishing their results in 1993 (Kern and Rodgers, 1993; Stovroff et al., 1995).  
 
The final major change in the treatment of empyema has been the introduction of intrapleural 
fibrinolytics to breakdown the fibrinous septations that divide up an organised empyema. Their use 
was first suggested in 1949, although they were not introduced into routine practice until much later 
(Kokoska and Chen, 2009). Future therapies may result from an increasing understanding of the 
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immunobiology of empyema, and are likely to be directed towards disruption of the pathogen 
triggered immune-mediated inflammatory pathways that drive the development of the condition.  
 
1.4.4 Current management 
 
Empyema is a painful condition due to stimulation of the pain receptors within the parietal pleura and 
adequate analgesia is very important. Appropriate analgesics include paracetamol, non-steroidal anti-
inflammatory drugs and opiates (Balfour-Lynn et al., 2005). Intravenous fluids are often needed 
initially due to poor fluid intake and increased losses. 
 
Patients should receive high dose antibiotics, but there is little published evidence regarding choice of 
agent. The British Thoracic Society guidelines suggest that Cefuroxime, Amoxicillin-clavulanate, 
Penicillin and Flucloxacillin, Ampicillin and Flucloxacillin or Clindamycin are all suitable (Balfour-
Lynn et al., 2005). Nosocomial, post-surgical or immunocompromised cases may require broader 
spectrum treatment to include coverage of Gram negative and anaerobic organisms.(Balfour-Lynn et 
al., 2005) Antibiotics are usually given intravenously before switching to the oral route following 
defervescence.  
 
The optimal treatment of empyema remains controversial. The absence of a firm evidence base, 
differing views on the most important outcome measures and significant regional variation in access 
to specialised services has resulted in varying approaches to management. It is agreed that the primary 
aim of treatment is clearance of the pleural cavity. Time to defervescence and length of hospital stay 
(LOS) are important surrogate measures of a successful response to treatment. There are two major 
contrasting approaches to management. Some favour early surgical intervention and drainage of the 
pleural cavity. This is usually, but inaccurately referred to as “decortication”. Other centres prefer an 
initial medical approach using instillation of fibrinolytics via an intrapleural chest drain, reserving 
definitive surgery for the approximately 10% of patients who fail to respond.  
 
The presence of fibrinous loculations separating pools of infected fluid within the pleural cavity 
means that chest drainage alone is unlikely to be effective. Effective clearance of pleural loculations 
can be achieved either by instillation of intrapleural fibrinolytics via a chest drain or by surgical 
intervention. The evidence for intrapleural fibrinolysis is limited. One multi-centre RCT supported 
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this approach reporting a significant reduction in length of stay of 2 days compared to normal saline 
placebo, but no reduction in time to defervescence (Thomson et al., 2002). The trial used Urokinase 
given intrapleurally twice daily for three days using 40,000 units in 40 ml of 0.9% saline and a four-
hour dwell time. A later RCT found no reduction in length of stay with Streptokinase, another form of 
fibrinolytic, when compared to saline as a control (Singh et al., 2004).  
 
Different types of chest drain are available but two types are in routine usage, pig-tail or large bore 
surgical drains. A post-hoc analysis of the Urokinase trial compared pig-tail drains with large bore 
surgical drains and found that length of stay was 2 days lower with pig-tail drains but this may have 
been confounded by a centre effect (Thomson et al., 2002). 
  
There are two main surgical techniques for the treatment of empyema: 
1.  “Mini-thoracotomy”. This achieves debridement and evacuation in a similar manner to 
VATS, but it is an open procedure. This is usually referred to as “decortication”, although 
technically this is not the case, as true decortication involves stripping the parietal pleura, 
which is not usually required in paediatric cases. 
 
2. Video-assisted thoracoscopic surgery (VATS). This involves thoracoscopic opening of the 
pleural cavity, debridement of the “rind” formed from fibrinous pyogenic material encasing 
the affected lung, breakdown of loculations and drainage of pus from the pleural cavity under 
direct vision. 
 
 
A chest drain is usually left in situ after either form of surgery, although this can often be removed 
after a few hours. 
 
The evidence base related to surgical intervention in empyema is weak. The literature is divided 
between commentators and studies favouring initial medical/non-operative management including 
Barnes et al. (2005); Jaffé and Balfour-Lynn (2005); Khalil et al. (2007) and those favouring primary 
operative intervention which include Coote and Kay (2005); Li and Gates (2008); Shah et al. (2011). 
A substantial number of these publications are retrospective reviews of single centre experiences of a 
small number of cases are therefore of limited usefulness. Of those published studies which are of 
44 
 
higher quality (RCT’s, meta-analyses and large multi-centre retrospective cohort studies) the results 
are mixed.  
 
A meta-analysis compared primary operative with non-operative management and suggested that 
early operative intervention was associated with lower mortality, re-intervention rate, LOS, time with 
tube thoracostomy and duration of antibiotic therapy compared with non-operative management 
(Avansino et al., 2005). However, this analysis included all forms of surgery and mixed various 
medical management options including antibiotics alone, making it difficult to have confidence in the 
author’s conclusions.  
 
A large scale retrospective cohort study compared primary operative drainage with medical 
management reported a reduction in LOS of 4.3 (95% confidence intervals 2.3-6.4) days in favour of 
operative management, as well as reduced costs and treatment failure rate (Li and Gates, 2008). This 
analysis had the advantage of using data gathered over one year reducing the potential for temporal 
trends that could introduce bias into retrospective cohort studies. The authors also took steps to 
control for potential centre effects. The authors used hospital coding data and reported an unusually 
low rate of fibrinolysis usage (7%), this raises concerns that the medical management group may not 
be representative and the procedural coding data may not have been accurate.   
 
Three RCTs have compared VATS with fibrinolysis and drainage as a primary treatment, with mixed 
results (Kurt et al., 2006; Sonnappa et al., 2006; St. Peter et al., 2009). St Peter et al (2009) and 
Sonnappa et al (2006) reported no significant differences in LOS between VATS and fibrinolysis and 
both sets of authors favoured fibrinolysis over VATS, on grounds of cost and invasiveness. Kurt et al 
(2006) compared primary VATS with initial chest tube drainage and subsequent fibrinolysis if 
primary chest tube drainage had failed making comparison with the other two trials challenging. They 
described a reduction in LOS, cost and risk of transfer when the primary drainage procedure was 
VATS. This is similar to the findings of Avansino et al (2005) and Li and Gates (2008), suggesting 
that chest drainage alone is less successful than primary VATS. Also of note is the large multi-centre 
retrospective cohort study conducted by Shah et al (2011), which compared VATS with fibrinolysis. 
These authors found no difference in length of stay between VATS and fibrinolysis but did find a 
lower re-intervention rate in the VATS group.    
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There is no trial evidence comparing VATS to mini-thoracotomy, although Li and Gates (2008) 
included a sub analysis comparing the two and found no significant difference in LOS, costs, 
treatment failure and complications between the two techniques. It is therefore currently not possible 
to determine whether one technique is superior to the other. Similarly, the benefits of early versus late 
surgical intervention remain unclear. VATS does require highly specialised and expensive equipment, 
and operators who are specifically trained in the technique. It is also a far more time consuming 
procedure than simple decortication. 
 
A summary of the published evidence regarding primary medical management and primary surgical 
management is shown in Table 1.2.
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Study  Type of study  Comparison Results  
Avansino (2005)  Meta-analysis  Any surgery vs. CTD or IFT Primary operative approach (VATS/OT) resulted in lower mortality, less 
need for re-intervention, shorter LOS, shorter duration of chest tube and 
antibiotics compared to primary medical therapy  
Kurt (2006) RCT  VATS vs. CTD VATS lowered LOS and cost and risk of transfer  
Sonnappa (2006)  RCT  VATS vs. IFT No difference between VATS and IFT in terms of LOS, days of CTD and 
procedure number. IFT less expensive  
Li and Gates 
(2008)  
Retrospective cohort 
review  
Any surgery vs. CTD or IFT Primary operative approach lowered LOS, cost and risk of transfer  
St Peter (2009)  RCT  VATS vs. IFT No difference between VATS and IFT in terms of LOS, febrile days and 
oxygen requirement  
Shah (2011)  Retrospective cohort 
review  
VATS vs. IFT VATS lowered need for re-intervention; no difference in LOS between 
VATS and IFT  
 
Table 1.2 Comparison of primary approaches in empyema treatment CTD - Chest tube drainage; IFT- Intrapleural fibrinolysis therapy; OT- Open 
thoracotomy; VATS - Video-assisted thoracoscopy; LOS - Length of stay; RCT - randomised controlled trial Comparison of primary approaches in 
empyema treatment. Adapted from Anselmo M Can Resp J (2010).  
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The most important factor determining optimal outcome is almost certainly the co-ordinated 
approach of an experienced team of surgeons, anaesthetists and paediatricians rather than the 
exact surgical approach.    
 
1.5 Study aims, hypotheses and thesis overview 
 
The epidemiology of paediatric empyema has changed over the last twenty years with a 
substantial rise in the incidence of the condition reported on different continents including 
Europe (Gupta and Crowley, 2006), North America (Li and Tancredi, 2010), and Asia (Finley 
et al., 2008). Despite this significant increase in incidence the processes responsible remain 
unclear.  
 
Historically different pathogens have predominated in childhood empyema (Heuer, 1932; 
Chonmaitree and Powell, 1983) but recently the majority of cases in the United Kingdom 
have been caused by S. pneumoniae (Eltringham et al., 2003; Saglani et al., 2005). Only a 
limited range of strains or serotypes appear responsible for cases of pneumococcal empyema 
(Byington et al., 2002b; Eltringham et al., 2003; Fletcher et al., 2006). At present all 
pneumococcal vaccines are of limited valency, protecting against only a finite number of 
serotypes. As a consequence, the introduction of these vaccines has the potential to 
substantially change the epidemiology of pneumococcal disease by altering the ecology of the 
species. The introduction of the seven valent pneumococcal conjugate vaccine in the USA 
was associated with an increase in the incidence of empyema, but this was linked to an 
expansion in disease due to non-vaccine serotypes (Byington et al., 2006). The impact of the 
introduction of this vaccine on the epidemiology of paediatric empyema in the UK has yet to 
be firmly established.         
 
The best method of treatment of empyema in childhood is controversial, with significant 
variation in approaches between hospitals and there is a paucity of comparative data to guide 
clinicians (Balfour-Lynn et al., 2005; Thomas et al., 2009). The rise in incidence of empyema 
has made it increasingly important that different treatment methodologies are compared in an 
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objective manner for the benefit of, both individual patients and to optimise the use of limited 
health care resources. 
  
This thesis will describe the epidemiology of paediatric empyema in details in order to 
understand the factors contributing to the rise in incidence. In addition, it will establish the 
impact of the introduction of the conjugate pneumococcal vaccine to the routine childhood 
immunisation schedule on the incidence of paediatric empyema in the UK. Finally, it will 
evaluate the comparative effectiveness of different treatment methodologies in empyema in 
children in the UK.    
 
Chapters 2 – 5 are focused around a series of hypotheses in line with these broad aims. These 
are: 
 
Chapter 2: Patterns in the incidence of paediatric empyema thoracis, the relationship to 
pneumonia and temporal associations with the activity of common bacterial respiratory 
pathogens 
Key hypotheses: 
- The incidence of empyema has increased  
- The increase in incidence of empyema has been driven by an increase in pneumonia 
- The incidence of empyema shows seasonality and cyclicity 
- The increase in the incidence of empyema is related to the activity of S. pneumoniae, 
S. aureus, S. pyogenes and M. pneumoniae 
- Seasonality and cyclicity seen in empyema is associated with the seasonality and 
cyclicity in the activity of S. pneumoniae, S. aureus, S. pyogenes and M. pneumoniae 
 
The incidence of paediatric empyema is modeled at local, regional and national level in the 
UK to establish robustly the presence and the magnitude of any increase in paediatric 
empyema. Seasonality in empyema incidence is investigated and defined in order to achieve 
this. The relationship between pneumonia and empyema is then addressed by modeling trends 
in hospital admissions for both conditions between 1997 and 2006 in England. The 
epidemiology of the condition is then further investigated by analysing national admissions 
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data for evidence of cyclicity and relating time trends and cyclicity within admissions data to 
the activity of common bacterial respiratory pathogens.   
 
Chapter 3: Spatial epidemiology of paediatric pneumonia and empyema 
Key hypotheses: 
- There is spatial variation in the risk of pneumonia and empyema. 
- Spatial variation in risk of pneumonia and empyema will be associated with 
community level deprivation, ethnicity and proximity to hospital.  
The spatial epidemiology of pneumonia and empyema in the North East of England is defined 
using specific spatial modelling techniques. The relationship of risk of pneumonia and 
empyema to community level co-variates including child specific deprivation measures, 
ethnicity, migration and health-care related factors is then investigated to evaluate possible 
factors associated with the spatial epidemiology of both conditions.    
 
Chapter 4: The impact of the seven valent pneumococcal conjugate vaccine on 
paediatric empyema in the North East of England 
 
Key hypothesis: 
 
- The introduction of the seven valent pneumococcal conjugate vaccine was associated 
with a reduction in the incidence of paediatric empyema in the North East of England 
 
The impact of the introduction of PCV-7 on the incidence of empyema in the North East of 
England is evaluated by use of an interrupted time series approach. This study has been 
prepared for submission for publication.  
 
Chapter 5: The influence of pathogen and pneumococcal serotype on illness length and 
the impact of primary pleural drainage methodology on outcomes in empyema 
 
Key hypotheses: 
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- Time to disease resolution in empyema is dependent on pathogen and pneumococcal 
serotype.  
- Surgical methods of primary pleural drainage in paediatric empyema are associated with 
shorter hospital stay. 
 
The impact of pathogen and pneumococcal serotype on illness length are investigated to 
establish whether the changes in the epidemiology of empyema have impacted on the clinical 
profile of the disease. Nationally representative data are then used to compare the 
effectiveness of primary pleural drainage method on LOS and readmission and complication 
rates in paediatric empyema in the UK.  
Chapter 6 is a summary of the previous chapters and conclusions.   
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2 Patterns in the incidence of paediatric empyema thoracis, the 
relationship to pneumonia and temporal associations with the 
activity of common bacterial respiratory pathogens 
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2.1 Introduction 
2.1.1 Incidence of disease 
 
Evaluating temporal trends in disease relies on the interpretation of consistent and comparable 
measurements of disease across time. The incidence rate (IR) is perhaps the most commonly 
used measure in this regard (Rothman et al., 2008). It is defined as the number of new cases 
divided by the person-time period of measurement and can be expressed mathematically as: 
                
                   
∑                                     
  (Rothman et al., 2008) 
Imprecision in the estimates of incidence rates can occur when there is a lack of certainty over 
the definition of the population at risk and when recurrent episodes of disease occur in the 
same individual. However, incidence rates are easy to calculate, easy to interpret and widely 
reported, making comparisons across studies possible. 
 
Analysis of changes in incidence rates of disease over time can have several difficulties. For 
example, the changing efficacy of detection of disease can mask true changes in incidence. 
This is a particular problem in longitudinal studies of infectious diseases based on 
surveillance, whereby increased awareness of disease and surveillance may lead to increased 
reporting year on year and artificial inflation of estimates of disease (Miller et al., 2011). 
Likewise healthcare rarely remains the same over time; diagnostic technologies and methods 
evolve; disease definitions are refined based on new emerging knowledge e.g. the move from 
the diagnostic and statistical manual of mental disorders DSM-IV to DSM-V which will lead 
to major redefinitions of three common and important mental illnesses – attention-deficit 
hyperactivity disorder, bipolar disorder and major depressive disorder (Allen, 2010). Such 
changes can introduce bias and misclassification error in longitudinal studies. Furthermore, 
healthcare systems evolve over time which can lead to difficulties in defining populations at 
risk and ascertainment of cases as base populations may be different and lack contiguity. All 
of these factors increase in relevance the longer the time period examined. They are also more 
likely to be an issue if secondary data sources are used e.g. health-care utilization data.    
 
2.1.2 Incidence of empyema – local, regional, national and international estimates 
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Empyema exists as part of a spectrum of pleural disease from an uncomplicated pleural 
effusion to the development of a fibrothorax. As it exists on a spectrum of disease, precisely 
defining it for the purposes of measuring incidence can be challenging. There is significant 
variation in definition across the literature (Byington et al., 2002b; Padman et al., 2007). 
Some of this variation is manifest in the range of terminology used. For example, complicated 
pneumonia and complicated parapneumonic effusion are terms frequently seen in the 
literature which can encompass empyema, although they can also refer to patients in the 
exudative or fibrinopurulent stages of pleural infection or other complications of pneumonia 
such as necrotic disease e.g. Wexler et al (2006) where complicated pneumonia included 
presence of pleural effusion (83 %), empyema (52 %), atelectasis (26 %), pneumatocele 
(19 %), and pneumothorax (10 %).  
 
The traditional and literal definition of empyema is the presence of pus within the pleural 
space. Therefore, the diagnosis of empyema requires invasive sampling of the pleural space 
and confirmation of the presence of pus. In children, this is combined with definitive 
treatment, in order to prevent the need for multiple painful procedures. As a consequence, 
disease definitions used in epidemiological studies often include treatment criteria, most often 
a requirement for invasive drainage. However, including treatment criteria within the disease 
definition complicates matters because significant variations in treatment exist between 
centers and even within centers (Thomas et al., 2009; Thomas et al., 2011). These variations 
arise because there is a lack of objective criteria as to which children require drainage and a 
lack of consensus as to which treatment modality is most effective. The consequence is that 
using a disease definition which includes a treatment component, e.g. in Spencer et al (2006) 
potentially introduces inaccuracies when comparing incidence between areas and time periods. 
These variations are likely to be even greater between countries than within countries.  
 
Reports of a change in the incidence of paediatric empyema emerged from the UK in the late 
1990’s. Two groups published reports of an increase in the number of cases of paediatric 
empyema presenting to separate hospitals (both tertiary management centres for empyema) in 
1997 (Playfor et al., 1997; Rees et al., 1997). However, this apparent increase did not appear 
to have been maintained when Playfor et al (1999) reported their further experience two years 
later. Shankar et al (2000) did not observe a rise in incidence in their single centre study 
covering the period 1980 to 1997. In contrast, Spencer et al (2006b) reported a six fold rise in 
cases of surgically managed empyema in from 1995 to 2006 at a further UK hospital.  
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Three national studies in the UK reported an increase in hospital admissions for empyema; 
Gupta and Crowley (2006) found that admissions in England rose from 14 per million 
children (0–14 years) in 1995 to 26 per million in 2003. Similarly, in Scotland admissions 
increased from <10 per million in 1998 to 37 per million in 2005 (Roxburgh et al., 2008). 
More recently, Koshy et al (2010) published updated data for England showing an increase in 
admission rates from 5 to 14 admissions per million children between 1997 and 2008. All 
three publications used hospital coding data and used two specific ICD-10 codes to identify 
cases – J86.0 and J86.9 (pyothorax and pyothorax with fistula) although the precise 
application varied between the three studies. The same method of identification of cases of 
empyema has recently been shown to have a high predictive value in adults aged from 15-39 
in Denmark (96% positive predictive value) but its accuracy in paediatric empyema is 
unknown (Sogaard et al., 2011).     
 
Following the reports of an increase in incidence of empyema in UK, a number of reports 
from elsewhere in the world emerged (summarized in Table 2.1). Byington et al (2002b) 
published the first non-UK report of an increase in parapneumonic empyema in Utah, USA. 
Similar single centre reports showing an increase in empyema have been published in 
Belgium and Spain (Deiros Bronte et al., 2006; Van Ackere et al., 2009). Large-scale or 
national-scale studies of coding data have demonstrated increases in Canada, Australia and 
the USA (Finley et al., 2008; Grijalva et al., 2010; Lee et al., 2010; Li and Tancredi, 2010). 
Three studies have reported an increase in empyema specifically as a complication of 
pneumococcal pneumonia (Hsieh et al., 2004; Wexler et al., 2006; Obando et al., 2008) 
leading to the possibility of the increase in incidence being linked to changes within 
pneumococci.      
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Source Country Disease Grouping Estimation Method Age Group Time Frame Change in Incidence 
Wexler et al 
(2006) 
Israel Complicated 
pneumococcal 
pneumonia† 
Retrospective case note review 0 – 16 yrs 1986 – 1997 
First year of rise 1991 
5 cases/yr (1986-90) – 12 cases/yr (1991-97) 
Finley et al 
(2008)  
Canada Empyema Hospital coding data 0 – 19 yrs 1995 – 2003 
First year of rise 1996 
Age specific data not presented however: 
Ratio of rate in 1995: rate in 2003 - 2.20 (95% 
CI 1.56 to 3.10) 
Deiros-Bronte 
et al (2006) 
Spain Parapneumonic 
effusion 
Retrospective case note review  < 15 yrs 1993 – 2003 
First year of rise 1995 
1993 - 18.1 per 100,000 children 
2003 - 42.9 per 100,000 
Byington et al 
(2002) 
USA Parapneumonic 
empyema 
Retrospective case note review < 19 yrs 1993 – 1999 
First year of rise 1995 
1993 – 1 per 100,000 (<19yrs) 
1999 – 5 per 100,000 
Strachan et al 
(2009) 
Australia Empyema Hospital coding data < 19 yrs 1993 – 2005 
First year of rise 1996 
1993-94 - 4 hospital admissions per million 
(<19yrs) 
2004-05 – 9.4 per million  
Grijalva et al 
(2010) 
USA Empyema Hospital coding data <5 yrs 1996 – 2007 
First year of rise 1997 
1996-98 - 3.5 hospitalisations per 100,000 
children 
2005-2007 7.0 per 100,000  
Hsieh et al 
(2004) 
Taiwan Complicated 
pneumonia‡ 
Retrospective case note review <15 yrs 1995 – 2002 
First year of rise 1997 
1995 – 25% of total pneumococcal pneumonia 
admissions complicated pneumonia 
2002 – 70%   
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Obando et al 
(2008) 
Spain Pneumococcal 
parapneumonic 
empyema 
Prospective recruitment, retrospective 
identification through microbiological 
isolates 
<18 yrs 1998 – 2006  
First year of rise 1999 
1998 – 5 cases* 
2006 – 66 cases* 
Van Ackere et 
al (2009) 
Belgium Complicated 
parapneumonic 
effusion 
Retrospective case note review <18 yrs  1993 – 2005  
First year of rise 2000 
1995-2002 – 20 to55 admissions per 100,000 
hospital admissions 
2002-05 – 120 to140 admissions per 100,000 
hospital admissions  
Li et al (2010) USA Empyema and 
complicated 
pneumonia 
(empyema, pleural 
effusion or 
bacterial 
pneumonia 
requiring a chest 
tube) 
Hospital coding data <18 yrs 1997 – 2006 
First year of rise 
2000** 
1997 empyema hospitalisations 2.2 
per 100 000 children,  
2006 empyema 
hospitalisations 3.7 per 100 000.  
 
Lee et al 
(2010) 
USA Local 
complications of 
community 
acquired 
pneumonia (>97% 
empyema) 
Hospital coding data <18 yrs 1997 – 2006 
First year of rise 
2000** 
77.8% increase in local complications  
1997 5.4 cases per 100 000 population, 
2006 9.6 cases per 100 000 population 
 
† Complicated pneumonia defined as pleural effusion (83 %), empyema (52 %), atelectasis (26 %), pneumatocele (19 %), and pneumothorax (10 %). Study 
population of four large hospitals in Jerusalem.  
‡Complicated pneumonia defined as necrotizing pneumonia and/or empyema  
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*Refers to figures from Seville and Malaga  
** Both studies did not use serial years, instead using 1997, 2000, 2003 and 2006 as estimates so first year of rise not accurately captured 
Table 2.1 Global changes in incidence of paediatric empyema 
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There has been consistency in the timing of the rise in incidence of empyema with >90% of studies 
reporting the rise as having begun in the five year period between 1995 and 2000 (Table 2.1). Also 
highlighted is the difficulty around precise definition of empyema with studies utilising a range of 
different definitions. This in turn makes direct comparisons more challenging, although all the studies 
where comparisons were possible fell within a relatively consistent range of between 1 admission per 
100,000 individuals and 10 admissions per 100,000 individuals (Roxburgh et al., 2008; Lee et al., 2010). 
None of the cited reports come from the developing world. Publication of data on empyema may be less 
likely from developing countries for several reasons including presence of other health priorities; higher 
death rates from initial infections; less funding available for health research; less resources available for 
diagnosis of empyema which may impact on recording, although it may also reflect the absence of an 
increase in incidence of empyema.    
 
Aside from Playfor et al (1999) and Shankar et al (2000) three other reports have failed to find an 
increase in the incidence of paediatric empyema or observed a rise followed by a reduction. Schultz et al 
(2004) found a halving in cases at one Texas children’s hospital after 2000. Buckingham et al (2003) 
tracked the annual incidence of complicated parapneumonic effusions and saw a progressive increase 
from 4.5 per 10000 discharges in 1996 to 25.0 in 1999 (p=0.0001), then a subsequent decline to 10.1 in 
2001 (p=0.03) at their centre. Koshy et al (2010) documented the substantial rise in empyema in England 
between 1998 and 2006, but noted a decrease of approximately 20% from 2006 to 2008 which they 
attributed to the introduction of the pneumococcal conjugate vaccine. However, their estimates of the 
incidence of empyema were substantially lower than other studies using the same or similar data and their 
methodology failed to account for seasonal variation in cases numbers which could potentially explain the 
variability within their results.   
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2.1.3 Relationship to pneumonia 
 
Given the pathophysiological relationship between the two conditions, one of the first hypotheses 
proposed to explain the increase in incidence of empyema was a rise in underlying cases of pneumonia 
(Roxburgh et al., 2008). A number of studies have reported changes in time of both conditions, but only 
four have addressed this specific hypothesis. Those that have, have reported contradictory results. These 
studies are listed in Table 2.2. Buckingham et al (2003) and Deiros Bronte et al (2006) retrospectively 
identified the proportion of pneumonia cases complicated by empyema at single centres and found that 
there was no variation over time in this, suggesting the changes in incidence empyema were attributable 
to changes in the incidence of pneumonia. In contrast, Roxburgh et al (2008) and Strachan and Jaffe 
(2009) looked indirectly at the relationship between the two conditions by comparing longitudinal trends 
in national coding data of both conditions. Roxburgh et al (2008) found that both empyema and 
pneumonia had increased in the 25 years between 1980 and 2005, but that the increase in empyema had 
occurred much later (>1995) and with a much steeper gradient than the increase in pneumonia. Strachan 
and Jaffe (2009) found that while empyema had increased significantly, pneumonia had not although 
there was a trend to an increase, suggesting some variation in the rate of empyema complicating 
pneumonia. Although not directly addressing the hypothesis of pneumonia driving the increase in 
empyema, three studies of national coding data in the USA reported an increase in empyema and a 
decrease in pneumonia after the introduction of the seven valent pneumococcal vaccine, suggesting 
variation in the rate of empyema complicating pneumonia over time (Li and Gates, 2008; Grijalva et al., 
2010; Lee et al., 2010).    
 
There is historical evidence that the incidence of empyema has been previously affected by periodic or 
cyclic changes in pathogen virulence which appeared to increase the rate of progression from pneumonia 
to empyema (Heuer, 1932; Middelkamp et al., 1964; Clagett, 1973). For example, Heuer (1932) was the 
first to relate patterns in empyema incidence and mortality to the perceived virulence of the predominant 
pathogen causing pneumonia and observed significant annual variations between streptococcal and 
pneumococcal empyema. However, no authors thus far have formally investigated and quantified 
periodicity within longitudinal studies of the relationship between empyema and pneumonia.  
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Study Country Data Methodology of 
comparison 
Conclusions 
Buckingham S et al 
(2001) 
USA Retrospective 
case note 
review 
Proportion over 
time 
Increase and subsequent 
decrease proportionally of both 
pneumonia and empyema 
Roxburgh CS et al 
(2007) 
Scotland Hospital 
coding data 
Indirect comparison 
of trends 
Both conditions increased, but 
rise in empyema occurred later 
and not correlated with 
pneumonia rise 
Bueno-Campana M 
et al (2008) 
Spain Retrospective 
case note 
review 
Proportion Increase in pneumonia, but 
constant proportion of 
empyema over time 
Strachan R et al 
(2009) 
Australia Hospital 
coding data 
Indirect comparison 
of trends 
Increase in percentage of 
empyema as proportion of 
pneumonia 
Grijivalva et al 
(2010) 
Lee et al (2010) 
Li et al (2010) 
USA Hospital 
coding data 
No direct 
comparison 
All three studies reported an 
increase in empyema despite a 
decrease in pneumonia, but did 
not formally address the 
relationship between the two 
 
Table 2.2 Studies addressing the hypothesis that the increase in empyema was driven by an increase 
in underlying cases of pneumonia.  
 
2.1.4 Seasonality, periodicity and cyclicity in respiratory infections including empyema 
 
Most human respiratory pathogens e.g. Influenza and respiratory infections e.g. pneumonia are seasonal 
with peaks in frequency in certain months, in addition they also show year on year variations in cyclicity 
or periodicity (Dowell and Ho, 2004). The mechanisms underpinning seasonality and cyclicity in 
respiratory infections are uncertain and have perhaps been neglected as a research topic in the past. 
Fisman (2007) suggests four broad mechanisms that may be relevant. These are:    
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1) Population behaviours – Seasonal variations in human activities may lead to alterations in disease 
transmission which support seasonality. Examples include increased viral transmission at the start 
of the school year in September or the mid-winter peak in pneumococcal disease which appears 
to coincide with Christmas and New Year holiday period when population mixing between age 
groups, e.g. children and grandparents, may potentiate transmission. 
2) Pathogen-pathogen interactions – The seasonality of some pathogens may allow increases in 
seasonal transmission of others e.g. seasonal influenza and pneumococcal and meningococcal 
disease. 
3) Environmental effects on pathogens – Certain environmental conditions appear to be favourable 
to some pathogens e.g. cold dry air appears to increase influenza viral particle’s survival in the 
environment. 
4) Environmental effects on hosts – There may be seasonal variation in human susceptibility to 
pathogens e.g. there is evidence of seasonal variation of immune function linked to photoperiod 
which may underpin infectious disease seasonality. 
 
Seasonality and cyclicity within empyema were described as early as the 1930’s but neither the 
magnitude nor the mechanisms underpinning them have been explored (Heuer, 1932). Seasonality and 
cyclicity both pose potential problems to longitudinal estimates of incidence in empyema. For example, if 
a condition is clustered in the winter, individual seasons are likely to differ in length and timing and 
therefore may be split across different years unevenly. This may under or overestimate the true incidence 
dependent on the timing and the subsequent distribution of the season within individual calendar years. 
The presence of cyclicity may also lead to inaccuracy in the estimation of the change in incidence, in 
particular if the magnitude of change is estimated by comparison of two arbitrary start and end points.  
 
Both empyema and pneumonia are subject to strong seasonal variations in incidence, with cases 
predominantly concentrated in the winter months (Hardie et al., 1996; Clark et al., 2007a). Furthermore, 
there is historical evidence that empyema has been previously affected by periodic or cyclic changes in 
both pathogen (periods of pneumococcal or staphylococcal dominance) or pathogen virulence (increase in 
rate of progression from pneumonia to empyema) (Heuer, 1932; Middelkamp et al., 1964; Clagett, 1973; 
Chonmaitree and Powell, 1983). However, this periodicity or cyclicity has never been quantified (Figure 
2.1) highlights evidence of possible cyclicity within empyema admissions in a recent study of the 
incidence of empyema in the USA (Grijalva et al., 2010).  
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Figure 2.1 Hospital admissions for all cause-pneumonia complicated by empyema from a US in-
patient sample, with evidence of potential six year cycle with peaks in 1999 and 2005 as well as 
upward trend (Grijalva et al., 2010) 
 
2.1.5 Bacterial respiratory pathogens associated with empyema 
 
The microbiological diagnosis of empyema is difficult and a causative agent is only isolated by routine 
culture in approximately 20-40% of cases (Byington et al., 2002b; Eastham et al., 2004). Molecular 
diagnostic techniques improve this to upwards of 60% (Saglani et al., 2005; Le Monnier et al., 2006). 
When summarising all published series of the bacteriological causes of empyema in children from 1950 
onwards, three organisms – Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus 
aureus predominate (Figure 1.2).   
 
Streptococcus pneumoniae appears consistently as the commonest cause of empyema in most recent 
epidemiological studies, including those that use molecular testing (Byington et al., 2002b; Eastham et al., 
2004). S. pneumoniae is an obligate human pathogen and is frequently carried in the nasopharynx (van 
der Poll and Opal, 2011). Carriage is highest in children under the age of five and associated with 
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institutional day care (Obaro et al., 1996). Over 90 capsular serotypes are recognised although only a 
smaller number appear associated with empyema (Byington et al., 2002b). It is the leading bacterial cause 
of pneumonia in children, accounting for approximately 20-30% of cases (van der Poll and Opal, 2011). 
Seasonal changes in the incidence of invasive pneumococcal disease are well recognised with peaks 
predominantly in the winter (Dowell et al., 2003). 
 
Staphylococcus aureus historically was an important cause of empyema. Several more recent studies have 
also reported it as the leading cause of empyema, particularly the Meticillin resistant strain (MRSA) 
(Buckingham et al., 2003; Schultz et al., 2004). Similar to S. pneumoniae it also carried in the 
nasopharynx and carriage is asymptomatic. Seasonality has been reported in S. aureus carriage, 
particularly in relation to seasonal upper respiratory tract viral infections (Harrison et al., 1999). 
 
Streptococcus pyogenes is a member of the group A streptococci. Like S. pneumoniae, S. pyogenes is an 
obligate human pathogen with no other biological host recognised. It is an important cause of empyema, 
although not the most frequent in recent cases series (Bessen, 2009). It can be carried asymptomatically 
and carriage is associated with both seasonal and epidemic or cyclical changes in prevalence (Lamagni 
TL et al., 2008).  
 
Mycoplasma pneumoniae is a rare cause of empyema. It has been widely observed to occur in 3-5 yearly 
epidemics with a low background rate of infectivity. It displays seasonal variation with increases in the 
summer months. M. pneumoniae was first identified in 1944 by Eaton from a patient with atypical 
pneumonia. It was initially thought to be a virus but reclassified once it’s treatability with antibiotics was 
recognised. It is a ubiquitous human pathogen with evidence of infection in all populations studied thus 
far (Waites and Talkington, 2004).  
 
It is recognised that different pathogens differ in their potential to progress from pneumonia to empyema 
and interactions between organisms may therefore be a key dynamic in understanding the recent change 
in the epidemiology of empyema. For example a leading cause of childhood pneumonia, Mycoplasma 
pneumoniae, is known to occur in ‘epidemic-like outbreaks’ of an approximate 48 month frequency and is 
much less likely to be a cause of empyema than the commoner causes S. pneumoniae and S. aureus (Ali 
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et al., 1986; Rasmussen JN, 2010) It could be therefore hypothesised that the rate of progression between 
pneumonia would be negatively correlated with isolations of M. pneumoniae. This could be explored by 
examining the temporal relationship of isolations of M. pneumoniae to empyema admissions and to the 
rate of progression from pneumonia to empyema. 
 
The discussion so far has assumed that the patient is immunologically normal and has no other congenital 
or acquired abnormalities of the lungs. It is well recognised that a wide variety of other organisms which 
are not normally regarded as causing empyema may rarely do so in unusual situations. Examples would 
include children with congenital or acquired immunodeficiency and following trauma to the lungs. 
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2.1.6 Aims & hypotheses 
 
The aims of this analysis were to investigate longitudinal trends in the incidence of childhood empyema 
and pneumonia at a regional and national scale in the UK with a view to quantifying the increase in 
incidence in both condition and the relationships between the two conditions. Longitudinal trends were 
investigated across three hierarchal populations. This approach was intended to establish whether changes 
in incidence were comparable, consistent, robust, and a consequence of true change in disease rather than 
changes in classification or health care systems, as can be a problem in longitudinal studies of hospital 
coding data.  
 
Both empyema and pneumonia show significant seasonal variation in incidence with concentration of 
cases within the winter months and therefore robust methods of addressing seasonality were required to 
accurately assess secular trends in incidence. This provided an opportunity to ascertain the magnitude of 
seasonal effects in empyema which have not been previously quantified and evaluate whether there were 
seasonal or cyclical trends beyond the annual cycle, the presence of which may provide information about 
the underlying mechanisms driving the change in incidence of empyema.   
 
Empyema represents a clinical syndrome with multiple possible pathogenic causes. An important 
hypothesis therefore in investigating the change in incidence of empyema is whether changes in the 
activity of one pathogen over others were associated with the observed longitudinal trends in empyema 
and its relationship to pneumonia. This was investigated by testing the association between the incidence 
of empyema and activity of the different pathogens over time at a national scale. Different pathogens are 
also associated with different rates of progression of pneumonia to empyema. To further delineate the 
relationship between the two conditions, the relationship of the rate of progression of pneumonia to 
empyema and the activity of different pathogens over time was also investigated on a national scale.   
 
Furthermore, as Fisman (2007) postulates a significant component of seasonality and cyclicity in 
respiratory infections are pathogen related changes. These factors were investigated in relation to the 
activity of different pathogens.  
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Secondary aims included the evaluation of accuracy of hospital coding data in determining the incidence 
of empyema compared to extant clinical data and estimation of the impact of any increase in empyema on 
health resources by calculating the costs associated with increasing empyema admissions.    
  
Key hypotheses: 
- The incidence of empyema has increased  
- The increase in incidence of empyema has been driven by an increase in pneumonia 
- The incidence of empyema shows seasonality and cyclicity 
- The increase in the incidence of empyema is related to the activity of S. pneumoniae, S. aureus, S. 
pyogenes and M. pneumoniae 
- Seasonality and cyclicity seen within empyema is associated with the seasonality and cyclicity in 
the activity of S. pneumoniae, S. aureus, S. pyogenes and M. pneumoniae 
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2.2 Methods 
 
Data on the incidence of empyema were collated from two sources: 
i) Data from the North East tertiary hospital responsible for the management of paediatric 
empyema 
ii) Hospital episode statistics (HES) on paediatric pneumonia and empyema admissions in 
England and at a regional level  
  
2.2.1 North East empyema data 
 
A historical record of all paediatric empyema patients managed at the Freeman Hospital, Newcastle-upon-
Tyne has been maintained since 1995.The Freeman Hospital is the regional cardiothoracic centre, serving 
the North East of England and the county of Cumbria. Patients with suspected empyema are referred from 
secondary care paediatric in-patient units across the region and are not directly admitted from primary 
care. There are no other paediatric empyema management centres within 100 miles by road of the 
Freeman Hospital. With this relative isolation, referral patterns are stable and there were no changes in the 
referral arrangements for children with empyema between 1995 and 2011. The UK-ESPE study received 
a favourable opinion from the Sunderland Regional Ethics Committee in October 2007 (Appendix Q). 
The National Information Governance Board approved the study, with informed consent required for the 
prospective collection of patient identifiable information but permission was given for the collection and 
storage of retrospective data. 
 
Case definition 
The case definition used was a clinical diagnosis of empyema with evidence of pleural fluid on imaging 
(either chest x-ray or thoracic ultrasound). All cases referred as suspected empyema were considered, but 
only those cases that required invasive management (pleural drainage and/or decortication) were included. 
The proportion of patients referred who required invasive management remained stable throughout the 
study period (83% 1995/2005 vs. 85% 2008/2009).   
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Data collection 
The period from May 1995 to December 2011 was studied. Data from 1995 to 2005 were collected by 
retrospective examination of ward admission diaries which were searched to identify any patients 
admitted with empyema or suspected empyema. Individual case records were then examined to establish 
whether the case required invasive management and were cross-checked with theatre logs to ensure 
accuracy. These data have been previously reported (Spencer et al., 2006b). Subsequent data were 
obtained as part of the UK Enhanced Surveillance of Paediatric Pneumococcal Empyema study (UK-
ESPE). Cases from September 2006 to September 2008 were identified in the manner stated previously, 
applying the same case definition. From September 2008 onwards cases were identified prospectively 
through daily contact with the cardiothoracic team by a member of the research team. No data were 
collected for the period January-May 2006 due to a transition between research staff; hence this period 
was excluded from analyses leaving a total of 195 months available.  
 
Data description 
The data from the period 1995-2005 are limited to the number of cases per month and the post-code of 
each case. Data from 2006 onwards contained detailed demographic information including post-code, 
microbiological, management and outcome data.   
 
Temperature data 
Data were obtained from the Meteorological Office Integrated Data Archive System land surface station 
database (MIDAS). All available records for the study region were searched and the surface station centre 
closest to the main centres of population and with the most complete records for the time period was used 
(Wallington, Grid Ref: 036844). The mean monthly maximum air temperature was calculated and values 
were available for 193 of 195 months.  
 
2.2.2 National and Regional Hospital episode statistics data 
 
Case definition within coding data 
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The definition of pneumonia in studies utilising hospital coding data has been variable historically 
(Roxburgh et al., 2008; Elemraid et al., 2010; Koshy et al., 2010). For this study, one comprised of ICD 
codes pertaining solely to bacterial pneumonia was used (J13-15 and J18.1). It includes all the codes that 
cover pneumonia with a specific bacterial diagnosis e.g. J13 Pneumonia due to Streptococcus pneumoniae 
and two more general codes. These are: J15.9 Bacterial pneumonia, unspecified and J18.1 Lobar 
pneumonia, unspecified (a full list of codes included is in Table 9.1 in the Appendix). This is a more 
conservative definition than other studies in the same setting have used, as it excludes any codes relating 
to viral pneumonia (Roxburgh et al., 2008; Koshy et al., 2010). This is justified as empyema occurs in the 
vast majority of cases as a progression from bacterial pneumonia rather than viral pneumonia (Chernick et 
al., 2006). Furthermore, there may be substantial seasonal shifts in both viral pneumonia and viral 
diagnostic testing in pneumonia in children which may obfuscate the true trends in pneumonia in relation 
to empyema (Byington et al., 2002a; Chan et al., 2002). It is possible that this is conservative, as it is 
recognised that a proportion of viral pneumonia may be occult, undiagnosed bacterial infection (Morens 
et al., 2008). Nevertheless, given the aim of investigating the relationship between empyema and 
pneumonia it is possible that large numbers of cases of viral pneumonia which have no risk of progression 
to empyema may distort or obfuscate the true pattern of the relationship.  
 
Two further codes, J15.9 Bacterial pneumonia, unspecified and J18.1 lobar pneumonia were included in 
the definition. J15.9 includes admissions where clinicians suspected bacterial pneumonia, but specific 
microbiological investigations had not been carried out, or where the results were unavailable when the 
admission was coded. Similarly lobar changes on a chest x-ray are likely to be due to bacterial pneumonia 
and therefore are likely to include admissions for bacterial pneumonia where a precise microbiological 
diagnosis was unavailable (Virkki et al., 2002). 
 
J86.0 & J86.9 which code for pyothorax with/without fistula respectively were used to identify empyema 
admissions in UK studies and were therefore used to allow direct comparisons to be made (Gupta and 
Crowley, 2006; Roxburgh et al., 2008; Koshy et al., 2010).  
 
Hospital Episode Statistics data 
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HES is a database containing details of all admissions to NHS hospitals in England maintained by The 
Information Centre for Health and Social Care (HESonline - Hospital Episode Statistics, 2010). It 
contains data on hospital admissions from 1989 onwards and approximately 12 million new records are 
added yearly. Each record contains clinical information about diagnoses and operations, patient 
demographics including age, sex and ethnicity, administrative information and geographical information, 
such as post-code of residence. Clinical information is recorded in the form of codes from the 
International Classification of Disease (ICD), published by the World Health Organization (WHO, 1990). 
The tenth iteration was published in 1990 (ICD-10). The ICD-10 classification was adopted by the NHS 
in April1996 following a two year transition from the ICD-9 system. Up to 14 diagnostic codes were 
included in an individual patient record up until April 2007 (seven up until April 2002, 20 post 2007). 
The initial code or diag_01 refers to the primary diagnosis. All other codes represent secondary or 
subsidiary diagnoses. Codes are attributed by hospital coding departments and are returned by individual 
hospitals. Coders examine all patients’ records and attribute the code based on their assessment of the 
records and the most appropriate diagnosis. Coders are specifically trained, but are not generally 
medically qualified. Each record refers to an individual episode of care under a named consultant, or other 
approved allied healthcare professional. As a result, a patient’s single hospital admission can span 
multiple records if care was transferred between different consultants. The HES data are produced on the 
timetable of the financial year and consequently admissions that are ongoing at the time of the production 
of the data may not be included in that year’s data, but will be included in the subsequent year. 
 
Data were obtained for all respiratory diagnoses (J00-J99) in children and young people aged up to 18 
years of age from April 1997 to April 2006. From this, monthly hospital episodes data were extracted for 
the period 1
st
 April 1997– 30th March 2006 for all children aged less than 14 years with a recorded 
diagnosis of bacterial pneumonia or empyema.  
 
The time-period 1
st
 April 1997– 30th March 2006 was selected for two reasons: 
- The coding classification fully changed from ICD-9 to ICD-10 in 1997, following a two year 
transition; hence data were not used from before this period to avoid the potential for differential 
ascertainment resulting from the change.  
- To avoid the potential confounding effects of the seven valent pneumococcal vaccine which was 
introduced in September 2006.   
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Data from all years were allocated to a Strategic Health Authority (SHA) using SHA boundaries as from 
1
st
 July 2006. The SHA of residence was used for all analyses. A map of SHA boundaries is shown in 
Figure 2.2 and total population for each SHA in Table 2.3. Data with each disease code were counted; 
those with an identical HES identification number were amalgamated in order to convert from episodes to 
hospital admissions. All duplicate records were removed. Readmissions were excluded if they occurred 
within a month of the original date of admission. A month was judged long enough because of the short 
average hospital stay in children (median 11 days for empyema from the UK-ESPE study). These counts 
were aggregated to give total counts of empyema and pneumonia admissions for each month both 
nationally and for each individual SHA. Admission rates were calculated using Office of National 
Statistics mid-year population estimates and all rates refer to admissions per million individuals aged 
between 0 and 14 years (Mid-year population estimates, 2011).  
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Figure 2.2 Map of Strategic Health Authorities in England in 2006. 
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SHA North East 
(NE) 
North West 
(NW) 
Yorkshire 
(Y) 
East Midlands 
(EM) 
West Midlands 
(WM) 
Population / 
million (2006) 
2.5 6.8 5.0 4.2 5.3 
SHA East of 
England 
(EE) 
London 
(L) 
South East 
(SE) 
South Central 
(SCE) 
South West 
(SW) 
Population / 
million (2006) 
5.4 7.4 4.1 3.9 5.0 
 
Table 2.3 Populations of Strategic Health Authorities in England in 2006. 
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2.2.3 Microbiological data 
 
As precise attribution of empyema to a pathogen is challenging and thought to be poorly recorded in 
hospital coding data, an approach using a measure of pathogen activity rather than directly measuring 
cases of empyema recorded as being caused by a specific organism was used. Four pathogens were 
investigated. These were S. pneumoniae, S. pyogenes, S. aureus and M. pneumoniae. S. pneumoniae, S. 
pyogenes and S. aureus were the three commonest causes of empyema in a review of studies of paediatric 
empyema published after 1950. M. pneumoniae while a rare but recognised cause of empyema displays 
significant seasonality and cyclicity with epidemic-like outbreaks occurring regularly. In addition, as it is 
a well-recognised cause of pneumonia in older children but a rare cause of empyema it may significantly 
influence the rate of progression from pneumonia to empyema. 
 
Monthly counts of isolations of the four organisms – S. pneumoniae, S. pyogenes, S. aureus and M. 
pneumoniae from children aged between 0 and 14 years in England from 1
st
 April 1997 – 30th March 
2006 (the same age group, geographical area and time period as the empyema admissions data) were 
obtained from the Health Protection Agency (HPA) of the UK Government. The term isolation refers to 
organisms detected by standard culture techniques in routine use in NHS hospitals from patient samples 
and notified to the HPA. Data for S. pneumoniae, S. pyogenes and S. aureus were for isolations defined as 
invasive. Invasive isolations are isolations from normally sterile body sites and include positive samples 
from blood, pleural fluid and cerebrospinal fluid. Data for M. pneumoniae was all detections of M. 
pneumoniae reported to the HPA Centre for Infections. All four sets of data were from routine 
surveillance carried out by the HPA which is the central body responsible for public health in the UK.         
        
2.2.4 Statistical methods 
 
Five discrete groups of analyses were carried out. Local changes in the incidence of empyema were 
evaluated using the Freeman hospital North East England data. National trends in empyema were 
analysed using the HES dataset. Regional variations in the change in empyema and pneumonia were 
analysed using the HES dataset at SHA level. The relationship of empyema to pneumonia was analysed 
using the national HES data. Finally the relationships between empyema and the activity of four different 
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pathogens – S. pneumoniae, S. aureus, S. pyogenes and M. pneumoniae was investigated using the 
national HES data and national surveillance data.  
 
Overview 
The overall aim of all the analyses was to investigate the changes in incidence in empyema and quantify 
the relationship between empyema and pneumonia. The outcomes of interest were therefore counts of 
cases or admissions at specific time points, and therefore in effect time series. Basic frequentist statistical 
analyses and linear regression rely on the fact that observed data are underpinned by mutually 
independent random processes. Time series by contrast are generally repeated serial observations and 
therefore are very unlikely to be independent, violating the assumption of independence required for 
linear regression and related techniques (Box et al., 2008). Time series analysis therefore requires specific 
techniques to account for this property.  
 
Several other concepts and definitions are important within time series. Trend refers to the non-random 
function present over time within a time series. Serial dependence is the concept that at least some 
observations are statistically dependent on other observations within the same series. The autocorrelation 
of a time series is the statistical function of the serial dependence present. Seasonality in general refers to 
known periodic behaviour e.g. annual variation in temperature; cyclicity refers to periodicity which may 
not be known a priori. Finally, stationarity refers to the fact that the stochastic variability (e.g. seasonality) 
within a time series does not vary with the time point sampled (Diggle, 1990). A range of methodologies 
have been developed to analyse time series dependent on the properties of series and the aim of the 
analysis e.g. forecasting, estimation of multi-variate relationships or extrapolation of trends.  
 
Generalised least squares regression models     
Generalised least squares (GLS) regression models are a form of extended linear model which allow the 
modelling of dependence within error structures (Pinhero and Bates, 2000). Historically, they have been 
developed for time series and spatial data, as both generally have the property of serial dependence 
(Pinhero and Bates, 2000). They are multivariate and allow the calculation of co-efficients describing the 
relative effect size of the suggested relationships between variables (Kitagawa, 2010). 
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Residual autocorrelation structures are used to model serial dependence. They vary in their sophistication 
but work by assuming the correlation between observations follows a predictable pattern. Zuur (2009) 
describes three levels of complexity. The simplest residual autocorrelation structure is known as 
compound symmetry and assumes that the residual correlation does not vary with time between 
observations. More complex is an auto-regressive model of order 1 (AR1), which models the residual at 
time s as a function of residual of time s – 1. The AR1 model can then be extended to a more complex 
model, the auto-regressive moving average model (ARMA). The ARMA model contains two terms, p, the 
number of auto-regressive parameters and q, the number of moving average parameters. The residuals are 
modelled as a function of the p previous time points and white noise. Different combinations of values of 
p and q may be need comparing before the optimal structure is found, although values above p = 3 and q 
= 3 may be impractical (Zuur et al., 2009). 
 
State-space models 
Dynamic or state-space models are stochastic models which can be used to represent time series. State 
space models have been defined by Kitagwa (2010) in two stages: 
                   (           ) 
             (                ) 
yn is an l variate time series. xn is a k-dimensional unobservable vector, referred to as the state, vn is the  
m dimensional system or state noise, wn the observation noise. Fn, Gn and Hn are the k x k, k x m and l x k 
matrices. The observation model is a regression model representing the time series yn and the system 
model expresses the time change of the regression coefficients. This approach is therefore able to handle 
non-stationarity within data from example variation in both frequency and amplitude of seasonality 
within the time series. Lundbye-Christensen et al (2009) demonstrated the usefulness of this approach in 
modelling hospital admissions with myocardial infarction. Similarly Fanshawe et al (2008) used state-
space models to predict spatio-temporal variation in air pollution levels in the North East of England.   
 
Within GLS regression models, the influence of seasonality can be compensated for by the introduction of 
harmonic parameters, as has been used elsewhere (Jensen et al., 2004), provided the seasonality has 
stationarity and does not vary in frequency or amplitude over time. If there is variation in seasonality over 
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time, then a modelling framework robust to time-varying regression coefficients should be used. State-
space or dynamic models are able to achieve this.    
 
Wavelet analysis 
Wavelet analysis is widely used in a number of fields including ecology, epidemiology and engineering. 
In infectious disease epidemiology, wavelet analysis has been used to demonstrate the relationship 
between increasing epidemic phase in measles and their relationship to immunisation rates in the UK 
(Grenfell et al., 2001), a highly significant association between El Nino, precipitation and dengue 
epidemics in Thailand (Cazelles et al., 2005) and the presence of ecological interference in epidemics of 
unrelated human pathogens (Rohani et al., 2003).  
 
Wavelet analysis is based on transformation of the signal of a time series into a series of functions 
(wavelets) that represent both the frequency and time-scale within that signal. As frequency and time-
scale are interdependent, decomposition of a time series necessitates a trade-off between time and 
frequency resolution and wavelet analysis has been described as the optimal trade-off between time-
frequency resolution (Cazelles et al., 2008). Wavelet analysis decomposes a time series into both a time 
domain and a frequency space, allowing the recognition of the relevant contributions of different 
periodicities within the time series (Zhang et al., 2009). Wavelet analysis also has the advantage of not 
requiring stationarity of periodicity within the data and can evaluate the whole extent of a time series 
(Cazelles et al., 2007).  
 
Wavelet coherence analysis is a method of quantifying statistically the linear relationship between non-
stationary time series. Wavelet coherence can be defined mathematically as 
   (   )  
     (   )   
      (   )   
 
     (   )   
 
 
 
Where    (   ) is the wavelet coherence between two signals x(t) and y(t), ‘< >’ denotes a smoothing 
operator in both time and scale.   (   ) represents the wavelet co-efficient following wavelet 
transformation of time series x, with frequency f and τ the time point (Cazelles et al., 2008). In addition 
the use of complex wavelets allows the calculation of phase difference between two time series.   
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General principles 
Analyses were performed using the R statistical programme (R-Development-Core-Team, 2011), using 
the nLME (Pinhero et al., 2011), MASS (Venables and Ripley, 2002), sspir (Dethlefsen et al., 2009), 
WaveletCo (Tian and Cazelles, 2011), Epitools (Aragon, 2010) and Lattice (Sarkar, 2008) packages. A 
progressive model building approach was used with the simplest acceptable model preferred. The 
principle of parsimony was adhered to with the exclusion of non-significant terms (Pinhero and Bates, 
2000). Residual distributions were plotted and quantified for serial dependence to ensure that model 
assumptions regarding linearity, homoscedascity, and independence were not violated. Where there were 
concerns over model assumptions log transformation was used to stabilise the variance and prevent 
violation of model assumptions (Faraway, 2005). Models were compared by a combination of Akaike 
Information Criterion (AIC) and the coefficient of determination R
2
 (calculated as correlation between 
observed outcome variable and model fitted values). A significance level of p<0·05 was used to assess the 
significance of regression co-efficients. 
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Local changes in the incidence of empyema (North East data) 
 
The incidence rates of paediatric empyema managed at the Freeman Hospital, Newcastle-upon-Tyne were 
calculated using the ONS population estimates for the North East SHA and Cumbria PCT for each 
epidemiological year from 1995 to 2010. Epidemiological years run from 1
st
 of July to the 30
th
 of June the 
following year (HPA, 2012) and were used to minimise the influence of year to year variation in the 
timing of peaks in case numbers. 95% confidence intervals for each estimate were derived assuming a 
Poisson distribution of the residuals (Rothman et al., 2008).  
 
GLS regression models were then used to test the hypotheses:  
a) that cases of paediatric empyema in the NE of England increased with time from 1995 
 
b) that monthly cases of paediatric empyema in the NE of England varied with season between 1995 
and 2010 
 
The initial model (T0) was defined as:  
                                                  
where α represented the intercept, β the regression co-efficient and є the error term.    
 
Monthly counts of cases were used in preference to annual counts for two reasons. Firstly to determine 
the magnitude of seasonal trends and secondly, to increase the power to detect secular trends in the 
incidence by increasing the number of observed time points. As cases were clustered in the winter and 
originated from one region, mean monthly air temperature from a central location in the North East was 
used to model the seasonal trend.        
 
Plotting of the model T0 residuals showed evidence of non-linearity and autocorrelation (Appendix B 
figures - Figure 9.1, Figure 9.2 and Figure 9.3). Count data can be transformed to an approximate 
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normal distribution by addition of a constant and application of a log transformation (Box and Cox, 1964; 
Gruttola and Tu, 1994), hence a second model (T1) was specified:   
  
    (               )                                     
Examination of the residuals of model T1 showed no violations of the assumption of linearity and only 
borderline evidence of autocorrelation (Appendix B figures - Figure 9.4, Figure 9.5 and Figure 9.6).  
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Modelling national trends in empyema and pneumonia 
National incidence rates for paediatric bacterial pneumonia and paediatric empyema in England were 
calculated for each epidemiological year from 1997/8 to 2004/5 using total hospital admissions. The ONS 
population estimates for individuals aged 0-14 years were used as the denominator and confidence 
intervals estimated assuming a Poisson distribution, as described previously.   
 
Trends in admissions for paediatric bacterial pneumonia and paediatric empyema were investigated using 
GLS regression models and a progressive modelling framework to test a series of linked hypotheses 
(Table 2.4). These were: 
a) that monthly admissions for paediatric bacterial pneumonia and paediatric empyema between 
April 1997 and April 2006 in England showed seasonal variation (Models M0a/b) 
b) that monthly admissions for paediatric empyema were significantly related to monthly 
admissions for paediatric bacterial pneumonia in England between April 1997 and April 2006 
(Model M1) 
c) that monthly admissions for paediatric empyema in England increased between April 1997 and 
April 2006 independently of monthly admissions for paediatric bacterial pneumonia (Model M2) 
d) that monthly admissions for paediatric empyema in England increased between April 1997 and 
April 2006 independently of monthly admissions for paediatric bacterial pneumonia and 
independent of population size (Model M3) 
e) that monthly admissions for paediatric empyema in England increased between April 1997 and 
April 2006 independently of monthly admissions for paediatric bacterial pneumonia and 
independent of seasonal variation (Model M4) 
 
Monthly counts of admissions of either pneumonia or empyema were the initial outcome variable for 
models, however as with the NE data evaluation of the residuals of models M0a/b showed significant 
autocorrelation in both models and evidence of non-linearity with increasing dispersion of the residuals as 
the fitted values increased (Appendix C Figure 2.29-2.34). Log-transformation was therefore used to 
transform the data to an approximate normal distribution. This was then used for all subsequent models 
that included count data. 
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Name Model structure 
M0a Empyema admissions ~ α + β1*sin(
       
  
) + β2*cos(
       
  
) + є 
M0b Pneumonia admissions ~ α + β1*sin(
       
  
) + β2*cos(
       
  
) + є 
M1 Log(Empyema admissions+1) ~ α + β1 (Pneumonia admissions + 1) + є 
M2 Log(Empyema admissions+1) ~ α + β1 *Log(Pneumonia admissions + 1) + β2*Time + є 
M3 Log(Empyema admissions+1) ~ α + β1 *Log(Pneumonia admissions + 1) + β2*Time +β3*Population Size +є 
M4 Log(Empyema admissions+1) ~ α + β1 *Log(Pneumonia admissions + 1) + β2*Time + β3*sin(
       
  
) + β4*cos(
       
  
) +є 
 
Table 2.4 Modelling framework for assessing trends in national empyema and pneumonia admissions   
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Definition of periodicity and cyclicity within national empyema admissions 
 
The results of models M0-M4 demonstrated that there were significant seasonal trends in national 
empyema admissions but that these trends did not appear to be an exact 12 month cycle. Wavelet 
periodicity analysis was therefore used to define the periodicity within the empyema admission time 
series with precision and these estimates were then used to specify seasonal harmonics of the same period 
to optimise the regression model M4. Although seasonality has been reported previously in paediatric 
empyema (Hardie et al., 1996) the periodicity and cyclicity within empyema admissions has not been 
previously precisely measured Establishment of the presence of significant periodicity and cyclicity 
within empyema admissions would provide hypothetical evidence of possible epidemiological 
mechanisms important in explaining any increase in incidence of empyema e.g. presence of cycles of 
similar duration to those of particular respiratory pathogens.  
 
Optimal periodicity was defined by analysis of the average wavelet power spectrum against period and 
the periods that had the greatest average power were recorded. As these estimates represented the average 
power, the ranges of periods that corresponded with the highest integer value of the average power were 
used. The highest and lowest integer values of this range and gradations of 0.25 in between were then 
used as the period n for the seasonal harmonics in Model M5:     
 
L  (         d          )        *L  (P  u       d           )          
  *   (
       
 
)    *c  (
       
 
)    
 
Model optimisation was judged on three characteristics: the model AIC, R
2
 and the significance of the 
included explanatory terms with the optimal model having the lowest AIC, highest R
2
 and all terms 
significant.  
 
A dynamic model was then specified to test whether allowing for time variation in the seasonal harmonics 
(i.e. allowing for non-stationarity of the seasonal effect) significantly increased the ability of the model to 
explain the observed trends. The model structure was: 
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                   (  )      (  )   
 
Where μt was the log of empyema admissions in month t, α, β and γ the regression co-efficients, B and C 
the time-varying regression co-efficients, P the log of pneumonia admissions in month t, ω referred to the 
optimal seasonal harmonic 
       
 
 and є the error component.  
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Regional trends in pneumonia and empyema admissions  
Regional trends in empyema and pneumonia were investigated at the level of the SHA. Population 
adjusted admissions were calculated using ONS population estimates for each SHA. These were used 
instead of counts of cases to account for the difference in population size between SHAs. The correlation 
between population adjusted admissions for pneumonia and empyema in each SHA was assessed by 
calculation of Spearman’s correlation co-efficient. A progressive linear and linear mixed effect modelling 
approach was then used to test the hypotheses:  
a) that population adjusted admissions for paediatric bacterial pneumonia and paediatric empyema 
varied significantly between SHAs between April 1997 and April 2006 (model S0a/b)  
b) that population adjusted admissions for paediatric bacterial pneumonia and paediatric empyema 
increased significantly in each SHA between April 1997 and April 2006 (model S1a/b) 
c) that there was a significant relationship between the monthly paediatric bacterial pneumonia and 
paediatric empyema population adjusted admissions in each SHA between April 1997 and April 
2006 (model S2) 
d) that there was significant variation in both the magnitude of the change in pneumonia and 
empyema population adjusted admissions and the rate of change between SHAs (model S3a/b)  
 
The modelling framework used is listed in Table 2.5. The initial models S0a/b indicated that there were 
significant differences in population adjusted admissions for both empyema and pneumonia between 
SHAs. Therefore in order to assess trends across both conditions at this regional level, methods of 
handling the structure introduced by the a priori differences between SHAs were required. Mixed effects 
models flexibly represent the covariance structure of data grouped in this manner and allow quantification 
of the relative effect attributable to unmeasured variation between SHAs (Pinhero and Bates, 2000).  
 
The hypothesis that populations adjusted admissions increased across all SHAs for both pneumonia and 
empyema was tested by specifying a model including the SHA as the sole random effect (model S1a/b). 
As previous analysis had demonstrated the presence of significant seasonality in both conditions, seasonal 
harmonics were included in the model, to test that the longitudinal trend was independent of this 
seasonality. The relationship of empyema to pneumonia was then tested (model S2). The hypothesis that 
there was significant variation in both the magnitude of the change in admission rate and the rate of 
change between SHAs was tested using models that contained random effects for variation in occurrences 
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of disease between different SHAs (intercept) and models that contained random effects for both variation 
in occurrences of disease (intercept) and variation in the rate of change of occurrences of the disease 
between SHAs (gradient) were compared by use of ANOVA (models S1a/b and models S3a/b). Model 
residuals were examined to ensure that assumptions of linearity and independence were met and are 
shown in Appendix E. 
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Name Model structure Model Type 
S0a Log(Pop. adjusted pneumonia admissions+1) ~ α + β1*SHA + є Linear  
S0b Log(Pop. adjusted empyema admissions+1) ~ α + β1*SHA + є Linear  
S1a Log(Pop. adjusted pneumonia admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +є1|SHA Mixed effects 
S1b Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +є1|SHA Mixed effects 
S2 Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) + 
β4*Log(Pop. adjusted pneumonia admissions+1) + є
1|SHA
 
Mixed effects 
S3a Log(Pop. adjusted pneumonia admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +єTime|SHA Mixed effects 
S3b Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +єTime|SHA Mixed effects 
 
Table 2.5 Modelling framework for assessing trends in regional empyema and pneumonia admissions.   
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Relationship between empyema and pneumonia in England  
 
The ratio of empyema to pneumonia admissions in England were calculated for each month between 
April 1997 and April 2006. Trends in the ratio of empyema to pneumonia admissions were then 
investigated using GLS regression models and a progressive modelling framework to test a series of 
linked hypotheses (Table 2.6). These were: 
a) that the monthly ratio of empyema to pneumonia admissions in England between April 1997 and 
April 2006 showed seasonal variation (Model R0) 
b) that the monthly ratio of empyema to pneumonia admissions in England significantly increased 
between April 1997 and April 2006 (Model R1) 
c) that the monthly ratio of empyema to pneumonia admissions in England significantly increased 
between April 1997 and April 2006 independent of seasonal variation (Model R2) 
 
Name Model structure 
R0 Ratio of empyema to pneumonia admissions ~ α + β1*sin(
       
  
) + β2*cos(
       
  
) + є 
R1 Ratio of empyema to pneumonia admissions ~ α + β1 Time + є 
R2 Ratio of empyema to pneumonia admissions ~ α + β1 Time + β2*sin(
       
  
) + β3*cos(
       
  
) + є 
 
Table 2.6 Modelling framework for assessing trends in monthly ratio of empyema to pneumonia 
admissions.   
Model diagnostic plots are shown in Appendix F.  
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Definition of periodicity and cyclicity within ratio of empyema to pneumonia admissions 
 
Similar to the analysis of empyema admissions, the results of models R0-2 demonstrated that there were 
significant seasonal trends in national empyema admissions but that these trends did not appear to fit an 
exact 12 month cycle. Wavelet periodicity analysis was therefore used again to define with precision the 
periodicity within the ratio time series and these estimates were then used to specify seasonal harmonics 
of the same period to optimise the regression model R2. Optimal periodicity and model optimisation were 
defined as previously. The same approach as that used for the national empyema admissions data was 
used to investigate periodicity and cyclicity within the ratio of empyema admissions to pneumonia 
admissions over time. Wavelet periodicity analysis was used to define the presence of cyclicity and refine 
the GLS regression models with seasonal harmonics of varying lengths. Model optimisation was judged 
using the same three characteristics – model AIC, R2 and significance of terms.  
 
The highest and lowest integer values of the range of periods with the highest average power and 
gradations of 0.25 in between were then used as the period n for the seasonal harmonics in model R3: 
Rat        1*        2*sin(
       
 
)   3*cos(
       
 
)     
 
As a second peak of average power was identified within the ratio time series the process was then 
repeated using model R4 constructed as: 
R t        1*        2*sin(
       
 
)   3*cos(
       
 
)   4*sin(
       
 
)   5*cos(
       
 
)     
where the term q was the range of highest average power in the second peak divided into 0.25 gradations.  
 
As with national empyema admissions a dynamic model (R5) was used to test whether allowing time-
variation of the seasonal harmonics improved model function in comparison to model R3/4. The model 
structure was: 
 
              (  )      (  )   
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Where μt is the ratio of admissions in month t, α, β and are the regression co-efficients, B and C are time-
varying regression co-efficients, ω refers to the seasonal harmonic 
       
 
 and є is the error component.  
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The relationship between national empyema admissions, the ratio of empyema to pneumonia 
admissions and isolations of S. pneumoniae, S. aureus, S. pyogenes and M. pneumoniae 
 
The relationship between admissions for paediatric empyema and isolations of S. pneumoniae, S. aureus, 
S. pyogenes and M. pneumoniae were investigated using GLS regression models and a progressive 
modelling framework to test a series of linked hypotheses. These were: 
a) that monthly admissions for paediatric empyema between April 1997 and April 2006 in England 
were temporally associated with isolations of S. pneumoniae, S. aureus, S. pyogenes and M. 
pneumoniae from the same population over the same time frame (Model P0) 
b) that the monthly ratio of empyema to pneumonia admissions in England between April 1997 and 
April 2006 were temporally associated with isolations of S. pneumoniae, S. aureus, S. pyogenes 
and M. pneumoniae from the same population over the same time frame (Model S0) 
 
Each organism was assumed to be an independent predictor of the monthly counts of admissions and of 
the ratio of empyema to pneumonia admissions. As the outcome variables were therefore counts, log 
transformation was applied as previously. The basic models were therefore:  
 
Name Model structure 
P0 Log(Empyema admissions+1) ~ α + β1* Log(Isolations of S. pneumoniae+1) + β2* Log(Isolations of S. 
pyogenes+1) + β3* Log(Isolations of S. aureus+1) + β4* Log(Isolations of M. pneumoniae+1) + є 
S0 Ratio of empyema to pneumonia admissions ~ α + β1* Log(Isolations of S. pneumoniae+1) + β2* 
Log(Isolations of S. pyogenes+1) + β3* Log(Isolations of S. aureus+1) + β4* Log(Isolations of M. 
pneumoniae+1) + є 
 
Table 2.7 Modelling framework for investigating relationship between national empyema 
admissions, the ratio of empyema to pneumonia and isolations of S. pneumoniae, S. aureus, S. 
pyogenes and M. pneumoniae. 
As isolations of the four pathogens are dependent on infective transmission, there was significant 
autocorrelation present within the series. This was confirmed by examination of the residuals from 
models P0 and S0 without the inclusion of a residual autocorrelation structure (Appendix I Figure 9.49 
and Figure 9.49).  
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In order to account for this, residual autocorrelative structures were included in both models (P0 and S0). 
Zuur et al (2009) suggest using a pragmatic approach to this problem by incorporating progressively more 
complex structures until a balance between complexity and model performance is achieved. This was 
assessed by comparison of the model AIC and where applicable the value of Phi and Theta (measures of 
correlation between residuals) for each model. Models that significantly improved AIC (a reduction of 
greater than three) and that minimised Phi and Theta were preferred (Zuur et al., 2009). The correlation 
structures included were compound symmetry, AR1 and ARMA with values of p and q of integers 
between 0 and 3. All combinations of p and q were examined as until the optimal combination was found. 
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Coherence between national empyema admissions and the ratio of empyema to pneumonia 
admissions and isolations of S. pneumoniae, S. aureus, S. pyogenes and M. pneumoniae  
 
Wavelet coherence analysis allows assessment of the relationship between two time series dynamically 
and identifies coherence between series at different periods i.e. at what times and frequencies do the series 
become statistically related. Phase difference identifies the direction of any relationship. While 
multivariate time series regression using GLS has the ability to identify linear relationships between 
counts of admissions and isolations of the four pathogens over time, coherence analysis allows 
identification of relationships at different periods or cycles between the two i.e. as part of a dynamic 
process. Identification of periodic relationships between admissions and individual pathogens would 
provide significant additional information about the role of that pathogen in the epidemiology of 
empyema that has not been previously determined.  
 
The wavelet coherence and phase difference between monthly isolations of S. pneumoniae, S. pyogenes, S. 
aureus and M. pneumoniae and monthly empyema admissions were calculated to further investigate the 
relationship between respiratory pathogens and national empyema admissions,. In addition, the wavelet 
coherence and phase difference between isolations of respiratory pathogens and the ratio of pneumonia to 
empyema admissions per month were calculated to investigate the relationship between isolations of 
individual pathogens and changes in the rate of progression of pneumonia to empyema. The same 
hypotheses were considered:  
a) that monthly admissions for paediatric empyema between April 1997 and April 2006 in England 
were temporally associated with isolations of S. pneumoniae, S. aureus, S. pyogenes and M. 
pneumoniae from the same population over the same time frame  
b) that the monthly ratio of empyema to pneumonia admissions in England between April 1997 and 
April 2006 were temporally associated with isolations of S. pneumoniae, S. aureus, S. pyogenes 
and M. pneumoniae from the same population over the same time frame  
 
Each relationship was assessed separately by calculation of the cross-wavelet coherence and phase 
difference between the outcome (either monthly counts of number of admissions for empyema or the 
monthly ratio of empyema to pneumonia) and the predictors (counts of isolations of each of the pathogens 
separately). The “Morlet wavelet” was used as the mother wavelet for all wavelet transformations as the 
Morelet wavelet allows the calculation of phase difference (Zhang et al., 2009).    
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2.3 Results 
 
2.3.1 Local changes in the incidence of empyema 
 
The incidence of paediatric empyema in NE England increased from a baseline of 13.5 (95% CI 5.83-26.6) 
cases per million children (0-14 yrs) in the epidemiological year 1995/6 to 51.43 (95% CI 33.59-75.35) in 
2010/11. The annual incidence for each year is shown in Figure 2.3. The incidence of empyema peaked 
in 2007/8 at 66.57 cases per million children before declining gradually between 2008 and 2011. The 
same data per month are shown in Figure 2.4.    
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Figure 2.3 Annual incidence of paediatric empyema in the population served by the Freeman 
hospital, Newcastle-upon-Tyne (*data unavailable for full year of 2005 therefore not included). 
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Figure 2.4 Monthly incidence of paediatric empyema in NE England demonstrating both the 
significant seasonal variation in cases of empyema with peaks consistently in the winter months and 
the increase in incidence over time. Red triangle indicates monthly count of cases per million children. 
Grey dashed line indicates month of December. 
 
T1 modelled the relationship between log transformed cases of paediatric empyema per month and time 
since 1995 and mean monthly air temperature. The regression co-efficients and model parameters are 
shown in Table 2.8. The increase in monthly cases from 1995 was statistically significant (p<0.001) and 
the back-transformed co-efficient of the increase was positive suggesting that cases increased on average 
by 0.00388 per month of the study period (equivalent to 0.0466 cases per year per million children). Mean 
monthly air temperature was also a significant predictor of the number of monthly cases, with an increase 
in cases associated with lower monthly temperatures (regression coefficient -0.0529, p<0.001). Figure 
2.5 shows the model fit which was moderate (R
2
: 0.5403).      
97 
 
 
Figure 2.5 Log transformed monthly incidence of paediatric empyema in NE England between 1995 
and 2011 (black line) and incidence predicted by model T1 (red line) (model R
2
: 0.5403).
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Variable 
Co-efficient SE t-value p-value 
(Intercept) 1.0653 0.1229 8.6662 <0.001 
Time from study start (Month) 0.0039 0.0006 5.9963 <0.001 
Mean maximum monthly temperature (
o 
C) -0.0529 0.0079 -6.6822 <0.001 
Model structure: Log(Empyema Cases +1) ~ α +βxTime + βxTemperature + є 
Residual SE: 0.523; Range of residuals: -2.672 to 2.333 
DF: 193 total; 190 residual 
AIC: 327.9389 ; R
2
 : 0.5402741 
 
Table 2.8 Regression co-efficients and model parameters for model T1 assessing relationship between empyema cases in the North East of 
England and trends over time and temperature. 
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2.3.2 National and regional changes in the incidence of empyema 
 
National data 
There were a total 59,178 pneumonia admissions and 1,789 empyema admissions between April 1997 
and April 2006. The relative contribution of different HES codes are shown in Table 2.9 and the change 
year to year in contribution by codes is shown in Figure 2.6 and Figure 2.7. Lobar pneumonia was the 
identifying code in over 85% of admissions, confirming that less than 15% of pneumonia admissions 
within HES data have a specific microbiological cause. The relative proportions of the pneumonia codes 
assigned remained consistent throughout the study period. In contrast, the proportion of empyema cases 
coded with the J86.0 pyothorax with fistula code halved from 16.4% in 1998 to 8.7% in 2005 (Chi-
squared 4.695, p=0.0302).  
 
Code n % 
J13 - Pneumonia due to Streptococcus pneumoniae 1469 3.19 
J14 - Pneumonia due to Haemophilus influenzae 311 0.68 
J151-9* - other bacterial pneumonia 4095 8.89 
J181 - Lobar pneumonia, unspecified 40187 87.25 
Total 46062 100 
   
 n % 
J860 - Pyothorax with fistula 144 9.14 
J869 - Pyothorax without fistula 1432 90.86 
Total 1576 100 
 
Table 2.9 Overall contribution of codes to pneumonia and empyema admissions for HES dataset (* 
see Appendix A for specific codes from J151-9) 
 
100 
 
 
Figure 2.6 Proportion of pneumonia admissions by codes and by year (showing complete years 
only). 
 
  
Figure 2.7 Proportion of empyema admissions coded as J860 or J869 by year. 
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Modelling national trends in empyema and pneumonia 
 
The incidence of empyema as measured by admissions increased from 9.68 (95% CI 7.79-11.89) 
admissions per million children (0-14 years) in the epidemiological year 1997/8 to 37.47 (95% CI 33.6 - 
41.66) in 2004/5. This was equivalent to an increase of 287% (Incidence rate ratio: 3.87, 95% CI: 3.063 - 
4.933) or 253 extra cases per annum. Similarly pneumonia (bacterial) increased from 421.8 (95% CI 
408.77 - 435.13) admissions per million children to 838.89 ((95% CI 820.17- 857.92). The median 
pneumonia admission rate over the whole time period was 67.7 per million individuals aged 0-14 
years/month (range: 25.8 – 174.8 and the median empyema admission rate 2.5 per million 0-14 yrs/month 
(range: 0.42 – 13.1). The admission rates for both bacterial pneumonia and empyema increased from a 
median of 30.6 and 0.48 admissions per month per million individuals aged 0-14 years in 1997-1998 to 
76.7 and 3.31 in 2005-2006 respectively. The monthly admission rates for both conditions from 1997 to 
2006 are shown in Figure 2.8. Both conditions demonstrated seasonal variation with peaks in winter 
months and a progressive increase in admission rate was observed over the time period.  
 
Models M0a and M0b (Table 2.10) confirmed that both empyema and pneumonia admissions displayed 
seasonal trends, as all four harmonic terms were significant (p<0.001). The seasonal trend explained 56% 
and 62% of the variation in empyema and pneumonia admissions respectively in these initial models. 
However, examination of the residuals (Appendix C Figures 7.7 to 7.12) revealed significant 
autocorrelation in both models and evidence of non-linearity, with increasing dispersion of the residuals 
as the fitted values increased. These findings suggest that the estimates of the significance of the co-
efficients may be inaccurate.  
 
Monthly admissions for paediatric empyema were significantly related to monthly admissions for 
paediatric pneumonia – co-efficient 1.163, p<0.001 (Model M1, Table 2.10) and explained approximately 
85% of the variation in empyema admissions. On considering the model diagnostic plots, there was 
evidence of significant autocorrelation (Appendix C Figure 9.15) and clustering of the residuals 
suggesting that further explanatory or confounding variables may be missing from the model. 
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Figure 2.8 Rates of pneumonia and empyema admission over time from April 1997 to April 2006 in England. 
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Variable 
Co-efficient SE t-value p-value 
Residual 
SE 
Range of 
residuals 
DF 
total 
DF 
residual 
AIC R
2 
Model M0a: Empyema admissions ~ α + β1*sin(
       
  
) + β2*cos(
       
  
) + є 
(Intercept) 16.564 1.018 16.269 <0.001 
10.581 
-2.160 to 
4.010 
108 105 814.045 0.564 Time from study start*cos(
       
  
) 8.037 1.440 5.581 <0.001 
Time from study start*sin(
       
  
) -6.092 1.449 -4.231 <0.001 
Model M0b: Pneumonia admissions ~ α + β1*sin(
       
  
) + β2*cos(
       
  
) + є 
(Intercept) 476.0464 18.301 26.011 <0.001 
190.195 
-1.902 to 
3.871 
108 103 1420.727 0.622 Time from study start*cos(
       
  
) 128.6495 25.882 4.971 <0.001 
Time from study start*sin(
       
  
) -166.757 25.882 -6.443 <0.001 
Model M1: Log(Empyema admissions+1) ~ α + β1*Log(Pneumonia admissions+1) + є 
(Intercept) -4.395 0.428 -10.274 <0.001 
0.358 
-2.710 to 
2.184 
108 106 97.019 0.848 
Log(Pneumonia admissions + 1) 1.163 0.0705 16.498 <0.001 
Model M2: Log(Empyema admissions+1) ~ α + β1 *Log(Pneumonia admissions+1) + β2*Time + є 
(Intercept) -3.486 0.444 -7.85549 <0.001 
0.329 
-3.100 to 
1.965 
108 105 91.431 0.875 Log(Pneumonia admissions+1) 0.962 0.079 12.189 <0.001 
Time from study start (Month) 0.0056 0.0012 4.551 <0.001 
Variable Co-efficient SE t-value p-value Residual Range of DF DF AIC R
2 
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SE residuals total residual 
Model M3: Log(Empyema admissions+1) ~ α + β1*Log(Pneumonia admissions +1)+ β2*Time +β3*Population Size +є 
(Intercept) -9.456 8.972 -1.054 0.294 
0.300 
-2.941 to 
1.980 
108 102 109.320 0.900 
Log(Pneumonia admissions+1) 0.629 0.112 5.604 <0.001 
Time from study start (Month) 0.012 0.004 2.720 <0.001 
Population size (Individuals 0-14 
years) 
0.000001 
0.0000
01 
0.869 0.387 
Time from study start*cos(
       
  
) 0.274 0.057 4.833 <0.001 
Time from study start*sin(
       
  
) -0.070 0.053 -1.325 0.188 
Model M4: Log(Empyema admissions+1) ~ α + β1 *Log(Pneumonia admissions + 1) + β2 Time + β3*sin(
       
  
) + β4*cos(
       
  
) +є 
(Intercept) -1.678 0.628 -2.673 0.009 
0.300 
-3.028 to 
2.090 
108 103 82.18054 0.900 
Log(Pneumonia admissions+1) 0.0082 0.0013 6.316 <0.001 
Time from study start (Month) 0.640 0.111 5.737 <0.001 
Time from study start*cos(
       
  
)  0.260 0.054 4.792 <0.001 
Time from study start*sin(
       
  
) -0.071 0.052 -1.361 0.176 
Table 2.10 Summary of models of longitudinal trends, seasonality and relationship between pneumonia and empyema admissions in 
England. 
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Monthly admissions for paediatric empyema increased independent of monthly pneumonia admissions, 
population size and seasonal variation (Models M2, M3 and M4, Table 2.10) – co-efficient 0.640, 
p<0.001 (Model M4). Model M4 provided the best model fit with an R
2
 of 0.900 and a reduction in AIC 
from 91.431 to 82.181 when compared to M2. Both the trend related to pneumonia admissions and the 
trend over time remained significant, but only the cosine seasonal harmonic was significant (p<0.001). 
This suggested two significant findings. Firstly that there is evidence of a seasonal trends in empyema 
above that related to pneumonia and secondly that such trends were not perfectly captured by an exact 12 
month cycle. The standardised residuals when compared to fitted values no longer showed any evidence 
of non-linearity allowing confidence in the model validity (Appendix C Figure 9.20). Autocorrelation of 
marginal significance was present only at lags of 3 and 6 months suggesting that the estimates of the 
significance of the co-efficients were likely to be reliable (Appendix C Figure 9.21). There remained 
some overdispersion of the residuals (Appendix C Figure 9.19), but this was minimal. The model fit 
against the observed values is shown in Figure 2.9.   
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Figure 2.9 Log transformed monthly counts of paediatric empyema in England between 1997 and 
2006 against those predicted by model M4 (model R
2
:0.900). Black line indicates log(admissions+1) 
and red line indicates predicted values of model.
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Definition of periodicity and cyclicity within national empyema admissions 
 
Figure 2.10 shows the wavelet periodicity analysis of national empyema cases. Analysis of the power 
spectrum against period indicated that periods of between 8 (average power 1.82) and 12 months (average 
power 1.94) had the highest average power (Figure 2.11). As a result of a series of models (M5) 
constructed as: 
Log(Empye    d          )        *L  (P  u       d           )          
  *   (
       
 
)    *c  (
       
 
)    
where n varied between 8 and 12 at intervals of 0.25 then tested. Three models had significantly lower 
AIC and greater R
2 
than the other models tested – those at lags of 11.5, 11.75 and 12 months (Figure 
2.12). Of these only in the model with a lag at 11.75 months were all parameters significant. Regression 
co-efficients and model parameters for this model (M5) are shown in Table 2.11 and observed vs. fitted 
values in Figure 2.13. There was no evidence of non-linearity or autocorrelation in the residuals of model 
M5 indicating the model is valid (Appendix D Figures 7.22 – 7.25). The results of the model 
optimisation and significance of the seasonal harmonics within model M5 indicated that the strongest 
signal within empyema admissions was of a season/cycle of 11.75 months duration. This reflects the 
aggregate within the time series and it is possible that other periods were relevant, for example within 
Figure 2.11 there is an indication of an increase in power at 35 months. The figure of 11.75 months is 
close to 12 months and may reflect annual climatic variation with some inter-year variation in exact 
timing or may be a function of the unequal distribution of days within the months of the year.     
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Figure 2.10 Wavelet periodicity analysis of national empyema cases. Wavelet periodicity analysis of 
national empyema cases. The x-axis represents the time period of April 1997 to April 2006 as 
months from 1-108. Periodicity is on the left y axis and is the period of the time series i.e. when the 
series is decomposed into a frequency signal where the peaks of activity occur as measured by the 
power of the wavelet effect – these are plotted as a heat map with red indicating high power. The 
same plot is then represented adjacent without the heat map. Dark blue cone indicates area where 
estimates are not at risk of edge effects.  The effect is concentrated at a period of 11 months.  
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Figure 2.11 Average power vs. period for wavelet periodicity analysis of national empyema cases. 
Periods between 8 and 12 months had the highest average power.   
  
110 
 
 
Figure 2.12 AIC vs. R
2
 for sequential model with increasing seasonal components in order to 
estimate optimum model performance as balance between lowest AIC and greatest R2 post wavelet 
periodicity analysis.  
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Model M5 
Variable Co-
efficient SE t-value p-value 
(Intercept) -2.326 0.602 -3.868 0.0002 
Log(Pneumonia admissions+1) 0.0074 0.0013 5.658 <0.0001 
Time from study start (Month) 0.754 0.107 7.038 <0.001 
Time from study start*cos(
       
     
)  0.174 0.060 2.864 0.0051 
Time from study start*sin (
       
     
) 0.118 0.0420 2.816 0.0058 
Residual SE: 0.306; Range of residuals: -2.929 to 2.125 
DF: 108 total; 103 residual 
AIC: 87.015; R
2
: 0.894 
 
Table 2.11 Regression co-efficients and model parameters for model M5 assessing association between pneumonia admissions and season. 
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Figure 2.13 Log transformed monthly counts of paediatric empyema in England between 1997 and 
2006 against those predicted by model M5 (R
2
 0.894). Black line indicates log(observed admissions+1) 
and red line indicates predicted values of model 
 
The dynamic model (M6) did not improve on the ability of Model M5 to explain the observed trends and 
had a lower R
2
 0.781 (M5 R
2
 0.894) and a higher AIC 392 (M5 AIC 87) suggesting that non-stationarity 
of the seasonal effects was minimal.   
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Regional trends in pneumonia and empyema admissions 
The maximum and minimum monthly admissions by SHA for bacterial pneumonia, empyema and the 
correlation co-efficient between the conditions are shown in Table 2.12. Both conditions were 
significantly correlated in all SHA’s, but the degree of correlation varied between 0.414 – 0.753. There 
were significant differences in population adjusted admissions for pneumonia and empyema between 
SHAs (Table 2.13).   
Both conditions increased across all SHAs - co-efficient for pneumonia: 0.0105 (95% CI 0.00671 to 
0.0142), empyema: 0.0094 (95% CI 0.0068 to 0.00120) (Models S1a/b, Table 2.14). The rate of increase 
was greatest in the North East for both pneumonia and empyema admissions, whereas the lowest rate of 
increase in pneumonia admissions was in the East of England and the lowest rate of increase in empyema 
admissions was in the South Central SHA (Range for pneumonia – 0.0025 to 0.021, range for empyema – 
0.0049 to 0.017). Figure 2.14 compares the relative rate of increase (as derived from the random effects) 
across all SHAs for both conditions.  
Population adjusted pneumonia admissions were a significant predictor of empyema admissions at a 
regional level – co-efficient 0.380, p<0.001 (Models S2, Table 2.14). There was significant variation in 
both the magnitude of the increase and the rate of increase in population adjusted pneumonia and 
empyema admissions between SHAs – pneumonia model likelihood ratio 110.93, p<0.001, empyema 
model likelihood ratio 23.94, p<0.001 (Models S3a/b, Table 2.14 and Table 2.15). The distribution of 
residuals and residual correlation were normal for all models (Appendix E, Figures 2.57 – 2.68)  
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SHA Min & max pneumonia admission 
rate (million 0-14 yr olds/month) 
Min and max empyema admission rate 
(month/million 0-14 yr olds/month) 
Spearman’s correlation co-efficient 
North West SHA 
4.4 - 124.9 0 - 11.3 
0.732 (p<0.001) 
East Of England SHA 
10.9 - 112.6 0 - 8.9 
0.482 (p<0.001) 
West Midlands SHA 
15.3 - 159.4 0 - 14.2 
0.642 (p<0.001) 
Yorkshire SHA 
12.3 - 224.9 0 - 8.7 
0.602 (p<0.001) 
East Midlands SHA 
7.6 - 150.2 0 - 5.2 
0.414 (p<0.001) 
South East Coast SHA 
6.7 - 148.6 0 - 10.6 
0.446 (p<0.001) 
South Central SHA 
12.2 - 158.5 0 - 9.8 
0.447 (p<0.001) 
London SHA 
16.8 - 137.4 0 - 7.4 
0.535 (p<0.001) 
North East SHA 
0 - 249.5 0 - 24.6 
0.753 (p<0.001) 
South West SHA 
14.8 - 203.4 0 - 8.2 
0.491 (p<0.001) 
 
Table 2.12 Minimum and maximum monthly pneumonia and empyema hospitalisations by SHA and correlation between both measures 
by SHA.  
115 
 
Pneumonia model Empyema model 
SHA 
Co-
efficient 
SE t-value p-value 
Co-
efficient 
SE t-value p-value 
EE Reference Reference Reference Reference Reference Reference Reference Reference 
EM 0.053 0.082 0.644 0.519 -0.268 0.092 -2.923 0.004 
L 0.097 0.082 1.177 0.240 0.036 0.092 0.396 0.692 
NE -0.080 0.082 -0.979 0.328 0.268 0.092 2.917 0.004 
NW -0.290 0.082 -3.532 <0.001 -0.101 0.092 -1.101 0.271 
SC 0.070 0.082 0.847 0.397 -0.013 0.092 -0.146 0.884 
SEC -0.108 0.082 -1.319 0.187 -0.216 0.092 -2.351 0.019 
SW 0.310 0.082 3.780 <0.001 0.192 0.092 2.089 0.037 
Residual standard error: 0.603 on 1070 degrees of 
freedom 
Residual standard error: 0.674 on 1070 degrees 
of freedom 
Multiple R-squared: 0.0810, Adjusted R-squared: 
0.0733 
Multiple R-squared: 0.0512, Adjusted R-
squared: 0.043 
F-statistic: 10.48 on 9 and 1070 DF, p-value:<0.001 
F-statistic: 6.409 on 9 and 1070 DF, p-value: 
<0.001 
Range of residuals: -3.674 to 1.850 Range of residuals: -1.077 to 2.167 
 
Table 2.13 Population adjusted admissions for paediatric bacterial pneumonia and paediatric 
empyema varied significantly between SHAs between April 1997 and April 2006.  
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Variable Co-efficient SE DF t-value p-value 
Random 
effects 
St. dev 
of 
residuals 
random 
effects 
Range of 
residuals 
AIC 
Log- 
likelihoo
d
 
Model S1a: Log(Pop. adjusted pneumonia admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +є1|SHA 
(Intercept) 3.257 0.063 1067 51.388 <0.001 
1|SHA 0.414 
-6.727 to 
3.071 
1228.9
11 
-608.455 
Time from study start (Month) 0.010 0.00041 1067 24.478 <0.001 
Time from study start*cos(
       
     
) 0.412 0.018 1067 23.072 <0.001 
Time from study start*sin 
(
       
     
) 
-0.034 0.018 1067 -1.929 0.054 
Model S1b: Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +є1|SHA 
(Intercept) 0.310 0.060 1067 5.152 <0.001 
1|SHA 0.570 
-2.726 to 
3.284 
1907.7
65 
-947.883 
Time from study start (Month) 0.009 0.00056 1067 16.223 <0.001 
Time from study start*cos(
       
     
) 0.294 0.025 1067 11.956 <0.001 
Time from study start*sin 
(
       
     
) 
0.055 0.025 1067 2.244 0.025 
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Model S2: Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) + β4*Log(Pop. adjusted pneumonia 
admissions+1) + є1|SHA 
(Intercept) -0.927 0.142 1066 -6.524 0.000 
1|SHA 0.548 
-2.900 to 
2.991 
1827.8
86 
-906.943 
Time from study start (Month) 0.005 0.00067 1066 7.910 <0.001 
Log(Pop. adjusted pneumonia 
admissions +1) 
0.380 0.040 1066 9.486 <0.001 
Time from study start*cos(
       
     
) 0.137 0.029 1066 4.763 <0.001 
Time from study start*sin 
(
       
     
) 
0.068 0.024 1066 2.884 0.004 
Model S3a: Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) + β4*Log(Pop. adjusted pneumonia 
admissions+1) + є1|SHA 
(Intercept) 3.257 0.141 1067 23.038 <0.001 
Time | 
SHA 
Time: 
0.0059 
Residual: 
0.375 
-5.952 to 
3.726 
1046.9
63 
-515.481 
Time from study start (Month) 0.010 0.0019 1067 5.192 <0.001 
Time from study start*cos(
       
     
) 0.412 0.016 1067 25.502 <0.001 
Time from study start*sin 
(
       
     
) 
-0.034 0.016 1067 -2.132 0.033 
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Model S3b: Log(Pop. adjusted empyema admissions+1) ~ α + β1*Time + β2*sin(
       
     
) + β3*cos(
       
     
) +єTime|SHA 
(Intercept) 0.310 0.067 1067 4.616 <0.001 
Time | 
SHA 
Time: 
0.0038 
Residual: 
0.558 
 
-2.990 to 
3.214 
1882.6
01 
-933.300 
Time from study start 0.009 0.0013 1067 6.840 <0.001 
Time from study start*cos(
       
     
) 0.294 0.024 1067 12.200 <0.001 
Time from study start*sin 
(
       
     
) 
0.055 0.024 1067 2.290 0.022 
 
Table 2.14 Summary of models examining regional trends in pneumonia and empyema admissions in England between 1997 and 2006. 
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Model 
Random 
effects 
ANOVA DF AIC BIC 
Log- 
likelihood 
Likelihood 
Ratio 
p-value 
Pop. adjusted pneumonia admission models 
S1a 1 | SHA 
S1a vs. S3a 
6 1228.911 1258.797 -608.455 
185.948 <0.001 
S3a Time | SHA 8 1046.963 1086.811 -515.481 
Pop. adjusted empyema admission models 
S1b 1 | SHA 
S1b vs. S3b 
6 1907.765 1937.651 -947.883 
29.164 <0.001 
S3b Time | SHA 8 1882.601 1922.449 -933.300 
 
Table 2.15 Summary of ANOVA comparing models S1 and S3 to establish random effects structure. 
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Figure 2.14 Relative rates of increase in population adjusted admissions for bacterial pneumonia and empyema by SHA in England from 
1997- 2006.
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2.3.3 Relationship between pneumonia and empyema admissions 
 
The ratio of monthly empyema admissions to pneumonia admissions in England increased from a median 
of 2.04 % in 1997/1998 to 4.31 % in 2005/2006. The variation in this ratio over time is shown in Figure 
2.15 and demonstrates seasonality, as well as the increase over time. A summary of models R0-R2 is 
presented in Table 2.16.   
 
Figure 2.15 Proportion of empyema to pneumonia hospitalisations in England from September 
1997 to April 2006 with general additive smoother to highlight trend. 
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Variable 
Co-efficient SE t-value p-value 
Residual 
SE 
Range of 
residuals 
DF 
total 
DF 
residual 
AIC R
2 
Model R0: Ratio of empyema to pneumonia admissions ~ α + β1*sin(
       
  
) + β2*cos(
       
  
) + є 
(Intercept) 0.0326 0.0011 28.479 <0.001 
0.012 
-2.284 to 
2.895 
108 105 -611.985 0.361 Time from study start*cos(
       
  
) 0.00637 0.0016 3.937 <0.001 
Time from study start*sin 
(
       
  
) 
-0.00077 0.0016 -0.479 0.6331 
Model R1: Ratio of empyema to pneumonia admissions ~ α + β1 Time + є 
(Intercept) 0.021 0.00212 10.110 <0.001 
0.011 
-2.244 to 
2.874 
108 105 -634.386 0.509 
Time from study start (Month) 0.00021 0.00037 6.084 <0.001 
Model R2: Ratio of empyema to pneumonia admissions ~ α + β1 Time + β2*sin(
       
  
) + β3*cos(
       
  
) + є 
(Intercept) 0.022 0.0020 10.999 <0.001 
0.010 
-2.209 to 
2.666 
108 105 -626.467 0.988 
Time from study start (Month) 0.00020 0.00003 6.457 <0.001 
Time from study start*cos(
       
  
) 0.0062 0.0014 4.489 <0.001 
Time from study start*sin 
(
       
  
) 
-0.000021 0.0014 -0.015 0.9879 
 
Table 2.16 Summary of models of seasonality and longitudinal trends in the monthly ratio of empyema to pneumonia in England 1997 – 
2006.  
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There was partial evidence of significant seasonal variation in the monthly ratio of empyema to 
pneumonia admissions as only one harmonic term was significant (Model R0, Table 2.16). Furthermore, 
there was significant autocorrelation in the residuals (Appendix F, Figure 9.39) and some fanning in the 
distribution of the residuals around the fitted values of 0.03 to 0.035 (Appendix F, Figure 9.38) indicating 
that there was non-constant variance in the errors and suggesting that significant explanatory variables 
such as rates of pneumococcal transmission, were not included in the model.  
 
The increase in the monthly ratio of empyema to pneumonia admissions was both significant and 
independent of seasonal variation – co-efficient 0.00020, p<0.001 (Models R1 and R2, Table 2.16) 
equivalent to an increase of 0.021 % per month (95 % CI 0.014 to 0.027). There was no evidence of 
violation of independence or normality within the final, although some autocorrelation of the residuals 
remained (Appendix G, Figure 9.48). The model fit is shown in Figure 2.16.  
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Figure 2.16 Ratio of empyema to pneumonia admissions and estimates from model R2 against time 
from 1997 to 2006 (R
2
 0.616). Black line indicates ratio of admissions and red line indicates predicted 
values of model. 
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Definition of periodicity and cyclicity within ratio of empyema to pneumonia admissions 
 
The same approach as that used for the national empyema admissions data was used to define periodicity 
and cyclicity within the ratio of empyema admissions to pneumonia admissions over time. Wavelet 
periodicity analysis was used to define the presence of cyclicity and refine the GLS regression models 
with seasonal harmonics of varying lengths. Model optimisation was judged using the same three 
characteristics – model AIC, R2 and significance of terms.  
Figure 2.17 shows the wavelet periodicity analysis of the ratio over time. Analysis of the power spectrum 
against period indicated that periods of between 8 (average power 1.134) and 12 months (average power 
1.129 had the highest average power (Figure 2.18). Model R3 therefore included seasonal terms where n 
varied between 8 and 12 at intervals of 0.25. Four models had significantly lower AIC and greater R
2 
than 
the other models tested – those at lags of 11.25, 11.5, 11.75 and 12 months (Figure 2.19). Of these, only 
in the model with a lag at 11.75 months were all parameters significant.  
A second peak between 33 and 35 months was also present. Model R4 therefore included terms where q 
varies between 33 and 35 at intervals of 0.25. There was no significant difference between any of these 
models in terms of AIC or R
2
 (significance defined as difference in R
2 
of 1 and AIC of 3 - Figure 2.20) 
and in no model were either of the later seasonal harmonics terms significant. The probable explanation 
for this, as supported by Figure 2.18 and the fact that these models all provided a better model fit than R2 
(R
2 
increased by a minimum of 0.13), is that the period is greater than 36 months. However, as the data 
series is only 108 months long (equivalent of exactly three 36 month cycles) there were insufficient cycles 
within the data to establish the correct period.  
The final acceptable model R3 is summarised in Table 2.17 and the model diagnostics included in 
Appendix G, Figures 7.46-7.48. The residual distributions were acceptable, although there was some 
significant autocorrelation of the residuals at lags 6 and 12 months. The fitted vs. observed values are 
shown in Figure 2.21.     
The dynamic model (R5) did not improve on Model R3 and had a lower R
2
 0.120 (R3 R
2
 0. 0.616) and a 
higher 371.266 (R3 AIC -624.298) suggesting that non-stationarity of the seasonal effects was minimal.   
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Figure 2.17 Wavelet periodicity analysis of ratio of empyema to pneumonia. The x-axis represents 
the time period of April 1997 to April 2006 as months from 1-108. Periodicity is on the left y axis 
and is the period of the time series i.e. when the series is decomposed into a frequency signal where 
the peaks of activity occur as measured by the power of the wavelet effect – these are plotted as a 
heat map with red indicating high power. The same plot is then represented adjacent without the 
heat map. Dark blue cone indicates area where estimates are not at risk of edge effects.   
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Figure 2.18 Average power vs. period for wavelet periodicity analysis of national empyema cases. 
Periods between 8 and 12 months and 33 and 35 months had the highest average power.   
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Figure 2.19 AIC vs. R
2
 for sequential model with increasing seasonal components in order to 
estimate optimum model performance as balance between lowest AIC and greatest R2 post wavelet 
periodicity analysis of the ratio of empyema to pneumonia admissions with lags between 8 and 12 
months.  
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Figure 2.20 AIC vs. R
2
 for sequential model with increasing seasonal components in order to 
estimate optimum model performance as balance between lowest AIC and greatest R2 post wavelet 
periodicity analysis of the ratio of empyema to pneumonia admissions with lags between 33 and 35 
months. 
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Variable 
Co-efficient SE t-value p-value 
(Intercept) 0.021 0.002 10.761 0.000 
Time from study start (Month) 0.0002 0.00003 6.487 0.000 
Time from study start*cos(
       
     
)  0.0039 0.0014 2.826 0.006 
Time from study start*sin (
       
     
) 0.0042 0.0014 3.046 0.003 
Model structure: Ratio of empyema to pneumonia ~ α + β1* Time + β2*sin(
       
     
) + β3*cos(
       
     
) + є 
Residual SE: 0.010; Range of residuals: -2.125 to 2.646 
DF: 108 total; 104 residual 
AIC: -624.298; R
2
: 0.605 
 
Table 2.17 Summary of trends in the monthly ratio of empyema to pneumonia in England from 1997 to 2006 following optimisation of the 
estimates of the seasonal trends (model R3).
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Figure 2.21 Ratio of empyema to pneumonia admissions in England between 1997 and 2006 and 
estimates from model R3 against time (R
2
 0.605). Black line indicates ratio of admissions and red line 
indicates predicted values of model. 
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2.3.4 Relationship between empyema admissions, the rate of progression of pneumonia to empyema 
and S. pneumoniae, S. pyogenes, S. aureus and M. pneumoniae 
 
Trends in microbiological data 
Monthly isolations of S. pneumoniae, S. pyogenes, S. aureus and M. pneumoniae in England from April 
1997 to March 2006 from children aged between 0-14 years against time are shown in Figure 2.22, 
Figure 2.23, Figure 2.24 and Figure 2.25 respectively. The distribution S. pneumoniae displayed a clear 
seasonal variation. Seasonal variation was less obvious in the isolations of S. pyogenes and S. aureus. M. 
pneumoniae displayed cyclical peaks in activity of approximately 3-4 years frequency. S. pneumoniae, S. 
pyogenes and S. aureus all increased significantly from 1997 to 2006 (Table 2.18).  
 
Figure 2.22 Monthly isolations of S. pneumoniae in England from April 1997 to March 2006 from 
children aged between 0-14 years. 
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Figure 2.23 Monthly isolations of S. pyogenes in England from April 1997 to March 2006 from 
children aged between 0-14 years. 
 
 
Figure 2.24 Monthly isolations of S. aureus in England from April 1997 to March 2006 from 
children aged between 0-14 years. 
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Figure 2.25 Monthly isolations of M. pneumoniae in England from April 1997 to March 2006 from 
children aged between 0-14 years. 
 
Organism 
Median monthly count 
of isolations (Range) 
Total number of 
isolations between 
April 1997 – 2006 
Significant increase 
over time period? 
S. pneumoniae 73 (18-163) 7830 Yes (p=0.03) 
S. pyogenes 13 (2-34) 1527 Yes (p<0.001) 
S. aureus 106 (62-165) 11487 Yes (p<0.001) 
M. pneumoniae 55 (2-207) 7561 No (p=0.39) 
 
Table 2.18 Summary of isolations of S. pneumoniae, S. pyogenes, S. aureus and M. pneumoniae from 
children (0-14 years) in England from April 1997 to April 2006.    
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The relationship between national empyema admissions, the ratio of empyema to pneumonia 
admissions and isolations of S. pneumoniae, S. aureus, S. pyogenes and M. pneumoniae 
 
Model P0 investigated the relationship between national empyema admissions and isolations of S. 
pneumoniae, S. aureus, S. pyogenes and M. pneumonia. The results of model P0 incorporating the best 
performing correlation structure are summarised in Table 2.19 and for the parsimonious model in Table 
2.20. Model S0 investigated the relationship between the ratio of empyema to pneumonia admissions and 
isolations of the four pathogens and is summarised in Table 2.21 (full model) and Table 2.22 
(parsimonious model). The results of fitting progressive correlation structures to each model are 
summarised in Appendix H - Table 9.2 and Table 9.3. For both models (P0 and S0) application of an 
auto-regressive moving average model provided the lowest model AIC and value of Phi. For P0 values of 
p=3 and q=0 provided the best overall performance, although this was a compromise as using values of 
p=2 and q=2 produced a significantly lower AIC but a high value of Phi. For model S0 values of p=3 and 
q=0 provided the best compromise between AIC and Phi. 
Isolations of S. pneumoniae (co-efficient 0.606 95% CI 0.434 - 0.778) and S. pyogenes (co-efficient 0.236 
95% CI 0.0885 – 0.3835) were significant positive predictors of monthly admissions for empyema 
suggesting that both pathogens were important causes of paediatric empyema. The magnitude of the 
association was greater for S. pneumoniae. No relationship was seen with isolations of S. aureus and M. 
pneumoniae. Predicted values from model P0 and log-transformed monthly empyema admissions over 
time are shown in Figure 2.26. The model R
2
 was 0.692. However, examination of the model diagnostic 
plots indicated the persistence of serial dependence of the residuals and autocorrelation meaning that the 
validity of the estimates of the significance of the co-efficients cannot be relied upon (Figure 2.27, 
Figure 9.51, Figure 9.52 and Figure 9.53). 
Only isolations of S. pyogenes were a significant predictor of the monthly ratio of empyema to pneumonia 
admissions (co-efficient: 0.00582 95% CI 0.00151 – 0.0101). Both S. pneumoniae and M. pneumoniae 
were negatively associated with the ratio of empyema to pneumonia admissions suggesting that 
increasing isolations of either pathogen may be associated with a reduction in the relative rate of 
progression of pneumonia to empyema, although both co-efficients were non-significant. Model fit is 
shown in Figure 2.28. The model R
2 
was 0.387. The model diagnostic plots indicated that similar to 
model S0 significant autocorrelation remained, although it was to a lesser degree than in model P0 
(Figure 9.54, Figure 9.55 and Figure 9.56).  
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Variable 
Co-efficient SE t-value p-value 
(Intercept) -1.119 1.144 -0.978 0.330 
Log(Isolations of S. pneumoniae + 1) 0.619 0.093 6.665 <0.001 
Log(Isolations of S. pyogenes + 1) 0.231 0.0766 3.022 0.0032 
Log(Isolations of S. aureus + 1) 0.129 0.205 0.630 0.530 
Log(Isolations of M. pneumoniae + 1) -0.00815 0.0773 -0.105 0.916 
Model structure: Log(Empyema admissions+1) ~ α + β1* Log(Isolations of S. pneumoniae+1) + β2* Log(Isolations of S. 
pyogenes+1) + β3* Log(Isolations of S. aureus+1) + β4* Log(Isolations of M. pneumoniae+1) + є  
Correlation structure: ARMA, p=3, q=0 
Phi: 0.26, 0.39, 0.18  
Residual SE: 0.555; Range of residuals: -1.987 to 1.836 
DF: total 108; residual  
AIC: 125.57 ; R
2
: 0.710 
 
Table 2.19 Final model (P0) results relating empyema admissions to isolations of S. pneumoniae, S. pyogenes, S. aureus and M. 
pneumoniae from children (0-14 years) in England from April 1997 to April 2006.    
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Variable 
Co-efficient SE t-value p-value 
(Intercept) -0.508 0.414 -1.226 0.223 
Log(Isolations of S. pneumoniae + 1) 0.606 0.0878 6.901 <0.0001 
Log(Isolations of S. pyogenes + 1) 0.236 0.0753 3.132 0.0023 
Model structure: Log(Empyema admissions+1) ~ α + β1*Log(Isolations of S. pneumoniae+1) + β2* Log(Isolations of S. 
pyogenes+1) + є  
Correlation structure: ARMA, p=3, q=0 
Phi: 0.26, 0.39, 0.18 
Residual SE: 0.568; Range of residuals: -1.999 to 1.849 
DF: total 108; residual 105 
AIC: 117.32 ; R
2
: 0.692 
 
Table 2.20 Parsimonious model (P0) relating empyema admissions to isolations of S. pneumoniae and S. pyogenes from children (0-14 
years) in England from April 1997 to April 2006.  
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Figure 2.26 Monthly empyema admissions in England from April 1997-April 2006 (log transformed) 
and parsimonious model predicted monthly admissions using covariates of isolations of S. 
pneumoniae and S. pyogenes against time. Red line – model predictions, black line – empyema 
admissions. 
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Figure 2.27 Autocorrelation plot of the residuals from model P0 investigating the relationship 
between empyema admissions and isolations of the four pathogens. The plot highlights the presence 
of continuing significant auto-correlation. Dotted lines indicate significance cut-off.   
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Variable 
Co-efficient SE t-value p-value 
(Intercept) 0.0274 0.0317 0.865 0.389 
Log(Isolations of S. pneumoniae + 1) -0.00159 0.00297 -0.534 0.595 
Log(Isolations of S. pyogenes + 1) 0.00632 0.00239 2.650 0.0093 
Log(Isolations of S. aureus + 1) 0.00142 0.00589 0.241 0.810 
Log(Isolations of M. pneumoniae + 1) -0.00274 0.00202 -1.354 0.179 
Model structure: Ratio of empyema to pneumonia admissions ~ α + β1* Log(Isolations of S. pneumoniae+1) + β2* 
Log(Isolations of S. pyogenes+1) + β3* Log(Isolations of S. aureus+1) + β4* Log(Isolations of M. pneumoniae+1) + є 
Correlation structure: ARMA, p=2, q=0 
Phi: 0.24. 0.22 
Residual SE: 0.012 ; Range of residuals: -2.173 to 3.148 
DF: total 108; residual 103 
AIC: -604.65 ; R
2
: 0.407 
 
Table 2.21 Final model (S0) results relating ratio of empyema to pneumonia admissions to isolations of S. pneumoniae, S. pyogenes, S. 
aureus and M. pneumoniae from children (0-14 years) in England from April 1997 to April 2006.    
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Variable 
Co-efficient SE t-value p-value 
(Intercept) 0.0176 0.0060 2.917 0.0043 
Log(Isolations of S. pyogenes + 1) 0.00582 0.0022 2.654 0.0092 
Model structure: Ratio of empyema to pneumonia admissions ~ α + β1* Log(Isolations of S. pyogenes+1) + є 
Correlation structure: ARMA, p=2, q=0 
Phi: 0.24, 0.22 
Residual SE: 0.0120; Range of residuals: -2.184 to 3.219  
DF: total 108; residual 103 
AIC: -636.88; R
2
: 0.387 
 
Table 2.22 Parsimonious model (S0) relating ratio of empyema to pneumonia admissions to isolations of S. pneumoniae, S. pyogenes, S. 
aureus and M. pneumoniae from children (0-14 years) in England from April 1997 to April 2006.  
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Figure 2.28 Monthly ratio of empyema to pneumonia admissions in England from April 1997-April 
2006 and parsimonious model predicted monthly admissions using covariates of isolations of S. 
pyogenes against time. Red line – model predictions, black line – empyema admissions. 
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Figure 2.29 Autocorrelation plot of the residuals from model S0 investigating the relationship 
between the ratio between empyema and pneumonia admissions and isolations of the four 
pathogens. The plot highlights the presence of continuing significant auto-correlation. Dotted lines 
indicate cut-off for presences of significant autocorrelation. ACF – autocorrelation function (size of 
autocorrelation, lag indicates number of months between observations when correlation occurs)   
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The relationship between periodicity and cyclicity within national empyema admissions and the 
ratio of empyema to pneumonia admissions and periodicity within isolations of S. pneumoniae, S. 
aureus, S. pyogenes and M. pneumoniae  
 
Coherence analysis of empyema admissions and isolations of S. pneumoniae, S. pyogenes, S. aureus and 
M. pneumoniae in England are shown in Figures 2.30 – 2.33.  
 
There was evidence of strong in-phase coherence between empyema admissions and isolations of S. 
pneumoniae at a period between 8 and 14 months indicating that seasonal peaks in empyema were 
temporally correlated with pneumococcal activity (Figure 2.30).    
 
Figure 2.30 Coherence between paediatric empyema admissions and isolations of S. pneumoniae 
between April 1997 and April 2006 from the same age group in England. Periodicity is on the left y 
axis and is the period of the time series i.e. when the series is decomposed into a frequency signal 
where the peaks of activity co-incide as measured by the power of the wavelet coherence – these are 
plotted as a heat map with red indicating high power. The same plot is then represented adjacent 
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without the heat map. Arrows indicate phase difference, left to right equalling in phase relationship, 
right to left anti-phase relationship. Cone indicates area stable from edge effects.  
There was evidence of coherence between empyema admissions and isolations of S. pyogenes at a period 
between 8 and 14 months indicating that seasonal peaks in empyema were temporally correlated with 
seasonal S. pyogenes activity, although there was some dissonance of phase of uncertain significance 
(Figure 2.31). Furthermore there was evidence of coherence around 18 and 32 months suggesting that 
other peaks in activity of S. pyogenes were likely to be contributing to empyema admissions.   
   
 
Figure 2.31 Coherence between paediatric empyema admissions and isolations of S. pyogenes 
between April 1997 and April 2006 from the same age group in England. Periodicity is on the left y 
axis and is the period of the time series i.e. when the series is decomposed into a frequency signal 
where the peaks of activity co-incide as measured by the power of the wavelet coherence – these are 
plotted as a heat map with red indicating high power. The same plot is then represented adjacent 
without the heat map. Arrows indicate phase difference, left to right equalling in phase relationship, 
right to left anti-phase relationship. Cone indicates area stable from edge effects.  
 
There was only limited evidence of coherence between empyema admissions and isolations of S. aureus 
at a period of approximately 24 months, furthermore the coherence was not in-phase and the phase varied 
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between periods (Figure 2.32). Overall, S. aureus activity was not temporally correlated with empyema 
admissions.  
 
 
Figure 2.32 Coherence between paediatric empyema admissions and isolations of S. aureus between 
April 1997 and April 2006 from the same age group in England. Periodicity is on the left y axis and 
is the period of the time series i.e. when the series is decomposed into a frequency signal where the 
peaks of activity co-incide as measured by the power of the wavelet coherence – these are plotted as 
a heat map with red indicating high power. The same plot is then represented adjacent without the 
heat map. Arrows indicate phase difference, left to right equalling in phase relationship, right to 
left anti-phase relationship. Cone indicates area stable from edge effects.  
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Figure 2.33 Coherence between paediatric empyema admissions and isolations of M. pneumoniae 
between April 1997 and April 2006 from the same age group in England. Periodicity is on the left y 
axis and is the period of the time series i.e. when the series is decomposed into a frequency signal 
where the peaks of activity co-incide as measured by the power of the wavelet coherence – these are 
plotted as a heat map with red indicating high power. The same plot is then represented adjacent 
without the heat map. Arrows indicate phase difference, left to right equalling in phase relationship, 
right to left anti-phase relationship. Cone indicates area stable from edge effects.  
 
Similarly, there was only inconsistent evidence of coherence between empyema admissions and M. 
pneumoniae (Figure 2.33). The strongest signal was between six and 16 months, however there was 
substantial variation in this across the whole of the study period with it being strongest between 40 and 60 
months and in the final ten months. Furthermore there is significant variation in the phase of the 
coherence between different periods. In conclusion, this suggests an inconsistent association between 
mycoplasma activity and empyema.  
 
Coherency analyses of the monthly ratio of empyema to pneumonia admissions and isolations of S. 
pneumoniae, S. pyogenes, S. aureus and M. pneumoniae in England are shown in Figures 2.34-2.37. 
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There was evidence of strong in-phase coherence between the two time series at a period between 8 and 
14 months indicating that seasonal increases in the rate of progression from pneumonia to empyema are 
temporally correlated with pneumococcal activity (Figure 2.34).  
There was evidence of in-phase coherence between the monthly ratio of empyema to pneumonia 
admissions and isolations of S. pyogenes at a period between 8 and 14 months, although this effect is not 
as clear in the early part of the study period (first 20 months) (Figure 2.35). Furthermore there were 
periods of consistent coherence at 24 and 32 months, indicating that there is coherence between the rate of 
progression of pneumonia to empyema and S. pyogenes activity at periods greater than the traditional 
seasonal variation. This coherence suggests that the greater than 12 month periodicity seen in the rate of 
progression of pneumonia to empyema may be explained by S. pyogenes.  
There was only limited evidence of coherence between the monthly ratio of empyema to pneumonia 
admissions and isolations of S. aureus at a period around 24 months, furthermore the coherence was not 
in-phase and the phase varied between periods (Figure 2.36).  
There was no consistent evidence of coherence between the monthly ratio of empyema to pneumonia 
admissions and isolations of M. pneumoniae. There was also significant phase variation in the coherence 
that was present. Similar to the relationship between empyema admissions and isolations of M. 
pneumoniae, this suggests an inconsistent association between mycoplasma activity and empyema, which 
is unlikely to be causal. 
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Figure 2.34 Coherence between the monthly ratio of empyema to pneumonia admissions and 
isolations of S. pneumoniae between April 1997 and April 2006 from the same age group in England. 
Periodicity is on the left y axis and is the period of the time series i.e. when the series is decomposed 
into a frequency signal where the peaks of activity co-incide as measured by the power of the 
wavelet coherence – these are plotted as a heat map with red indicating high power. The same plot 
is then represented adjacent without the heat map. Arrows indicate phase difference, left to right 
equalling in phase relationship, right to left anti-phase relationship. Cone indicates area stable from 
edge effects.  
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Figure 2.35 Coherence between the monthly ratio of empyema to pneumonia admissions and 
isolations of S. pyogenes between April 1997 and April 2006 from the same age group in England. 
Periodicity is on the left y axis and is the period of the time series i.e. when the series is decomposed 
into a frequency signal where the peaks of activity co-incide as measured by the power of the 
wavelet coherence – these are plotted as a heat map with red indicating high power. The same plot 
is then represented adjacent without the heat map. Arrows indicate phase difference, left to right 
equalling in phase relationship, right to left anti-phase relationship. Cone indicates area stable from 
edge effects.  
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Figure 2.36 Coherence between the monthly ratio of empyema to pneumonia admissions and 
isolations of S. aureus between April 1997 and April 2006 from the same age group in England. 
Periodicity is on the left y axis and is the period of the time series i.e. when the series is decomposed 
into a frequency signal where the peaks of activity co-incide as measured by the power of the 
wavelet coherence – these are plotted as a heat map with red indicating high power. The same plot 
is then represented adjacent without the heat map. Arrows indicate phase difference, left to right 
equalling in phase relationship, right to left anti-phase relationship. Cone indicates area stable from 
edge effects.  
.  
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Figure 2.37 Coherence between the monthly ratio of empyema to pneumonia admissions and 
isolations of M. pneumoniae between April 1997 and April 2006 from the same age group in 
England. Periodicity is on the left y axis and is the period of the time series i.e. when the series is 
decomposed into a frequency signal where the peaks of activity co-incide as measured by the power 
of the wavelet coherence – these are plotted as a heat map with red indicating high power. The 
same plot is then represented adjacent without the heat map. Arrows indicate phase difference, left 
to right equalling in phase relationship, right to left anti-phase relationship. Cone indicates area 
stable from edge effects.  
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2.4 Discussion 
 
The increase in empyema over the study period was consistent at local, regional and national levels. In 
England, empyema increased by 287% (Incidence rate ratio: 3.87, 95% CI: 3.063-4.933) between 1997 
and 2005, equivalent to 253 extra cases per annum. Empyema admissions showed significant seasonal 
variation. 
 
Pneumonia and empyema admissions were significantly correlated and pneumonia admissions alone 
explained approximately 85% of the variation in empyema admissions suggesting that the bulk of the 
increase in empyema was explained by an increase in pneumonia. However, the median ratio of empyema 
to pneumonia admissions per month doubled over the study period from 2.04 % to 4.13 % and this trend 
was both significant and independent of seasonal changes implying that while there was an increase in 
base-line levels of pneumonia, the rate of progression from pneumonia to empyema substantially 
increased. Furthermore, the rate of progression varied seasonally (11.75 months) and there was evidence 
of a greater than 36 month cycle. 
 
Admission rates for pneumonia and empyema increased across all ten of the SHAs in England, although 
the relative rate of increase varied significantly between each SHA. Also, there was marked variation in 
the correlation between the two conditions between SHAs, suggesting that processes determining the rate 
of progression from pneumonia to empyema vary regionally.   
 
Isolations of S. pneumoniae and S. pyogenes were positively associated with numbers of admissions to 
hospital with empyema in England and both increased between 1997 and 2006. Isolations of S. pyogenes 
were also a significant predictor of the monthly ratio of pneumonia to empyema admissions between 1997 
and 2006. Isolations of S. aureus and M. pneumoniae were not significantly associated with either 
empyema admissions or the ratio of empyema to pneumonia admissions.   
 
Strong coherence was seen between pneumococcal isolations and both empyema admissions and the rate 
of progression between pneumonia and empyema on a seasonal basis, strongly suggesting that the 
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observed increase in empyema has been pneumococcal in origin. Similarly there was clear coherence 
between S. pyogenes isolations and both between the monthly ratio of empyema to pneumonia admissions. 
Interestingly this was at a traditional seasonal periodicity but also at higher periodicities which overlapped 
with the cyclicity seen in empyema admissions and the rate of progression between the two conditions. 
This suggests that cyclical changes in S. pyogenes activity increase both the number of empyema 
admissions but also increase the rate of progression of pneumonia to empyema. Neither S. aureus nor M. 
pneumoniae activity appeared consistent with empyema admissions or the rate of progression from 
pneumonia to empyema. 
 
2.4.1 Strengths and limitations 
 
This analysis has several significant strengths. The consistency of results across local, regional and 
national populations and between different methods of data collection allows confidence that the trends 
described are robust. Furthermore, by using a framework for addressing and investigating seasonality the 
estimates of the change in incidence of empyema are of greater precision than have been previously 
derived. This analysis also represents the first attempt to examine the change in incidence of empyema in 
relation to different pathogens at national level. The data are comprehensive, at a sufficient scale and 
cover a long enough time period to allow accurate judgement of trends in relation to the four pathogens 
and empyema. Furthermore, the results of the analysis of the relationship between empyema and the 
different pathogens are consistent across two different analytical processes (GLS multi-variate time series 
regression and wavelet coherence analysis). 
 
However, there are several limitations both within the data and the modelling framework. There have 
been legitimate concerns over the appropriateness of using HES data for time series analyses due to 
possible changes in the data collection systems used in clinical coding between institutions and within the 
same institution over time that could lead to bias. However, HES data are widely used for research into 
many aspects of healthcare including the burden of specific illnesses (Melegaro et al., 2006). The upward 
trend in admissions for both conditions is consistent through the time period both nationally and 
regionally suggesting that the increase in admissions for both diseases is genuine and not a function of 
unrecognised changes in the systematic recording of data.  
155 
 
Total childhood hospital admissions in England increased from 1996/7 to 2006/7 by 18%. This may be a 
consequence of the increased use of Accident and Emergency departments as primary care units. As such, 
it is possible that some of the increase in pneumonia admissions may not reflect a true increase in cases of 
disease (Callery et al., 2010). However, due to the severity of empyema, cases will almost invariably 
require hospital admission, and it is therefore much less likely to be affected by these variations.  
 
The final models for the NE data series and the ratio of empyema had R
2
 of approximately 0.6 and while 
this is acceptable for biological systems it suggests significant explanatory variables may not be present 
within the models. A second limitation relates to the periodicity analysis. While there was some evidence 
of a second period in the time series of the ratio of empyema to pneumonia admissions, none of the 
models evaluated contained significant terms for that period. As the available data only allow up to three 
cycles of a maximum of 36 months, it was not possible to establish whether the true period was greater 
than this or whether this represents an epiphenomenon. In addition, the use of months as the unit of the 
time series introduces inaccuracy to the analysis as all months are not the same length and the finding of 
an 11.75 month period may reflect this or may be as a consequence of year to year variations in the timing 
of seasons.   
 
There were several limitations to the analysis of the microbiological data that require more detailed 
discussion. All the microbiological data were obtained through the HPA national surveillance system. 
Changes in surveillance data may not result solely from changes in the incidence of individual pathogens 
but instead from changes in case ascertainment. Factors such as changes in clinical practice e.g. reduced 
levels of sampling of blood cultures, or increased reporting can confound surveillance data (Flasche et al., 
2011). Flasche and colleagues (2011) analysed trends in pneumococcal bacteraemia and two control 
conditions before and after the introduction of universal pneumococcal vaccination. They found evidence 
of such changes influencing the estimated incidence of non-pyogenic streptococcal infections in the under 
5’s in the UK at the rate of approximately 9% increase per year. It would reasonable to consider this as a 
possibility in the surveillance data presented here. However, this is more of a concern when quantifying 
absolute changes in incidence rather than when looking at temporal associations.    
 
The presence of autocorrelation in the models P0 and S0 leads to uncertainty as to the accuracy of the 
estimates of the significance of the co-efficients (Zuur et al., 2009). While the attempts to fit a suitable 
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autocorrelative function were ultimately unsuccessful in modelling all the autocorrelation present, this 
approach should have ameliorated the impact as much as possible. The serial dependence may also have 
inflated the estimate of the model R
2
.  
 
The presence of significant autocorrelation is to be expected when modelling counts of infectious disease. 
The driver of serial dependence is infectious transmission within the population, which is largely 
unobserved as it occurs through asymptomatic carriers (Cooper and Lipsitch, 2004; Paul et al., 2008). All 
four organisms can be are spread in this manner. The dependency within the residuals is therefore to some 
degree determined by the rate of transmission in the asymptomatic population. More complex modelling 
approaches are being developed which better account for these processes such as the use of hidden 
Markov models (Cooper and Lipsitch, 2004).     
 
A further limitation of the approach used is the assumption that there is no interaction between the four 
pathogens modelled. For example, S. pneumoniae and S. aureus occupy a similar ecological niche within 
the nasopharynx and are recognised to compete actively  with each other. How this interaction manifests 
on a population level is uncertain. Future analyses should account for and investigate interactions between 
pathogens.  
 
Finally, the use of isolations data in preference to pathogen specific coding data is both a strength and a 
limitation of this analysis. The strength comes from avoiding the limitations of pathogen recording in 
coding data which have been described previously. A major limitation comes from the fact that isolations 
represent purely culture positive disease. There are recognised differences in the rate of culture positivity 
between pneumococcal serotypes and changes in pneumococcal serotypes have been implicated in the 
observed increase in empyema in a number of settings. An increase in pneumococcal disease due to 
serotypes that have lower rates of culture positivity may result in increases in empyema but not in 
isolations because these cases would not be recognised. This would impact on the accuracy of the 
relationship observed between isolations of pneumococcal disease and empyema.            
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2.4.2 Findings related to other studies 
 
The findings of studies that have explored the hypothesis that an increase in admissions for paediatric 
pneumonia is responsible for a proportionate increase in admissions for empyema have been 
contradictory. One Scottish study examined national admission rates for paediatric pneumonia and 
empyema from 1980 to 2005. These authors observed an increase in the incidence of paediatric 
pneumonia and empyema over the study period, but concluded that the increase in empyema was a more 
recent phenomenon, predominantly occurring from 1998 onwards, uncorrelated with the gradual rise in 
cases of pneumonia (Roxburgh et al., 2008). A more recent study from Spain examined the incidence of 
probable bacterial pneumonia and empyema from 1995 to 2005 and concluded that the incidence of 
probable bacterial paediatric pneumonia had also increased but, that the complication rate (including 
empyema) had remained constant at around 16% (Deiros Bronte et al., 2006). An Australian study 
reported a trend towards a rise in incidence of pneumonia that was not statistically significant (p=0.07, 
R
2
=0.29) and a statistically significant rise in empyema from 4 to 9.6 admissions per million children (0-
16 yrs) (p<0.05, R
2
=0.51) over the time period 1993/4 – 2004/5. These authors also reported an overall 
increase in the percentage of empyema as a proportion of pneumonia of 0·27% to 0·7% (Strachan and 
Jaffé, 2009). Following the introduction of the 7 valent pneumococcal vaccine (PCV-7) in the USA 
pneumonia hospitalisations complicated by empyema increased 2.01-fold from 3.5 cases per 100,000 
children in 1996–1998 to 7.0 cases per 100,000 children in 2005–2007, while total hospitalisations for 
pneumonia fell (Grijalva et al., 2010). Two further large scale hospital coding studies have further 
confirmed this trend (Lee et al., 2010; Li and Tancredi, 2010).  
 
In this analysis, variation in pneumonia explained 85% of the variation in empyema admissions, yet the 
proportion of empyema to pneumonia admissions per month doubled over the study period from 2.04 % 
to 4.13 %. These results suggest a more complex process than simply an increase in pneumonia being 
solely responsible for the increase in empyema. Direct comparisons with historical studies are challenging 
because of the variation in both case definition and methodology in previous studies. Strachan and Jaffé 
(2009) observed a change in the proportion of pneumonia to empyema of similar magnitude to this 
analysis, as did the coding studies from the USA (Grijalva et al., 2010; Lee et al., 2010; Li and Tancredi, 
2010), although there was significant variation in the baseline rate in their study.    
 
In this analysis pneumococcal and group A streptococcal infections were temporally associated with 
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empyema hospitalisations and increases in the rate of progression of empyema to pneumonia. While no 
previous studies have investigated the cause of the increase in incidence of empyema by establishing 
temporal associations between isolations of different pathogens and empyema on a national scale, one 
study has reported changes in the incidence of empyema due to different pathogens using coding data. 
Grijvala et al (2011) examined changes in the incidence of empyema across all age groups in the USA 
using a nationally representative sample of hospital coding data. They observed an increase in empyema 
in both adults and children between 1996 and 2008. In children the magnitude of the rise was 1.9 fold 
(test for trend, p<0.001). In contrast to the findings above, pneumococcal empyema rates remained stable 
among children (rate ratio 1.1, 95% CI 0.7 to 1.7, p value for test for trend p=0.093) whereas the rate of 
streptococcal (non-pneumococcal) empyema increased 2.7 fold (95% CI 1.5 – 5), staphylococcal 
empyema 2.4 fold (1.4 – 4.1) and empyema without a detected organism 2.5 fold (1.7 – 3.5). The overall 
organism detection rate within the analysis was 38%.  
 
Culture-negative empyema (empyema initially without a detected organism) in children in the UK has 
been shown to be predominantly pneumococcal on molecular testing (Eltringham et al., 2003). It is 
impossible to be certain of the extent of microbiological testing used in the cohort described by Grijvala 
et al as methods may vary significantly between institutions. However, molecular detection techniques 
were not routine during that time and it is therefore a fair assumption that the majority used only standard 
culture. It is quite possible that the increase seen in empyema without a detected organism represented 
changes in pneumococcal empyema, concurring with the temporal correlation between empyema and 
pneumococcal isolations seen in this analysis of UK data.  
 
The increase in incidence of streptococcal empyema reported by Grijvala et al supports the finding of an 
association with isolations of S. pyogenes. However, Grijvala et al did not differentiate between different 
streptococci, as these are not distinguished in coding data based on ICD-9. In adults, Streptococcus mitis 
spp is the commonest bacterial cause of empyema in the UK (Maskell et al., 2005). It appears to be rare 
in children but it is not unrecognised. It is therefore unlikely but possible that the changes seen in the 
USA may be a reflection of changes in this group of organisms. This further highlights the difficulties in 
using coding data to measure longitudinal trends in pathogen specific diseases.  
    
The finding of coherence between the rate of progression between pneumonia and empyema and 
isolations of S. pyogenes at non-seasonal frequencies could provide an explanation for the epidemic like 
rises in the incidence of empyema observed in 1999 and 2005 in the USA (Grijalva et al., 2010). 
Examination of the organism specific data presented by Grijalva et al in 2011 would support this theory 
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for 1999 but not for 2005. S. pyogenes frequently displays epidemic spread and may have a significantly 
greater potential for complicating pneumonia in children than pneumococcal infection (Musser et al., 
1995).         
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2.4.3 Implications and future research 
 
Eighty five per cent of the variation in empyema can be explained by changes in pneumonia which, in 
conjunction with the significant level of correlation of 0.86 (p<0.001) between the two conditions, 
strongly suggests that the increase in empyema admissions has been driven by an increase in underlying 
bacterial pneumonia. However, given the significant regional variation in the increase in the rate of 
empyema; the significant increase in the ratio of empyema to pneumonia admissions per month and the 
significance of a secular increasing trend separate from that predicted by pneumonia suggest other 
processes are likely to be relevant to the observed increase in empyema. Hypotheses proposed elsewhere 
for the increase in incidence include a change in circulating pneumococcal serotypes or increasing 
pathogen virulence (Gupta and Crowley, 2006; Wexler et al., 2006); a change in causative organism 
(Schultz et al., 2004); changes in community antibiotic prescribing (Strachan and Jaffé, 2009) and 
increasing usage of Ibuprofen (François et al., 2010). All are possible explanations and such processes are 
very likely to be multi-factorial. Changes in antibiotic prescribing almost certainly reflect regional 
variation and it is plausible that reduction in antibiotic prescribing for respiratory tract infections in 
primary care may increase the risk of progression from pneumonia to empyema. Furthermore antibiotic 
prescribing for lower respiratory tract infections in children in the UK fell by 56% from 1996 to 2006 
(Thompson et al., 2009). Similarly Ibuprofen may modify the rate of progression from pneumonia to 
empyema and authors in France have demonstrated correlation between an increase in total sales of 
Ibuprofen and the increase in incidence of empyema (François et al., 2010). However, changes in 
pathogen are the most likely explanation. Prescribing habits are highly variable between different 
countries and increases in empyema have been seen in countries described as “low antibiotic users” e.g. 
the UK and “heavy antibiotic users” e.g. Spain and the USA (Gupta and Crowley, 2006; Obando et al., 
2008; Reinert et al., 2010). Furthermore, the contemporaneity with which the increase in incidence of 
empyema occurred across different countries with 90% of reports occurring within the same 5 year band 
coupled to the variations in prescribing between countries make this less plausible. In contrast, the 
contemporaneity favours the hypothesis of pathogen related changes with global spread. Finally, the 
presence of two separate cycles within the rate of progression between empyema and pneumonia is 
suggestive of a pathogen related explanation as respiratory pathogens show cyclical epidemic like 
behaviour e.g. Streptococcus pyogenes or Mycoplasma pneumoniae (Colman et al., 1993; Rasmussen JN, 
2010). 
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The increase in incidence of empyema seen between 1997 and 2006 in England was associated with 
pneumococcal and streptococcal (S. pyogenes) disease with the biggest association seen with 
pneumococcal disease. Only S. pyogenes was associated with an increase in the rate of progression 
between pneumonia and empyema, whereas S. pneumoniae and M. pneumoniae were negatively 
associated with the rate of progression. This combination suggests that the bulk of empyema was caused 
by pneumococcal infection. A smaller proportion was associated with S. pyogenes but S. pyogenes had a 
greater tendency towards causing pneumonia complicated by empyema. 
 
S. pyogenes has not been previously implicated in the change in incidence of empyema elsewhere despite 
historically being a significant pathogen in empyema. Different strains of S. pyogenes are recognised as 
characterised by M-typing and these demonstrate somewhat distinct pathogenic characteristics,. 
Streptococcal M types interact in a similar manner to pneumococcal capsular serotypes, and epidemic 
spread of individual types is recognised. Future research should attempt to define the M-types associated 
with childhood empyema and chart longitudinal changes in the incidence of different M-types in 
childhood empyema to better understand the processes that drive the observed fluctuations in incidence. 
Recognition of the role of S. pyogenes also has significant clinical implications. The clinical profile of 
streptococcal empyema is different to that of pneumococcal disease and may be more severe. For example, 
Grijalva et al (2011) reported a higher in-hospital case fatality ratio in streptococcal empyema than 
pneumococcal empyema (0.6 (95% CI 0.2 – 1) vs. 0.8 (0 – 1.5).     
 
S. pneumoniae was temporally associated with empyema hospitalisations in a predictable seasonal pattern 
strongly suggesting that seasonality in empyema is related to seasonality in pneumococcal disease. This 
relationship also extends to changes in the relative rate of progression of pneumonia to empyema. S. 
pyogenes is an important driver of empyema and behaves in both a seasonal and epidemic manner in the 
short time series reported here. Future work should seek to better define the possible relationships 
between the two organisms and seek to understand the underlying mechanisms that drive both seasonal 
and epidemic behaviour. 
 
There was no observable relationship between empyema hospitalisations and S. aureus isolations, despite 
the fact that S. aureus has been highlighted as a frequent cause of empyema in a number of recent cases 
series. The reasons for this are likely to be multi-factorial and may reflect differences in methods of 
detection e.g. blood culture rate, antibiotic prescribing patterns or antibiotic resistance all of which may 
impact on rates of detection. 
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Future research into the epidemiology of paediatric empyema at a population scale should take advantage 
of advances in the science of infectious disease modelling, incorporate methods of adjusting for the 
unobserved transmission of the relevant pathogens and analyse changes both in time and space (Paul et al., 
2008).  
    
A major implication of the increase in incidence is the impact on limited health resources. Several 
estimates of the cost of treatment of empyema have been published. The most representative for the UK is 
that of Sonnappa et al (2006) which reported costs associated with medical treatment with fibrinolytics 
and VATS from a UK centre. Using the increase in annual incidence estimated by the national HES data 
between 1997 and 2005 which predicts an additional 253 cases per annum, the associated costs would be 
an extra £1,103,437 per year (fibrinolysis) and £1,494,544 (VATS). To put this in context, the annual 
budget from the Department of Health for the management of all non-HIV infectious disease in both 
adults and children in England was £800 million in 2006 (the first year figures were produced) 
('Programme budgeting tools and data,' 2011). Assuming this resource is divided equally according to 
population demographics (proportion of children in population in 2006 17.7%) this provides an annual 
budget for the care of children of approximately £136 million. The increase in empyema would account 
for between 0.75 and 1.1% of this depending on treatment methodology which is clearly a substantial sum.  
These finding have significant implications for patients. Longer term outcomes from empyema are largely 
unknown, but assumed to be good following treatment (Balfour-Lynn et al., 2005). The long-term 
outcome data that is available is limited both in scale and by methodological issues. The commonest 
outcome reported is lung spirometry in the year following the acute episode, however the majority of 
empyema cases occur in the under – five age group and children below the age of six years often lack the 
co-ordination required to perform spirometry measurements in a repeatable manner. The consequence of 
this is that the majority of children contributing follow-up data were older than average when they 
contracted the illness and may not be representative of the whole population of interest. The majority of 
published data show no reduction in lung function compared to that predicted by age, sex and height in 
children who have had empyema and no differences between different treatment groups (McLaughlin et 
al., 1984; Redding et al., 1990; Sarihan et al., 1998; Kohn et al., 2002; Mew et al., 2009). The total 
number of patients reported and the associated methodological problems, such as the absence of pre-
morbid data or population level comparisons mean that this should be interpreted with caution.  
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Eastham et al (2008) suggested that children who have had serious lung infections may be at risk of 
chronic respiratory symptoms, such as chronic cough, however the longer term implications of this 
remain unclear. There has been increasing interest in childhood respiratory infections as the antecedents 
of chronic adult respiratory diseases, in particular chronic obstructive pulmonary disease (COPD). While 
there is no specific data on a linkage with childhood empyema, this may well be of importance given the 
dramatic rise in incidence of empyema.    
     
2.5 Conclusions 
 
The incidence of childhood empyema has increased locally, nationally and regionally. In England, cases 
increased by 287% from 1997 to 2006. Evidence from national data suggests that the rise in empyema 
was driven to a significant degree by a contemporaneous increase in pneumonia hospitalisations. The 
proportion of empyema to pneumonia hospitalisations doubled from a median of 2.04 % to 4.13% over 
the same time period. There is evidence that the relationship between pneumonia and empyema is 
complex as the rate of increase in both conditions varied markedly at a regional level and because of the 
presence of periods of strong concordance between pneumonia and empyema. This suggests that other 
factors such as variation in certain pathogens require further investigation to understand the mechanisms 
underpinning the increase in empyema. The relevance of variation in pathogens was supported by the 
positive association of isolations of S. pneumoniae and S. pyogenes with numbers of admissions to 
hospital with empyema. Seasonal variation in empyema was associated with both S. pneumoniae and S. 
pyogenes. S. pyogenes was associated with periodic changes in empyema, suggestive of epidemics of the 
condition. Further research is required to establish whether these associations are seen in other 
populations and over different time periods.  
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3 Spatial epidemiology of paediatric pneumonia and empyema 
 
  
165 
 
Declaration 
A Blain implemented the Bayesian spatial models used in this chapter and produced the observed and 
predicted maps. All study design, analysis and interpretation were my own work.    
3.1 Introduction 
3.1.1 Introduction to spatial epidemiology 
 
Spatial epidemiology is the description and analysis of geographic variations in disease with respect to 
demographic, environmental, behavioural, socioeconomic, genetic, and infectious risk factors (Elliott and 
Wartenberg, 2004). In particular, investigating spatial epidemiology can provide insights into the 
pathogenesis of disease (Mayer, 1983). This relies on the general principle that: “The demonstration of 
association of a disease with place implies either that the inhabitants of the particular place possess 
characteristics of etiologic importance in the disease and different from those of the inhabitants of other 
places, or that etiologic factors are present in the biologic, chemical and physical, or social environments 
of the people inhabiting the affected places, or that both these types of explanations apply.”(Mayer, 1983)  
 
The origins of spatial epidemiology stem from the disease mapping studies of the 1800s (Elliott and 
Wartenberg, 2004). In these early studies direct mapping of cases elucidated the likely causes and 
mechanisms of transmission of a range of infectious diseases (Elliott and Wartenberg, 2004). Of these, 
perhaps the most famous is John Snow's mapping of cholera cases in Soho, London in 1854 and 
subsequent identification of the Broad Street pump as the epicentre of the outbreak (Snow, 2008). 
Through the 20
th
 century, spatial epidemiology has led to a wide range of insights into pathogenesis 
which have been of major importance to public health. Keys study of seven countries leading to the 
recognition of the importance of dietary fat in coronary heart disease (Epstein, 1996), whilst Cliff and 
Smallman-Raynor's identification of an association between AIDS cases and trucking routes in Uganda 
helped to elucidate the patterns of transmission of HIV (Cliff and Smallman-Raynor, 1992). Spatial 
epidemiology has also provided clues to infectious aetiology in conditions not thought to be infectious e.g. 
the recognition of the association between Hepatitis B infection and hepatocellular carcinoma (Elliott and 
Wartenberg, 2004). As well as identifying factors relevant to pathogenesis, spatial analyses have also 
been used to identify areas of increased risk which may benefit from targeted public health intervention 
e.g. Law et al's spatial analysis of sexually transmitted infections (STI) in North Carolina which identified 
166 
 
heterogeneity in risk of STI but overlap between areas of risk of different types of infection, thereby 
identifying areas that may benefit most from targeted public health intervention (Law et al., 2004).  
 
3.1.2 Rationale for analysis of spatial epidemiology of pneumonia and empyema 
 
Pneumonia is the leading cause of childhood mortality in children under 5 years, with greater than 2 
million deaths a year occurring worldwide (Wardlaw et al., 2006).
 
Although the greatest burden of the 
disease occurs in developing and newly industrialised countries (151 million of an estimated total of 156 
million cases) it remains a serious cause of child morbidity and mortality in the developed world (Rudan 
et al., 2008b). Empyema is the presence of infection within the pleural membranes that overlie the lungs 
and most often arises as a complication of pneumonia in the underlying lung. It appears to have changed 
over the last 20 years, with a sharp rise in incidence reported across Western Europe, North America and 
the Far East (Gupta and Crowley, 2006; Grijalva et al., 2010). In the UK, admissions increased from <10 
per million in 1998 to 37 per million in 2005 (Roxburgh et al, 2008).  
 
As described in more detail below, there is a paucity of information relating to the spatial epidemiology of 
either disease in childhood. The epidemiology of empyema appears to have changed and is not yet well-
characterised. Characterising the spatial epidemiology of empyema is therefore an important step in 
understanding empyema and identifying factors that have led to the change in epidemiology. Furthermore, 
in order to understand the epidemiology of empyema it is necessary to explore and understand the 
epidemiology of pneumonia given the interconnectedness of the two conditions.  
      
There is evidence from the limited previous spatial studies available and from individual level studies that 
deprivation, ethnicity, migration and healthcare factors may be relevant factors in the spatial 
epidemiology of both diseases (Crighton et al., 2007; Kazembe and Namangale, 2007; Charland et al., 
2011). By extending the analysis to beyond the establishment of the presence of spatial variation in both 
conditions and testing the influence of these as spatial co-variates, their relevance to the spatial 
epidemiology of both conditions can be evaluated. Their relevance in either condition will then provide 
insights into the potential mechanisms underpinning the spatial epidemiology of both conditions.        
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3.1.3 Current evidence in spatial epidemiology of pneumonia and empyema 
 
Two studies have reported significant spatial variation in pneumonia (Crighton et al., 2007; Kazembe and 
Namangale, 2007). Crighton et al (2007) examined risk of hospitalisation from influenza and pneumonia 
across the Canadian state of Ontario, using spatial and non-spatial regression methods and identified 
significant spatial variation. Furthermore within the child population, low education score for district and 
proportion of population of Aboriginal race were significantly associated with increased rates of 
hospitalisation. Kazembe et al (2007) examined risk of pneumonia, fever and diarrhoea using data from a 
self-reported health questionnaire in children in Malawi and identified significant spatial variation in 
pneumonia with increased risk in rural areas. They also identified some clustering in the South of the 
country where deprivation rates are highest, but the authors were unable to include HIV data or use other 
specific spatial variables which might have further identified putative causative factors. 
 
Published data on spatial variation in empyema in children is more limited, with only one available study 
which found no evidence of spatial clustering of cases between 1988 and 1994 in Ohio, USA (Hardie et 
al., 1996).  
 
3.1.4 Possible risk factors in the spatial epidemiology of pneumonia and empyema  
 
A link between socio-economic deprivation and risk of pneumonia in children has been previously 
reported in a number of individual level studies, (Hawker et al., 2003; Clark et al., 2007a; Flory et al., 
2009) but the results of spatial studies have been mixed (Crighton et al., 2007; Charland et al., 2011). For 
example, Charland et al (2011) in a spatial study of clinic attendance with influenza and pneumonia 
observed significantly higher rates in areas of greatest material deprivation but could not establish a linear 
relationship between risk and the level of deprivation. They found no significant link with social 
deprivation. The influence on socio-economic deprivation on empyema is less certain. It has been 
associated with increasing severity in pneumonia but a specific link to empyema has not been reported 
(Clark et al., 2007a). Given the close relationship of the two conditions, it could be hypothesised that 
similar associations in empyema may exist.  
 
Ethnicity was a predictor of spatial variation in risk of pneumonia and influenza hospitalisations in 
children in Ontario and a significant determinant of childhood asthma admissions in the UK with 
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increased in risk in ethnic minority groups in both settings (Gilthorpe et al., 1998; Crighton et al., 2007). 
The relevance in empyema is unknown. Increased population mixing is well known to potentiate the 
transmission of infectious diseases, therefore it could be hypothesised that migration levels may be 
relevant in explaining any spatial variation in either pneumonia or empyema (Wilson, 1995). 
 
Health-care related factors may also be risk factors for spatial variation in pneumonia and empyema. For 
example, the ratio of population to physicians has been found to be predictive of mortality in childhood 
lower respiratory tract infections in Bangladesh, although a similar measure was not significantly 
associated with pneumonia hospitalisations in Canada.(Ali et al., 2001; Crighton et al., 2007) The 
distance to treatment centre was also a significant predictor of mortality in Bangladesh, highlighting that 
beyond availability, accessibility may also be relevant in determining spatial variation (Ali et al., 2001).    
    
3.1.5 Challenges of area based analysis in spatial epidemiology 
 
Beale et al. (2008) argue that “because of data limitations, most spatial epidemiological studies use data 
aggregated at the area level … and therefore require that spatial epidemiology analyses be carried out at 
an ecological level”. However, this approach can be associated with significant challenges. Distribution 
and classification issues in particular can lead to significant bias and error in estimates of association but 
are intrinsic to area level data. For example, boundaries used to divide areas such as postcodes or SHAs 
are often primarily administrative and may change over time, potentially causing significant errors of 
attribution within spatial data. Furthermore, it is likely disease and disease risk varies continuously 
throughout space but by using an area level approach this variation is subdivided. This will lead to 
distortion of the estimates of disease risk to some degree according to the boundary structure used. These 
will also be influenced by the relative homogeneity and heterogeneity of the areas used.  
 
Looking at healthcare related data further complicates matters due to the hierarchy through which care is 
delivered. For example, if hospitalisations in the UK are used as the outcome measure of interest then 
several spatially varying factors are likely to be relevant. Access to general practitioners, individual 
practitioner behaviour and local healthcare networks are likely to be factors prior to referral to hospital. 
Practitioner behaviour, resource priorities and local clinical guidelines are likely to also have an impact at 
the hospital institutional level.            
 
Finally, there is also the need to avoid the ecological fallacy when interpreting spatial epidemiological 
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analyses whereby, associations determined at an ecological level are translated into associations at the 
individual level, as these may not follow. Any area or spatial based analysis is therefore going to be to 
involve significant assumptions and be potentially affected by these factors. These can be mollified to 
some degree by employing a robust modelling strategy and by ensuring that any conclusions drawn are at 
the community and ecological level.   
 
3.1.6 Aims & hypotheses 
 
The aims of this analysis were twofold. One to establish whether there was spatial variation in pneumonia 
and empyema in the North East of England. Secondly, to move beyond this and establish what 
community level risk factors may contribute to the risk of both conditions. Possible risk factors identified 
previously include socio-economic deprivation, ethnicity and health-care factors. 
 
Both pneumonia and empyema are infectious diseases and therefore factors likely to explain spatial 
variation in risk of either may be related to transmission or susceptibility within a population or 
community. For example, socio-economic deprivation may predispose a population to pneumonia in 
different ways. Socio-economic deprivation is linked to poor quality housing which may increase 
individual’s susceptibility to respiratory infection. It also linked to overcrowding which increases 
transmission of respiratory pathogens, thereby increasing risk of pneumonia. Both of these factors are 
often aggregated at a community level. For example, deprived communities are likely to have higher 
levels of poor quality housing and overcrowding and hence the effects may be manifest at a community 
level. Transmission may also be potentiated by migration and communities with high levels of migration 
may be at greater risk than those with lower levels of migration. Ethnicity is linked to variations in an 
individual’s susceptibility to disease, for example Native American populations have been found to have 
higher rates of both carriage of pneumococci and infection with invasive pneumococcal disease than other 
populations (Singleton et al., 2007). As communities are often arranged along ethnic lines, these effects 
are likely to be seen at an area or community level. Similarly health care factors, such as immunisation 
rates will also influence susceptibility at a community level. Health care factors may also influence risk of 
pneumonia or empyema by mechanisms other than transmission or susceptibility. For example, the 
proximity of a community to hospital may influence attendance and hence diagnosis rate. In addition, 
hospitals and doctors are not homogenous and have different diagnostic thresholds, all of which may alter 
perceived community level risk.    
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In order to achieve these aims two hypotheses were investigated: 
       
- There is spatial variation in the risk of pneumonia and empyema. 
- Spatial variation in risk of pneumonia and empyema will be associated with community level 
deprivation, ethnicity and proximity to hospital.  
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3.2 Methods 
 
3.2.1 Pneumonia data 
 
Data on childhood hospitalisations in the North East of England SHA area (shown in Figure 3.1) from 1st 
April 1997– 30th March 2007 with a diagnosis of bacterial or lobar pneumonia ICD-10 codes J13, J14 
and J150–9, J181) in children under 15 years of age were extracted from HES (HESonline - Hospital 
Episode Statistics, 2010). There is a more detailed description of HES data in Chapter 2.2.2.  
 
All data with each disease code were counted and all those with the same HES identification number were 
amalgamated to convert from episodes to hospital admissions. Duplicate entries were removed and 
readmissions were excluded if they occurred within a month of the initial admission. Each HES entry 
contains partial postcode data, through which all hospitalisations over the time period were linked to 
postcode districts. Residence data were missing or unusable in 15 of 3889 (0.4%) hospitalisations and 
these were therefore excluded. 
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1. North Tyneside General Infirmary, Whitley 
Bay 
9.  Darlington Memorial Hospital, Darlington 
2. South Tyneside District Hospital, South 
Shields 
10. University Hospital of Hartlepool, Hartlepool 
3. Newcastle General Hospital, Newcastle-upon-
Tyne 
11. University Hospital of North Tees, Stockton-
on-Tees 
4. Royal Victoria Infirmary, Newcastle-Upon-
Tyne 
12. James Cook University Hospital, 
Middlesbrough 
5. Queen Elizabeth Hospital, Gateshead 13. Friarage Hospital, Northallerton  
6. Sunderland Royal Infirmary, Sunderland 14. West Cumberland Hospital, Whitehaven 
7. University Hospital of North Durham 15. Cumberland Infirmary, Carlisle 
8. Bishop Auckland Hospital, Bishop Auckland 16. Freeman Hospital, Newcastle-upon-Tyne 
 
Figure 3.1 North East of England with postcode district markings included. White area indicates 
pneumonia study population, grey shading indicates additional districts included in empyema study 
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3.2.2 North East empyema data 
 
Records of cases of childhood empyema managed at the tertiary referral centre (Freeman Hospital, 
Newcastle-upon-Tyne) between May 1995 and 2010 were used, as described in Chapter 2.2.1. The 
collection of empyema data was part of a wider study of paediatric empyema, the UK Enhanced 
Surveillance of Paediatric Pneumococcal Empyema project (UK-ESPE). All cases included had full 
postcode data.  
 
3.2.3 Spatial units and study area boundaries 
 
HES pneumonia data and empyema case data represent individual level or point data i.e. events which 
have occurred in or to individuals. These individuals clearly have a precise geographical location, 
however they have been grouped into areal data. This is as a consequence of the nature of the data. HES 
data contain only partial postcode data to maintain the confidentiality and to prevent identification of 
individuals. Furthermore, individual level spatial covariate data were not available for HES data and not 
collected for empyema cases.  
 
The areal unit used in the analysis was the postcode district. Postcode districts are part of postcode 
classification system in the UK. The postcode classification system is widely used in research, as they are 
widely known and recognised within the population which makes their collection as a geo-locator 
straightforward. However, they have several significant drawbacks; one that they change over time, with 
creation of new codes and recycling of old ones causes difficulty in longitudinal studies. Secondly, they 
are not always contiguous with other geographical classifications which can lead to errors of attribution 
during conversion between different classifications. Finally, there is substantial variation in population 
size between different postcodes (Mid-year population estimates). The ONS created and used the output 
area classification for the 2001 census, in order to counter the problems of the postcode classification 
system (HESonline - Hospital Episode Statistics). A comparison between the two classification systems is 
shown in Figure 3.2.    
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Figure 3.2 Comparing the postcode and output area classification. 
 
Postcode district was used to protect data accuracy and because it provided the most sensible choice in the 
balance between the need to avoid zero-inflation (from having large numbers of areas without cases, such 
as would have been the case if postcode sectors were used) and the need to have sufficient contrasting 
areas to reflect the true spatial heterogeneity.  
 
The two study areas were different reflecting the varying data sources. The pneumonia data represented 
the areas contained within the North East (SHA) area, a total of 116 postcode districts. Childhood 
pneumonia in the North East SHA has been previously characterised and reported (Clark et al., 2007a). 
The empyema data came from the single supra-regional centre for the management of the condition and 
the study area therefore represents the catchment population for this centre, a total of 150 postcode 
districts comprising the whole of the North East SHA and Cumbria. This was a conscious decision to 
maximise the available data given the relative rarity of empyema.    
 
3.2.4 Spatial covariate data 
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Spatial covariate data were obtained from several sources. Data were obtained from the Local Index of 
Child Well-being (CWI), a child specific small area deprivation dataset published in 2009 by the 
department of Communities and Local Government of the UK government (Bradshaw et al., 2009). It 
includes a measurement for each of the 32,482 lower super output areas in England and comprises seven 
separate domains covering different aspects of child well-being. These, in turn are comprised of 
combinations of different indicator measurements and are as follows: 
 
 i) Material deprivation - children living in households in receipt of both in work and out of work means 
tested benefits.   
ii) Health - all emergency hospital admissions, all outpatient attendances for children living in the area 
and children receiving disability living allowance as a proportion of all children in each area. 
iii) Education - school absence rates for children living in that area, standardised test and exam scores and 
entry into higher education rate.   
iv) Crime - police recorded crime data for burglary, theft, criminal damage and violence. 
v) Housing - access to housing (as measured by overcrowding rate, proportion of shared housing and 
homelessness) and quality of housing (proportion of children living in accommodation lacking central 
heating).  
vi) Children in need - expected rate of children requiring local authority social support 
vii) Environment - environmental quality (air quality, percentage of green space and woodland, number of 
bird species and child road accident rate) and environmental access (average number of leisure and sports 
facilities within area and average road distance to school).  
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The correlation between co-variates is shown Table 3.1: 
 
 
M
at
er
ia
l 
 
E
d
u
ca
ti
o
n
  
H
ea
lt
h
  
E
n
v
ir
o
n
m
en
t 
 
C
ri
m
e 
 
H
o
u
si
n
g
  
C
h
il
d
re
n
 i
n
 n
ee
d
  
O
v
er
al
l 
 
Material  1.00  0.80  0.56  0.07  0.55  0.63  0.96  0.90  
Education   1.00  0.57  0.03  0.53  0.48  0.86  0.83  
Health    1.00  0.05  0.36  0.31  0.59  0.68  
Environment     1.00  -0.02  0.16  0.07  0.30  
Crime      1.00  0.35  0.54  0.63  
Housing       1.00  0.59  0.69  
Children in need        1.00  0.91  
Overall well-
being  
       1.00  
Table 3.1 Spearman rank correlation matrix between the domains and overall well-being (all 
coefficients are statistically significant at the <0.01 level). Adapted from Bradshaw J, Bloor K, 
Huby M, et al. Local index of child well-being: Summary report: Department of Communities and 
Local Government, 2009. 
 
Measurements of ethnicity (proportion of non-Caucasian individuals within the district) and migration (all 
inward migrants, outward migrants and those moving within the district in the year prior to the census) 
were derived from the UK Census 2001 key statistics dataset at the level of super output area (Mid-year 
population estimates). All spatial covariate data were then matched to counts of cases in each study 
postcode district. Finally, the distance to each of the admitting hospitals from each postcode district was 
estimated using the centroids of each district and the centroid of the district containing each hospital. The 
shortest possible distance for each district was then used and for cases residing in the same district as a 
hospital this was zero. 
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3.2.5 Statistical methodology 
 
Relative risks were calculated by using the conditional autoregressive models developed by Besag, York 
& Mollie (Besag et al., 1991). These were Poisson spatial models with the observed number of cases as 
the dependent variable, expected number of cases as offset and random effects terms that take the 
following into account: (a) effects that vary in a structured manner in space (postcode district contiguity) 
and (b) a component that models the effects that vary among census tracts in an unstructured manner 
(postcode district heterogeneity). The first of these represents an attempt to model unmeasured spatial 
dependency associated with the proximity of residential postcodes, whilst the second allows for 
significant differences between postcodes over the study area.  
  
It was assumed that the numbers of observed cases (Oi) for each postcode district (i=1,…,n) follow a 
Poisson distribution with mean μi=EiOi, where Ei are the expected cases for each postcode district 
obtained by indirect standardisation, and θi is the relative risk (RR) for each specific area. The expected 
numbers of cases were calculated with the age-specific population (0-14 years old ONS census 2001 data) 
of the study region within the study period. 
 
The null model took the following form: 
 
Oi ~ Po(Ei μi) 
 
  log(μi) <- log(Ei) + α + bi + hi 
 
Where Oi is the observed number of cases in area i; Ei are the expected cases; μi is the relative risk in area 
i, α is the intercept; hi is the postcode district heterogeneity term; and bi is the spatial term. Initially, the 
null model included no explanatory variable. Subsequent iterations were fitted to include a covariate 
effect, using the following general model: 
178 
 
 
Oi ~ Po(Ei μi) 
 
  log(μi) <- log(Ei) + α + βcovi + bi + hi 
 
Where covi is the covariate value in area i. Models were fitted with a variety of covariates using this 
general model structure. The null model was compared with models from three groups containing 
covariates for a) Overall CWI, ethnicity, migration and distance from admitting unit separately b) The 
seven individual CWI domains that make up the CWI Index, c) all possible combinations of those 
covariates from a) and b) that were shown to be significant at 95% Bayesian Credibility Intervals (BCI). 
 
The models were fitted using Bayesian Markov chain Monte Carlo (MC) simulation methods within 
WinBUGS 1.14.(Spiegelhalter DJ et al., 2001) A 10,000 iteration ‘burn-in’ was followed by a 50,000 
iteration sample. In all cases, the MC error for each area was less than 5% of the standard deviation, 
indicating sufficient iterations of the model had been run after convergence. Model assessment involved 
the comparison of DIC (Deviance Information Criterion) scores for each model, with the model with the 
lower DIC score preferred. A difference in DIC greater than 3 indicates a significant difference in model 
performance (Spiegelhalter et al., 2002). Following the principle of parsimony, the best performing model 
was judged to be the one with the lowest DIC which contained only significant variables.   
 
Areas were considered significant areas where the 95% BCI around the estimated relative risk excluded 1. 
A covariate was considered significant if 97.5% of its posterior distribution lay either above or below zero. 
To depict the spatial distribution of relative risk across the study area postcode district maps obtained 
from UK Borders (EDINA) were used alongside R 2.12.2 (Team, 2010) and WinBUGS (Spiegelhalter DJ 
et al., 2001).  
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3.3 Results 
3.3.1 Spatial variation in the risk of pneumonia 
 
There were 3874 pneumonia admissions with postcode data during the study period. The spatial 
distribution of these admissions is presented at the postcode district level in Figure 3.3. The most 
admissions were found in TS3 (Brambles Farm, Thorntree, Park End, North Ormesby, Berwick Hills, 128 
cases) and NE4 (Fenham, Westgate & Wingrove, 106 cases).  
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Figure 3.3 The number of observed cases of pneumonia across the postcode districts of North East 
England.  
 
The expected incidence of pneumonia for each postcode district is presented in Figure 3.4. 
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Figure 3.4 The number of expected cases of pneumonia across the postcode districts of North East 
England.  
 
Figure 3.5 presents the spatial distribution of those postcode districts that, according to the null model, 
were shown to have either a significantly low (shaded green) or high (shaded red) relative risk of 
childhood pneumonia. 
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Figure 3.5 The location of postcode districts with significantly high (red) or low (green) relative risk 
of pneumonia, according to the null model. 
 
Significant spatial variation in risk of admission to hospital with pneumonia was found, with 53 (47%) of 
districts having either a significantly higher or lower risk compared to that predicted by child population 
alone (Range of RR: 0.32-2.34). Clusters of areas of highest risk were in the urban centers of major cities 
of Newcastle and Middlesbrough. Large rural districts to the North and West of the region had the lowest 
risk. 
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Model 
Group 
No. Covariates Covariates Minimum 
RR 
Maximum 
RR 
No. 
significant 
low RR 
No. significant 
high RR 
Model 
DIC 
Null 0  0.319 2.338 31 22 749.68 
A 1 CWI 0.459 3.017 32 14 746.01 
B 7 CWI Individual Scores 0.500 3.086 31 13 742.28 
C 3 CWI Significant Scores (Material 
deprivation, Health, Children in Need)  
0.437 2.915 37 13 741.50 
A 1 Material deprivation 0.413 2.993 27 13 749.35 
A 1 Children in Need 0.404 2.990 28 12 750.88 
A 1 Health 0.406 2.898 36 16 743.93 
A 1 Distance to hospital 0.279 2.938 29 12 746.34  
C 4 Distance to hospital, Health, Material 
deprivation and Children in Need 
0.379 2.917 37 13 740.94 
        
Best performing model 
 
C 3 Material deprivation, Health, Children in 
Need 
0.437 2.915 37 13 741.50 
Abbreviations – CWI = Child Well-being Index, RR = Relative Risk, DIC = Deviance Information Criterion  
Table 3.2 Summary statistics for models of relative risk of hospitalisation with pneumonia. 
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Variable Median (Range) Estimate of 
mean of 
posterior 
distribution 
SD of posterior 
distribution 
CWI 158.93 (47.82 ; 393.21) 0.0027 0.00045 
Distance to hospital 
(km) 
6.83 (0 ; 70.89) -0.019 0.0057 
Material deprivation 0.21 (0.04 ; 0.63) 3.92 1.14 
Children in Need 0.03 (0.01 ; 0.09) -26.74 9.1 
Health 0.47 (-1.103 ; 1.62) 0.31 0.092 
Table 3.3 Significant spatial covariates for pneumonia Abbreviations – CWI = Child Well-being 
Index, SD = Standard deviation 
 
Table 3.2 presents summaries of models of the spatial distribution of pneumonia cases. Table 3.3 
contains details of significant spatial covariates. Relative childhood deprivation, as measured by the 
Local Index of Child Well-being, was associated with a significant increased risk of admission in a 
district. Greater material deprivation, higher health domain score (indicating higher rates of 
admissions, clinic attendances and disability in an area) and higher Children in Need score (indicating 
a greater number of children requiring local authority support) components of the CWI were 
significant predictors of increased risk.  
 
Distance to hospital was a significant covariate when added to the null model, with increased 
admissions in districts closest to hospitals. This was a non-significant factor when added to a model 
containing the significant CWI covariates and did not improve the DIC sufficiently to warrant 
retaining (DIC 740.94 vs. 741.50). Ethnicity, migration levels, education, housing, crime and the 
environment domain were all non-significant.  
 
The best performing model contained the three significant CWI covariates alone (DIC 741.50) 
although the three models containing i) all seven separate components of the CWI, ii) health alone and 
iii) distance to hospital, health, material deprivation and Children in Need, were not significantly 
inferior by comparison of DIC (DIC 742.48, 743.93 and 740.94). In the best performing model 50 
(44%) of the districts had a significantly increased (n=13) or decreased (n=37) risk (range of RR was 
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0.44 to 2.92) and are shown in Figure 3.6.  
 
 
Figure 3.6 The location of postcode districts with significantly high (red) or low (green) relative 
risk of pneumonia, according to the best performing model. 
3.3.2 Spatial variation in the risk of empyema 
 
Figure 3.7 shows the distribution of cases of empyema across the study region. In total, there were 
293 cases spread across 150 postcode districts. The most cases in any district were found in DH8 
(Consett) and NE6 (Walker, Byker and Heaton), where eight instances were recorded in each. Forty 
postcode districts contained no reported cases of empyema. 
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Figure 3.7 The number of observed cases of empyema across the postcode districts of Northern 
England.  
 
The expected incidence of empyema for each postcode district is presented in Figure 3.8. 
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Figure 3.8 The number of expected cases of empyema, according to relative childhood 
populations across postcode districts in Northern England. 
 
The low numbers of observed and expected cases resulted in no postcode districts showing 
significantly high or low relative risks. This remained the case when the credible interval was lowered 
to 90% and also when the spatial boundaries were increased to the coarser scale of postcode area. An 
analysis using expected cases calculated from the rate of bacterial or lobar pneumonia in each district 
was also carried out. This identified four areas of significantly lower risk. However, there was no 
evidence of clustering and the expected counts of disease in each were low (<5 cases). Consequently, 
this finding does not represent reliable evidence of spatial variation in risk of empyema.     
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3.4 Discussion 
3.4.1 Strengths and limitations 
 
The strengths of these analyses include the use of child specific deprivation measurements not been 
previously available for this type of study in the population in question, the use of a well-validated 
and reported statistical methodology robust in the handling of spatial auto-correlation, and a 
comprehensive geographical dataset.  
 
As this is an ecological study there are limitations regarding causation, due to the use of aggregated 
rather than individual level data. The use of hospital coding data to determine cases is a further 
limitation. Coding data has been used to examine childhood pneumonia in a number of other studies, 
but concerns have been raised about its specificity.(Elemraid et al., 2010; Koshy et al., 
2010).Although the study relates to a large and varied region, it only relates to one area of the United 
Kingdom and factors unique to the study area will inevitably influence the generalisability of the 
findings.  
3.4.2 Findings related to other studies 
 
There was significant spatial variation in the risk of hospitalisation of children with pneumonia 
between postcode districts in the North of England. The range of relative risks was 0.44 to 2.92 
indicating an approximately six fold variation between districts. Significant covariates in explaining 
the variation were material deprivation, CWI health domain score, number of children requiring local 
authority support and distance to hospital. Ethnicity, migration levels, housing, education, crime and 
environment were not significant covariates. There was no evidence of spatial variation in the risk of 
hospitalisation with empyema.  
 
The existence of significant spatial variation in risk of hospital admission for pneumonia is in keeping 
with the findings of other spatial studies of risk of pneumonia (Crighton et al., 2007; Kazembe and 
Namangale, 2007). Direct comparisons of the magnitude of the effect are difficult to make, because of 
differences in statistical methodology. The variation in pneumonia and influenza admission rates 
between counties described by Crighton et al (2007) was three-fold, which is lower than this finding 
of a six-fold variation (0.44 to 2.92). This may be due to the smaller geographical units used in our 
study, which are likely to provide heterogeneity between individual areas.   
189 
 
 
A number of studies have reported an association between deprivation and increased risk of 
hospitalisation for respiratory tract infections in children and this study supports these previous 
findings (Spencer et al., 1996; Hawker et al., 2003; Crighton et al., 2007). Defining the mechanisms 
underpinning this increased risk has been controversial (Crighton et al., 2007). Proposed hypotheses 
have included, increased pathogen transmission from overcrowding and increased host susceptibility 
resulting from poor nutrition (Cohen, 1999; Hawker et al., 2003). Absolute material deprivation is 
rare in the UK child population and primary health care access is free at the point of use, suggesting 
that other factors linked to relative deprivation are likely to be relevant (Wilkinson, 1997). The most 
obvious is exposure to exhaled tobacco smoke through living with adult smokers. Smoking rates are 
correlated with socio-economic status and have been linked to increasing hospitalisation for childhood 
respiratory infections (Colley et al., 1974; Spencer et al., 1996; Cook and Strachan, 1999). It is not 
possible to separate the contribution of smoking from that of material deprivation within this dataset. 
Given the magnitude of disparity in risk between different areas, public health interventions 
emphasising the benefits of reducing children’s exposure to second hand smoke should be targeted at 
these areas to reduce these inequalities.  
 
The health domain was also a significant explanatory variable for the variation in risk between 
districts. It is comprised of three indicators, total child hospital admissions, total child hospital out-
patient attendances and the proportion of children receiving disability living allowance. Factors within 
a community that modify overall admissions to hospital will therefore contribute to both the number 
of pneumonia admissions in a district and the health domain score. Differences in access to healthcare 
resources have been reported as a significant factor in the variation in childhood hospital admissions 
in other settings (Erzen et al., 1997; Crighton et al., 2007). The significance of distance to hospital as 
a covariate would suggest this in our population. Admission policies for children with pneumonia at 
individual hospitals vary, contributing to the variation in risk. These disparities are insufficient to 
fully explain the magnitude of variation between areas, as national guidelines for the management of 
childhood pneumonia were widely implemented during the study period. Children with co-morbidities 
such as cerebral palsy predisposing to pneumonia are more likely to be in receipt of disability living 
allowance, and this will also contribute to the association with the health domain (Owayed et al., 
2000).     
 
The Children in Need domain was also a significant predictor, but the association was counter-
intuitive with higher levels of risk in districts with lower numbers of children requiring local authority 
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social support. It is recognised that children in local authority care suffer from worse long-term health 
outcomes (Polnay and Ward, 2000). However, there were difficulties with missing data and this 
domain was partially estimated using a combination of income and education scores which are highly 
correlated with material deprivation (correlation co-efficient 0.96) (Bradshaw et al., 2009). It is 
therefore not easy to explain the difference in polarity between the two observed associations. One 
possibility is that the effect of material deprivation is to some degree ameliorated by children being in 
local authority care. Most likely however is that the problem of data derivation means this is an 
epiphenomenon.     
 
Housing characteristics were not significant determinants of risk at a community level, as measured 
by either overcrowding or housing quality. This was surprising as individual level studies have 
identified both as risk factors for pneumonia (McCarthy et al., 1985; Mann et al., 1992). This finding 
may be a consequence of the community level aggregation, although it is also possible that these 
levels of inadequate housing were simply not of significant magnitude to have adverse consequences 
in the population studied.  
  
No variation in the relative risk of hospitalisation was found for empyema, even when the spatial scale 
was increased. This could reflect the true absence of spatial variation in risk. It is also possible that it 
is a consequence of the low number of cases per district. Conditional autoregressive models have been 
shown to be conservative, and they may not identify significant variation in risk if the variation 
between areas is less than two-fold and the expected number of cases less than 50 (Richardson S et al., 
2004).  
 
3.4.3 Implications and future research 
 
There was a six-fold variation in risk of admission to hospital for children with pneumonia in different 
postcode districts in the North East of England between 1997 and 2007. These variations appear to be 
associated with deprivation, specifically levels of material deprivation, childhood illness and disability 
and proximity to hospital. The relationships between hospital admissions determined by coding data 
and the true incidence of disease are complex and many factors such as coding accuracy, physician 
behaviour, and access to secondary care may be relevant (Campbell et al., 2001). The magnitude of 
these variations suggests that these findings indicate true differences in the incidence of this disease. 
This has important public health implications, particularly given the increasing evidence of significant 
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associations between childhood pneumonia and morbidity in later life (Sethi and Murphy, 2001).  
 
There was no evidence of spatial variation in risk of empyema. This is unexpected given the close 
relationship between pneumonia and empyema. It may represent a true negative but given the 
relatively low number of cases per postcode district and the conservatism of CAR models in assessing 
risk in rarer conditions, it is more likely to represent a failure to detect variation rather than true 
absence of variation in risk.   
 
3.5 Conclusions 
 
There is significant spatial variation in the risk of hospital admission with pneumonia but not 
empyema, in the North of England above that determined by population alone. Levels of material 
deprivation, childhood illness and disability help explain these variations but significant unexplained 
variation remains. Further studies are required to quantify to what extent these spatial differences in 
risk represent differences in health behaviour as opposed to a genuine increase in the risk of disease. 
Research directed at understanding the role of public health measures at a community level, such as 
smoking cessation campaigns in reducing hospital admissions for childhood pneumonia could also 
help to elucidate which factors are truly relevant in determining variations in risk of pneumonia. 
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4 The impact of the seven valent pneumococcal conjugate vaccine on 
paediatric empyema in the North East of England 
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Note: This chapter is a manuscript that was submitted to the European Respiratory Journal in 2011.   
4.1 Introduction 
 
The incidence of empyema thoracis in children has risen in Europe, Australia and North America over 
the last 15 years (Rees et al., 1997; Byington et al., 2002b; Strachan and Jaffé, 2009; Van Ackere et 
al., 2009). In England, admissions for empyema rose from 14 per million children (0–14 years) in 
1995 to 26 per million in 2003 (Gupta and Crowley, 2006). Similarly, in Scotland admissions 
increased from <10 per million in 1998 to 37 per million in 2005 (Roxburgh et al., 2008).   
 
While a range of pathogens are known to cause empyema, paediatric empyema in the United 
Kingdom (UK) is predominantly a pneumococcal disease (Eastham et al., 2004). This is in contrast to 
adult disease where the most common cause of culture positive disease is streptococci of the 
anginosus group (Maskell et al., 2005). Pneumococci display antigenic diversity in their 
polysaccharide capsules and over 90 different serotypes or serogroups are recognised (Lipsitch, 1999). 
Pneumococcal conjugate vaccines comprise multiple pneumococcal capsular polysaccharides 
covalently coupled to molecules of carrier protein, but these vaccines only contain antigen derived 
from a limited number of serotypes (Lipsitch, 1999).  
 
PCV-7 was added to the UK routine immunisation schedule in September 2006 and a replacement 13-
valent pneumococcal conjugate vaccine was introduced in April 2010. The current schedule includes 
doses at two, four and 12 months. A catch-up programme for children under two years of age was 
undertaken when PCV-7 was introduced.   
 
PCV-7 contains antigen from serotypes 4, 6B, 9V, 14, 18C, 19F and 23F accounting for 
approximately 65% of culture-positive paediatric invasive pneumococcal disease according to 
national surveillance prior to the introduction of PCV-7 (Miller et al., 2000). These serotypes 
previously accounted for only 20% of culture-positive and negative paediatric empyema cases, 
suggesting that any impact of the immunisation on empyema may be modest (Eastham et al., 2004; 
Fletcher et al., 2006).  
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Studies investigating the incidence of paediatric empyema after the introduction of PCV-7 have 
produced conflicting results. One study, using hospital coding data, reported a drop in admissions in 
England in 2008 from a peak in 2006 which was attributed to PCV-7 (Koshy et al., 2010). This 
finding was in marked contrast to three large US studies of hospital coding data  using robust 
methodologies reporting an increase in paediatric empyema following the introduction of PCV-7 
(Grijalva et al., 2010; Lee et al., 2010; Li and Tancredi, 2010).  
 
4.1.1 Aims and objectives 
 
The objective of this study was to investigate whether the introduction of PCV-7 was associated with 
a change in the incidence of paediatric empyema. An interrupted time-series analysis approach was 
used, which has been successfully used in the past to assess the impact of PCV-7 on childhood 
pneumonia, as well as other health outcomes (Wagner et al., 2002; Grijalva et al., 2007). A secondary 
objective was to test the hypothesis that any vaccine impact will be primarily focused towards the age 
group who are direct vaccine recipients as opposed to those benefitting from the consequences of 
enhanced herd immunity.  
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4.2 Methods 
 
The case data used were those from the North East dataset described in chapter 2.2.1. PCV-7 
immunisation rates were obtained from the HPA Immunisation department and covered each quarter 
from July 2007 until June 2010 (Immunisation Department). The transition period for the introduction 
of the vaccine was considered to be from September 2006 until July 2007 when uptake of two vaccine 
doses by 12 months of age was greater than 90%.  
 
Data on the individual vaccination status of cases were not available. All children born after 5 
September 2004 were possible vaccine recipients, either through the primary or catch-up vaccine 
programmes. The pattern of vaccine uptake was progressive, thus in any one year after introduction in 
2006 an increasing proportion of the at risk population will have been vaccinated. The proportion of 
empyema cases in this cohort of possible vaccine recipients was calculated for each year after July 
2007 and compared to the numbers of cases in the equivalent cohort for all years from 1995–2006.  
 
4.2.1 Seasonality 
 
Empyema incidence is strongly seasonal, with most cases occurring in winter. As monthly count data 
were used to increase the robustness of the time series analysis, a variable to account for the seasonal 
variation was required and air temperature was used in same manner as in Chapter 2.2.1. Data were 
obtained from MIDAS as previously described.  
 
4.2.2 Statistical methods 
 
Rates of cases per month per head of population were calculated using the UK ONS mid-year 
population estimates for the relevant health authority areas (North East Strategic Health Authority 
area (NE-SHA) and Cumbria Teaching Primary Care Trust (CT-PCT)).The rate of empyema cases per 
month per million individuals aged 0-14 years was used as the outcome measure. Interrupted time-
series regression analysis was used to investigate the relationships between this rate and the 
introduction of PCV-7. All models were fitted using a least squares regression approach.  
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The outcome data were log-transformed to stabilise the variance. Analysis of the residuals of the final 
models did not demonstrate any violation of distributional assumptions. Autocorrelation was 
quantified against all lags up to 12 months and no evidence of primary or secondary autocorrelation 
was observed. Since the variance in case rate increased with time from study start, a weighting 
function was used to counterbalance the effect of heteroscadascity and prevent violation of the model 
assumptions (Faraway, 2005). The power of the study to detect a 20% change in the rate of cases 
based on a significance level of 0.05, with 174 months of data and in the absence of significant 
autocorrelation was 0.996 (Cohen, 1998).  
 
Pearson’s chi-squared test was used to assess the differences between age distributions. The R 
statistical package version 2.9.1 (The R Foundation for Statistical Computing, 2009) was used for all 
analyses.   
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4.3 Results 
 
A total of 298 cases were included in the analysis, over a time period of 179 months from May 
1995 to April 2010. Fifty-six percent were males and the median age at diagnosis was 4.6 years 
(range: 0–14). Separate analyses were performed to either include or exclude the transition 
period. As no significant differences were found between the two estimates the reported results 
exclude the transition period.  
 
The incidence of empyema increased significantly from a mean monthly rate of 1.1 cases per 
million children in 1996 to 5.2 per million in 2009 (p<0.0001). The introduction of PCV-7 was 
not associated with a decrease in cases; instead both the incidence and the rate of rise in 
incidence appeared to increase following the introduction of PCV-7 (Figure 1). By March 2010, 
predicted cases of empyema per month per million children were 17 % higher than the level 
predicted by extrapolation of the linear trend prior to introduction of the PCV-7 (Figure 4.1). 
This was equivalent to an additional 2.07 cases per million children per year after the 
introduction of PCV-7, although this effect was not significant (95 % confidence interval -3.38, 
10.98, p=0.53). Furthermore, the variable of time from vaccine introduction was not significant 
suggesting that despite the increasing number of individuals in the population who had received 
the vaccine there was no significant change in incidence (p=0.25). 
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Figure 4.1 Trends in the incidence of paediatric empyema in the North of England from 
1995 to 2010, pre and post the introduction of PCV-7.   
The results of the regression models are summarised in Table 4.1 and Table 4.2.  
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    Co-efficient
†
     95 % Confidence 
Intervals 
p-value 
Mean Monthly Minimum 
Temperature / 
o
C     
-0.0042 -0.086 ; 0.0052 0.083 
Month From Study Start 0.010 0.0061 ; 0.014 <0.0001 
Vaccine programme present 0.17 -0.28 ; 0.91 0.53 
Month From Vaccine Programme Start -0.010 -0.027 ; 0.0071 0.25 
Interaction Term (Month From Study 
Start * Mean Monthly Minimum 
Temperature)  
-0.00049
 
-0.00098 ; 
0.00001 
0.046 
Akaike Information Criteria (AIC) 390.73 
 
Table 4.1 Regression model predicting monthly cases of empyema using time, temperature 
and introduction of the PCV-7 vaccine (n= 174).  
† - All co-efficients represent change in cases per million individuals per month for a unit 
change in the co-variate. 
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 Co-efficient
†
     95 % Confidence 
Intervals 
p-value 
Interaction Term (Month From Start * 
Mean Monthly Minimum Temperature) 
-0.00083
 
-0.0011 ; -0.00056 <0.0001 
 
Month From Study Start 0.011 0.0088 ; 0.0013 <0.0001 
Akaike Information Criteria (AIC) 374.66 
 
Table 4.2 Final parsimonious regression model containing only significant variables in 
predicting monthly cases of empyema (n=174, R
2
 0.402).   
† - All co-efficients represent change in cases per million individuals per month for a unit 
change in the co-variate  
There was strong evidence of an interaction between temperature and time on the rate of cases, 
suggesting the need for an interaction term between the two variables. The included term was 
significant (p<0.0001) which equates to the observation that the number of cases increased more 
in association with low temperatures throughout the sampling period than in summer. Also, on 
inclusion of the interaction term, measures of the ability of the model to explain the observed 
data, e.g. the Akaike Information Criteria (AIC) significantly improved (AIC -84.3 without vs. -
87.83 with). 
 
The results of Pearson’s chi-squared testing for difference in age distribution are shown in Table 
3. There were no significant differences in the age distribution of cases in the three years after 
vaccine that were tested.   
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Year 
Cases in vaccine 
cohort† 
Cases outside 
vaccine cohort 
Χ2 
Degrees of 
freedom 
p – value 
1995-05 67 105 
0.013 1 0.91 
Jul 2007- Jun 08 13 21 
1995-05 88 84 
2.1 1 0.15 
Jul 2008 - Jun 09 13 18 
1995-05 105 67 
0.70 1 0.40 
Jul 2009 - Apr 
10 
 
18 7 
 
Table 4.3 Chi-squared testing for differences in age distribution before and after the 
introduction of PCV-7. 
† Corresponds to:   
Jul 2007- Jun 08: Cases aged 0 – 3 years 10 months  
Jul 2008 - Jun 09: Cases aged 0 – 4 years 10 months 
Jul 2009 - Apr 10: Cases aged 0 – 5 years 10 months 
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4.4 Discussion 
 
Cases of empyema increased following the introduction of the PCV-7 in September 2006, 
however this change was non-significant and no change in age cohort of cases was seen. 
 
4.4.1 Strengths and limitations 
 
There are three main strengths of this study. Firstly, the length of the time period reported is 
sufficient to allow accurate extrapolation of secular trends and judgement of an intervention 
whose efficacy might change with time. Secondly, the study has sufficient power to detect an 
effect of the magnitude previously described (Koshy et al., 2010). Finally, the analysis is based 
on a stable population with a high rate of vaccine uptake, by July 2007 91.3% of children had 
received two doses of PCV-7 by their first birthday (Immunisation Department).    
 
This was an ecological study addressing changes in total cases of empyema, therefore specific 
causation of the observed changes cannot be attributed directly or solely to the effects of PCV-7. 
This is a limitation of all studies using this methodology and while it is important to recognise 
this, the observation that the introduction of PCV-7 was not associated with a decrease in 
incidence of empyema remains valid.   
 
The method of data collection switched from retrospective to prospective identification in 2008. 
This is significant in a time series analysis as case ascertainment may change as a result 
resulting in false associations. However, when included as a variable within the time series 
analysis, this factor was not associated with a change in incidence (co-efficient -0.322, 95% CI -
1.16; 5.21, p=0.45) and the use of a consistent case definition should have limited the impact of 
this change.   
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A further potential limitation was that the second period of data collection required informed 
consent from participants, but only one case over the whole study period refused this and was 
therefore excluded. A final limitation stems from the use of a procedure based case definition 
and a study period of 15 years. There have been no overt changes in empirical therapy, referral 
threshold, imaging usage and threshold for invasive management at the study centre over the 
study period. However, we recognise that subtle changes in clinical practice may remain 
unrecognised and could potentially influence time series data over such a period of time. On 
balance, as the increase in incidence was of such magnitude and was sustained, it is unlikely that 
these factors significantly influenced the results.  
 
4.4.2 Findings related to other studies 
 
The incidence of empyema in children in the North East of England increased from 13.6 to 62.9 
cases per million from 1996 to 2009. This finding of a large increase in cases from 1995 
onwards is in line with other UK based studies (Gupta and Crowley, 2006; Roxburgh et al., 
2008; Koshy et al., 2010). This equates to a change in the mean monthly rate from 1.1 to 5.2 
cases per million children over the same time period. These data are similar to previously 
reported figures from Scotland (Roxburgh et al., 2008) and England, (Gupta and Crowley, 2006) 
but this estimate is somewhat larger than that of Koshy et al (2010) who reported a change from 
4.7 admissions per million children in England to a peak of 17.5 per million and a subsequent 
fall to 13.7 per million by 2008. Koshy et al acknowledged that their estimates of empyema 
incidence were lower than those of other studies and cited their usage of more specific 
diagnostic codes as a potential explanation for the difference. They also estimated a 22% 
reduction in empyema between the calendar years 2006 and 2008 which they relate to the 
introduction of PCV-7, whereas we find no such change despite our study having sufficient 
power to detect such a magnitude of effect. One possible explanation for these differences is that 
estimates based on single paired calendar years may be distorted by the distribution of empyema 
incidence during individual winter seasons, and by random fluctuations in the annual totals for 
the paired years. An alternative explanation would be that local factors might have been 
operating to substantially increase the incidence of empyema in our region, although there is no 
evidence to suggest this.   
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The observation of an increase in empyema despite the introduction of PCV-7 is in keeping with 
a number of studies in the USA where it was introduced into the routine immunisation schedule 
in 2000-01. For example, in Utah, the overall incidence of cases continued to rise substantially, 
from a mean of 38 to 71.5 cases per year in the periods of 1996-2000 and 2001-2004 
respectively following the introduction of PCV-7. Although the percentage of cases due to 
serotypes covered by the vaccine did decrease from 37% to 14% (Byington et al., 2006). This 
same trend of increasing empyema incidence after introduction of PCV-7, particularly in 
children between the ages of 1 and 4 years, has been recently corroborated by three large scale 
studies based on hospital coding data (Grijalva et al., 2010; Lee et al., 2010; Li and Tancredi, 
2010).  
 
Perhaps the most likely explanation for the rise in empyema despite the introduction of PCV-7 is 
that non-PCV-7-vaccine serotypes are responsible for the greatest burden of disease and 
therefore disease due to these serotypes is not reduced by the introduction of the vaccine. An 
alternative explanation that has been proposed in several settings is serotype replacement disease 
(Byington et al., 2006; Hendrickson et al., 2008). It is difficult to be certain that this 
phenomenon is truly responsible for the increase in empyema given the relatively low rate of 
vaccine serotypes causing the disease and the fact that many centres reported a synchronous 
upward trend in incidence before the vaccine was introduced (Fletcher et al., 2006; Roxburgh et 
al., 2008; Grijalva et al., 2010). Furthermore, pneumococcal serotypes exhibit natural variation 
over time and in any given population. This may account for the fact that an increase in serotype 
1, which is a non-PCV-7 serotype was seen before the introduction of the conjugate vaccine 
(Byington et al., 2002b).   
 
The changing incidence of other infections causing empyema in children also needs to be 
considered, along with their possible relationships to changes in pneumococcal ecology. For 
example in one study from Texas Staphylococcus aureus infection increased substantially, from 
18% to 60% over ten years, and several other series have reported similar findings (Buckingham 
et al., 2003; Schultz et al., 2004). Analysis of the incidence of other causative organisms was 
beyond the scope of this analysis, so we cannot determine whether this was a significant factor 
within the North East population  
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The time–temperature interaction term 
 
There was a significant interaction between temperature and time on the number of incident 
cases. In effect, winter case numbers increased through time, to a greater degree than did 
summer case numbers. This may be as a result of the overall distribution of cases or as a result 
of different mechanisms involved in the aetiology of empyema. We are unable to delineate this 
further.  
 
Changes in age distribution 
 
It was hypothesised that any preventative effect of the vaccine would be seen initially in those 
children who were direct vaccine recipients. There were no differences in the age distribution of 
cases year on year following the introduction of vaccine. This is further evidence that 
introduction of PCV-7 was not responsible for any reduction in the incidence of paediatric 
empyema in the North East of England. 
 
4.4.3 Implications and future research 
 
Our results suggest that the introduction of the PCV-7 immunisation was not associated with a 
reduction in the incidence of empyema in the North East of England. It is perhaps surprising that 
we are unable to report any effect as previous estimates have suggested that up to 20% of UK 
cases may be due to serotypes covered by the vaccine (Eltringham et al., 2003; Fletcher et al., 
2006). PCV-7 has been shown to be very effective in the prevention of invasive pneumococcal 
disease due to vaccine serotypes and uptake in our region was high (O'Brien et al., 2003; Cutts 
et al., 2005). Serotype replacement may have contributed to this lack of impact. It is more likely 
that PCV-7 serotypes did not contribute significantly to these cases and other factors such as the 
circulation of epidemic strains of serotype 1, changes in organism virulence or an increase in the 
underlying cases of pneumonia may be responsible. It is not possible from the data available to 
address these possibilities. However, the ongoing UK-ESPE study, which is a multi-centre 
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prospective observational study of paediatric empyema will have the scope and the power to 
address these factors.  
 
Further detailed epidemiological studies are required to establish the processes that are driving 
the change in empyema incidence, and to monitor the impact of the next generation of 
pneumococcal conjugate vaccines.  
 
4.5 Conclusions 
 
The introduction of PCV-7 did not alter the incidence of empyema within the North East of 
England. 
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5 The influence of pathogen and pneumococcal serotype on illness 
length and the impact of primary pleural drainage methodology on 
outcomes in empyema 
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5.1 Introduction 
 
5.1.1 Pathogen, pneumococcal serotype and outcomes in empyema 
 
Historically empyema has been considered in terms of its pathophysiology related to the 
accumulation of pus with loculation within the pleural cavity. Considerably less attention has 
been given to the underlying pathogenic cause. There has however been an awareness of 
differing risks associated with infection by different pathogens from the earliest scientific 
literature onwards. The Hippocratic Corpus described different constitutions of infected fluid 
drained in empyema and attributed them both to different predicted outcomes and different 
causes (Christopoulou-Aletra and Papavramidou, 2008). Heuer (1932) commented that 
streptococcal (implying Streptococcus pyogenes) empyema carried a greater risk of death than 
pneumococcal empyema. Since 1997, when the first modern reports of an increase in the 
incidence of paediatric empyema emerged (Playfor et al., 1997; Rees et al., 1997), only one 
study has directly examined the clinical profile and outcomes of empyema caused by different 
pathogens. This study found significant increases in hospital stay associated with staphylococcal 
empyema (Blaschke et al., 2011).   
 
Attention has been paid to empyema associated with different pneumococcal serotypes and 
certain pneumococcal serotypes appear to be associated with particular complications of 
empyema. In one London case series from 2002 to 2009, 91% empyema cases complicated by 
formation of a bronchopleural fistula were associated with Serotype 3 (equivalent to 10/16 cases, 
p<0.0001). This was accompanied by a significant increase in median hospital stay (7 vs. 10 
days, p<0.001) and surgical intervention rate (2% vs. 14%, p=0.001) (McKee et al., 2011). 
Serotype 19A has been associated with an increased risk of other complications including 
necrotising pneumonia and haemolytic uraemic syndrome (Reinert et al., 2010; Andrade et al., 
2011). Mortality in adults with pneumococcal pneumonia differs between pneumococcal 
serotypes with serotypes 3, 6A, 6B, 9N, and 19F being associated with an increased risk of death. 
Not of all of the patients in this series suffered from, or died from empyema (Weinberger et al., 
2010).      
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Understanding the varying patterns of empyema between different pathogens is important, as the 
increases in the incidence of the condition which occurred after 1997 appear to be related to 
changes in the nature of the individual organisms and may have been responsible for the 
significant changes in the clinical profile of the disease.  
 
5.1.2 Impact of primary pleural drainage procedure in empyema 
 
As the incidence of empyema has increased since 1997, another important question is what is 
the best way to manage empyema? Clinical management has routinely been based on draining 
the fluid in the pleural cavity. This is required to relieve the pressure and the pain associated 
with empyema and to allow healing to occur. The optimal method for achieving adequate 
pleural drainage has not been agreed between different specialists. The UK national guidelines 
explicitly acknowledge the paucity of firm evidence underpinning the management of empyema 
in children (Balfour-Lynn et al., 2005). Areas of particular controversy include the choice of 
primary pleural drainage procedure, the role of fibrinolysis in treatment and the usage of 
computerised tomography scanning in diagnosis of empyema (Balfour-Lynn et al., 2005). The 
UK guidelines recommend that initial management may be either thoracocentesis with the 
installation of intrapleural fibrinolytics, such as Urokinase or surgical drainage using either a 
mini-thoracotomy or VATS approach. The evidence underpinning this is limited. Intrapleural 
drainage with fibrinolysis has been shown to shorten hospital stay in children when compared to 
drainage with saline placebo in one small (n=60 children in total) randomised controlled trial 
(Thomson et al., 2002). Interestingly, the use of fibrinolytic agents in adults is associated with 
increased morbidity and mortality (Tokuda et al., 2006).  
 
The data comparing surgical and medical primary pleural drainage procedure is contradictory. 
Two small RCT’s (n=60 and 30 respectively) have demonstrated no difference between medical 
and surgical management in terms of length of stay, days of pleural drainage, days of fever and 
procedure number (Sonnappa et al., 2006; St. Peter et al., 2009). In contrast one small RCT (18 
patients), two large cohort studies and a meta-analysis have shown some benefit from a primary 
surgical approach (Avansino et al., 2005; Kurt et al., 2006; Li and Gates, 2008; Shah et al., 
2011). Further large scale studies comparing outcomes between the different treatment 
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modalities would be a significant contribution to the clinical management of paediatric patients 
with empyema.  
 
5.1.3 Measuring outcomes in empyema 
 
One factor which has contributed to the lack of concensus regarding treatment in empyema is 
the lack of agreed outcomes with which to compare treatments. Of those that have been used, 
none have included patient related outcome measures – outcome measures derived from direct 
questioning of patients and/or their parents.   
 
A number of different outcome measures have been used previously in studies of paediatric 
empyema. These include mortality, length of hospital stay, time to defervescence, treatment 
costs, complication rate and treatment failure rate (Thomson et al., 2002; Sonnappa et al., 2006; 
Li and Gates, 2008). Other comparators are required because specialists do not always concur on 
the relevance of each of these parameters. Death rates are not a useful outcome measure as the 
mortality from empyema is extremely low in children in industrialised nations (Balfour-Lynn et 
al., 2005).  
 
Length of hospital stay (LOS) has been consistently used as the predominant outcome 
measurement. LOS is a surrogate measure of the need for relatively intensive clinical care. The 
more severe the condition the longer the need for in-hospital care. There is a strong argument for 
the usage of LOS metrics to compare treatments because it is simple and easy to measure. LOS 
is objective but has several limitations. However, this outcome is confounded by treatment 
which may prevent early discharge and by other factors determining discharge. It can also be 
dependent on organisational factors such as the availability of hospital beds, and the ability and 
willingness of parents to take their child home to recuperate. LOS does not relate to any measure 
of patient or parental satisfaction.  
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When comparing pathogen and serotype differences, there is some evidence of significant 
differences in the duration of pre-hospital symptoms between pathogens, suggesting that a 
measure of pre-hospital symptom length should also be included in any comparator (Blaschke et 
al., 2011).    
 
5.1.4 Aims & hypotheses 
 
The aims of this analysis were twofold. Firstly, to investigate whether the clinical profile of 
empyema differed between pathogens and pneumococcal serotypes. Secondly, to evaluate the 
effectiveness of different methods of treating empyema to better inform management of the 
condition. It was assumed that LOS was an accurate surrogate of illness severity and that 
hospital discharge was the final event in the patient’s experience of the illness. By using 
discharge as an event or outcome in this manner, survival analysis can be used to model factors 
impacting on this outcome. Differences in the clinical profile of paediatric empyema between 
pathogens and pneumococcal serotypes were then investigated by survival analysis with 
discharge from hospital as the primary outcome. Similarly, LOS stay was modelled to compare 
primary pleural drainage methodologies in the treatment of empyema using Cox’s proportional 
hazards models to assess factors impacting on risk of discharge. Readmission and complication 
rates were also compared between different drainage methodologies to investigate failure and 
safety of the methods. The key hypotheses were therefore: 
 
Key hypotheses: 
- Time to disease resolution in empyema is dependent on pathogen and pneumococcal 
serotype.  
- Surgical methods of primary pleural drainage are associated with shorter hospital stay in 
paediatric empyema. 
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5.2 Methods 
 
5.2.1 Ethical approval  
 
The UK-ESPE study received a favourable opinion from the Sunderland Regional Ethics 
Committee in October 2007 (Appendix Q). The National Information Governance Board 
approved the study, with informed consent required for the prospective collection of patient 
identifiable information. 
  
5.2.2 Clinical data  
 
Demographic, clinical and microbiological data on children with empyema undergoing pleural 
drainage were obtained from 19 paediatric respiratory centres from September 2006 until March 
2011 as part of the UK-ESPE study (Study protocol is included as separate Appendix P). Data 
were collected through the use of a web-access form stored on a secure database. Forms were 
completed by a nominated clinical team in each respiratory centre for each patient.  
The inclusion criteria were: 
- Age up to 16 years 
- Clinical diagnosis of empyema 
- Undergoing some form of invasive pleural drainage    
 
The clinical data were linked by surname and date of birth to the separate database of detected 
pneumococcal serotypes from the HPA. In September 2006, the HPA established enhanced 
surveillance of paediatric culture negative empyema for England in collaboration with members 
of the British Paediatric Respiratory Society (BPRS). Samples were forwarded from admitting 
hospitals managing patients with empyema. Those that were pneumococcal PCR positive 
underwent non-culture serotyping using a multiplex antigen detection assay capable of detecting 
14 serotypes/groups (1, 3, 4, 5, 6A/C, 6B, 7F/A, 8, 9V, 14, 18, 19A, 19F and 23F) (Sheppard et 
al., 2011).  
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Primary pleural drainage management strategy was defined as that used in the first 48 hours of 
pleural drainage and all cases were divided into two categories – primary medical management 
and primary surgical management and four sub-categories – drainage alone, drainage and 
fibrinolysis (primary medical management), mini-thoracotomy and VATS (primary surgical 
management). The cut off of 48 hours was used to distinguish between patients who had primary 
surgical management from those that had failure of primary medical management requiring later 
surgical treatment.  
 
Two LOS measurements were used – total hospital stay and tertiary hospital stay. Tertiary 
hospital stay was defined as the stay in the hospital where definitive drainage was carried out 
and in those cases where children were admitted directly to the tertiary centre was equivalent to 
the total hospital stay. For comparisons between empyema caused by different organisms and 
different pneumococcal serotypes, a third time metric named illness length was used. This was 
defined as the total hospital stay in days added to the length of pre-hospital symptoms. The 
relationship between all three measurements is shown in Figure 5.1.    
 
 
Figure 5.1 Relationship between illness length and LOS measurements. 
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Three further outcome measures were used for comparisons between treatment groups. These 
were the readmission rate, the complication rate and the pneumothorax rate. The readmission 
rate was proposed as an indicator of treatment failure. The complication and pneumothorax rates 
were included as important safety indicators for different treatments. Complications were 
defined by the clinician collecting data in each centre and were recorded in a free-text box in the 
web-access proforma. Pneumothoraces were all listed as complications in this manner, rather 
than as a separate question.   
 
5.2.3 Statistical methods 
 
Survival analysis is a broad term referring to a range of techniques employed whereby the main 
outcome variable is time to observe a particular events (Kirkwood and Sterne, 2003). Data 
recorded during this analysis were generally not normally distributed and were often positively 
skewed. Secondly, not all individuals in the study reached the endpoint of interest during the 
observation period leading to the phenomenon of right censoring (Everitt and Rabe-Hesketh, 
2001). Several statistical techniques are available that allow for the analysis of these data and are 
known collectively as survival methods (Kirkwood and Sterne, 2003).  
 
Three primary outcome measures were examined. These were illness length, total hospital stay 
and tertiary centre stay. Each was assessed for normality by plotting of the frequency 
distribution and using the Shapiro-Wilks test for normality (Royston, 1982) (Appendix - Figure 
9.57, Figure 9.58, Figure 9.59). All three measures were found to not conform to the 
underlying statistical assumptions of normality insofar as they were positively skewed. These 
findings support a survival analysis approach. Furthermore, age, sex, hospital or centre and 
admission to intensive care were hypothesised to be likely to relevant to determining illness 
length and hospital stay length, hence a multivariate approach, as opposed to a simple univariate 
survival approach using survivor functions was required. The most widely applied method of 
analysing multivariate regression of survival data is the Cox proportional hazards model 
(Kirkwood and Sterne, 2003). The Cox proportional hazards model can be expressed as: 
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   ( ( ))     (  ( ))                    
 
where h(t) is the hazard at time t, h0(t) is the baseline hazard (the hazard for an individual in 
whom all exposure variables = 0) at time t, and x1 and xp are the p exposure variables (Kirkwood 
and Sterne, 2003). An assumption of the Cox model is that the hazards remain proportional over 
the time period.  
Cox proportional hazards models were built using the Survival package in R 2.14.0 (Therneau, 
2011). Ties were handled using the Efron approximation. (Therneau, 2011).  
Two models were proposed to investigate differences in illness length between pathogens and 
pneumococcal serotypes. 
 
Model Org: 
Illness length ~    (  ( )) + β1*Sex + β2*Age + β3*Organism detected + є 
 
Model Sero: 
Illness length ~    (  ( )) + β1*Sex + β2*Age + β3*Serotype detected + є 
 
Age, sex, pre-hospital illness length, paediatric intensive care unit (PICU) admission, chest drain 
type, co-morbidity, antibiotic choice and treatment group were included as co-variates in the 
initial models comparing treatment. Four initial models were proposed, two comparing primary 
medical and primary surgical methods and two comparing the four specific treatment 
methodologies such as mini-thoracotomy (Table 5.1). The principles of parsimony and 
backward selection were followed so non-significant parameters were removed stepwise and 
significant parameters retained in the models.   
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There were significant differences in both LOS measures between different centres. 
Stratification by centre was initially considered in order to remove the influence of centre. 
Stratification has often been used to adjust for the unwanted effect of centre within multi-centre 
trials of treatments (Everitt and Rabe-Hesketh, 2001). However, while there was intra-centre 
variation in primary pleural drainage procedure, not all centres carried out all methods of pleural 
drainage, meaning that stratification by centre would not be possible. Therefore, in order to 
adjust for the influence of centre when comparing the LOS between treatment methods, a frailty 
term was used. Frailty terms represent random effects within survival models and in the context 
of a multivariate regression model represent common unmeasured covariates between the 
groupings specified as the frailty term (Andersen et al., 1999; Therneau and Grambsch, 2000). 
For example, centres may differ in approaches to pain management in children with empyema, 
but this is likely to be consistent within the hospital. Pain management may in turn influence 
LOS but would usually not be specifically measured. It is likely there are multiple unmeasured 
variables of potential influence that may vary considerably between centres. This unmeasured 
variation was included in the models as a frailty term.       
 
Model HSa Total hospital stay ~    (  ( )) + β1*Sex + β2*Age + β3*PICU Admission + 
β4*Chest drain type + β5*Co-morbidity + β6*Antibiotic choice + β7*Treatment 
method (Medical vs. Surgical) + fraility (Centre) + є 
Model TCa Tertiary centre stay ~    (  ( )) + β1*Sex + β2*Age + β3*PICU Admission + 
β4*Chest drain type + β5*Co-morbidity + β6*Antibiotic choice + β7*Treatment 
method (Medical vs. Surgical) + fraility (Centre) + є 
Model HSb Total hospital stay ~    (  ( )) + β1*Sex + β2*Age + β3*PICU Admission + 
β4*Chest drain type + β5*Co-morbidity + β6*Antibiotic choice + β7*Treatment 
method (Specific methodology) + fraility (Centre) + є 
Model TCb Tertiary centre stay ~    (  ( )) + β1*Sex + β2*Age + β3*PICU Admission + 
β4*Chest drain type + β5*Co-morbidity + β6*Antibiotic choice + β7*Treatment 
method (Specific methodology) + fraility (Centre) + є 
 
Table 5.1 Modelling framework for analysis of primary pleural drainage method on length 
of stay in empyema 
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Testing of non-proportionality of hazards was carried out by plotting the Schoenfeld residuals 
for the models and by regression of the weighted residuals, as outlined by Grambsch and 
Therneau (1994).   
 
Readmission, complication and pneumothorax rates represented binomial outcomes. The effect 
of different treatment groups on each rate was interrogated using binomial generalised linear 
models where odds ratios for each treatment group were calculated. Not all outcomes occurred 
in all centres and as such centre was omitted from the model. A binomial generalised linear 
model was also used to compare baseline differences in age, sex, co-morbidity and PICU 
admission between the medical and surgical groups.    
 
LOS data are prone to the influence of outliers (Sills et al., 2000). For example, children with 
serious underlying co-morbidity or complex psycho-social needs are at risk of staying 
significantly longer in hospital (Mahon and Kibirige, 2004). The removal of the 2% highest and 
lowest LOS values has been used elsewhere to counterbalance this (Markowitz et al., 1996; Sills 
et al., 2000). The range the three outcome measures before and after this adjustment are shown 
in  
Table 5.2: 
 
Measure Pre-adjustment Post-adjustment 
Illness length / days 6 – 134 9 – 88 
Total hospital stay / days 3 – 134 5 – 43 
Tertiary hospital stay / days 2 – 103 3 – 33 
 
Table 5.2 Range of outcome measures pre and post adjustment. 
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5.3 Results 
 
5.3.1 Summary of clinical data 
 
Data on a total of 637 children were obtained (56% male, median age 4.3 years). Their 
characteristics are summarised in  
Table 5.3. The spread of cases by year of the study is shown in  
Figure 5.2. 
 
 
 
 
Figure 5.2 Cases recruited in each year of the UK-ESPE study 
 
Where a microbiological cause was identified (n=287), Streptococcus pneumoniae accounted for 
68%. The full details of microbiological data are included in  
Table 5.4. A pneumococcal serotype was detected in a 123 patients with serotype 1 accounting 
for 46% of these. Other prominent serotypes were 3(22%), 7(12%) and 19A(9%) ( 
Table 5.5). 
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The median tertiary LOS was 8 days (range 3-33) and median total hospital stay (THS) 11 days 
(range 5-43). One in five children was admitted to PICU. There was an even split between 
medical (51%) and surgical (49%) primary pleural drainage procedures, with mini-thoracotomy 
being the commonest approach used (46%).     
 
Variable  % (Count) / Median 
(Range) 
Respondents (n=637) 
Age (years)  4.3 (0-16) 637 
Sex  56% (359) 637 
Pre-hospital illness length 
(days)  
6  (0-60) 613 
Pre-hospital antibiotics given?  34% (163) 477 
Any co-morbidity?  10% (65) 637 
Antibiotics in tertiary centre   637 
- Penicillins  5% (31)  
- Clindamycin  22% (141)  
- Cephalosporins  18% (120)  
Drain type   610 
- Large bore  62% (378)  
- Pigtail  38% (232)  
PICU admission  21% (125) 609 
Any listed complication?  9% (60) 637 
Illness length (days) 18 (9-88) 603 
Total hospital stay (days)  11 (5-43) 637 
Stay at tertiary centre (days)  8 (3-33) 637 
Primary pleural drainage 
procedure 
 637 
- Drainage & fibrinolysis 45% (288)  
- Drainage alone 6% (36)  
- Mini-thoracotomy 46% (295)  
- VATS 3% (18)  
- Primary medical 
(Drainage alone & 
drainage and 
fibrinolysis) 
51% (324)  
- Primary surgical (Mini-
thoracotomy & VATS) 
49% (313)  
 
Table 5.3 Demographics of cases of paediatric empyema included in the analysis (n=637).  
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Organism recovered % (Count)  
S. aureus 10 (16) 
S. pyogenes 6.3 (40) 
S. mitis 1.1 (7) 
S. pneumoniae 28.7 (183) 
Other organism 6.8 (43) 
No organism recovered 48.7 (306) 
Unknown 6.1 (39) 
 
Table 5.4 Organisms recovered from the 637 children included in the analysis. 
 
Pneumococcal serotype recovered % (Count)  
1 43.4 (59) 
14 2.2 (3) 
19A 10.3 (14) 
3 20.6 (28) 
5 2.2 (3) 
7 11 (15) 
8 0.7 (1) 
Non assay serotype 9.6 (13) 
 
Table 5.5 Distribution of pneumococcal serotypes detected in 136 children matched to the 
HPA pneumococcal serotype database.   
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5.3.2 Variation between centres 
 
 
A total of 19 centres contributed data. The number of patients included from each centre is 
shown in Figure 5.3. One centre (Newcastle) provided 23% of study patients. There were no 
significant differences in the age of patients (Kruskal-Wallis, p= 0.1255) and the sex distribution 
(Fisher’s test, p= 0.1496) between centres. However, pre-hospital antibiotic usage (Fisher’s test, 
p<0.001) and pre-hospital illness length (Kruskal-Wallis, p<0.001) did vary significantly. There 
was also significant variation in management between centres. Primary pleural drainage 
approach by centre is shown in  
Figure 5.4 confirming both inter-centre and intra-centre variation in approach. Chest drain type 
(Fisher’s test, p<0.001) and PICU admission (Fisher’s test, p<0.001) varied significantly 
between centres. Perhaps most importantly, length of stay outcomes were also significantly 
different between centres ( 
Figure 5.5,  
Figure 5.6 and Figure 5.7). These differences confirmed the need to model the centre effect 
explicitly when analysing the effects of primary pleural drainage procedure on the outcome 
measures.   
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Figure 5.3 Numbers of patients included from each centre (STO – North Staffordshire 
Hospitals, SOT – Southampton General Hospital, SHE – Sheffield Children’s Hospital, PLY 
– Derriford Hospital, Plymouth, OXF – John Radcliffe Infirmary, Oxford, NOT – 
Nottingham Royal Infirmary, NEW – Freeman Hospital, Newcastle, MAN – Manchester 
Children’s Hospital, LIV – Alder Hey Hospital for Sick Children, LEI – Leicester Royal 
Infirmary, GOS – Great Ormond Street Hospital for Sick Children, GLA – Royal Hospital for 
Sick Children, Glasgow, EDI – Royal Hospital for Sick Children, Edinburgh, COR – Royal 
Cornwall Hospital, Truro, CAM – Addenbrookes Hospital, Cambridge, BRO – Royal 
Brompton Hospital, London, BRI – Bristol Royal Infirmary, BCH – Birmingham Children’s 
Hospital, BAR – Royal London Hospital, London)   
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Figure 5.4 Proportion of different primary pleural drainage procedure in each study 
centre (VATS – video assisted thoracoscopic surgery, Thorac – thoracotomy, Fib – drainage 
and intrapleural fibrinolysis, Drain – pleural drainage only; STO – North Staffordshire 
Hospitals, SOT – Southampton General Hospital, SHE – Sheffield Children’s Hospital, PLY 
– Derriford Hospital, Plymouth, OXF – John Radcliffe Infirmary, Oxford, NOT – 
Nottingham Royal Infirmary, NEW – Freeman Hospital, Newcastle, MAN – Manchester 
Children’s Hospital, LIV – Alder Hey Hospital for Sick Children, LEI – Leicester Royal 
Infirmary, GOS – Great Ormond Street Hospital for Sick Children, GLA – Royal Hospital for 
Sick Children, Glasgow, EDI – Royal Hospital for Sick Children, Edinburgh, COR – Royal 
Cornwall Hospital, Truro, CAM – Addenbrookes Hospital, Cambridge, BRO – Royal 
Brompton Hospital, London, BRI – Bristol Royal Infirmary, BCH – Birmingham Children’s 
Hospital, BAR – Royal London Hospital, London).    
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Figure 5.5 Variation in total illness length between study centres (Test for difference in 
illness length, Kruskal-Wallis, p<0.001).  
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Figure 5.6 Variation in total length of hospital stay between study centres (Test for 
difference in total length of hospital stay, Kruskal Wallis, p<0.001). 
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Figure 5.7 Variation in tertiary hospital stay between study centres (Test for difference in 
tertiary hospital stay, Kruskal-Wallis, p<0.001). 
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5.3.3 Influence of pathogen on illness length 
 
In order to test whether changes in the epidemiology of empyema had led to changes in the 
severity of clinical disease, the relationship between illness length and the pathogen causing 
empyema was investigated. 
 
While there was no relationship between sex and pathogen (Fisher’s test, p=0.5246), there was a 
significant interaction between age and pathogen, with those known to have been infected with S. 
aureus and S. pyogenes being the youngest (Figure 5.8, Kruskal-Wallis, p<0.001). As a 
consequence, age was included as a covariate in the initial model Org. However, this was shown 
to be non-significant and was therefore subsequently excluded from the analysis (Age – Hazard 
0.9885 (95% CI 0.969 – 1.008), p=0.2487).  
 
Figure 5.8 Significant differences in the age of children with empyema caused by different 
pathogens (Kruskal-Wallis chi-squared = 43.1226, df = 5, p-value = <0.001) 
There was a significant relationship between illness length and pathogen. The event curves for 
each pathogen are shown in Figure 5.9. Table 5.6 contains the hazard estimates and model 
diagnostic information. There was no violation of the proportional hazards assumption (Plots of 
Schoenfeld residuals and results of regression of residuals are shown in Appendix - Table 9.4 
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and Figure 9.60). Children who isolated S. pneumoniae had a 110% reduction in their illness 
length when compared to children who isolated S. aureus (Hazard 2.121, (95% CI 1.117 – 
4.028), p=0.021) suggesting that the predominance of pneumococcus in causing empyema may 
have led to less severe disease.  
 
Figure 5.9 Event curves comparing illness length between pathogens in children with 
empyema in the UK.  
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Illness length 
Variable Co-efficient Hazard 
Standard 
Error 
95% CI P-value 
S. aureus REFERENCE 
S. pyogenes 0.367 1.444 0.356 0.719 ; 2.899 0.302 
S. mitis 0.096 1.101 0.494 0.418 ; 2.901 0.846 
No organism 
detected 
0.670 1.954 0.324 1.036 ; 3.685 0.039 
Other 0.408 1.504 0.359 0.745 ; 3.039 0.255 
S. pneumoniae 0.752 2.121 0.327 1.117 ; 4.028 0.021 
 
Concordance = 0.548 (se = 0.014 ) 
R squared = 0.026 
Likelihood ratio test = 14.82 on 5 df, p=0.011 
Wald test = 13.22 on 5 df, p=0.021 
Score (logrank) test = 13.5 on 5 df, p=0.019 
 
Table 5.6 Results of parsimonious model Org investigating the relationship between illness 
length and pathogen in UK children with empyema.  
230 
 
5.3.4 Influence of pneumococcal serotype on illness length  
 
The relationship between pneumococcal serotype and illness length was investigated using the 
same approach as for the relationship between pathogen and illness length. There was no 
difference in the sex distribution between pneumococcal serotypes (Fisher’s test, p-value = 
0.8572). There was a significant interaction between age and serotype. Serotype 19A and 
serotype 3 had the lowest median age and whereas serotype 1 showed the greatest median age 
(Figure 5.10 (Kruskal Wallis, p-value <0.001). Age was therefore included as a covariate in the 
initial model Sero. This was found to be non-significant and was therefore excluded from 
subsequent analysis (Age – Hazard -0.0171 (95% CI 0.9341 - 1.0345), p=0.5104).  
 
Figure 5.10 Significant differences in age between cases of pneumococcal empyema caused 
by individual pneumococcal serotypes (Kruskal Wallis - chi-squared = 44.9934, df = 4, p-
value <0.001).  
Illness length varied significantly between pneumococcal serotypes. The event analysis curves 
are shown in Figure 5.11 and the relationship between illness length and serotype is displayed 
231 
 
in Table 5.7. Children infected with pneumococcal serotype 19A had on average a 60% longer 
illness (95% CI 25% - 78%) compared to those infected with serotype 1. The hazards remained 
constant over the whole time period (Plots of Schoenfeld residuals and results of regression of 
residuals are shown in Appendix Figure 9.61 and Table 9.5). 
 
Illness length 
Variable Co-efficient Hazard 
Standard 
Error 
95% CI P-value 
Serotype 1 REFERENCE 
Serotype 19A -0.8965 0.4080 0.3189 
0.2184 ; 
0.7623 
0.0049 
Serotype 3 -0.2915 0.7472 0.2331 
0.4731 ; 
1.1799 
0.2112 
Serotype 7 -0.6159 0.5402 0.3151 
0.2913 ; 
1.0018 
0.0507 
Other 
serotype 
-0.2210 0.8017 0.2618 0.48 ; 1.3392 0.3986 
 
Concordance = 0.568 (standard error = 0.031) 
R-squared = 0.077 
Likelihood ratio test = 10.66 on 4 df, p=0.03067 
Wald test = 9.73 on 4 df, p=0.04519 
Score (logrank) test = 10.06 on 4 df, p=0.03946 
 
 
Table 5.7 The results of the parsimonious model Sero investigating the relationship 
between illness length and pneumococcal serotype in UK children with empyema. 
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Figure 5.11 Event curves comparing illness length between pneumococcal serotypes in children 
with empyema in the UK.
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5.3.5 Impact of primary pleural drainage methodology on outcomes in empyema 
 
The impact of primary pleural drainage method on total hospital stay and tertiary centre stay was 
investigated by survival modelling including centre as a frailty term. The results of the 
parsimonious models investigating total hospital stay (HSa and HSb) and tertiary centre stay 
(TCa and TCb) are shown in Table 5.8 and Table 5.9. Surgical methods (Thoracotomy or 
VATS) were associated with a decrease in total hospital stay of 40% (95% CI 5-87%) when 
compared to non-surgical methods (thoracocentesis +/- fibrinolysis). A similar relationship was 
seen in tertiary centre stay (30% (95% CI -0.03-71%) but was of borderline significance 
(p=0.056). 
 
When comparing the four subgroups of treatments and using thoracocentesis and fibrinolysis as 
the reference treatment, thoracocentesis alone was associated with a significant increase in 
tertiary centre stay. A similar direction of effect was seen with total hospital stay but was non-
significant (p=0.061). Thoracotomy was associated with a reduction in both length of stay 
measures but neither association reached significance.  
  
PICU admission was associated with a significant increase in LOS in all models. Older children 
had a slightly longer total hospital stay (2% (95% CI 0-4%) HSa and 2% (0-3.9% (HSb)). The 
centre frailty term was significant in all models. 
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Total hospital stay (HSa) 
Variable Co-efficient Hazard SE 
95% 
CI 
P-value 
Concordance R-squared LRT Wald test Variance 
of frailty 
PICU Admission -0.816 0.442 0.121 
0.349; 
0.56 
<0.001 
0.695 
(se: 0.016 ) 
0.234 
156 on 
17.7 df,   
p<0.001 
52.6 on 
17.7 df,   
p<0.001 
0.299 
I-L: -
3087.7 
Age (Years) -0.020 0.980 0.010 
0.961; 
1 
0.049 
Medical Treatment REFERENCE 
Surgical Treatment 0.338 1.402 0.146 
1.053; 
1.87 
0.021 
Frailty (Centre) <0.001 
Tertiary centre stay (TCa) 
Variable Co-efficient Hazard SE 
95% 
CI 
P-value 
Concordance R-squared LRT Wald test Variance 
of frailty 
PICU Admission -0.985 0.374 0.121 
0.295; 
0.473 
<0.001 
0.720 
(se: 0.016 ) 
0.284 
195 on 
17 df, 
<0.001 
70.5 on 
17 df,   
p<0.001 
0.323 
I-L: 
-
3062.
5 
Medical Treatment REFERENCE 
Surgical Treatment 0.265 1.303 0.139 
0.997; 
1.711 
0.056 
Frailty (Centre) <0.001 
Table 5.8 Analysis of primary medical vs. surgical pleural drainage method in UK children with empyema (LRT = likelihood ratio 
test, I-L = I likelihood).  
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Total hospital stay (HSb) 
Variable Co-efficient Hazard SE 
95% 
CI 
P-value Concordance R-squared LRT Wald test 
Variance 
of frailty 
PICU Admission -0.793 0.452 0.120 
0.357 ; 
0.573 
<0.001 
0.694 
(se:0.016 ) 
0.244 
163 on 
19.4 df, 
p<0.001 
57.6 on 
19.4 df,   
p<0.001 
0.310 
I-L: -
3084.5 
Age (Years) -0.020 0.980 0.010 
0.961 ; 
1 
0.046 
Drainage & fibrinolysis REFERENCE 
Drainage alone -0.417 0.659 0.222 
0.426 ; 
1.019 
0.061 
Mini-thoracotomy 0.280 1.323 0.199 
0.896 ; 
1.954 
0.160 
VATS -0.091 0.913 0.293 
0.514 ; 
1.622 
0.760 
Frailty(Centre) <0.001 
Tertiary centre stay (TCb) 
Variable Co-efficient Hazard SE 
95% 
CI 
P-value Concordance R-squared LRT Wald test 
Variance 
of frailty 
PICU Admission -0.972 0.378 0.12 
0.299 ; 
0.479 
<0.001 
0.726 
(se: 0.016) 
0.297 
206 on 
18.9 df, 
P<0.001 
78.6 on 
18.9 df, 
p<0.001 
0.343 
I-L: -
3057.5 
Drainage & fibrinolysis REFERENCE 
Drainage alone -0.546 0.579 0.221 
0.375 ; 
0.894 
0.014 
Mini-thoracotomy 0.155 1.168 0.182 
0.817 ; 
1.67 
0.390 
VATS -0.248 0.78 0.289 
0.442 ; 
1.375 
0.390 
Frailty(Centre) <0.001 
 Table 5.9 Comparison of the four primary pleural drainage procedure in UK children with empyema (LRT = likelihood ratio test, 
I-L = I likelihood).
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Assumptions governing the use of proportional hazards was tested for all models by visual 
examination of the plotted scaled Schoenfeld residuals and by regression of the weighted 
residuals (Appendix Table 9.6, Figure 9.62, Figure 9.63, Figure 9.64 and Figure 9.65).   
 
Regression of the weighted residuals indicated there was significant non-proportionality in all 
four models. Examination of the plotted Schoenfeld residuals indicated that the non-
proportionality was moderate and unlikely to significantly affect the accuracy of the estimates of 
the co-variate effects (Therneau and Grambsch, 2000).  
 
Higher values of non-proportionality were seen in the surgical methods and thoracotomy groups 
in all four models. The estimate of the effect of surgery was positive (i.e. a reduction in length of 
stay) across all the models until approximately 14 days when the effect changes polarity and the 
probability of discharge associated with surgery declines (example shown in Figure 5.12).  
 
Figure 5.12 Non-proportional hazards in surgical treatment group in total hospital stay 
model (HSa). 
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Early surgery appears to confer a shorter stay when compared to medical treatment in the 
majority of patients, given the median stay was 11 days. However a minority seem to experience 
the opposite effect.  
 
Comparison of the baseline characteristics of patients in the medical and surgical treatment 
groups is shown in Table 5.10. Overall patients who had primary surgery were significantly 
older and more likely to have co-morbidity. Comparison of the characteristics of just those who 
stayed longer than 14 days indicated that surgical patients were significantly more likely to have 
a co-morbidity than those given medical treatment (OR 2.76, 95% CI 1.076 to 7.34, p=0.0365). 
There were no significant differences in age, sex and PICU admission between the two 
treatment groups in those that stayed more than 14 days. Co-morbidity alone was associated 
with an increase in hospital stay across the whole cohort of patients (co-efficient 2.47, 95% CI 
0.94 to 4.00, p=0.0016).  
 
The absence of a significant difference in the rate of PICU admission between the two groups 
suggests that the observed variation in effect of surgery may not be related to disease severity, 
although PICU admission is at best only a proxy measurement of severity and may be 
influenced by other uncontrolled variables such as bed availability. 
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Variable Odds Ratio 95% CI P-value 
Deviance 
residuals 
Null 
Deviance 
Residual 
Deviance 
AIC 
Age (Years) 1.041 1.000 ; 1.083 0.049 
-1.782 to 
1.377 
844.25 on 
608 DF 
824.85 on 
604 DF 
834.85 
Sex 1.031 0.744 ; 1.430 0.853 
PICU Admission 0.844 0.600 ; 1.269 0.416 
Co-morbidity 2.750 1.567 ; 5.016 <0.0001 
 
Table 5.10 Comparison of baseline characteristics between medical and surgical treatment groups (medical treatment group reference).
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Treatment Odds Ratio 95% CI P-value 
Range of 
Deviance 
Residuals 
Null 
Deviance 
Residual 
Deviance 
AIC 
Readmissions 
Medical management REFERENCE -0.478 to 
2.675 
248.98  on 
591 DF 
243.00  on 
588 DF 
251 
Surgical management 0.410 0.182 ; 0.863 0.0231 
Drainage & fibrinolysis REFERENCE 
-0.485 to  
2.697 
 
248.98  on 
591 DF 
242.45  on 
586 DF 
254.45 
Drainage alone 0.792 0.122 ; 2.916 0.7614 
Mini-thoracotomy 0.378 0.161 ; 0.826 0.0185 
VATS 0.846 0.0455; 4.566 0.875 
Any complications 
Medical management REFERENCE -0.518 to 
2.564 
350.44  on 
636 DF 
338.00  on 
633 DF 
346 
Surgical management 0.338 0.169 ; 0.634 0.00116 
Drainage & fibrinolysis REFERENCE 
-0.756 to 
2.588 
 
350.44  on 
636 DF 
333.87  on 
631 DF 
345.87 
Drainage alone 2.602 1.026 ; 6.061 0.033 
Mini-thoracotomy 0.383 0.184; 0.750 0.00684 
VATS 0.535 0.0291; 2.764 0.551 
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Treatment Odds Ratio 95% CI P-value 
Deviance 
residuals 
Null 
Deviance 
Residual 
Deviance 
AIC 
Pneumothorax 
Medical management REFERENCE -0.424 to 
2.986 
191.32  on 
636 DF 
183.15  on 
633 DF 
191.15 
Surgical management 0.377  0.133 ; 0.934  0.0454 
Drainage & fibrinolysis REFERENCE 
-0.630 to 
2.965 
191.32  on 
636 DF 
179.66  on 
631 DF 
191.66 
Drainage alone 3.054 0.807 ; 9.562  0.033 
Mini-thoracotomy 0.482 0.165 ; 1.268  0.007 
VATS 0  ∞  0.551 
 
Table 5.11 Analysis of readmission rates, complications and pneumothorax rates by treatment group in UK children with 
paediatric empyema. 
241 
 
A total of 32 patients were readmitted to hospital following their initial discharge. Fifty patients 
experienced complications (Full list of complications is shown in Appendix Table 9.7). Of these, 
22 had a pneumothorax.  
 
The results of the analysis of readmission, complication and pneumothorax rates between the 
different treatment classifications are shown in Table 5.11. Early surgery (VATS or mini-
thoracotomy) was associated with a reduced risk of readmission (OR 0.41, 95% CI: 0.18-0.86), 
any complications (0.34, 0.17-0.63) and pneumothorax (0.38, 0.13-0.93). When comparing the 
four treatment groups and using drainage and fibrinolysis as the reference group, drainage alone 
was associated with increased risk of complications (2.60, 1.03-6.06). Mini-thoracotomy was 
associated with a reduced risk of readmission (0.38, 0.16-0.83) and complications (0.38, 0.18-
0.75).  
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5.4 Discussion 
 
A typical patient with paediatric empyema in the UK between 2006 and 2011 was a four year 
old boy who stayed in hospital for a total of eleven days. If a cause was found for the empyema 
it was likely to be pneumococcal and of pneumococcal cases, pneumococcal serotype 1 was the 
most likely to be isolated. Staphylococcal disease was associated with significantly increased 
length of illness. Children with disease due to serotype 19A had a significantly prolonged illness 
length relative to other pneumococcal serotypes. 
 
There were significant differences in the in-patient stay between different centres. Independent 
of centre effects, surgery as the primary pleural drainage procedure was associated with an 
approximate 40% reduction in LOS but there was significant heterogeneity in response between 
patients, possibly related to co-morbidity. Furthermore surgery was associated with a reduced 
risk of readmission, complications and pneumothoraces. There were no significant differences in 
length of stay when comparing the four individual treatment groups. 
 
There were baseline differences in the four treatment groups. It therefore seems likely that the 
non-proportionality of the hazards associated with surgical treatment reflect in part a patient 
selection issue. Patients with co-morbidity are likely to have a longer stay independent of 
treatment method and are more likely to be selected to undergo surgery.  
 
5.4.1 Strengths and limitations 
 
Strengths of this analysis include the size of the cohort and the use of a robust modelling 
framework. The size of the study means that it will significantly add to the literature examining 
the impact of the change in epidemiology of empyema on the natural history of the disease as 
experienced by patients. Furthermore 637 patients represent a cohort that is substantially larger 
that have been based on directly collected clinical data than any previously used to evaluate 
empyema management in children. Only studies based on hospital coding data and therefore 
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with limited accuracy have been larger in scope (Li and Gates, 2008; Shah et al., 2011). Other 
studies that have used directly collected clinical data have either been based at a single centre or 
have not used methods for assessing the influence of centre related effects (Khalil et al., 2007; 
Shomaker et al., 2011). This data will therefore provide an important contribution to the 
evidence base supporting clinicians making decisions about the treatment of paediatric 
empyema.      
 
The modelling framework used allows estimation and adjustment for centre effects thereby 
allowing accurate comparisons of different treatment methodologies. This is particularly 
important in the context of the widespread variation in approach to the management of 
paediatric empyema in the UK and given the observational nature of the study. While national 
guidance for the management of empyema in the UK exists, this study highlights the fact that 
not only approaches but outcomes vary significantly between centres. The presence of this 
heterogeneity therefore required explicit modelling of a centre effect.  
 
Despite these strengths there remain significant limitations in this analysis. One limitation is the 
microbiological data. Pathogens were identified in several ways. Standard microbial culture of 
blood or pleural fluid was applied to all patients entered into the study. However, a proportion of 
patients were identified as having pneumococcal infection by use of non-culture molecular 
detection through the use of pneumococcal antigen specific PCR on pleural fluid. This was 
carried out by the HPA in England and the Scottish Haemophilus Legionella Meningococcus & 
Pneumococcus Reference Laboratory. The protocol was for all enrolled patients whose pleural 
fluid was culture negative to be forwarded for molecular testing. Due to a technical error by the 
third party collaborator however no record of which samples were tested were kept until March 
2010. Furthermore not all laboratories consistently forwarded samples, leaving significant 
uncertainty about the status of patients recorded as having no organism identified.  
 
To compound matters the web-based proforma did not distinguish between identifications made 
via culture or non-culture methods. Individual centres did not generally keep records of which 
samples were forwarded for non-culture testing. It is therefore possible that samples identified as 
pneumococcal were either detected through culture and non-culture methods. Those where no 
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pathogen was detected may be as a consequence two different chains of events. Standard 
cultures may have been negative and no further testing was carried out or standard cultures were 
negative and non-culture pneumococcal testing was negative. Therefore those samples that were 
listed as no organism detected may in fact represent both undetected pneumococcal disease and 
culture negative non-pneumococcal disease, significantly compromising the interpretability of 
the microbiology results.  
 
There are also some limitations from the analytical approach. Readmission, complication and 
rates of pneumothoraces were insufficiently common to allow adjustment for a centre effect. Yet 
it is likely that in particular readmission rates are subject to centre related factors such as bed 
availability, admission criteria and perhaps more importantly discharge criteria. The presence of 
a significant centre effect would therefore have acted as a potential source of bias.  
 
The non-proportionality of the hazards associated with surgical treatment methods potentially 
limits the generalisability of the results. The overall non-proportionality was moderate. It was 
not judged to have significantly affected the results and had a plausible causal explanation in the 
form of selection bias towards those patients with co-morbidity.  
        
5.4.2 Findings related to other studies 
 
Within the UK-ESPE cohort, children who had pneumococcal empyema had an illness length of 
approximately half of that experienced by those who had a staphylococcal empyema. Blaschke 
and colleagues (2011) compared outcomes of children with S. pneumoniae, S. pyogenes and S. 
aureus. Children with staphylococcal empyema had hospital stays approximately twice as long 
as those with pneumococcal and streptococcal empyema (21 days vs. 10 and 11 days 
respectively) consistent with the UK-ESPE cohort, although the overall numbers of children 
were small and no statistically significant differences were found between the groups.  
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The difference in illness length between pathogens is likely to be a consequence of several 
factors. Firstly, culture positivity is associated with shorter pre-hospital symptom length but 
significantly prolonged hospital stay. Secondly, differences in culture positivity rates between 
different pathogens are well recognised in paediatric empyema (Blaschke et al., 2011). Culture 
positivity may also be affected by a number of factors other than the pathogen involved 
including previous antibiotic usage, sampling frequency and laboratory technique. These caveats 
are supported by significant geographical variation in blood culture positivity rates between 
different countries, notably the USA and countries in Western Europe (Jefferson et al., 2006). In 
addition, both pathogen and host specific factors are considered to be relevant in determining 
illness length. These factors are also likely to interact and impact on pathogen acquisition, 
probability of invasiveness and subsequent response to treatment. All of which in turn will have 
a direct impact on illness length. In a similar manner, pathogen related factors such as presence 
of virulence factors, invasiveness potential and antibiotic resistance will also impact on illness 
length. Finally treatment factors may be also be relevant. Discordant initial antibiotic use was 
the only significant risk factor found for death in empyema in adults in one study of empyema in 
Asia (Tsang et al., 2007).   
 
Children with pneumococcal infection had a much reduced illness length compared to those 
infected with other pathogens, differences between pneumococcal serotypes were observed with 
serotype 19A associated with a significantly prolonged illness length when compared to the 
most common serotype, serotype 1. The pneumococcal capsule is an important virulence factor, 
and hence differences in disease severity between serotypes are well described, although illness 
length has not previously been specifically reported (Reinert et al., 2010). Picazo and colleagues 
found high rates of PICU admission (63.6%) and complications (27.3%) in Spanish children 
with empyema due to serotype 19A (Picazo et al., 2011). Similar high rates of PICU admission 
associated with empyema due to Serotype 19A have been described elsewhere (Blaschke et al., 
2011).   
    
As outlined previously, the literature comparing medical and surgical primary pleural drainage 
approaches is heterogeneous. Since 2005 a total of six high quality studies have been published, 
including three randomised controlled trials. The findings of these are re-summarised in Table 
5.12. A finding in favour of primary surgery as primary pleural drainage procedure is consistent 
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with the findings of previous retrospective cohort studies and the previous meta-analysis 
(Avansino et al., 2005; Li and Gates, 2008; Shah et al., 2011). Interestingly of the three separate 
RCT’s addressing this question, two have reported no difference between primary surgery and 
medical management and one found in favour of VATS. It is worth commenting that the total 
number of patients enrolled in RCT’s was small when compared to the other studies (114 vs. 
8728 including those from the UK-ESPE study). It is therefore possible that the RCT’s carried 
out thus far have not had sufficient power to discriminate between the different approaches.  
 
It is also of interest that consistent with the findings of Shah et al (2011) there were no 
significant differences between the four individual treatment sub-categories. This may indicate 
that there is no true difference in LOS between different surgical approaches.     
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Study  Type of study  Comparison Results  
Avansino (2005)  Meta-analysis  Any surgery vs. CTD or 
IFT 
Primary operative approach (VATS/OT) lowered mortality, need 
for re-intervention, LOS, duration of chest tube and antibiotics 
compared to primary medical therapy  
Kurt (2006)  RCT  VATS vs. CTD VATS lowered LOS and cost and risk of transfer  
Sonnappa (2006)  RCT  VATS vs. IFT No difference between VATS and IFT in terms of LOS, days of 
CTD and procedure number. IFT less expensive  
Li and Gates 
(2008)  
Retrospective cohort 
review  
Any surgery vs. CTD or 
IFT 
Primary operative approach lowered LOS and cost and risk of 
transfer  
St Peter (2009)  RCT  VATS vs. IFT No difference between VATS and IFT in terms of LOS, febrile days 
and oxygen requirement  
Shah (2011)  Retrospective cohort 
review  
VATS vs. IFT VATS lowered need for re-intervention; No difference in LOS 
between VATS and IFT  
UK-ESPE Prospective (& 
retrospective) cohort 
review 
Any surgery vs. CTD or 
IFT 
Reduced LOS, readmission and complication rate in favour of 
surgery 
CTD = Continuous tube drainage without fibrinolysis, IFT = Drainage and intrapleural fibrinolysis, OT = open thoracotomy 
Adapted from Anselmo M Can Resp J (2010)  
Table 5.12 Update of Table 1.2 Summary of studies comparing primary pleural drainage procedure in empyema.
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5.4.3 Implications for further research 
 
The above findings raise a number of intriguing questions. If the observed change in the epidemiology 
of empyema is as consequence of predominantly pneumococcal disease then does this imply an era of 
more frequent but much less severe disease in contrast to that historically associated with 
staphylococcal infection? Furthermore do changes in the incidence of different pneumococcal 
serotypes have important clinical implications? Detailed above is further evidence of the association 
of serotype 19A infection with increasing disease severity. Continuing surveillance will be required to 
monitor changes in the pneumococcal serotype distribution, particularly following the introduction of 
the latest generation of pneumococcal vaccines as these changes are likely to have clinical impacts. 
 
While this study provides further evidence to support surgery as the most efficacious primary pleural 
drainage procedure, two large cohorts have now not found any difference between open and VATS 
approaches suggesting that expending effort investigating this further may not be fruitful. Instead, 
future work should focus on establishing a multi-centre randomised controlled trial of sufficient 
power to evaluate the effectiveness of early surgery in the treatment of empyema in children when 
compared to optimal medical management. Similar trials have been carried out very successfully in 
adult patients with empyema in the UK and would probably be achievable in children (Rahman et al., 
2011).  
 
A significant weakness of this work and that previously published in the field is that none of the 
outcome measures are patient based. Future trials need to address this and include adequate and 
appropriate measures of patient and parent satisfaction, as well as health economic factors and more 
traditional outcome measures such as LOS. A further weakness is the lack of longer term outcome 
data such as outcome at 1 year after discharge. Future studies must address this gap if truly informed 
decisions regarding the most appropriate methods of managing empyema are to be made.   
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5.5 Conclusions 
 
Staphylococcal disease was associated with significantly increased illness length in contrast to the 
more prevalent pneumococcal disease. Children with disease due to pneumococcal serotype 19A had 
a significantly prolonged illness length. Further work both in epidemiological surveillance and in 
specific surveillance of pneumococcal serotypes are needed to monitor future changes, as such 
changes are likely to have clinical impacts.   
 
Surgery as the primary pleural drainage procedure was associated with an approximate 40% reduction 
in length of stay but there was significant heterogeneity in response between patients possibly 
reflective of co-morbidity. Surgery was associated with a reduced risk of readmission, complications 
and pneumothoraces.  
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6 Conclusions 
6.1 Summary of findings 
 
This thesis set out to explore and define the epidemiology of paediatric empyema in response to the 
increase in the incidence of the disease observed across different continents from 1995 onwards.  
 
The first step towards this aim was to confirm as robustly as possible that paediatric empyema had 
increased in the populations available to study. Analyses confirmed a consistent and substantial rise in 
the incidence of empyema in children. In England, the incidence of empyema as measured by hospital 
admissions increased from 9.68 (95% CI 7.79; 11.89) admissions per million children (0-14 years) in 
1997/8 to 37.47 (95% CI 33.6; 41.66) in 2004/5. This was equivalent to an extra 253 cases per annum. 
Similarly, cases increased in the North East of England from a baseline of 13.5 (95% CI 5.83; 26.6) 
cases per million children in 1995/6 to 51.43 (95% CI 33.59; 75.35) in 2010/11.  
 
The increase in the incidence of empyema in England between 1997 and 2006 was associated with a 
concurrent increase in bacterial pneumonia. The relationship between the two conditions varied over 
time with a doubling of the proportion of admissions to hospital with pneumonia complicated by 
empyema over the same period. Similarly, there were significant variations in the rate of increase of 
both conditions between different SHAs in England.  
 
Isolations of S. pneumoniae and S. pyogenes were positive predictors of empyema admissions, 
suggesting that both pathogens were responsible for the increase in incidence of empyema, with the 
bigger effect size seen with S. pneumoniae. S. pyogenes was also a positive predictor of the monthly 
rate of progression from empyema to pneumonia. Hospital admissions for empyema and the rate of 
progression between empyema and pneumonia both displayed significant seasonal variation. This 
seasonal variation correlated with activity of both S. pneumoniae and S. pyogenes.  There was some 
evidence of cyclicity within the rate of progression of pneumonia to empyema operating at an 
approximate 3 year cycle. This correlated with activity of S. pyogenes indicating that streptococcal 
pneumonia has a higher rate of progression to empyema than pneumococcal pneumonia.  
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There was no spatial variation in the risk of hospital admission with empyema in children in the North 
East of England at postcode district or area level. There was, however, a six-fold variation in the risk 
of hospital admission with pneumonia in the North East between different postcode districts. These 
differences were partially explained by variation in levels of family poverty in each district, total 
numbers of hospital admissions per district, levels of disability living allowance and hospital out-
patient attendances. The introduction of PCV-7 to the routine UK immunisation schedule in 
September 2006 was not associated with a reduction in the monthly incidence of empyema in the 
North East (co-efficient of the vaccine programme 0.17, 95% CI -0.28; 0.91), nor a change in the age 
profile of cases.  
 
Children with empyema in the UK between 2006 and 2011 were more likely to be male (56%), under 
the age of five (median age 4.3 years) and had a median total hospital stay of eleven days. If a cause 
was found for the empyema it was likely to be pneumococcal and of pneumococcal cases, serotype 1 
was the most frequently isolated. Staphylococcal empyema was associated with double the illness 
length when compared to pneumococcal empyema (Hazard 2.121, 95% CI 1.117; 4.028). 
Approximately half of all cases received primary medical treatment (46%) and half primary surgical 
treatment (49%). Those who had primary surgery were older (OR 1.041 95% CI 1.000; 1.083) and 
more likely to have co-morbidity (OR 2.750 95% CI 1.567; 5.016). Those in the primary surgical 
treatment group had a significantly shorter total hospital stay (Hazard ratio 1.402 95% CI 1.053; 
1.870), lower risk of readmission and any complication.        
 
6.2 Understanding the increase in the incidence of childhood empyema thoracis  
 
One major conclusion from this thesis is that the predominant mechanism underpinning the increase 
in the incidence of childhood empyema thoracis in England between 1997 and 2006 was an increase 
in childhood bacterial pneumonia caused by S. pneumoniae and to a lesser degree S. pyogenes.  
 
The predominance of pneumococcal empyema over staphylococcal empyema is a return to the pattern 
of causation of empyema seen in the pre-penicillin era (Heuer, 1932; Lionakis et al., 1958).  This 
raises the intriguing question of what factors have led to the resurgence of pneumococcal empyema.  
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One explanation for the resurgence of pneumococcal infection as the predominant cause of childhood 
empyema is the spread of a virulent pneumococcal serotype or clone (Byington et al., 2002a). This 
thesis reports that pneumococcal serotype 1 was the most common cause of paediatric empyema, as 
have a number of others (Byington et al., 2002b; Eltringham et al., 2003; Byington et al., 2006; 
Fletcher et al., 2006) raising the possibility that the increase in empyema was driven by expansion of 
this serotype. Serotype 1 has been observed to cause empyema within an outbreak situation and is 
recognised to spread epidemically (Kalin M, 1998; Gupta A et al., 2008). In the USA between 1993 
and 2002 89% of isolates of serotype 1 causing invasive pneumococcal disease in were multi-locus 
sequence type (MLST) 227 suggesting a close common lineage (Gonzalez et al., 2004). Similarly all 
serotype 1 isolates from children with invasive pneumococcal disease in Utah between 1996 and 2002 
were sequence type ST227 (Byington et al., 2005).  
 
Obando et al (2008) found that all serotype 1 isolates causing parapneumonic empyema in Spain 
between 2005 and 2007 were from a major lineage of ST types which included ST227 found across 
Europe and North America. Byington et al (2010) also reported that serotype 1 pneumococci causing 
paediatric empyema in Utah were related to the same lineage. In addition, clonal expansion of similar 
MLST types have been associated with an epidemic of meningitis in Ghana (Leimkugel et al., 2005). 
Some commentators have gone as far as to refer to these sequences types of serotype 1 as behaving 
near pandemically (Marimon et al., 2009). It is therefore tempting to conclude that the increase in the 
incidence of paediatric empyema thoracis was driven by clonal expansion and near pandemic spread 
of certain sequence types of serotype 1 pneumococcus.  
 
What remains uncertain is the mechanisms that determined the expansion of these sequence types. 
The pneumococcus is recognised to be a highly recombinogenic pathogen with a very active 
phylogeny and associated high spontaneous mutation rate (Croucher et al., 2011). Different factors 
can exert selection pressures on pathogens like the pneumococcus. These include anthropological 
changes such as increasing hygiene and decreasing overcrowding altering pneumococcal transmission, 
host factors such as immunodeficiency related to HIV infection and clinical factors such as antibiotic 
usage and pneumococcal vaccination (Croucher et al., 2011). The recognised selection pressures of 
antibiotic usage and limited valency immunisation appear unlikely to be directly relevant in this case, 
as the rate of antibiotic resistance remains very low in these sequence types and their spread and the 
associated increase in incidence of empyema predates the introduction of the pneumococcal conjugate 
vaccine (Byington et al., 2010). Furthermore, serotype 1 is recognised to cause invasive 
pneumococcal disease in otherwise healthy individuals, suggesting that host factors are less likely to 
be relevant (Grau et al., 2012). Perhaps the simplest explanation for the increase in incidence was a 
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random mutation giving rise to highly virulent clone whose particular expression of virulence factors 
predisposes to infection of the pleural space. This gave it a significant selection advantage relative to 
other clones and predisposed it to pandemic spread. At present, our understanding of the biology of 
serotype 1 and in particular its recent evolution is incomplete and this hypothesis cannot be directly 
proven but on the basis of the available evidence appears most likely.        
 
Serotype 1 is not the only serotype reported in paediatric empyema. For example, Hsieh et al (2004) 
reported a significant increase in the incidence of paediatric empyema in Taiwan but found no cases 
of serotype 1. It is also difficult to explain the observed increase in streptococcal empyema in the 
context of the spread of a virulent pneumococcal clone. Other potential contributory factors that may 
explain the rise of pneumococcal and streptococcal empyema include reductions in community 
antibiotic prescribing for respiratory tract infections in children, increasing pneumococcal and 
streptococcal antibiotic resistance and a decline in invasive staphylococcal infections. 
 
6.3 Projected impact of PCV-13 on paediatric empyema in the UK   
 
In April 2010 PCV-7 was replaced by PCV-13 in the routine immunisation schedule of the UK. 
Inferred from the limited data available about the pneumococcal serotype distribution in empyema, 
the projected reduction from PCV-7 was an approximately 20% reduction in cases (Fletcher et al., 
2006). The potential impact of PCV-13 is much greater with PCV-13 serotypes accounting for 96% of 
cases of culture-negative paediatric empyema in England between 2006 and 2009 (Sheppard et al., 
2011). However, the experience in the USA following the introduction of PCV-7 demonstrates a need 
for caution and continued surveillance. There was a significant expansion in non-PCV-7 serotypes 
(notable serotype 1, 3 and 19A) causing empyema in children in the years following the introduction 
of PCV-7 (Byington et al., 2006). Analysis of the MLST types of these pneumococci highlighted that 
this process was driven by clones that were circulating prior to the introduction of PCV-7 (Byington 
et al., 2010). The expansion of non-vaccine serotypes into the ecological niche left by vaccine 
serotypes is but one mechanism of vaccine related serotype replacement. Another potential 
mechanism is serotype switching or vaccine escape where individual pneumococcal clones change 
their expression of capsular serotype in response to the selective pressures of limited valency vaccines. 
This process has already been demonstrated to have occurred in response to PCV-7 in the USA and 
has been associated with the rise of serotype 19A as the predominant cause of invasive pneumococcal 
disease in that country (Pelton et al., 2007). Furthermore, these shifts in pneumococcal serotype 
distribution have serious clinical consequences, as shown by the significant increase in length of 
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hospital stay seen in serotype 19A empyema cases in this cohort compared to the commonest serotype, 
serotype 1. The propensity of limited valency conjugate vaccines to act as a selective pressure driving 
the evolution of pneumococci in empyema has already been demonstrated and careful surveillance of 
the molecular epidemiology of paediatric empyema will be required for the foreseeable future. 
 
6.4 Moving forward the management of empyema in children 
 
The management of empyema in children remains controversial, largely due to a dearth of high 
quality evidence. In this cohort, patients managed with primary surgical drainage had significantly 
reduced hospital stay, complication and readmission rates. Furthermore, there were significant 
differences in length of stay between UK centres. These centre based differences need further 
investigation to ensure that all patients receive the highest quality care and best outcomes.  
 
This analysis has demonstrated with the finding of heterogeneity in patients’ response to surgery and a 
significant centre effect. Comparisons of management in empyema are complex and can be 
challenging to interpret. Outcomes measures such as length of stay are not the only factors relevant to 
patients and their families, and there is a need to develop patient related outcome measures in this 
condition. Data regarding the acceptability of surgery to patients and their families are also needed.  
 
Two large scale multi-centre RCT’s of treatment of pleural infection in adults in the UK have been 
carried out in recent years. Assessment of the optimal management of paediatric empyema needs to be 
investigated in a similar fashion with national collaboration (Maskell et al., 2005; Rahman et al., 
2011). The UK-ESPE study has shown the potential for multi-centre co-operation between centres in 
the UK managing this condition, and will hopefully be the beginning of further fruitful collaborations 
in this area.    
 
Future work needs to be broad based, employ a range of methodologies and address a series of 
interlinked problems. Firstly, there is a need to define what outcomes in empyema matter most to 
patients and their families. This question is likely to require mixed approach with both quantitative 
and qualitative approaches needed. Qualitative interview methods can better identify outcomes that 
may not have been previously considered relevant in empyema. Quantitative methods could then be 
used to develop and standardise tools for the measurement of these outcomes. Secondly, appropriately 
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controlled randomised trials are needed to evaluate current management using the identified outcomes, 
in particular comparisons of primary surgery versus medical management, minimally invasive surgery 
versus open surgery and early surgery versus later surgery are required. Newer therapies used in 
adults, such as combination therapy with intrapleural DNAse and fibrinolytics also need investigation 
in children. Single centre retrospective reviews need to be avoided given the significant bias from 
centre effects. Finally, longer term outcomes in empyema need careful investigation. As discussed 
previously, data on the long term effects of empyema on lung function and respiratory health are 
currently very limited. While the assumption is that the long term outlook is excellent for the 
respiratory health of children who develop empyema, there is increasing evidence that the antecedents 
of adult respiratory disease begin in childhood and the outcomes in empyema need investigating 
longitudinally in cohorts of sufficient size to detect potential effects. The UK-ESPE study has 
identified a large prospective cohort of children with empyema and can provide the basis for both the 
identification of patient related and clinically relevant outcomes in paediatric empyema and the 
longitudinal study of the long term outcomes of the condition.    
 
There is also the possibility of further changes in the clinical profile of empyema which need 
consideration in the context of the management of the condition. In this study, serotype 19A was 
associated prolonged hospital stay. Other studies have found other non-PCV-7 serotypes associated 
with increased risk of necrotic complications of empyema, such as bronchopleural fistula formation 
(McKee et al., 2011). If disease due to non-vaccine serotypes continues to rise and the experience 
remains similar then arguments for earlier definitive treatment become stronger. Future developments 
in the management of empyema need to account for changes in the clinical profile of the disease.  
 
In conclusion, further research in this area should comprise on-going careful clinical epidemiological 
studies longitudinally evaluating clinical changes in pleural infection in children. An extension, 
perhaps concentrated in several sentinel centres of the current UK-ESPE study could fulfil this role. In 
conjunction with this a detailed study of the molecular epidemiology of the pneumococci causing 
paediatric empyema using non-culture methods e.g. non-culture MLST typing to map further 
evolution of this group of pathogens in particular in response to the introduction of pneumococcal 
conjugate vaccines. With regard to improving the management of the condition, a small scale study 
using quantitative and qualitative methods is required to identify patient-related outcome measures (a 
small pilot study is underway in Newcastle) which will then feed into a series of UK wide RCT’s 
aimed at establishing the role of surgery in the management of empyema.  
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6.5 Conclusions 
 
The increase in the incidence of paediatric empyema in England was driven predominantly by an 
increase in pneumococcal and streptococcal pneumonia re-establishing the epidemiological picture 
seen in the pre-antibiotic era. The increase in pneumococcal pneumonia appears likely to have been 
driven by the near pandemic spread of virulent pneumococcal serotype 1 clones. Although no 
reduction in the incidence of paediatric empyema was seen in North East England in response to 
PCV-7, the potential impact of broader valency vaccines on paediatric empyema, in particular PCV-
13 remains very promising. Careful surveillance will be required however to monitor changes both in 
the pneumococcal serotypes causing paediatric empyema but also any change in the clinical profile of 
the disease associated with the introduction of this vaccine. Primary surgery in empyema allowed 
earlier discharge in this cohort, but further research is needed to establish which outcomes are most 
acceptable to patients and their families, what the longer term outcomes of empyema are and how best 
to manage the condition.   
 257 
 
7 List of Publications, Presentations and Conference Abstracts 
 
Publications 
 
Thomas MF, Sheppard CL, Guiver M, Slack MP, George RC, Gorton R, Paton JY, Simmister C, 
Cliff D, Elemraid MA, Clark JE, Rushton SP, Spencer DA. Emergence of pneumococcal 19A 
empyema in UK children. Arch Dis Child. 2012 Oct 16. [Epub ahead of print] PubMed PMID: 
23076341. 
 
Thomas MF, Spencer DA. Necrotising pneumonia, pneumatoceles and the pneumococcus. Thorax. 
2012 Oct;67(10):925. Epub 2012 Feb 16. PubMed PMID: 22343709. 
 
Thomas MF, Spencer DA. Management and complications of pneumonia. Paediatr and Child Health. 
2011; 21: 207-12 
 
Elemraid MA, Pollard K, Thomas MF, Gennery AR, Eastham KM, Rushton SP, Hampton F, 
Singleton P, Gorton R, Spencer DA, Clark JE; North East of England Paediatric Respiratory Infection 
Study Group. Validity of using Hospital Episode Statistics data on monitoring disease trends. Thorax. 
2011 Sep;66(9):827; author reply 827-8. Epub 2010 Dec 2. PubMed PMID: 21131299. 
 
Presentations and conference abstracts 
 
MF Thomas, C Simmister, D Cliff, MA Elemraid, JE Clark, SP Rushton, R Gorton, JY Paton, DA 
Spencer. The UK-ESPE study: Paediatric empyema in the UK. Oral presentation, Royal College of 
Paediatrics and Child Health Annual Meeting, July 2012 
 
 258 
 
M F Thomas, C Simmister, D Cliff, M A Elemraid, J E Clark, S P Rushton, R Gorton, J Y Paton, D 
A Spencer. Comparison of primary pleural drainage strategies in paediatric empyema. Extended 
poster presentation, British Thoracic Society Winter Meeting, December 2011 
 
M F Thomas, C L Sheppard, M Guiver, R C George, C Simmister, D Cliff, R Gorton, M A Elemraid, 
J E Clark, S P Rushton, J Y Paton, D A Spencer. Changes in pneumococcal serotype distribution of 
paediatric empyema in the age of pneumococcal conjugate vaccines. Extended poster presentation, 
British Thoracic Society Winter Meeting, December 2011 
 
D A Spencer, M F Thomas, C L Sheppard, M Guiver, R C George, R Gorton, J Y Paton, C 
Simmister, D Cliff, M A Elemraid, J E Clark, S P Rushton. Emergence of pneumococcal serotype 
19A as a cause of severe complicated pneumonia with empyema in children in England. Extended 
poster presentation, British Thoracic Society Winter Meeting, December 2011 
 
Thomas MF, Rushton SP, Shirley MDF, Elemraid MA, Clark JE, Gorton R, Spencer DA. 
Understanding the changing epidemiology of paediatric empyema: the relationship with pneumonia. 
Poster presentation, Health Protection 2011, May 2011 
 
Thomas MF, Blain AP, Shirley MDF, Simmister C, Elemraid MA, Gorton R, Pearce MS, Clark JE, 
Rushton SP, Spencer DA. Geographical variation in the risk of childhood pneumonia and 
relationships to socio-economic and health deprivation. Poster presentation, European Respiratory 
Society Annual Congress, September 2011 
 
Spencer DA, Close
 
AJ, Simmister C, Cliff D, Elemraid MA, Clark JE, Rushton SP, Thomas MF. 
Limited impact of the 7-valent pneumococcal vaccine on paediatric empyema in the North of England. 
Elite poster presentation European Society of Paediatric Infectious Diseases Congress, June 2011 
 
Spencer DA, Close
 
AJ, Simmister C, Cliff D, Elemraid MA, Clark JE, Rushton SP, Thomas MF. 
Impact of the 13-valent pneumococcal vaccine on the incidence of paediatric empyema in the North 
 259 
 
of England. Elite poster presentation European Society of Paediatric Infectious Diseases Congress, 
June 2011 
 
Thomas MF, Simmister C, Rushton SP, Spencer DA. The changing incidence of paediatric empyema 
in NE England 2006 – 2010. Poster presentation, British Thoracic Society Winter Meeting, December 
2010 
 
Thomas MF, Cliff D, Rushton SP, Gorton R, Shirley MDF, Clark J, Spencer DA. Trends in 
paediatric pneumonia and empyema in England 1997-2006. Oral presentation, European Respiratory 
Society Annual Congress, September 2010 
  
 260 
 
8 References 
 
Ali, M., Emch, M., Tofail, F. and Baqui, A.H. (2001) 'Implications of health care provision on acute 
lower respiratory infection mortality in Bangladeshi children', Social Science & Medicine, 52(2), pp. 
267-277. 
 
Ali, N.J., Sillis, M., Andrews, B.E., Jenkins, P.F. and Harrison, B.D.W. (1986) 'The Clinical Spectrum 
and Diagnosis of Mycoplasma pneumoniae Infection', QJM, 58(3-4), pp. 241-251. 
 
Allen, F. (2010) 'The first draft of DSM-V', BMJ, 340. 
 
Andersen, P.K., Klein, J.P. and Zhang, M.-J. (1999) 'Testing for centre effects in multi-centre survival 
studies: a Monte Carlo comparison of fixed and random effects tests', Statistics in Medicine, 18(12), 
pp. 1489-1500. 
 
Andrade, A.L., Toscano, C.M., Minamisava, R., Costa, P.S. and Andrade, J.G. (2011) 'Pneumococcal 
disease manifestation in children before and after vaccination: What's new?', Vaccine, 29, Supplement 
3(0), pp. C2-C14. 
 
Antony, V.B. (2003) 'Immunological mechanisms in pleural disease', ERJ, 21(3), pp. 539-544. 
 
Aragon, T. (2010) epitools: Epidemiology Tools (Version R package version 0.5-6.) [Computer 
program]. Available at: http://CRAN.R-project.org/package=epitools. 
 
Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S and Reid RD 
(1976) 'Prevention of pneumococcal pneumonia by vaccination', Trans Assoc Am Physicians, 89, pp. 
184-94. 
 
Avansino, J.R., Goldman, B., Sawin, R.S. and Flum, D.R. (2005) 'Primary Operative Versus 
Nonoperative Therapy for Pediatric Empyema: A Meta-analysis', Pediatrics, 115(6), pp. 1652-1659. 
 
Balfour-Lynn, I.M., Abrahamson, E., Cohen, G., Hartley, J., King, S., Parikh, D., Spencer, D., 
Thomson, A.H. and Urquhart, D. (2005) 'BTS guidelines for the management of pleural infection in 
children', Thorax, 60(SUPPL. 1), pp. i1-i21. 
 
 261 
 
Barnes, N.P., Hull, J. and Thomson, A.H. (2005) 'Medical management of parapneumonic pleural 
disease', Pediatr Pulmonol, 39(2), pp. 127-134. 
 
Beale, L., Abellan, J.J., Hodgson, S. and Jarup, L. (2008) 'Methodologic Issues and Approaches to 
Spatial Epidemiology', Environ Health Perspect, 116(8). 
 
Bekri, H., Cohen, R., Varon, E., Madhi, F., Gire, R., Guillot, F. and Delacourt, C. (2007) 
'[Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France]', Arch 
Pediatr, 14(3), pp. 239-43. 
 
Besag, J., York, J. and Mollié, A. (1991) 'Bayesian image restoration, with two applications in spatial 
statistics', Annals of the Institute of Statistical Mathematics, 43(1), pp. 1-20. 
 
Bessen, D.E. (2009) 'Population biology of the human restricted pathogen, Streptococcus pyogenes', 
Infection, Genetics and Evolution, 9(4), pp. 581-593. 
 
Blaschke, A.J., Heyrend, C., Byington, C.L., Obando, I., Vazquez-Barba, I., Doby, E.H., Korgenski, 
E.K., Sheng, X., Poritz, M.A., Daly, J.A., Mason, E.O., Pavia, A.T. and Ampofo, K. (2011) 
'Molecular Analysis Improves Pathogen Identification and Epidemiologic Study of Pediatric 
Parapneumonic Empyema', Pediatr Infect Dis J , 30(4), pp. 289-294 10.1097/INF.0b013e3182002d14. 
 
Boersma, W.G., Löwenberg, A., Holloway, Y., Kuttschrütter, H., Snijder, J.A. and Koëter, G.H. 
(1993) 'Rapid detection of pneumococcal antigen in pleural fluid of patients with community acquired 
pneumonia', Thorax, 48(2), pp. 160-162. 
 
Box, G., Jenkins, G. and Reinsel, G. (2008) Time Series Analysis: Forecasting and control. Hoboken: 
Wiley. 
 
Box, G.E.P. and Cox, D.R. (1964) 'An Analysis of Transformations', Journal of the Royal Statistical 
Society. Series B (Methodological), 26(2), pp. 211-252. 
 
Bradshaw, J., Bloor, K., Huby, M., Rhodes, D., Sinclair, I., Gibbs, I., Noble, M., McLennan, D. and 
Wilkinson, K. (2009) Local index of child well-being: Summary report. Government, D.o.C.a.L. 
[Online]. Available at: 
http://www.communities.gov.uk/publications/communities/childwellbeing2009 (Accessed: 18 
February 2011). 
 262 
 
Brims, F.J.H., Lansley, S.M., Waterer, G.W. and Lee, Y.C.G. (2010) 'Empyema thoracis: new 
insights into an old disease', European Respiratory Review, 19(117), pp. 220-228. 
 
Brook, I. (1990) 'Microbiology of empyema in children and adolescents', Pediatrics, 85(5), pp. 722 - 
726. 
 
Buckingham, S.C., King, M.D. and Miller, M.L. (2003) 'Incidence and etiologies of complicated 
parapneumonic effusions in children, 1996 to 2001', Pediatr Infect Dis J, 22(6), pp. 499-504. 
 
Byington, C.L., Castillo, H., Gerber, K., Daly, J.A., Brimley, L.A., Adams, S., Christenson, J.C. and 
Pavia, A.T. (2002a) 'The Effect of Rapid Respiratory Viral Diagnostic Testing on Antibiotic Use in a 
Children's Hospital', Arch Pediatr Adolesc Med, 156(12), pp. 1230-1234. 
 
Byington, C.L., Hulten, K.G., Ampofo, K., Sheng, X., Pavia, A.T., Blaschke, A.J., Pettigrew, M., 
Korgenski, K., Daly, J. and Mason, E.O. (2010) 'Molecular Epidemiology of Pediatric Pneumococcal 
Empyema from 2001 to 2007 in Utah', J. Clin. Microbiol., 48(2), pp. 520-525. 
 
Byington, C.L., Korgenski, K., Daly, J., Ampofo, K., Pavia, A. and Mason, E.O. (2006) 'Impact of the 
pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema', Pediatr Infect Dis J, 
25(3), pp. 250 - 254. 
 
Byington, C.L., Samore, M.H., Stoddard, G.J., Barlow, S., Daly, J., Korgenski, K., Firth, S., Glover, 
D., Jensen, J., Mason, E.O., Shutt, C.K. and Pavia, A.T. (2005) 'Temporal Trends of Invasive Disease 
Due to Streptococcus pneumoniae among Children in the Intermountain West: Emergence of 
Nonvaccine Serogroups', Clin Infect Dise, 41(1), pp. 21-29. 
 
Byington, C.L., Spencer, L.Y., Johnson, T.A., Pavia, A.T., Allen, D., Mason, E.O., Kaplan, S., Carroll, 
K.C., Daly, J.A., Christenson, J.C. and Samore, M.H. (2002b) 'An epidemiological investigation of a 
sustained high rate of pediatric parapneumonic empyema: Risk factors and microbiological 
associations', Clin Infect Dis, 34(4), pp. 434-440. 
 
Calder, A. and Owens, C.M. (2009) 'Imaging of parapneumonic pleural effusions and empyema in 
children', Pediatric Radiology, 39(6), pp. 527-537. 
 
Callery, P., Kyle, R.G., Campbell, M., Banks, M., Kirk, S. and Powell, P. (2010) 'Readmission in 
children's emergency care: an analysis of hospital episode statistics', Arch Dis Child, 95(5), pp. 341-
346. 
 263 
 
Campbell, S.E., Campbell, M.K., Grimshaw, J.M. and Walker, A.E. (2001) 'A systematic review of 
discharge coding accuracy', J Public Health, 23(3), pp. 205-211. 
 
Cazelles, B., Chavez, M., Berteaux, D., Ménard, F., Vik, J., Jenouvrier, S. and Stenseth, N. (2008) 
'Wavelet analysis of ecological time series', Oecologia, 156(2), pp. 287-304. 
 
Cazelles, B., Chavez, M., Magny, G.C.d., Guégan, J.-F. and Hales, S. (2007) 'Time-dependent 
spectral analysis of epidemiological time-series with wavelets', Journal of The Royal Society Interface, 
4(15), pp. 625-636. 
 
Cazelles, B., Chavez, M., McMichael, A.J. and Hales, S. (2005) 'Nonstationary Influence of El Niño 
on the Synchronous Dengue Epidemics in Thailand', PLoS Med, 2(4), p. e106. 
 
Chan, P.W.K., Chew, F.T., Tan, T.N., Chua, K.B. and Hooi, P.S. (2002) 'Seasonal variation in 
respiratory syncytial virus chest infection in the tropics', Pediatr Pulmonol, 34(1), pp. 47-51. 
 
Charland, K.M., Brownstein, J.S., Verma, A., Brien, S. and Buckeridge, D.L. (2011) 'Socio-economic 
disparities in the burden of seasonal influenza: the effect of cocial and material deprivation on rates of 
influenza infection', PLoS ONE, 6(2), p. e17207. 
 
Chernick, V., Boat, T., Wilmott, R. and Bush, A. (eds.) (2006) Kendig's Disorders of the Respiratory 
Tract in Children. Seventh Edition edn. Philadelphia: Saunders Elsevier. 
 
Chonmaitree, T. and Powell, K.R. (1983) 'Parapneumonic pleural effusion and empyema in children. 
Review of a 19-year experience, 1962-1980', Clinical Pediatrics, 22(6), pp. 414-9. 
 
Christopoulou-Aletra, H. and Papavramidou, N. (2008) '"Empyemas" of the Thoracic Cavity in the 
Hippocratic Corpus', Ann Thorac Surg, 85, pp. 1132-1134. 
 
Clagett, O.T. (1943) 'Chronic empyema', Journal of Thoracic Surgery, 12, pp. 464-83. 
 
Clagett, O.T. (1973) 'Changing aspect of the etiology and treatment of pleural empyema', Surgical 
Clinics of North America, 53, pp. 863-66. 
 
Clark, J.E., Hammal, D., Hampton, F., Spencer, D. and Parker, L. (2007) 'Epidemiology of 
community-acquired pneumonia in children seen in hospital', Epidemiol and Infect, 135(2), pp. 262-
269. 
 264 
 
Cliff, A.D. and Smallman-Raynor, M.R. (1992) 'The Aids Pandemic: Global Geographical Patterns 
and Local Spatial Processes', The Geographical Journal, 158(2), pp. 182-198. 
 
Cohen, J. (1998) Statistical power analysis for the behavioural sciences. 2nd edn. New York: 
Psychology Press. 
 
Cohen, S. (1999) 'Social Status and Susceptibility to Respiratory Infections', Annals of the New York 
Academy of Sciences, 896(1), pp. 246-253. 
 
Cole, D. (1937) 'Management of Empyema', Chest, 3, pp. 40-42. 
 
Colley, J.R.T., Holland, W.W. and Corkhill, R.T. (1974) 'Influence of passive smoking and parental 
phlegm on pneumonia and bronchitis in early childhood', Lancet, 304(7888), pp. 1031-1034. 
 
Colman, G., Tanna, A., Efstratiou, A. and Gaworzewska, E.T. (1993) 'The serotypes of Streptococcus 
pyogenes present in Britain during 1980–1990 and their association with disease', Journal of Medical 
Microbiology, 39(3), pp. 165-178. 
 
Cook, D.G. and Strachan, D.P. (1999) 'Summary of effects of parental smoking on the respiratory 
health of children and implications for research', Thorax, 54(4), pp. 357-366. 
 
Cooper, B. and Lipsitch, M. (2004) 'The analysis of hospital infection data using hidden Markov 
models', Biostatistics, 5(2), pp. 223-237. 
 
Coote, N. and Kay, E. (2005) 'Surgical versus non-surgical management of pleural empyema', 
Cochrane Data Sys Rev, (4). 
 
Crighton, E.J., Elliott, S.J., Moineddin, R., Kanaroglou, P. and Upshur, R. (2007) 'A spatial analysis 
of the determinants of pneumonia and influenza hospitalisations in Ontario (1992-2001)', Social 
Science & Medicine, 64(8), pp. 1636-1650. 
 
Cutts, F.T., Zaman, S.M.A., Enwere, G., Jaffar, S., Levine, O.S., Okoko, J.B., Oluwalana, C., 
Vaughan, A., Obaro, S.K., Leach, A., McAdam, K.P., Biney, E., Saaka, M., Onwuchekwa, U., Yallop, 
F., Pierce, N.F., Greenwood, B.M. and Adegbola, R.A. (2005) 'Efficacy of nine-valent pneumococcal 
conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, 
double-blind, placebo-controlled trial', Lancet, 365(9465), pp. 1139-1146. 
 265 
 
Davila, R. and Crouch, E. (1995) 'Anatomic organisation and function of the human pleura', Semin 
Respir Crit Care Med, 16(4), pp. 261-68. 
 
Deiros Bronte, L., Baquero-Artigao, F., Garcia-Miguel, M.J., Hernandez Gonzalez, N., Pena Garcia, P. 
and del Castillo Martin, F. (2006) '[Parapneumonic pleural effusion: an 11-year review]', An Pediatr 
(Barc), 64(1), pp. 40-5. 
 
Dethlefsen, C., Lundbye-Christensen, S. and Christensen, A. (2009) sspir: State Space Models in R 
(Version R package version 0.2.8) [Computer program]. Available at: http://CRAN.R-
project.org/package=sspir. 
 
Diggle, P. (1990) Time series: A biostatistical introduction. Oxford: Clarendon Press. 
 
Dowell, S.F. and Ho, M.S. (2004) 'Seasonality of infectious diseases and severe acute respiratory 
syndrome–what we don't know can hurt us', Lancet Infect Dis, 4(11), pp. 704-708. 
 
Dowell, S.F., Whitney, C.G., Wright, C., Rose, C.E., Jr. and Schuchat, A. (2003) 'Seasonal patterns of 
invasive pneumococcal disease', Emerg Infect Dis, 9(5), pp. 573-9. 
 
Dunham, E.K., Graham, E.A., Mitchell, J.F., Moschcowitz, A.V., Kinsella, R.A., Bell, R.D., Stevens, 
F.A., Tower, W.L., Hartman, C.C., Rivers, T.M., Zeman, F.D., Cohen, M.B., Hays, M.H., Stocking, 
B.E. and Jacobs, E.P. (1918) 'Cases of empyema at Camp Lee, VA. Preliminary Report', JAMA, 71(5), 
pp. 366-373. 
 
Eastham, K.M., Freeman, R., Kearns, A.M., Eltringham, G., Clark, J., Leeming, J. and Spencer, D.A. 
(2004) 'Clinical features, aetiology and outcome of empyema in children in the north east of England', 
Thorax, 59(6), pp. 522-5. 
 
Eastham, K.M., Hammal, D.M., Parker, L. and Spencer, D.A. (2008) 'A follow-up study of children 
hospitalised with community-acquired pneumonia', Archives of Disease in Childhood, 93(9), pp. 755-
759. 
 
EDINA '2001 UK Census: Digitised Boundary Data (England and Wales)'. 21 February 2011. Census 
Geography Data Unit (UKBORDERS), EDINA (University of Edinburgh). Available at: 
http://edina.ac.uk/ukborders/. 
 
 266 
 
Elemraid, M.A., Pollard, K., Thomas, M.F., Gennery, A.R., Eastham, K.M., Rushton, S.P., Hampton, 
F., Singleton, P., Gorton, R., Spencer, D.A. and Clark, J.E. (2010) 'Validity of using hospital episode 
statistics data on monitoring disease trends', Thorax,  [Online]. Available at: 
http://thorax.bmj.com/content/early/2010/12/02/thx.2010.153551.short DOI: 
10.1136/thx.2010.153551 (Accessed: December 2, 2010). 
 
Elliott, P. and Wartenberg, D. (2004) 'Spatial Epidemiology: Current Approaches and Future 
Challenges', Environ Health Perspect, 112(9). 
 
Eltringham, G., Kearns, A., Freeman, R., Clark, J., Spencer, D., Eastham, K., Harwood, J. and 
Leeming, J. (2003) 'Culture-negative childhood empyema is usually due to penicillin-sensitive 
Streptococcus pneumoniae capsular serotype 1', J Clin Microbiol, 41(1), pp. 521-2. 
 
Epstein, F.H. (1996) 'Cardiovascular Disease Epidemiology : A Journey From the Past Into the 
Future', Circulation, 93(9), pp. 1755-1764. 
 
Erzen, D., Carriere, K.C., Dik, N., Mustard, C., Roos, L.L., Manfreda, J. and Anthonisen, N.R. (1997) 
'Income level and asthma prevalence and care patterns', Am J Respir Crit Care Med, 155(3), pp. 1060-
1065. 
 
Eskola J and Anittila, M. (1999) 'Pneumococcal conjugate vaccines', Pediatr Infect Dis J, 18(6), pp. 
543-551. 
 
Everitt, B. and Rabe-Hesketh, S. (2001) Analyzing Medical Data Using S-PLUS. New York: 
Springer-Verlag. 
 
Fajardo JE and Chang MJ (1987) 'Pleural empyema in children: A nationwide retrospective study', 
Southern Medical Journal, 80(5), pp. 593-96. 
 
Fanshawe, T.R., Diggle, P.J., Rushton, S., Sanderson, R., Lurz, P.W.W., Glinianaia, S.V., Pearce, 
M.S., Parker, L., Charlton, M. and Pless-Mulloli, T. (2008) 'Modelling spatio-temporal variation in 
exposure to particulate matter: a two-stage approach', Environmetrics, 19(6), pp. 549-566. 
 
Faraway, J. (2005) 'Checking Error Assumptions', in  Texts in Statistical Science: Linear Models with 
R. Boca Raton: Chapman & Hall/CRC,  pp. 53-8. 
 
 267 
 
Finley, C., Clifton, J., Fitzgerald, J.M. and Yee, J. (2008) 'Empyema: an increasing concern in 
Canada', Can Respir J, 15(2), pp. 85-9. 
 
Fisman, D.N. 28 (2007) 'Seasonality of infectious diseases'. pp. 127-143. Available at: 
http://www.scopus.com/inward/record.url?eid=2-s2.0-
34249742034&partnerID=40&md5=43c00c222607ac52614a44d20808af34. 
 
Flasche, S., Slack, E. and Miller, L. (2011) 'Long term trends introduce a potential bias when 
evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales', 
Eurosurveillance, 16(20), pp. 1-5. 
 
Fletcher, M., Leeming, J., Cartwright, K. and Finn, A. (2006) 'Childhood empyema: limited potential 
impact of 7-valent pneumococcal conjugate vaccine', Pediatr Infect Dis J, 25(6), pp. 559-60. 
 
Flory, J.H., Joffe, M., Fishman, N.O., Edelstein, P.H. and Metlay, J.P. (2009) 'Socioeconomic risk 
factors for bacteraemic pneumococcal pneumonia in adults', Epidemiology and Infection, 137(05), pp. 
717-726. 
 
François, P., Desrumaux, A., Cans, C., Pin, I., Pavese, P. and Labarère, J. (2010) 'Prevalence and risk 
factors of suppurative complications in children with pneumonia', Acta Pædiatrica, 99(6), pp. 861-
866. 
 
Geha AS (1970) 'Pleural empyema: Changing etiologic, bacteriologic, and therapeutic aspects', 
Journal of Thoracic and Cardiovascular Surgery, 61(4), pp. 626-635. 
 
Gilthorpe, M.S., Lay-Yee, R., Wilson, R.C., Walters, S., Griffiths, R.K. and Bedi, R. (1998) 
'Variations in hospitalisation rates for asthma among Black and minority ethnic communities', 
Respiratory Medicine, 92(4), pp. 642-648. 
 
Gonzalez, B.E., Hulten, K.G., Kaplan, S.L., Mason, E.O. and the, U.S.P.M.P.S.S.G. (2004) 'Clonality 
of Streptococcus pneumoniae Serotype 1 Isolates from Pediatric Patients in the United States', Journal 
Clin Micro, 42(6), pp. 2810-2812. 
 
Graham, E.A. and Berck, M. (1933) 'Principles versus details in the treatment of acute empyema', Ann 
Surg, 98, pp. 520-27. 
 
 268 
 
Grambsch, P. and Therneau, T. (1994) 'Proportional hazards tests and diagnostics based on weighed 
residuals', Biometrika, 81(3), pp. 515-26. 
 
Grenfell, B.T., Bjornstad, O.N. and Kappey, J. (2001) 'Travelling waves and spatial hierarchies in 
measles epidemics', Nature, 414(6865), pp. 716-723. 
 
Grijalva, C.A.G., Nuorti, J.A P., Zhu, Y. and Griffin, Marie R. (2010) 'Increasing Incidence of 
Empyema Complicating Childhood Community Acquired Pneumonia in the United States', Clin Infect 
Dis, 50(6), pp. 805-813. 
 
Grijalva, C.G., Nuorti, J.P., Arbogast, P.G., Martin, S.W., Edwards, K.M. and Griffin, M.R. (2007) 
'Decline in pneumonia admissions after routine childhood immunisation with pneumococcal 
conjugate vaccine in the USA: a time-series analysis', Lancet, 369(9568), pp. 1179-1186. 
 
Grijalva, C.G., Zhu, Y., Nuorti, J.P. and Griffin, M.R. (2011) 'Emergence of parapneumonic 
empyema in the USA', Thorax, 66, pp 663-668. 
 
Groff DB, Randolph JG and Blades B (1966) 'Empyema in childhood', JAMA, 195(7), pp. 164-66. 
 
Gruttola, V.D. and Tu, X.M. (1994) 'Modelling Progression of CD4-Lymphocyte Count and Its 
Relationship to Survival Time', Biometrics, 50(4), pp. 1003-1014. 
 
Gupta A, Khaw FM, Stokle E, George RC, Pebody R, Stansfield C, Sheppard CL, Slack M, Gorton R 
and Spencer DA (2008) 'Outbreak of Streptococcus pneumoniae serotype 1 pneumonia in a United 
Kingdom school', BMJ, 337. 
 
Gupta, R. and Crowley, S. (2006) 'Increasing paediatric empyema admissions', Thorax, 61(2), pp. 
179-180. 
 
Hamm, H. and Light, R.W. (1997) 'Parapneumonic effusion and empyema', ERJ, 10(5), pp. 1150-
1156. 
 
Hardie, W., Bokulic, R., Garcia, V.F., Reising, S.F. and Christie, C.D. (1996) 'Pneumococcal pleural 
empyemas in children', Clin Infect Dis, 22(6), pp. 1057-63. 
 
Harley, R. (1987) 'Anatomy of the pleura', Seminars in respiratory medicine, 9, pp. 1-6. 
 269 
 
Harrison, L.M., Morris, J.A., Telford, D.R., Brown, S.M. and Jones, K. (1999) 'The nasopharyngeal 
bacterial flora in infancy: effects of age, gender, season, viral upper respiratory tract infection and 
sleeping position', FEMS Immunology & Medical Microbiology, 25(1-2), pp. 19-28. 
 
Hawker, J.I., Olowokure, B., Sufi, F., Weinberg, J., Gill, N. and Wilson, R.C. (2003) 'Social 
deprivation and hospital admission for respiratory infection: an ecological study', Respiratory 
Medicine, 97(11), pp. 1219-1224. 
 
Hendrickson, D.J., Blumberg, D.A., Joad, J.P., Jhawar, S. and McDonald, R.J. (2008) 'Five-fold 
increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine', 
Pediatr Infect Dis J, 27(11), pp. 1030-2. 
 
HESonline - Hospital Episode Statistics (2010). Available at: 
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=537 (Accessed: 
22/04/2010). 
 
Heuer, G.J. (1932) 'Acute empyema', Journal of Thoracic Surgery, 1, pp. 461-84. 
 
Hewett, F.C. (1876) 'Thoracentesis: The Plan of Continuous Aspiration', Bmj, 1(793), pp. 317-317. 
 
HPA (2012) Epidemiological data. Available at: 
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MeningococcalDisease/Epidemiologi
calData/ (Accessed: 21/02/2012). 
 
Hsieh, Y.-C., Hsueh, P.-R., Lu, C.-Y., Lee, P.-I., Lee, C.-Y. and Huang, L.-M. (2004) 'Clinical 
manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by 
Streptococcus pneumoniae in children in Taiwan', Clin Infect Dis, 38(6), pp. 830-5. 
 
Immunisation Department, C.F.I. 'Cover of Vaccination Evaluated Rapidly (COVER) '. Health 
Protection Agency. 
 
Ishiguro, T., Takayanagi, N., Ikeya, T., Yoshioka, H., Yanagisawa, T., Hoshi, E., Hoshi, T., Sugita, Y. 
and Kawabata, Y. (2010) 'Isolation of Candida Species is an Important Clue for Suspecting  
Gastrointestinal Tract Perforation as a Cause of Empyema', Internal Medicine, 49(18), pp. 1957-1964. 
 
Jaffé, A. and Balfour-Lynn, I.M. (2005) 'Management of empyema in children', Pediatr Pulmonol, 
40(2), pp. 148-156. 
 270 
 
Jefferson, T., Ferroni, E., Curtale, F., Giorgi Rossi, P. and Borgia, P. (2006) 'Streptococcus 
pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old',  
Lancet Infect Dis, 6(7), pp. 405-410. 
 
Jensen, E., Lundbye-Christensen, S., Samuelsson, S., Sørensen, H. and Carl Schønheyder, H. (2004) 
'A 20-year ecological study of the temporal association between influenza and meningococcal disease', 
European Journal of Epidemiology, 19(2), pp. 181-187. 
 
Kalin M (1998) 'Pneumococcal serotypes and their clinical relevance', Thorax, 1998(53), pp. 159-62. 
Kazembe, L. and Namangale, J. (2007) 'A Bayesian multinomial model to analyse spatial patterns of 
childhood co-morbidity in Malawi', European Journal of Epidemiology, 22(8), pp. 545-556. 
 
Kern, J.A. and Rodgers, B.M. (1993) 'Thoracoscopy in the management of empyema in children', 
Journal of Pediatric Surgery, 28(9), pp. 1128-1132. 
 
Khalil, B., Corbett, P., Jones, M., Baillie, C., Southern, K., Losty, P. and Kenny, S. (2007) 'Less is 
best? The impact of urokinase as the first line management of empyema thoracis', Pediatric Surgery 
International, 23(2), pp. 129-133. 
 
Kiesewetter WB, Rusnock JR and Girdany BR (1959) 'Pediatric empyema: a second look at its 
incidence and importance', Journal of Pediatrics, 54(81), pp. 81-6. 
 
Kirkwood, B. and Sterne, J. (2003) Essential Medical Statistics. Oxford: Blackwells Publishing. 
Kitagawa, G. (2010) Introduction to Time Series Modelling. Boca Raton: Chapman & Hall. 
 
Ko, S.-C., Chen, K.-Y., Hsueh, P.-R., Luh, K.-T. and Yang, P.-C. (2000) 'Fungal Empyema Thoracis', 
Chest, 117(6), pp. 1672-1678. 
 
Kohn, G., Walston, C., Feldstein, J., Warner, B., Succop, P. and Hardie, W. (2002) 'Persistent 
abnormal lung function after childhood empyema', Am J Respir Med, 1(6), pp. 441-5. 
 
Kokoska, E.R. and Chen, M.K. (2009) 'Position paper on video-assisted thoracoscopic surgery as 
treatment of pediatric empyema', Journal of Pediatric Surgery, 44(1), pp. 289-293. 
 
Koshy, E., Murray, J., Bottle, A., Sharland, M. and Saxena, S. (2010) 'Impact of the seven-valent 
pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for 
 271 
 
bacterial pneumonia and empyema in England: national time-trends study, 1997–2008', Thorax, 65(9), 
pp. 770-774. 
 
Kurt, B.A., Winterhalter, K.M., Connors, R.H., Betz, B.W. and Winters, J.W. (2006) 'Therapy of 
Parapneumonic Effusions in Children: Video-Assisted Thoracoscopic Surgery Versus Conventional 
Thoracostomy Drainage', Pediatrics, 118(3), pp. e547-e553. 
 
Lahti, E., Mertsola, J., Kontiokari, T., Eerola, E., Ruuskanen, O. and Jalava, J. (2006) 'Pneumolysin 
polymerase chain reaction for diagnosis of pneumococcal pneumonia and empyema in children', 
European Journal of Clinical Microbiology & Infectious Diseases, 25(12), pp. 783-789. 
 
Lamagni TL, Neal S, Keshishian C, Alhaddad N, George R, Duckworth G, Vuopio-Varkila J and 
Efstratiou, A. (2008) 'Severe Streptococcus pyogenes infections, United Kingdom, 2003–2004', 
Emerg Infect Dis, 14(2), pp. 201-209. 
 
Law, D.C.G., Serre, M.L., Christakos, G., Leone, P.A. and Miller, W.C. (2004) 'Spatial analysis and 
mapping of sexually transmitted diseases to optimise intervention and prevention strategies', Sexually 
Transmitted Infections, 80(4), pp. 294-299. 
 
Le Monnier, A., Carbonnelle, E., Zahar, J.R., Le Bourgeois, M., Abachin, E., Quesne, G., Varon, E., 
Descamps, P., De Blic, J., Scheinmann, P., Berche, P. and Ferroni, A. (2006) 'Microbiological 
diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, 
and pneumococcal antigen detection in pleural fluids', Clin Infect Dis, 42(8), pp. 1135 - 1140. 
 
Lee, G.E., Lorch, S.A., Sheffler-Collins, S., Kronman, M.P. and Shah, S.S. (2010) 'National 
Hospitalisation Trends for Pediatric Pneumonia and Associated Complications', Pediatrics, 126(2), pp. 
204-213. 
 
Leimkugel, J., Adams Forgor, A., Gagneux, S., Pflüger, V., Flierl, C., Awine, E., Naegeli, M., Dangy, 
J.-P., Smith, T., Hodgson, A. and Pluschke, G. (2005) 'An Outbreak of Serotype 1 Streptococcus 
pneumoniae Meningitis in Northern Ghana with Features That Are Characteristic of Neisseria 
meningitidis Meningitis Epidemics', J of Infect Dis, 192(2), pp. 192-199. 
 
Lewis, R.A. and Feigin, R.D. (2002) 'Current issues in the diagnosis and management of pediatric 
empyema', Seminars in Pediatric Infectious Diseases, 13(4), pp. 280-288. 
 272 
 
Li, S.-T.T. and Gates, R.L. (2008) 'Primary Operative Management for Pediatric Empyema: 
Decreases in Hospital Length of Stay and Charges in a National Sample', Arch Pediatr Adolesc Med, 
162(1), pp. 44-48. 
 
Li, S.-T.T. and Tancredi, D.J. (2010) 'Empyema Hospitalisations Increased in US Children Despite 
Pneumococcal Conjugate Vaccine', Pediatrics, 125(1), pp. 26-33. 
 
Light, R.W., Macgregor, M.I., Luchsinger, P.C. and Ball, W.C. (1972) 'Pleural Effusions: The 
Diagnostic Separation of Transudates and Exudates', Annals of Internal Medicine, 77(4), pp. 507-513. 
 
Lionakis, B., Gray, S.W., Skandalakis, J.E. and Hopkins, W.A. (1958) 'Empyema in children: A 
twenty-five-year study', The Journal of Pediatrics, 53(6), pp. 719-725. 
 
Lipsitch, M. (1999) 'Bacterial Vaccines and Serotype Replacement: Lessons from Haemophilus 
influenzae and Prospects for Streptococcus pneumoniae', Emerg Infect Dis, 5(3), pp. 336-345. 
 
Lundbye-Christensen, S., Dethlefsen, C., Gorst-Rasmussen, A., Fischer, T., Schønheyder, H., 
Rothman, K. and Sørensen, H. (2009) 'Examining secular trends and seasonality in count data using 
dynamic generalized linear modelling: a new methodological approach illustrated with hospital 
discharge data on myocardial infarction', European Journal of Epidemiology, 24(5), pp. 225-230. 
 
MacLeod, C.M., Hodges, R.G., Heidelberger, M. and Bernhard, W.G. (1945) 'PREVENTION OF 
PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR 
POLYSACCHARIDES', The Journal of Experimental Medicine, 82(6), pp. 445-465. 
 
Mahon, M. and Kibirige, M.S. (2004) 'Patterns of admissions for children with special needs to the 
paediatric assessment unit', Arch Dis Child, 89(2), pp. 165-169. 
 
Mann, S.L., Wadsworth, M.E. and Colley, J.R. (1992) 'Accumulation of factors influencing 
respiratory illness in members of a national birth cohort and their offspring', Journal of Epidemiology 
and Community Health, 46(3), pp. 286-292. 
 
Markowitz, J., Pashko, S., Gutterman, E., Linde-Zwirble, W. and Newbold, R. (1996) 'Death rates 
among patients hospitalized with community-acquired pneumonia: a reexamination with data from 
three states', Am J Public Health., 86(8), pp. 1152-4. 
 273 
 
Maskell, N.A., Davies, C.W.H., Nunn, A.J., Hedley, E.L., Gleeson, F.V., Miller, R., Gabe, R., Rees, 
G.L., Peto, T.E.A., Woodhead, M.A., Lane, D.J., Darbyshire, J.H. and Davies, R.J.O. (2005) 'U.K. 
Controlled Trial of Intrapleural Streptokinase for Pleural Infection', N Eng J Med, 352(9), pp. 865-874. 
 
Mayer, J. (1983) 'The role of spatial analysis and geographic data in the detection of disease causation', 
Social Science & Medicine, 17(16), pp. 1213-1221. 
 
McCarthy, P., Byrne, D., Harrisson, S. and Keithley, J. (1985) 'Respiratory conditions: effect of 
housing and other factors', Journal of Epidemiology and Community Health, 39(1), pp. 15-19. 
 
McKee, A.J., Ives, A. and Balfour-Lynn, I.M. (2011) 'Increased incidence of bronchopulmonary 
fistulas complicating pediatric pneumonia', Pediatr Pulmonol, 46(7), pp. 717-721. 
 
McLaughlin, F., Goldmann, D., Rosenbaum, D., Harris, G., Schuster, S. and Strieder, D. (1984) 
'Empyema in children: clinical course and long-term follow-up', Pediatrics., 73(5), pp. 587-93. 
 
Melegaro, A., Edmunds, W.J., Pebody, R., Miller, E. and George, R. (2006) 'The current burden of 
pneumococcal disease in England and Wales', Journal of Infection, 52(1), pp. 37-48. 
 
Menezes-Martins, L.F., Menezes-Martins, J.J., Michaelsen, V.S., Aguiar, B.B., Ermel, T. and 
Machado, D.C. (2005) 'Diagnosis of parapneumonic pleural effusion by polymerase chain reaction in 
children', Journal of Pediatric Surgery, 40(7), pp. 1106-1110. 
 
Merino, J.M., Carpintero, I., Alvarez, T., Rodrigo, J., Sánchez, J. and Coello, J.M. (1999) 
'Tuberculous Pleural Effusion in Children', Chest, 115(1), pp. 26-30. 
 
Mew, R., Jaffe, A., Biassoni, L. and Sonnappa, S. (2009) 'Ventilation-perfusion scans in children 
treated for empyema', Thorax., 64(3), p. 273. 
 
Mid-year population estimates (2011). Available at: http://www.ons.gov.uk/ons/publications/all-
releases.html?definition=tcm:77-22371 (Accessed: 22/03/2011). 
 
MIDAS 'UK MIDAS Land Surface Stations Data '. 10/01/2012. United Kingdom Met Office. 
Available at: http://badc.nerc.ac.uk/data/dataset_index/. 
 
Middelkamp, J.N., Purkerson, M.L. and Burford, T.H. (1964) 'The Changing Pattern of Empyema 
Thoracis in Pediatrics', Journal of Thoracic & Cardiovascular Surgery, 47, pp. 165-73. 
 274 
 
Miller, E., Andrews, N.J., Waight, P.A., Slack, M.P.E. and George, R.C. (2011) 'Herd immunity and 
serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and 
Wales: an observational cohort study', Lancet Infect Dis, 11(10), pp. 760-768. 
 
Miller, E., Waight, P., Efstratiou, A., Brisson, M., Johnson, A. and George, R. (2000) 'Epidemiology 
of invasive and other pneumococcal disease in children in England and Wales 1996–1998', Acta 
Pædiatr, 89, pp. 11-16. 
 
Molnar, T.F., Hasse, J., Jeyasingham, K. and Rendeki, S. (2004) 'Changing dogmas: history of 
development in treatment modalities of traumatic pneumothorax, hemothorax, and posttraumatic 
empyema thoracis', Ann Thorac Surg, 77(1), pp. 372-378. 
 
Morens, D.M., Taubenberger, J.K. and Fauci, A.S. (2008) 'Predominant Role of Bacterial Pneumonia 
as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness', 
Journal of Infectious Diseases, 198(7), pp. 962-970. 
 
Musser, J.M., Kapur, V., Szeto, J., Pan, X., Swanson, D.S. and Martin, D.R. (1995) 'Genetic diversity 
and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent 
intercontinental spread of a subclone causing episodes of invasive disease', Infection and Immunity, 
63(3), pp. 994-1003. 
 
O'Brien, K.L., Moulton, L.H., Reid, R., Weatherholtz, R., Oski, J., Brown, L., Kumar, G., Parkinson, 
A., Hu, D., Hackell, J., Chang, I., Kohberger, R., Siber, G. and Santosham, M. (2003) 'Efficacy and 
safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group 
randomised trial', Lancet, 362(9381), pp. 355-361. 
 
Obando, I., Munoz-Almagro, C., Arroyo, L.A., Tarrago, D., Sanchez-Tatay, D., Moreno-Perez, D., 
Dhillon, S.S., Esteva, C., Hernandez-Bou, S., Garcia-Garcia, J.J., Hausdorff, W.P. and Brueggemann, 
A.B. (2008) 'Pediatric parapneumonic empyema, Spain', Emerg Infect Dis, 14(9), pp. 1390-7. 
 
Obaro, S.K., Adegbola, R.A., Banya, W.A. and Greenwood, B.M. (1996) 'Carriage of pneumococci 
after pneumococcal vaccination', Lancet, 348(9022), pp. 271-2. 
 
Odell, J. (1994) 'Management of empyema thoracis', JRSM, 87, pp. 466-470. 
Owayed, A.F., Campbell, D.M. and Wang, E.E.L. (2000) 'Underlying causes of recurrent pneumonia 
in children', Arch Pediatr & Adol Med, 154(2), pp. 190-194. 
 275 
 
Padman, R., King, K.A., Iqbal, S. and Wolfson, P.J. (2007) 'Parapneumonic Effusion and Empyema 
in Children: Retrospective Review of the duPont Experience', Clinical Pediatrics, 46(6), pp. 518-522. 
 
Paul, M., Held, L. and Toschke, A.M. (2008) 'Multivariate modelling of infectious disease 
surveillance data', Statistics in Medicine, 27(29), pp. 6250-6267. 
 
Pelton, S.I., Huot, H., Finkelstein, J.A., Bishop, C.J., Hsu, K.K., Kellenberg, J., Huang, S.S., 
Goldstein, R. and Hanage, W.P. (2007) 'Emergence of 19A as Virulent and Multidrug Resistant 
Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal 
Conjugate Vaccine', Pediatr Infect Dis J, 26(6), pp. 468-472 10.1097/INF.0b013e31803df9ca. 
 
Penberthy, G.C. and Benson, C. (1936) 'A ten year study of empyema in children:1926-1936', Ann 
Surg, 104, pp. 579-84. 
 
Peters, R. (1989) 'Empyema thoracis: Historical perspective', The Annals of Thoracic Surgery, 48(2), 
pp. 306-308. 
 
Picazo, J., Ruiz-Contreras, J., Hernandez, B., Sanz, F., Gutierrez, A., Cercenado, E., Meseguer, M.A., 
Delgado-Iribarren, A., Rodriguez-Avial, I. and Méndez, C. (2011) 'Clonal and clinical profile of 
Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: A 2-year (2007–2009) 
laboratory-based surveillance in Madrid', Vaccine, 29(9), pp. 1770-1776. 
 
Pinhero, J.C. and Bates, D.M. (2000) Mixed-Effects Models in S and S-Plus. 1st edn. New York: 
Springer. 
 
Pinhero, J.C., Bates, D.M., DebRoy, S. and Sarkar, D. (2011) nlme: Linear and Nonlinear Mixed 
Effects Models (Version R package version 3.1-102) [Computer program]. 
 
Playfor, S.D., Smyth, A.R. and Stewart, R.J. (1997) 'Increase in incidence of childhood empyema', 
Thorax, 52(10), p. 932. 
 
Polnay, L. and Ward, H. (2000) 'Promoting the health of looked after children', BMJ, 320(7236), pp. 
661-662. 
 
Proesmans, M. and De Boeck, K. (2009) 'Clinical practice: Treatment of childhood empyema', 
European Journal of Pediatrics, 168(6), pp. 639-645. 
 276 
 
 'Programme budgeting tools and data' (2011). 21/02/2012. UK Government: Department of Health. 
Available at: 
http://www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/Programmebudgeting/DH_
075743#_3. 
 
R-Development-Core-Team (2011) R: A Language and Environment for Statistical Computing 
(Version 2.14) [Computer program]. R Foundation for Statistical Computing. Available at: 
http://www.R-project.org. 
 
Rahman, N.M., Maskell, N.A., West, A., Teoh, R., Arnold, A., Mackinlay, C., Peckham, D., Davies, 
C.W.H., Ali, N., Kinnear, W., Bentley, A., Kahan, B.C., Wrightson, J.M., Davies, H.E., Hooper, C.E., 
Lee, Y.C.G., Hedley, E.L., Crosthwaite, N., Choo, L., Helm, E.J., Gleeson, F.V., Nunn, A.J. and 
Davies, R.J.O. (2011) 'Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural 
Infection', NEJM, 365(6), pp. 518-526. 
 
Rasmussen JN, V.M., Andersen RL, Ellermann-Eriksen S, Jensen TG, Johansen HK, Kolmos B, 
Mølvadgaard M, Nielsen SS, Olsen E, Schønning K, Uldum SA (2010) 'Increased incidence of 
Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010', 
Euro Surveill., 15(45).(pii), p. 19708. 
 
Ravitch MM and Fein R (1961) 'The changing picture of pneumonia and empyema in infants and 
children', JAMA, 175(12), pp. 87-91. 
 
Redding, G., Walund, L., Walund, D., Jones, J., Stamey, D. and Gibson, R. (1990) 'Lung function in 
children following empyema', Am J Dis Child., 144(12), pp. 1337-42. 
 
Rees, J.H., Spencer, D.A., Parikh, D. and Weller, P. (1997) 'Increase in incidence of childhood 
empyema in West Midlands, UK', Lancet, 349(9049), p. 402. 
 
Reinert, R., Jacobs, M.R. and Kaplan, S.L. (2010) 'Pneumococcal disease caused by serotype 19A: 
Review of the literature and implications for future vaccine development', Vaccine, 28(26), pp. 4249-
4259. 
 
Richardson S, Thomson A, Best N and Elliott P (2004) 'Interpreting posterior relative risk estimates in 
disease-mapping studies', Environmental Health Perspectives., 112(9), pp. 1016-25. 
 
 277 
 
Rohani, P., Green, C.J., Mantilla-Beniers, N.B. and Grenfell, B.T. (2003) 'Ecological interference 
between fatal diseases', Nature, 422(6934), pp. 885-888. 
 
Rothman, K., Greenland, S. and Lash, T. (2008) Modern Epidemiology. Third edn. Philadelphia: 
Lippincott Williams & Wilkins. 
 
Roxburgh, C.S., Youngson, G.G., Townend, J.A. and Turner, S.W. (2008) 'Trends in pneumonia and 
empyema in Scottish children in the past 25 years', Arch Dis Child, 93(4), pp. 316 - 318. 
 
Royston, P. (1982) 'An extension of Shapiro and Wilk's W test for normality to large samples', 
Applied Statistics, 31, pp. 115-124. 
 
Rudan, I., Boschi-Pinto, C., Biloglav, Z., Mulholland, K. and Campbell, H. (2008) 'Epidemiology and 
etiology of childhood pneumonia', Bull World Health Organ, 86(5), pp. 408-16. 
 
Ruoff, K.L. (1988) 'Streptococcus anginosus ("Streptococcus milleri"): the unrecognised pathogen', 
Clin Microbiol Rev, 1, pp. 102-08. 
 
Saglani, S., Harris, K.A., Wallis, C. and Hartley, J.C. (2005) 'Empyema: the use of broad range 16S 
rDNA PCR for pathogen detection', Arch Dis Child, 90(1), pp. 70-73. 
 
Samson, P.C. (1971) 'Empyema Thoracis: Essentials of Present-Day Management', Ann Thorac Surg, 
11(3), pp. 210-221. 
 
Sarihan, H., Cay, A., Aynaci, M., Akyazici, R. and Baki, A. (1998) 'Empyema in children', J 
Cardiovasc Surg (Torino). 39(1), pp. 113-6. 
 
Sarkar, D. (2008) Lattice: Multivariate Data Visualisation with R [Computer program]. 
 
Schultz, K.D., Fan, L.L., Pinsky, J., Ochoa, L., Smith, E.O., Kaplan, S.L. and Brandt, M.L. (2004) 
'The changing face of pleural empyemas in children: epidemiology and management', Pediatrics, 
113(6), pp. 1735-40. 
 
Schwartz, L., Flippin, H. and Turnbull, W. (1939) 'Treatment of pneumococci pneumonia: a 
comparative study of 351 patients treated at the Philadelphia General Hospital', Ann Intern Med, 13, 
pp. 1005-12. 
 278 
 
Sethi, S. and Murphy, T.F. (2001) 'Bacterial infection in chronic obstructive pulmonary disease in 
2000: a state-of-the-art review', Clin Microbiol Rev, 14(2), pp. 336-363. 
 
Shah, S.S., Hall, M., Newland, J.G., Brogan, T.V., Farris, R.W.D., Williams, D.J., Larsen, G., Fine, 
B.R., Levin, J.E., Wagener, J.S., Conway, P.H. and Myers, A.L. (2011) 'Comparative effectiveness of 
pleural drainage procedures for the treatment of complicated pneumonia in childhood', J Hosl Med, 
6(5), pp. 256-263. 
 
Shankar, K.R., Kenny, S.E., Okoye, B.O., Carty, M.L., Lloyd, D.A. and Losty, P.D. (2000) 'Evolving 
experience in the management of empyema thoracis', Acta Pædiatrica, 89(4), pp. 417-420. 
 
Sheppard, C.L., Guiver, M., Hartley, J., Harrison, T.G. and George, R.C. (2011) 'The use of a 
multiplexed immunoassay for detection of serotype-specific Streptococcus pneumoniae antigen in 
pleural fluid and CSF specimens', J Med Microbiol, 60(12), pp 1879-81. 
 
Shomaker, K.L., Weiner, T. and Esther, C.R. (2011) 'Impact of an evidence-based algorithm on 
quality of care in pediatric parapneumonic effusion and empyema', Pediatr Pulmonol, 46(7), pp. 722-
728. 
 
Sills, M.R., Huang, Z.J., Shao, C., Guagliardo, M.F., Chamberlain, J.M. and Joseph, J.G. (2000) 
'Pediatric Milliman and Robertson Length-of-Stay Criteria: Are They Realistic?', Pediatrics, 105(4), 
pp. 733-737. 
 
Singh, M., Mathew, J.L., Chandra, S., Katariya, S. and Kumar, L. (2004) 'Randomized controlled trial 
of intrapleural streptokinase in empyema thoracis in children', Acta Pædiatrica, 93(11), pp. 1443-
1445. 
 
Singleton, R.J., Hennessy, T.W., Bulkow, L.R., Hammitt, L.L., Zulz, T., Hurlburt, D.A., Butler, J.C., 
Rudolph, K. and Parkinson, A. (2007) 'Invasive pneumococcal disease caused by nonvaccine 
serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine 
coverage', JAMA, 297(16), pp. 1784-1792. 
 
Snow, S.J. (2008) 'John Snow: the making of a hero?', The Lancet, 372(9632), pp. 22-23. 
Sogaard, M., Kornum, J., Schonheyder, H. and Thomsen, R. (2011) 'Positive predictive value of the 
ICD-10 hospital diagnosis of pleural empyema in the Danish National Registry of Patients', Clin 
Epidemiol., 3, pp. 85-9. 
 279 
 
Sonnappa, S., Cohen, G., Owens, C.M., van Doorn, C., Cairns, J., Stanojevic, S., Elliott, M.J. and 
Jaffe, A. (2006) 'Comparison of Urokinase and Video-assisted Thoracoscopic Surgery for Treatment 
of Childhood Empyema', Am J Respir Crit Care Me., 174(2), pp. 221-227. 
 
Spencer, D., Iqbal, S., Hamilton, J. and Hasan, A. (2006a) 'Twin Peaks: The changing epidemiology 
of complicated pneumonia and empyema in children', British Thoracic Society Winter Meeting. 
London. p. ii96. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104788/. 
 
Spencer, D.A., Iqbal, S.M., Hasan, A. and Hamilton, L. (2006b) 'Empyema thoracis is still increasing 
in UK children', Bmj, 332(7553), p. 1333. 
 
Spencer, N., Logan, S., Scholey, S. and Gentle, S. (1996) 'Deprivation and bronchiolitis', Archives of 
Disease in Childhood, 74(1), pp. 50-52. 
 
Spiegelhalter DJ, Thomas A, Best NG and D, L. (2001) WinBUGS, Version 1.4 [Computer program]. 
MRC Biostatistics Unit. Available at: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml. 
 
Spiegelhalter, D.J., Best, N.G., Carlin, B.P. and Linde, A.v.d. (2002) 'Bayesian Measures of Model 
Complexity and Fit', Journal of the Royal Statistical Society. Series B (Statistical Methodology), 64(4), 
pp. 583-639. 
 
St. Peter, S.D., Tsao, K., Harrison, C., Jackson, M.A., Spilde, T.L., Keckler, S.J., Sharp, S.W., 
Andrews, W.S., Holcomb Iii, G.W. and Ostlie, D.J. (2009) 'Thoracoscopic decortication vs tube 
thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial', Journal of 
Pediatric Surgery, 44(1), pp. 106-111. 
 
Stovroff, M., Teague, G., Heiss, K.F., Parker, P. and Ricketts, R.R. (1995) 'Thoracoscopy in the 
management of pediatric empyema', Journal of Pediatric Surgery, 30(8), pp. 1211-1215. 
 
Strachan, R. and Jaffe, A. (2009) 'Assessment of the burden of paediatric empyema in Australia', J 
Paediatr Child Health, 45(7-8), pp. 431-6. 
 
Team, R.D.C. (2010) R: A language and environment for statistical computing. [Computer program]. 
R Foundation for Statistical Computing. Available at: http://www.R-project.org/. 
 
Therneau, T. (2011) Survival analysis, including penalised likelihood (Version 2.36-10) [Computer 
program]. Available at: http://r-forge.r-project.org. 
 280 
 
Therneau, T. and Grambsch, P. (2000) Modelling survival data - Extending the Cox model. New York 
Springer. 
 
Thomas, M., Cliff, D., Beaton, S., Rushton, S., Paton, J. and Spencer, D. (2009) 'Paediatric empyema 
management in the UK', Thorax, 64 Suppl. 4. 
 
Thomas, M., Simmister, C., Cliff, D., Elemraid, M., Clark, J., Rushton, S., Gorton, R., Paton, J. and 
Spencer, D. (2011) 'Comparison of primary pleural drainage strategies in paediatric empyema ', 
Thorax, 66 Suppl. 4, pp. A137-A138  
 
Thompson, A., Reid, A., Shields, M., Steen, H. and Taylor, R. (1999) 'Increased incidence in 
childhood empyema thoracis in Northern Ireland', Ir Med J, 92(7), p. 438. 
 
Thompson, L.D., Edwards, J.C. and Hoagland, C.L. (1940) 'Experiences in the treatment of lobar 
pneumonia', Ann Intern Med, 13, pp. 1138-49. 
 
Thompson, P.L., Spyridis, N., Sharland, M., Gilbert, R.E., Saxena, S., Long, P.F., Johnson, A.P. and 
Wong, I.C.K. (2009) 'Changes in clinical indications for community antibiotic prescribing for children 
in the UK from 1996 to 2006: will the new NICE prescribing guidance on upper respiratory tract 
infections just be ignored?', Arch Dis Child, 94(5), pp. 337-340. 
 
Thomson, A.H., Hull, J., Kumar, M.R., Wallis, C. and Balfour Lynn, I.M. (2002) 'Randomised trial of 
intrapleural urokinase in the treatment of childhood empyema', Thorax, 57(4), pp. 343-347. 
 
Tian, H. and Cazelles, B. (2011) WaveletCo: Wavelet Coherence Analysis. (Version R package 
version 1.0) [Computer program]. Available at: http://CRAN.R-project.org/package=WaveletCo. 
 
Tillet, W.S., Cambier, M.J. and McCormack, J.E. (1944) 'The treatment of lobar pneumonia and 
pneumococcal empyema with penicillin', Bull N Y Acad Sci, 20, pp. 142-78. 
 
Tokuda, Y., Matsushima, D., Stein, G.H. and Miyagi, S. (2006) 'Intrapleural Fibrinolytic Agents for 
Empyema and Complicated Parapneumonic Effusions:A Meta-analysis', Chest, 129(3), pp. 783-790. 
 
Tsang, K., Leung, W., Chan, V., Lin, A. and Chu, C. (2007) 'Complicated parapneumonic effusion 
and empyema thoracis: microbiology and predictors of adverse outcomes', Hong Kong Medical 
Journal, 13, pp. 178-86. 
 281 
 
Van Ackere, T., Proesmans, M., Vermeulen, F., Van Raemdonck, D. and De Boeck, K. (2009) 
'Complicated parapneumonic effusion in Belgian children: increased occurrence before routine 
pneumococcal vaccine implementation', Eur J Pediatr, 168(1), pp. 51-58. 
 
van der Poll, T. and Opal, S.M. (2011) 'Pathogenesis, treatment, and prevention of pneumococcal 
pneumonia', The Lancet, 374(9700), pp. 1543-1556. 
 
Venables, W. and Ripley, B. (2002) MASS: Modern applied statistics with S [Computer program]. 
 
Virkki, R., Juven, T., Rikalainen, H., Svedström, E., Mertsola, J. and Ruuskanen, O. (2002) 
'Differentiation of bacterial and viral pneumonia in children', Thorax, 57(5), pp. 438-441. 
 
Wagner, A.K., Soumerai, S.B., Zhang, F. and Ross-Degnan, D. (2002) 'Segmented regression analysis 
of interrupted time series studies in medication use research', J Clin Pharm Thera, 27(4), pp. 299-309. 
 
Waites, K.B. and Talkington, D.F. (2004) 'Mycoplasma pneumoniae and Its Role as a Human 
Pathogen', Clin Microbiol Rev, 17(4), pp. 697-728. 
 
Wang, N. (1985) 'Anatomy and physiology of the pleural space', Clinics in chest medicine, 6(1), pp. 
3-16. 
 
Wardlaw, T., Salama, P., Johansson, E.W. and Mason, E. (2006) 'Pneumonia: the leading killer of 
children', Lancet, 368(9541), pp. 1048-1050. 
 
Weinberger, D.M., Harboe, Z.B., Sanders, E.A.M., Ndiritu, M., Klugman, K.P., Rückinger, S., Dagan, 
R., Adegbola, R., Cutts, F., Johnson, H.L., O'Brien, K.L., Scott, J.A. and Lipsitch, M. (2010) 
'Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta-Analysis', 
Clin Infect Dis, 51(6), pp. 692-699. 
 
Wexler, I.D., Knoll, S., Picard, E., Villa, Y., Shoseyov, D., Engelhard, D. and Kerem, E. (2006) 
'Clinical characteristics and outcome of complicated pneumococcal pneumonia in a pediatric 
population', Pediatr Pulmonol, 41(8), pp. 726 - 734. 
 
WHO (1990) International Classification of Diseases (ICD) 10 Available at: 
http://www.who.int/classifications/icd/en/ (Accessed: 22/04/2010). 
 
 282 
 
Wilkinson, R.G. (1997) 'Socioeconomic determinants of health: health inequalities: relative or 
absolute material standards?', BMJ, 314(7080), p. 591. 
 
Williams, D.J., Hall, M., Brogan, T.V., Farris, R.W.D., Myers, A.L., Newland, J.G. and Shah, S.S. 
(2011) 'Influenza Coinfection and Outcomes in Children With Complicated Pneumonia', Arch Pediatr 
Adolesc Med, 165(6), pp. 506-512. 
 
Wilson, M., E. (1995) 'Travel and the emergence of infectious diseases', Emerg Infect Dis., 1(2), pp. 
39-46. 
 
Wolfe WG, Spock A and Bradford WD (1968) 'Pleural fluid in infants and children', American 
Review of Respiratory Disease, 98, pp. 1027-32. 
 
Zhang, Z., Cazelles, B., Tian, H., Christian Stige, L., Bräuning, A. and Stenseth, N.C. (2009) 'Periodic 
temperature-associated drought/flood drives locust plagues in China', Proceedings of the Royal 
Society B: Biological Sciences, 276(1658), pp. 823-831. 
 
Zocchi, L. (2002) 'Physiology and pathophysiology of pleural fluid turnover', ERJ, 20(6), pp. 1545-
1558. 
 
Zuur, A.F., Ieno, E.N., Walker, N.J., Saveliev, A.A. and Smith, G.M. (2009) Mixed Effects Models 
and Extensions in Ecology with R. New York: Springer. 
 
 
  
 283 
 
9 Appendices 
9.1 Appendix A - ICD-10 Codes for bacterial pneumonia 
 
ICD-10 Codes Bacterial pneumonia 
J13 Pneumonia due to Streptococcus pneumoniae 
J14 Pneumonia due to Haemophilus influenzae 
J15.0  Pneumonia due to Klebsiella pneumoniae 
J15.1 Pneumonia due to Pseudomonas 
J15.2 Pneumonia due to staphylococcus 
J15.3 Pneumonia due to streptococcus, group B 
J15.4 Pneumonia due to other streptococci 
J15.5 Pneumonia due to Escherichia coli 
J15.6 Pneumonia due to other aerobic Gram-negative bacteria 
J15.7 Pneumonia due to Mycoplasma pneumoniae 
J15.8 Other bacterial pneumonia 
J15.9 Bacterial pneumonia, unspecified 
J18.1 Lobar pneumonia, unspecified 
 
Table 9.1 ICD-10 codes included in the definition of pneumonia. 
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9.2 Appendix B - Model diagnostic plots for changes in the incidence of empyema in 
the NE (Models T0-T1) 
 
 
Figure 9.1 Scatter plot of residual and fitted values to assess homoscedascity, independence and 
variance of the residual distribution for model T0. Distribution of the residuals reflects the 
constraints and lack of variation in numbers of cases per months (Range: 0 – 9 cases).  
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Figure 9.2 Normal probability plot of standardised residuals to assess distribution of errors and 
detect any evidence of non-normal residual distribution and abnormal variance from model T0.  
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Figure 9.3 Autocorrelation plot of model T0 showing evidence of significant autocorrelation at 
lags 9 and 19. Dotted lines indicate cut-off for presences of significant autocorrelation. ACF – 
autocorrelation function (size of autocorrelation, lag indicates number of months between 
observations when correlation occurs) 
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Figure 9.4 Normal probability plot of standardised residuals to assess distribution of errors and 
detect any evidence of non-normal residual distribution and abnormal variance from model T1. 
  
 288 
 
 
Figure 9.5 Scatter plot of residual and fitted values to assess homoscedascity, independence and 
variance of the residual distribution for model T1. 
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Figure 9.6 Autocorrelation plot of model T1, with lag 19 of borderline significance. Dotted lines 
indicate cut-off for presences of significant autocorrelation. ACF – autocorrelation function (size 
of autocorrelation, lag indicates number of months between observations when correlation occurs) 
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9.3 Appendix C - Model diagnostic plots for national trends in empyema and 
pneumonia (Models M0a/b – M4) 
 
 
Figure 9.7 Normal probability plot of standardised residuals to assess distribution of errors and 
detect any evidence of non-normal residual distribution and abnormal variance from model 
M0a. 
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Figure 9.8 Normal probability plot of standardised residuals to assess distribution of errors and 
detect any evidence of non-normal residual distribution and abnormal variance from model 
M0b. 
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Figure 9.9 Scatter plot of residual and fitted values to assess homoscedascity, independence and 
variance of the residual distribution for Model M0a.  
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Figure 9.10 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for Model M0b. Increasing variance over time is seen.   
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Figure 9.11 Plot illustrating autocorrelation over all lags in model M0a. Dotted lines indicate cut-
off for presences of significant autocorrelation. ACF – autocorrelation function (size of 
autocorrelation, lag indicates number of months between observations when correlation occurs). 
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Figure 9.12 Plot illustrating autocorrelation over all lags in model M0b. Dotted lines indicate cut-
off for presences of significant autocorrelation. ACF – autocorrelation function (size of 
autocorrelation, lag indicates number of months between observations when correlation occurs) 
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Figure 9.13 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
M1. 
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Figure 9.14 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for Model M1. A normal distribution of fitted values 
are seen. 
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Figure 9.15 Autocorrelation plot demonstrating significant autocorrelation at lags 2, 6 and 12 in 
model M1. Dotted lines indicate cut-off for presences of significant autocorrelation. ACF – 
autocorrelation function (size of autocorrelation, lag indicates number of months between 
observations when correlation occurs). 
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Figure 9.16 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
M2 showing potential overdispersion at lower residual values.  
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Figure 9.17 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for Model M2. Normal distribution of the residuals is 
seen.   
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Figure 9.18 Autocorrelation plot of model M2 demonstrating significant autocorrelation at lags 
12 and 19. Dotted lines indicate cut-off for presences of significant autocorrelation. ACF – 
autocorrelation function (size of autocorrelation, lag indicates number of months between 
observations when correlation occurs). 
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Figure 9.19 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
M4 illustrating minor overdispersion of the residuals at the extremes.  
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Figure 9.20 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for model M4. Normal distribution seen.  
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Figure 9.21 Autocorrelation plot of model M4 with autocorrelation of marginal significance at 
lags 3 and 6. Dotted lines indicate cut-off for presences of significant autocorrelation. ACF – 
autocorrelation function (size of autocorrelation, lag indicates number of months between 
observations when correlation occurs). 
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9.4 Appendix D - Model diagnostic plots for definition of periodicity and cyclicity 
within national empyema admissions (Model M5) 
 
 
Figure 9.22 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
M5 illustrating minor overdispersion of the residuals at the extremes.  
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Figure 9.23 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for model M5.   
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Figure 9.24 Autocorrelation plot showing no significant autocorrelation in model M5. Dotted 
lines indicate cut-off for presences of significant autocorrelation. ACF – autocorrelation function 
(size of autocorrelation, lag indicates number of months between observations when correlation 
occurs). 
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9.5 Appendix E - Model diagnostic plots for population adjusted pneumonia and 
empyema admissions (Models S0a/b-S3a/b) 
 
Figure 9.25 Residuals from model S0a – linear model relating population adjusted pneumonia 
admissions to SHA. Three outlying values identified from the North East SHA corresponding to 
June, July and August 1997. There were two, two and zero recorded cases of pneumonia in 
those months respectively. Similarly low values are observed in the same months at different 
points and admissions for pneumonia are recognised to be low at this time of year suggesting 
that these values are real rather than artefact.  
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Figure 9.26 Residuals from model S0a – linear model relating population adjusted empyema 
admissions to SHA. The residuals are clustered due to the limited range of values of population 
adjusted empyema admission seen within the data.  
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Figure 9.27 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
S1a. Three outlying values as in model S0a were identified.  
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Figure 9.28 Scatter plot of residual to assess homoscedascity, independence and variance of the 
residual distribution from model S1a. Normal distribution except for three outlying values are 
seen.  
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Figure 9.29 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
S1b. 
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Figure 9.30 Scatter plot of residual to assess homoscedascity, independence and variance of the 
residual distribution from model S1b.  
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Figure 9.31 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
S2.  
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Figure 9.32 Scatter plot of residuals to assess homoscedascity, independence and variance of the 
residual distribution from model S2.  
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Figure 9.33 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution from model S3a.  
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Figure 9.34 Residuals from model S3a. 
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Figure 9.35 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
S3b.  
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Figure 9.36 Scatter plot of residuals to assess homoscedascity, independence and variance of the 
residual distribution from model S3b.  
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9.6 Appendix F - Model diagnostic plots for ratio of empyema admissions to 
pneumonia admissions (Models R0-2) 
 
Figure 9.37 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
R0 illustrating some overdispersion of the residuals at the extremes.  
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Figure 9.38 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for model R0. There is clear variation in the variance 
of the distribution suggesting abnormal variance in the residuals suspicious of a lack of 
independence between observations.    
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Figure 9.39 Autocorrelation plot illustrating significant autocorrelation in residuals of model R0. 
Dotted lines indicate cut-off for presences of significant autocorrelation. ACF – autocorrelation 
function (size of autocorrelation, lag indicates number of months between observations when 
correlation occurs). 
 
 
  
 
 323 
 
 
Figure 9.40 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
R1 showing some mild overdispersion of extreme values. 
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Figure 9.41 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for model R1. The residuals have a normal and 
symmetrical distribution suggesting the model assumptions of independence are valid.  
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Figure 9.42 Autocorrelation plot illustrating presence of significant autocorrelation in residuals 
of model R1 at lags7, 12 and 19. Dotted lines indicate cut-off for presences of significant 
autocorrelation. ACF – autocorrelation function (size of autocorrelation, lag indicates number of 
months between observations when correlation occurs). 
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Figure 9.43 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
R2. There is evidence of overdispersion of the residuals at the extreme values.  
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Figure 9.44 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for model R2. The residual distribution is normal.  
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Figure 9.45 Autocorrelation plot illustrating presence of significant autocorrelation in residuals 
of model R2 at lags 7 and 12.  Dotted lines indicate cut-off for presences of significant 
autocorrelation. ACF – autocorrelation function (size of autocorrelation, lag indicates number of 
months between observations when correlation occurs). 
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9.7 Appendix G - Model diagnostic plots for definition of periodicity and cyclicity 
within ratio of empyema to pneumonia admissions (Model R3) 
 
Figure 9.46 Normal probability plot of standardised residuals from model R3. 
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Figure 9.47 Scatter plot of residual and fitted values to assess homoscedascity, independence 
and variance of the residual distribution for model R3. The residual distribution is normal.  
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Figure 9.48 Plot illustrating presence of significant autocorrelation in residuals of model R3 at 
lags 6 and 12. Dotted lines indicate cut-off for presences of significant autocorrelation. ACF – 
autocorrelation function (size of autocorrelation, lag indicates number of months between 
observations when correlation occurs). 
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9.8 Appendix H - Model diagnostic plots from investigation of relationship between 
empyema admissions and isolations of S. pneumoniae, S. pyogenes, S. aureus and 
M. pneumoniae (Model P0 and S0). 
 
The residuals of the initial models which did not include any autocorrelative structure demonstrated 
clear evidence of serial dependence (Models P0 (Figure 9.49) and S0 (Figure 9.50)).     
 
Figure 9.49 Residuals of initial time series model (P0) without autocorrelation structure relating 
empyema admissions to isolations of S. pneumoniae, S. pyogenes, S. aureus and M. pneumoniae 
from children (0-14 years) in England from April 1997 to April 2006 demonstrating significant 
serial dependence. 
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Figure 9.50 Residuals of initial time series model (S0) without autocorrelation structure relating 
ratio of empyema admissions to pneumonia admissions to isolations of S. pneumoniae, S. 
pyogenes, S. aureus and M. pneumoniae from children (0-14 years) in England from April 1997 
to April 2006 demonstrating serial dependence. 
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Correlation structure AIC Phi / Theta 
None 159.47 - 
Compound symmetry 161.47 -3.44 x 10
-18 
(Rho) 
Auto-regressive model of order 1 142.79 0.52 
Auto-regressive moving average p = 1, q = 0 142.79 0.52 
Auto-regressive moving average p = 2, q = 0 125.92 0.34 , 0.43 
Auto-regressive moving average p = 3, q = 0 125.58 0.26, 0.39, 0.18 
Auto-regressive moving average p = 1, q = 1 NA NA 
Auto-regressive moving average p = 2, q = 1 NA NA 
Auto-regressive moving average p = 3, q = 1 NA NA 
Auto-regressive moving average p = 1, q = 2 NA NA 
Auto-regressive moving average p = 1, q = 3 NA NA 
Auto-regressive moving average p = 2, q = 2 112.49 7.12 x 10
-7
, 0.99, 0.22, -0.77 
Auto-regressive moving average p = 2, q = 3 NA NA 
Auto-regressive moving average p = 3, q = 3 NA NA 
Auto-regressive moving average p = 0, q = 1 153.24 0.24 
Auto-regressive moving average p = 0, q = 2 142.75 0.27, 0.34 
Auto-regressive moving average p = 0, q = 3 140.29 0.32, 0.38, 0.17 
 
Table 9.2 Results of modelling relating empyema admissions to isolations of S. pneumoniae, S. 
pyogenes, S. aureus and M. pneumoniae from children (0-14 years) in England from April 1997 
to April 2006 and optimization of the residual autocorrelation structure – Model P0.  
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Correlation structure AIC Phi / Theta 
None -599.97 - 
Compound symmetry -597/97 3.78 x 10
-9
 (rho) 
Auto-regressive model of order 1 -602.56 0.24 
Auto-regressive moving average p = 1, q = 0 -602.56 0.24 
Auto-regressive moving average p = 2, q = 0 -604.65 0.24. 0.22 
Auto-regressive moving average p = 3, q = 0 -602.67 0.25, 0.23, -0.016 
Auto-regressive moving average p = 1, q = 1 NA NA 
Auto-regressive moving average p = 2, q = 1 NA NA 
Auto-regressive moving average p = 3, q = 1 NA NA 
Auto-regressive moving average p = 1, q = 2 -609.02 0.996.68 x 10
-9
, -1 
Auto-regressive moving average p = 1, q = 3 NA NA 
Auto-regressive moving average p = 2, q = 2 NA NA 
Auto-regressive moving average p = 2, q = 3 NA NA 
Auto-regressive moving average p = 3, q = 3 NA NA 
Auto-regressive moving average p = 0, q = 1 -601.09 0.16 
Auto-regressive moving average p = 0, q = 2 -603.41 0.23, 0.21 
Auto-regressive moving average p = 0, q = 3 -601.42 0.23, 0.21, 0.0086 
 
Table 9.3 Results of modelling relating ratio of empyema admissions to pneumonia admissions 
to isolations of S. pneumoniae, S. pyogenes, S. aureus and M. pneumoniae from children (0-14 
years) in England from April 1997 to April 2006 and optimization of the residual 
autocorrelation structure – Model S0.  
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Figure 9.51 Normal probability plot of standardised residuals from model P0 which is within 
acceptable limits. 
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Figure 9.52 Scatter plot of residuals to assess homoscedascity, independence and variance of the 
residual distribution for model P0 showing clearly pattern to the residuals suggesting a lack of 
independence between the observed data.  
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Figure 9.53 Autocorrelation plot of model P0 with autocorrelation present until lag 14. Dotted 
lines indicate cut-off for presences of significant autocorrelation. ACF – autocorrelation function 
(size of autocorrelation, lag indicates number of months between observations when correlation 
occurs). 
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9.9 Appendix I - Model diagnostic plots for testing of relationship on monthly rate of 
progression from pneumonia to empyema and isolations of S. pneumoniae, S. 
pyogenes, S. aureus and M. pneumoniae (Model S0) 
 
 
Figure 9.54 Normal probability plot of standardised residuals to assess distribution of errors 
and detect any evidence of non-normal residual distribution and abnormal variance from model 
S0 with overdispersion of the residuals at the extreme values. 
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Figure 9.55 Scatter plot of residuals to assess homoscedascity, independence and variance of the 
residual distribution for model S0 showing clearly pattern to the residuals suggesting a lack of 
independence between the observed data. 
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Figure 9.56 Autocorrelation plot of model P0 with autocorrelation present at lags 
1,2,4,6,7,8,9,10 and 12 months. Dotted lines indicate cut-off for presences of significant 
autocorrelation. ACF – autocorrelation function (size of autocorrelation, lag indicates number of 
months between observations when correlation occurs). 
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9.10 Appendix J - Distribution of length of stay including illness length 
 
 
Figure 9.57 Frequency distribution of illness length in empyema cases illustrating non-
normality (Shapiro-Wilk test for normality - W = 0.7653, p-value <0.001) 
 
Figure 9.58 Frequency distribution of total hospital stay in empyema cases illustrating non-
normality (Shapiro-Wilk test for normality - W = 0.8432, p-value <0.001) 
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Figure 9.59 Frequency distribution of tertiary hospital stay in empyema cases illustrating non-
normality (Shapiro-Wilk test for normality - W = 0.8375, p-value <0.001) 
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9.11 Appendix K - Schoenfeld residuals and assessment of proportionality of hazards 
organism and illness length model (Model Org) 
 
Figure 9.60 Plot of Schoenfeld residuals from analysis of relationship between organism and 
illness length. 
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Variable Correlation Chi-squared p-value 
S. aureus -0.0187 0.193 0.660 
S. pyogenes 0.0198 0.216 0.642 
S. mitis -0.0136 0.102 0.749 
No organism detected -0.0268 0.395 0.530 
Other -0.0416 0.946 0.331 
Global NA 6.621 0.250 
 
Table 9.4 Assessment of proportionality of hazards over time for relationship between organism 
and illness length (correlation between smoothing function and scaled Schoenfeld residuals, chi-
squared test for each covariate and overall chi-squared).    
  
 346 
 
9.12 Appendix L - Schoenfeld residuals and assessment of proportionality of hazards 
pneumococcal serotype and illness length model (Model Sero) 
 
 
Figure 9.61 Plot of Schoenfeld residuals from serotype illness length model. 
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Variable Correlation Chi-squared p-value 
Serotype 19A -0.1012 1.3237 0.2500 
Serotype 3 0.0121 0.0194 0.8890 
Serotype  7 -0.0182 0.0476 0.8270 
Other serotypes -0.0277 0.1020 0.7490 
Global NA 1.5558 0.8170 
 
Table 9.5 Assessment of proportionality of hazards over time for illness length model 
(correlation between smoothing function and scaled Schoenfeld residuals, chi-squared test for 
each covariate and overall chi-squared).   
 348 
 
9.13 Appendix M - Schoenfeld residuals and assessment of proportionality of hazards 
in treatment models (Models HSa/b and THSa/b) 
 
Co-variate Rho Chi-squared P-value 
Model HSa 
PICU Admission 0.0487 1.6457 0.2000 
Age (Years) 0.0033 0.0063 0.9370 
Surgical treatment -0.1282 29.5792 <0.0001 
Global hazard NA 31.3129 <0.0001 
Model THSa 
PICU Admission 0.0359 0.8820 0.3480 
Surgical treatment -0.1568 39.0640 <0.0001 
Global hazard 0.0359 0.8820 0.3480 
Model HSb 
PICU Admission 0.0662 3.0103 0.0827 
Age (Years) 0.0081 0.0387 0.8440 
Drainage alone -0.1045 13.5879 0.0002 
Mini-thoracotomy -0.1418 62.5865 <0.0001 
VATS -0.0368 0.9130 0.3390 
Global hazard NA 64.3161 <0.0001 
Model THSb 
PICU Admission 0.0504 1.7100 0.1910 
Drainage alone -0.1064 12.5100 0.0004 
Mini-thoracotomy -0.1752 78.7900 <0.0001 
VATS -0.0398 1.1100 0.2930 
Global hazard NA 80.9000 <0.0001 
Table 9.6 Results of regression of weighted residuals to test for proportionality of hazards over 
time for all four parsimonious models.  
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Figure 9.62 Plot of Schoenfeld residuals from serotype model HSa investigating the relationship 
between total hospital stay and surgical and non-surgical treatment methods. 
Tre_group_alt)Tho refers to surgical treatment methods.  
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Figure 9.63 Plot of Schoenfeld residuals from serotype model THSa investigating the 
relationship between tertiary centre stay and surgical and non-surgical treatment methods. 
Tre_group_alt)Tho refers to surgical treatment methods. 
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Figure 9.64 Plot of Schoenfeld residuals from serotype model HSb investigating the relationship 
between total hospital stay and the four treatment methods.  
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Figure 9.65 Plot of Schoenfeld residuals from serotype model HSb investigating the relationship 
between tertiary centre stay and the four treatment methods 
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9.14 Appendix N - List of free-text complications  
Abscess + necrotic lung+bronchopleural fistula-VV ECMO BC19A 
Air leak 
Albumin 11, oedematous 
Albumin 17 
ARF secondary to pneumococcal HUS requiring PD then HD 
broncho pleural fistula requring a second drain 
Cellulitis at drain site 
Chylothorax 
Drain migrated 
Drain migration 
Drain recurrent infection 15/1, redo right decortication + wound debridement 20/1 
Drain removed by patient 
Glomerulonephritis 
Group A strep sepsis-toxic shock, retropharyngeal abscess, celulitis R torso/neck, rsv positive 
HUS-VA ECMO pre decortication. Died 
Influenza A H1N1, strep A Toxic shock septicemia, Left pleural effusion, pneumonia and RSV 
positive 
Left sided pleural effusion, Influenza A H1N1 low level positive pcr suggestive of recent infection 
Loculated pneumothorax - had pleuroplasty as 2nd op & drain with Heimlich 
Lung abscesses 
Necrotising pneumonia-consolidation of left lower lobe, adenovirus low level positive 
Pancytopenia, pneumothorax. Discharged to Rochdale for IVs 
Pneumatocoele 
Pneumothorax 
Pneumothorax - drain reinserted 19/01/2010 Bronchopleural fistula 
Pneumothorax (prior to drain) 
Pneumothorax 1 mnth post decortication 
Pneumothorax and surgical emphysema 
Pneumothorax Chest drain reinserted, removed 2/1/11 
Pneumothorax req 2nd chest drain 
Pneumothorax x2, necrotic lung abscess, bronchopleural fistula, Heimlick valve needed 
Pneumothorax, lung abscess 
Presumed streptococcal vasculitis 
Reaccumulation pleural effusion-chest drain with USS guidance. Died 26/12/2009 
Readmitted -  required further drainage 
Readmitted with pneumothorax. Given 6x2 doses urokinase 
Redo decortication 
Required decortication 
Residual pneumothorax 
RSV pos,L pneumothorax and pleural effusion, septic shock, hypoglycemia and metabolic 
acidosis 
Septic shock at presentation. Pneumothorax . extravasation injuries 
Severe anaemia, requiring transfusion 
Small pneumothorax 
Small pneumothorax 
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Small pneumothorax -not drained 
Small residual pneumothorax 
Toxic shock syndrome. Chest drain re-inserted 31.03.11 removed 06.04.11 8 doses of Urokinase. 
Toxic shock, facial tics 
VATS was partial decortication, hypoalbuniaemia, lung abscess 
Wound debridement & resuturing 1 wk post op 6 wks pneumothorax 
x3 procedures (adult services) 3rd op. stapling necrotic lung. MRSA in wound 
 
 
Table 9.7 All free text entries of complications included in analysis  
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9.15 Appendix O - Emergence of pneumococcal 19A empyema in UK children 
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ABSTRACT 
Introduction – Invasive pneumococcal disease due to serotype 19A has become a major concern, 
particularly in the USA and Asia. We describe the characteristics of pneumococcal serotype 19A 
related empyema and changes in its incidence in the UK. 
Methods –Data from paediatric empyema patients between September 2006 and March 2011 were 
collected from 17 respiratory centres in the UK. Pneumococcal serotypes were identified as part of the 
Health Protection Agency (HPA) enhanced paediatric empyema surveillance programme.  
Results – Four serotypes accounted for over 80% of 136 cases (Serotype 1:43%, 3:21%, 7:11% and 
19A:10%). The incidence of empyema due to serotype 19A quadrupled from 0.48 (0.16-1.13) cases 
per million children in 2006/7 to 2.02 (1.25-3.09) in 2010/11. Severity of disease was significantly 
increased in children with 19A infection when compared to other serotypes.  
Conclusions – The incidence of empyema due to pneumococcal serotype 19A infection has increased 
significantly and is associated with substantial morbidity. 
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INTRODUCTION 
Streptococcus pneumoniae is the leading cause of bacterial pneumonia in children worldwide, and is 
responsible for an estimated 700,000 to one million deaths annually in children under 5 years of 
age.(Reinert et al., 2010) There are over 90 recognised serotypes of S. pneumoniae, but not all are 
commonly associated with human disease.(Reinert et al., 2010) Conjugated pneumococcal vaccines 
currently provide protection against a limited number of serotypes with the seven valent conjugate 
vaccine (PCV-7) providing protection against seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) and 
the 13-valent vaccine (PCV-13), which was recently introduced in the UK, active against an 
additional six serotypes (1, 3, 5, 6A, 7F and 19A).  
 
The range of pneumococcal serotypes causing invasive disease is changing. In particular, the 
incidence of serotype 19A (Spn19A) has increased substantially in some countries, notably the USA, 
Spain and South Korea.(Reinert et al., 2010) In the USA, Spn19A was present in only 2.5% of  
isolates from children under 5 years of age prior to the introduction of PCV-7 in 1998-1999 but was 
identified in 47.2% of isolates six years later and prior to the introduction of PCV-13 became the 
leading cause of invasive pneumococcal disease in children in that country.(Reinert et al., 2010) In 
England and Wales, a recent report from the HPA has highlighted the emergence of Spn19A as a 
cause of invasive pneumococcal disease.(Miller et al., 2011) 
  
Historically, Spn19A has not been a recognised cause of paediatric empyema in the UK (Eastham et 
al., 2004; McKee et al., 2011) but it has been linked to the rise in incidence of empyema in the 
USA.(Reinert et al., 2010) Complication rates in paediatric empyema have been shown to vary 
between pneumococcal serotypes but Spn19A has not been previously highlighted as a 
concern.(McKee et al., 2011) In light of the increasing importance of Spn19A in pneumococcal 
disease we describe changes in the incidence of Spn19A infection in empyema in England and 
evaluate the resulting changes in disease severity.  
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METHODS 
Pneumococcal serotype surveillance 
From September 2006, culture negative pleural fluid samples from children (0-16 years) with 
empyema were forwarded to the HPA from microbiology laboratories across England as part of the 
programme of enhanced surveillance of pneumococcal empyema in UK children (UK-ESPE). 
Samples were tested with a pneumococcal PCR (pneumolysin and autolysin) and positive samples 
underwent serotyping. Serotyping involved a non-culture multiplex polysaccharide antigen detection 
assay that has been described previously.(Sheppard et al., 2011) Serotyping of culture negative 
pleural fluid was used as the source of pneumococcal serotyping data as in the majority of cases (127 
of the 136 (93%) UK-ESPE cases included) pleural fluid in children with pneumococcal empyema 
was sterile at the point of testing, presumably because of antibiotic use prior to referral.(Sheppard et 
al., 2011)  
 
Clinical characteristics 
Detailed clinical data on children (0-16 years) with empyema requiring pleural drainage between 
September 2006 and March 2011 were collected from 17 collaborating UK-ESPE centres. A secure 
web-accessed pro-forma was completed on each patient by the clinical team at the relevant 
collaborating centre. These data were then matched to the national serotyping surveillance data. 
Additional patients from Scottish centres collaborating with the UK-ESPE study were added where 
serotyping results were available. Caldicott approval for the collection of clinical data was obtained. 
 
Statistical analysis 
Incidence calculations were based on total numbers of patients identified by the PCR based culture 
negative surveillance carried out by the HPA in England from 2006 onwards. Clinical characteristics 
were analysed using Kruskal-Wallis and Fisher’s exact test for continuous and categorical variables 
respectively. Cox’s proportional hazard models were used for length of stay analysis. All analyses 
were carried out using the R statistical package (v.11.2).  
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RESULTS 
Cases of complicated pneumonia and empyema due to Spn19A in England increased from 5 in 2006/7 
(the year following the introduction of PCV-7) to 21 cases in 2010/11 which was the year following 
the replacement of PCV-7 with PCV-13. The incidence increased from 0.48 cases per million children 
(95% confidence intervals (CI) 0.16-1.13) in 2006/7 to 2.02 (95% CI 1.25-3.09) in 2010/11, giving an 
incidence rate ratio of 4.17 (95% CI 1.53-14.2).  
 
Of the 136 UK-ESPE cases (134 from England and 2 from Scotland) where a pneumococcal serotype 
was identified and clinical details were available, 14 (10%) were serotype 19A. Serotypes 1, 3 and 7 
(43%, 20.6% and 11%) were the other common serotypes detected. Of Spn19A cases, 5 (36%) had a 
positive blood culture and all but one had culture negative pleural fluid (7%). One isolate was 
resistant to Penicillin, Tetracycline and Clindamycin but sensitive to Cephalosporins on standard 
testing. No evidence of antibiotic resistance was reported in any of the other isolates. Characteristics 
of children with Spn19A infection and those with other pneumococcal serotypes are shown in Table. 
Four of five children with Spn19A infection who developed complications had culture positive 
disease. Duration of hospital admission was increased by 50% in patients with 19A disease compared 
to all other serotypes (adjusting for age and sex - Hazard: 0.52, 95% CI 0.28-0.95, p=0.034). 
Survivorship curves are shown in the Figure.  
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DISCUSSION 
The incidence of empyema due to Spn19A infection has increased dramatically in UK children. It is 
unclear exactly what has driven this change in incidence but antibiotic pressure, vaccine induced 
serotype replacement, existing secular trends and introduction of new clones are all potentially 
relevant factors.(Reinert et al., 2010; Miller et al., 2011) In the absence of molecular epidemiological 
and pre-vaccine data it is impossible to be certain which of these factors are relevant.  
 
The most striking finding from our data was the severity of disease. Children with Spn19A related 
empyema stayed longer in hospital. They were significantly more likely to require intensive care and 
had higher complication rates when compared to children with empyema due to other pneumococcal 
serotypes. There were no differences in co-morbidity, pre-hospital antibiotic usage and surgical 
intervention rate suggesting that the increased severity was serotype related rather than due to patient 
or treatment factors. Furthermore, Picazo and colleagues found similar high rates of intensive care 
admission (63.6%) and complications (27.3%) in Spanish children with empyema due to 
Spn19A.(Picazo et al., 2011) The pneumococcal capsule is an important virulence factor, and hence 
differences in disease severity between serotypes are well described.(Reinert et al., 2010) However, 
this level of disease severity is in marked contrast to the traditional clinical picture in paediatric 
empyema and is of significant concern.(McKee et al., 2011)  
 
We found only limited evidence of antibiotic resistance within the Spn19A isolates, although 
molecular testing for resistance e.g. by use of pbp2b PCR assay was not available. These findings are 
in contrast to the experience in the USA and Asia where Spn19A isolates are frequently resistant to 
multiple antibiotics, possibly as a consequence of excess antibiotic usage in the community.(Reinert et 
al., 2010)     
 
Miller and colleagues have previously demonstrated that the epidemiology of invasive pneumococcal 
disease is changing both in children and in adults in the UK.(Miller et al., 2011) Spn19A related 
empyema has increased in UK children and this change may have been driven by vaccine related 
serotype replacement disease following the introduction of PCV-7. PCV-13 introduced in 2010 in the 
UK contains antigen for 19A. This is likely to lead to a significant reduction in Spn19A disease but 
given the PCV-7 experience further changes in the clinical profile of pneumococcal disease are 
possible. Continued surveillance will be required to monitor for further evolutionary changes in this 
group of organisms. 
  
 
Acknowledgements 
The authors would also like acknowledge S Beaton, Glasgow University for his support of the web-based 
data collection, T Harrison, Health Protection Agency and all those at the UK-ESPE collaborating centres 
study: C Wallis, V Rasiah, R Thursfield – Great Ormond Street Hospital, London; C Murray, J Mercy – 
Royal Manchester Children’s Hospital, Manchester; C Pao – Royal London Hospital, London; R Ross-
Russell – Addenbrooke’s Hospital, Cambridge; J Bhatt, R Radcliffe, K Ward – Nottingham Children’s 
Hospital; A Thomson – Children’s Hospital, Oxford; I Balfour-Lynn – Royal Brompton Hospital, London; 
W Lenney – University Hospital of North Staffordshire, Stoke-on-Trent; J Clarke, I Brookes – 
Birmingham Children’s Hospital, Birmingham; R Primhak – Sheffield Children’s Hospital, Sheffield; E 
Carroll, J Clark – Alder Hey Children’s Hospital, Liverpool; T Hilliard – Bristol Royal Hospital for 
Children, Bristol; A Cade – Derriford Hospital, Plymouth; A Prendiville, H Soloman, Royal Cornwall 
Hospital, Truro; S Cunningham, Royal Hospital for Sick Children, Edinburgh   
Disclosure 
CLS has received support from Pfizer Inc. to attend overseas conferences. MPES is a member of advisory 
boards of GSK and Pfizer Inc, has received funding to her institution from GSK and Pfizer Inc. for 
investigation of multiple pneumococcal serotype carriage using DNA microarray, been an invited speaker 
at scientific meetings organized by GSK and Pfizer Inc., and has received support from both companies to 
attend conferences. RCG received funding to his institution from GSK and Pfizer Inc. for pneumococcal 
diagnostics and characterization studies. He also received support from GSK and Pfizer Inc. to attend 
overseas conferences. JEC has received pneumonia research funding from Pfizer Inc. The UK-ESPE 
study has been supported by unrestricted grants from GSK and Pfizer Inc. to DAS. GSK and Pfizer Inc. 
had no involvement in the study design; in the collection, analysis and interpretation of data; in the 
writing of the report; and in the decision to submit the paper for publication.   
  
 
 
 
Figure: Survivorship curves of hospital stay of patients with empyema caused by pneumococcal serotype 
19A vs. patients with empyema caused by other pneumococcal serotypes.  
  
  
 
Characteristics  
Serotype 19A 
(n=14)  
All other 
serotypes (n=122)  
KW/Fisher’s test, p 
value  
Median age of patients / years (Range)  2.0 (0.2-5.4)  4.3 (0.4-15.7)  0.002  
Male % (n)  57% (8)  56% (68)  1  
Median pre-hospital symptom duration 
/ days (Range)
* 
7 (3-14) 6 (1-41) 0.703 
Pre-hospital antibiotics % (n)
*
 25% (2) 39% (33) 0.706 
Any co-morbidity % (n) 7% (1) 7% (8) 1 
Surgery as primary drainage 
procedure % (n) 
43% (6) 56% (68) 0.573 
Any surgical procedure % (n) 57% (8)  64% (78) 0.402 
Readmission % (n)
*
 0% (0) 5% (6) 1 
Complications
†
 % (n)  36% (5)  11% (13)  0.022 
Intensive care admission % (n)
*
  36% (5)  12% (14)
 
 0.019 
Assisted ventilation % (n)
*
  36% (5)  9% (10)  0.007  
Extra corporeal membrane oxygenation 
required  
2 0 - 
Deaths
‡ 
 1  0  -  
†
Complications (n): 19A – Pneumothorax (1); broncho-pleural fistula (1); lung abscess and lung necrosis (1); 
haemolytic-uraemic syndrome (2); Non-19A – Pneumothorax (7); broncho-pleural fistula (3); lung abscess and lung 
necrosis (1); cellulitis at drain site (1); streptococcal vasculitis (1)  
  
 
*
Indicates data unavailable for some patients; Pre-hospital symptom duration % non-respondents = 0%(19A), 
4%(other serotypes); Pre-hospital antibiotics 50%,30%; Readmission 14%,10%; Intensive care admission 14%,7%; 
Assisted ventilation 14%,11%.  
‡The child who died had no significant pre-existing co-morbidity 
Table: Characteristics of patients with empyema caused by pneumococcal serotype 19A vs. patients with 
empyema caused by other pneumococcal serotypes. 
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What is already known on this topic? 
Pneumococcal 19A infection has become the commonest cause of invasive disease in children in the USA 
but has not been a significant problem in the UK 
There are differences in the disease severity caused by infection with different pneumococcal serotypes  
 
What this study adds? 
The incidence of paediatric empyema due to pneumococcal serotype 19A has increased in the UK 
Serotype 19A related empyema is associated with significantly higher levels of morbidity than empyema 
related to other pneumococcal serotypes 
  
  
 
9.16 Appendix P - UK-ESPE study protocol 
 
Summary 
  
The incidence of paediatric empyema thoracis has risen dramatically over the last decade(Rees et al., 
1997)
,
(Playfor et al., 1997)
,
(Thompson et al., 1999; Byington et al., 2002b; Hsieh et al., 2004; Deiros 
Bronte et al., 2006; Gupta and Crowley, 2006; Roxburgh and Youngson, 2007) and Streptococcus 
pneumoniae serotype 1 has been identified as the principal pathogen in the UK(Eltringham et al., 2003; 
Eastham et al., 2004; Fletcher et al., 2006). Various suggestions have been proposed to explain the 
observed rise in incidence including changes in diagnostic criteria and referral practice, and alterations in 
pathogen virulence. At present there is insufficient evidence in favour of any single hypothesis.  
 
The 7-valent pneumococcal conjugate vaccine was introduced into the national immunisation schedule 
September 2006. This vaccine does not offer protection against serotype 1 disease. It has been suggested 
that introduction of this vaccine may lead to a further increase in pneumococcal disease. This might occur 
as a result of progressive increase in serotype 1 disease as well as an increase in disease due to other non-
vaccine pneumococcal serotypes. There is some evidence that this phenomenon is already beginning to 
occur in the United States. 
 
This project is intended to monitor the changing incidence of pneumococcal empyema thoracis in children 
throughout the UK, to determine the prevalence of different pneumococcal serotypes over time and to 
explore epidemiological and genetic factors. It represents collaboration between clinicians, 
microbiologists, epidemiologists, genetic scientists and those with expertise in biological modelling in an 
effort to elucidate the mechanisms responsible for this phenomenon. 
 
  
 
Research Questions 
We propose to explore the following hypotheses: 
 
1. That the incidence of pneumococcal empyema will continue to increase in British children. That the 
increase will occur as a result of a progressive increase in serotype 1 disease which commenced before 
the introduction of the conjugate vaccine, as well as increase in disease from other non-vaccine serotypes.  
 
2. That antibiotic treatment in primary care influences disease progression. 
 
3. That space-time patterning of empyema cases will be related to environmental exposure to air-born 
pollutants. 
 
4. That spatial patterning of empyema cases will be related to socio-economic 
factors. 
 
5. That certain gene polymorphisms will be associated with an increased risk of development of 
pneumococcal empyema 
 
In order to explore these hypotheses in detail it will be necessary to:  
 
1. Investigate the existence of spatial and temporal variation in incidence and clustering of cases of 
empyema. 
 
2. Identify and monitor potential risk factors predisposing to the development of empyema. 
 
  
 
3. Closely monitor changes in the prevalence of different pneumococcal serotypes causing 
complicated pneumonia and empyema in children. 
 
4. Monitor changes in the incidence and severity of empyema thoracis over time. 
 
5. Relate these changes to the introduction of the 7 valent conjugate pneumococcal vaccine into the 
routine childhood immunisation programme in the UK, and to the possible introduction of future 
vaccines with extended coverage against other pneumococcal serotypes. 
 
6. Relate these changes to the national guidance aimed at reducing the use of antibiotics for simple 
respiratory tract infections in primary care. 
 
7. Investigate links between the incidence of empyema and socio-economic indicators and 
environmental predictors. 
 
8. Develop data collection systems which will facilitate the performance of future multi-centre 
studies to compare current and future medical and surgical interventions in the management of 
complicated pneumonia and empyema in children. 
 
9. Audit outcomes according to variations in clinical management across the UK. 
 
10.  Investigate gene polymorphisms that may influence susceptibility to the development of invasive 
pneumococcal disease (IPD) and empyema in children.  
 
  
 
Epidemiology 
Pneumonia kills more children than any other illness, accounting for over 2 million deaths in children 
under-five years of age worldwide every year(Rudan et al., 2008a). Although death is rare in developed 
countries, the condition is associated with significant acute and chronic morbidity(Clark et al., 2007b). 
Pleural disease is a relatively common complication of pneumonia, occuring in approximately 3-4% of 
children hospitalised with community acquired pneumonia in the UK(Clark et al., 2007b). Fluid may 
accumulate within the potential pleural space and cause a spectrum of problems ranging from simple 
pleural effusion to complicated empyema loculated by the formation of fibrin bands.  
 
The great majority of patients with empyema will not respond to antibiotics alone, and some form of 
surgical drainage is usually required. Various management options are employed including simple 
thoracocentesis, thoracocentesis with instillation of urokinase and either early or late thoracotomy with 
debridement (“decortication”). Thoracotomy may be performed traditionally using direct vision, or using 
video assisted thoracotomy (VATS). Opinion is divided regarding the management strategies, and there 
are wide regional and national variations in therapeutic approaches, which partially reflects differences in 
the availability of skills and resources(Balfour-Lynn et al., 2005).  
 
An increase in the incidence of paediatric empyema was first reported from the West Midlands, UK in 
1997(Rees et al., 1997). In this series there was a seven-fold increase in cases when compared to the 
previous three years. This observation has now been confirmed in many other centres in North America, 
Europe  and Asia(Byington et al., 2006; Spencer et al., 2006b; Munoz-Almagro et al., 2008; Obando et 
al., 2008; Spencer and Cliff, 2008). We have recently reported a progressive increase in the number of 
cases since 1997 with those requiring surgical intervention increasing up to 60/ year(Spencer et al., 
2006b). We have estimated that there are currently 800-1,000 cases/year in the UK. The cause or causes 
for these changes are not known, however, various hypotheses have been proposed:  
 
1. Changes in referral practice or management of cases 
2. Changes in antibiotic prescribing practice in primary care 
3. Effect of changes in UK vaccination policy 
4. Antibiotic tolerance 
  
 
5. Changes in the ecology of bacterial colonisation of the nasopharynx 
6. Loss of herd immunity to S. pneumoniae serotype 1 
      7.  Increase in inherent pneumococcal virulence 
 
Most culture positive cases of childhood empyema thoracis in Europe and the USA are related to 
infection with S. pneumoniae(Eastham et al., 2004; Byington et al., 2006; Le Monnier et al., 2006). 
 
However, these
 
studies are hindered by the fact that routine bacterial culture of pleural fluid is usually 
negative, probably due to antibiotic use prior to hospital admission. Certain pneumococcal serotypes such 
as 1 and 5 are typically antibiotic sensitive whereas others such 6,9,14,19 and 23 are typically antibiotic 
resistant, so that undue reliance on bacterial culture results may give a false impression of the true pattern 
of disease in the community(Hausdorff et al., 2005; Sanchez-Tatay et al., 2008). Use of PCR and 
serotype specific ELISA in pleural fluid from children with culture negative disease has demonstrated that 
most UK cases are related to S. pneumoniae, with serotype 1 as the dominant serotype(Eltringham et al., 
2003). Serotype 1 has also been reported to be the dominant pathogen in both culture positive and culture 
negative disease in both Europe and the USA. (Table 1)
  
 
Table 1  
Author Proportion of cases of pneumococcal empyema 
attributable to serotype 1 (%) 
Hardie et al 31 
Byington et al 50 
Buckingham et al 25 
Eltringham et al  63 
Tan et al  24.4 
Eastham et al 68 
Fletcher at al 67 
Bekri et al 23 
Obando et al 48 
 
 
Serotype 1 is rarely isolated from the nasopharynyx of healthy individuals, raising questions regarding the 
mode of transmission and suggesting that isolation of this serotype is associated with a high attack 
rate(Sleeman et al., 2006). We have recently reported a small school outbreak of pneumococcal serotype 
1 disease in which transmission may have occurred via nasopharyngeal carriage from an adult(Gupta et 
al., 2008).  
 
It has been reported that the introduction of the conjugate pneumococcal vaccine into some communities 
in the USA has been associated with an increase in the incidence of empyema thoracis due to infection 
with serotypes that are not contained within the 7-valent vaccine, a phenomenon which has been referred 
to as ‘serotype replacement’ disease(Byington et al., 2006). 
 
  
 
The UK government commenced universal paediatric vaccination with the heptavalent pneumococcal 
conjugate vaccine (Prevenar
©
 or Prevnar
©
) in September 2006. The serotypes contained within the 
vaccine are 4, 6B, 9V, 14, 18C, 19F and 23 F. The vaccine was first licensed for use in 2000 and was 
introduced into the universal immunisation programme in the USA in 2001. As the first country to 
introduce the vaccine, the USA provides the greatest breadth of experience of the impact of the 
introduction of the conjugate vaccine on serotype ecology and incidence.  
 
The US Centres for Disease Control and Prevention (CDC) has reported surveillance data on the 
incidence of invasive pneumococcal disease (IPD) in 2005 compared with the pre-vaccine years. Overall 
IPD rates among children aged 5 and under decreased by 77% (incidence 98.7 cases per 100,000 during 
1998-1999 compared to 23.4 per 100,000 in 2005) with an estimated 13,000 fewer cases('Invasive 
pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005,' 
2008). The public health impact was described as “dramatic” with the additional benefits of herd 
immunity also being evident in the adult population('Invasive pneumococcal disease in children 5 years 
after conjugate vaccine introduction--eight states, 1998-2005,' 2008).However, several groups have now 
reported an increase in invasive pneumococcal disease (IPD) caused by non-vaccine serotypes, so called 
‘serotype replacement disease’. The most dramatic of these reports is from Singleton et al who reported 
an increase of 140% of non-vaccine serotypes causing invasive pneumococcal disease in native Alaskan 
children, which nearly ablates the net reduction in invasive pneumococcal disease related to 
vaccination(Singleton et al., 2007). Other groups have shown more modest increases in IPD related to 
non-vaccine serotypes, with the balance following the introduction of Prevenar
© 
still significantly towards 
an overall reduction in total IPD case numbers. Similar experiences of increase in IPD caused by non-
vaccine serotypes and increase in incidence of empyema following the introduction of Prevenar
©
 have 
also been reported from Spain
17
. 
 
There are significant differences in the reported serotype distribution between the USA and 
Europe(Hausdorff, 2002).  This partially reflects the consequences of defining infection in terms of 
bacterial culture, and the fact that antibiotic sensitive serotypes are less likely to be cultured in patients 
who have received antibiotics prior to sampling(Hausdorff et al., 2005). This further hampers our ability 
to extrapolate data on the impact of immunisation from America to Europe.    
 
  
 
The Health Protection Agency (HPA) in the United Kingdom has been monitoring weekly trends in 
serotype incidence since the introduction of the conjugate pneumococcal vaccine in to the routine 
vaccination schedule. The latest data is shown below. 
  
 
Figure 1 – Incidence of invasive pneumococcal disease caused by serotypes contained within Prevenar© 
conjugate vaccine 2003 – present in children under the age of 2 years(Agency, 2009b) 
 
 
    
Figure 2 – Incidence of invasive pneumococcal disease caused by serotypes not contained within 
Prevenar
©
 conjugate vaccine 2003 – present in children under the age of 2 years(Agency, 2009a). 
 
  
 
These graphs demonstrate the benefits of vaccination in reducing invasive disease related to vaccine 
serotypes, but suggest that disease due to non-vaccine serotypes is emerging in the UK. This data has 
been produced from a passive screening programme of culture positive invasive pneumococcal disease 
and suffers from the intrinsic weaknesses of such a system. We estimate on the basis of extrapolating our 
comprehensive regional data that this represents in the region of only 5-10% of the total burden of 
invasive pneumococcal disease. This is because approximately 90% of disease is culture negative and that 
recruitment to the surveillance programme will vary considerably across regions and over time. It should 
also be appreciated that differences in the antibiotic sensitivity of individual pneumococcal serotypes will 
result in a bias towards reporting a disproportionately high percentage of disease attributable to antibiotic 
resistant serotypes when surveillance systems are based solely on bacterial culture. For these reasons the 
HPA agreed to introduce enhanced surveillance for paediatric pneumococcal empyema in England and 
Wales using culture negative techniques.  
 
Further evidence of changing serotype ecology and prevalence related to immunisation is also 
demonstrated by studies of pneumococcal nasopharyngeal carriage. Groups in the Netherlands and the 
USA have demonstrated an increase in carriage of non-vaccine serotypes following mass immunisation, 
providing a possible mechanism by which serotype replacement disease may occur(Bogaert et al., 2005; 
Hanage et al., 2007).   
 
  
 
Antibiotic prescribing 
In recent years there has been considerable pressure exerted to reduce the use of antibiotics in primary 
care for presumed viral upper respiratory tract infection. Although the public health benefits of this policy 
are fully appreciated, there is some reasonable concern that a reduction in antibiotic prescribing in the 
community could lead to an increase in the incidence of some severe bacterial diseases presenting to 
hospital(Sharland et al., 2005). The evidence base for these concerns is weak, largely because of the 
major epidemiological difficulties in proving such associations. The National Institute for Health and 
Clinical Excellence (NICE) has recently issued guidance aimed at further reducing inappropriate 
prescribing(NICE, 2008). It is likely that this will have a major impact on reducing the use of antibiotics 
prescribed for presumed viral upper respiratory tract infections in children. 
 
The clinical features of pneumonia in children at first presentation are often rather non-specific. Not all 
children have respiratory symptoms and localising physical signs may be absent. The majority of children 
presenting with empyema have received antibiotics in primary care, which also casts some doubt as to the 
effectiveness of this intervention in preventing the progression to severe disease. It is conceivable that any 
further reductions in the prescription of antibiotics in primary care could lead to an increase in cases of 
complicated pneumonia in children. It would therefore be sensible and prudent to monitor long term 
changes in the incidence of paediatric empyema nationally, and to relate this data to antibiotic prescribing 
information available from the Prescription Prescribing Authority (PPA) and other evolving sources of 
national paediatric drug prescribing data. 
 
Environmental variables 
Invasive pneumococcal disease and childhood empyema both demonstrate marked seasonal variation in 
incidence, suggesting that environmental factors are of critical importance. Variability of climate, changes 
in seasonal  prevalence of viral infections and exposure to airborne pollutants have all been implicated as 
possible explanations for these phenomena(Kim et al., 1996; Dowell et al., 2003; Murdoch and Jennings, 
2009). The results of research in this field are difficult to interpret and contradictory results have 
frequently been reported.  
 
Genetic Susceptibility to Invasive Pneumococcal Disease 
  
 
Recent work has demonstrated that the genetic make-up of an individual plays an important role in 
determining their likelihood of developing IPD, including pneumococcal empyema. In addition to 
providing a comprehensive study of the clinical and environmental factors that underlie the development 
of empyema in childhood, the current research aims to identify gene variants that may determine why 
some individuals are particularly susceptible to IPD. Our previous research in this area has been 
successful in identifying a small number of susceptibility genes for IPD, including genes encoding 
mannose-binding lectin, C-reactive protein, PTPN22, Mal/TIRAP and NFKBIA(Roy et al., 2002a; Roy et 
al., 2002b; Chapman et al., 2006; Khor et al., 2007). Many more genes are likely to be involved, however, 
and their identification is dependent upon the use of larger sample collections of DNA from individuals 
with this disease. In particular, large DNA sample collections allow the use of ‘genome-wide’ approaches 
which study markers across all human genes; such an approach has recently proven extremely 
successfully in the identification of novel genetic polymorphisms responsible for common conditions 
such as asthma and diabetes, but has not previously been used in the study of pneumococcal disease.  
 
  
 
Methods 
In order to institute long term surveillance and research in to this problem it has been necessary to 
introduce a robust and efficient system of data collection which is able to record both laboratory and 
clinical data on individual patients in a manner which is compatible with the Data Protection Act and 
fulfils the Caldicott guidelines on recording patient identifiable data. The British Paediatric Respiratory 
Society (BPRS) initially established a web-based system for recording such information administered by 
Dr James Paton, Reader in Respiratory Paediatrics at the University of Glasgow. This system is secure 
and uses high-level encryption of data, which has been further enhanced by incorporation of the 
“Soundex” system for securing patient identifiable information. The system was initially used to record 
data for the national annual paediatric acute asthma audit, and has now been successfully modified to 
record data on paediatric empyema. 
 
The BPRS research committee has formally endorsed this study and the HPA is collaborating actively. 
A clinical lead responsible for coordination of specimen and data collection has been established at each 
site. It is intended that data entry is performed during the course of the hospital stay or shortly thereafter. 
Clinical data obtained via the web based remote data collection system includes relevant past medical 
history, antibiotic history, treatment, length of stay, outcome and patient demographics. The HPA also 
contacts the general practitioner of positive cases that are within the age groups eligible to receive one or 
more doses of conjugate vaccine.   
 
Most UK respiratory paediatricians do not routinely differentiate between post-pneumonic effusion and 
empyema, and these are now generally regarded as representing parts of spectrum of infection-related 
pleural disease. As such, all paediatric patients within the UK in whom pleural fluid is being removed as 
part of their routine management will be eligible for inclusion in the study. In practice this will be limited 
to patients receiving some form of surgical management (either simple thoracocentesis, thoracocentesis 
with installation of urokinase or decortication). It is not normal practice within the UK for patients being 
managed solely with antibiotics to have needle aspiration performed, and so this study is intentionally 
limited to patients with more severe disease. However, the great majority of patients with true empyema 
will not respond to antibiotics alone. 
 
Saliva samples are also being collected from each patient for DNA analysis. Two different but 
complimentary genetic study approaches will be taken using the DNA samples: 
1) Investigation of 'candidate' genes 
  
 
2) A 'genome-wide' screen, which studies a very large number of genetic markers spread across the 
entire genome 
 
DNA analysis is being performed in the laboratory of Professor Adrian Hill based at the Wellcome Trust 
Centre for Human Genetics, University of Oxford. 
 
Study of candidate genes involves the specific examination of a relatively small number of genes which 
on the basis of existing information are strongly suspected to play a role in disease causation. A genome-
wide screen, on the other hand, studies a very large number of common genetic markers spread across 
the entire genome in an attempt to capture information about the role of the majority of human genes in 
susceptibility to disease. For both approaches, polymorphism frequencies in patients with IPD will be 
compared with those of healthy individuals from the United Kingdom. These have previously been 
determined by the Sanger Institute in Cambridge and are freely available to investigators on-line. Such an 
approach has now been extensively used for genome-wide studies and is well-validated. Genetic variants 
that appear to affect susceptibility to IPD will also be examined within the patient group for a possible 
role in clinical outcome.  
 
The collaborating team has complete control over the clinical, microbiological and genetics data with Dr 
David Spencer, the Chief Investigator being responsible for the overall conduct of the study.  
 
The duration of the study is expected to be 10 years. Recruitment commenced in August 2006.  
 
Samples 
A specimen of pleural fluid from every patient recruited is sent to Drs Ray Borrow and Malcolm Guiver 
at the HPA laboratory in Manchester. An initial screening PCR for pneumolysin is performed and screen 
positives are then dispatched to Dr Robert George at the RSIL laboratory, Colindale, London, who 
performs a confirmatory PCR and tests positive samples for serotype-specific antigen using the Bioplex 
method as originally developed by Borrow and Leeming. This assay currently detects 13 serotypes, 
including serotype 1. If positive for one of these 13 this confirms pneumococcal infection and identifies 
the serotype. If negative then confirmation of pneumococcal infection is sought with an autolysin PCR.  
 
A saliva sample is also collected from each patient in order to provide a DNA specimen.  
 
  
 
A flow chart of progress through the study is attached in Appendix A.  
 
Data validation and ascertainment 
In order to effectively calculate rates of recruitment and ascertainment of the number of cases of 
empyema in children in individual hospitals, it is necessary to use hospital coding data. The coding 
departments of the hospitals who have recruited patients for the study will be approached to supply 
hospital coding data on the number of patients between the ages of 0-16 years with the diagnosis of 
empyema (International Classification of Disease - 10 codes – J86.0 and J86.9) and their demographics to 
allow cross-checking with study data.  
 
  
 
Ethical approval 
An application has been approved by the national research and ethics committee (REC). Informed 
consent is obtained for obtaining saliva samples from individual patients and patient information 
leaflets/consent forms are provided along with the sampling kit. Section 60 support from the Patient 
Information and Advisory Group has been granted to retrospectively use patient identifiable data without 
having to gain informed consent. Informed consent is obtained for prospective use of patient identifiable 
data. Caldicott approval has been granted at centres receiving patient identifiable information and is 
being sought at collaborating centres as required. All necessary measures have been taken to ensure 
compatibility with the Data Protection Act.  
 
Statistical analysis 
The data will allow us to establish changes in the incidence of empyema thoracis over time, and be used 
to test conceptual models of the epidemiology of empyema thoracis. The clinical data-base will be 
integrated with a Geographical Information System (GIS) which will allow linkage between residential 
address of cases with environmental and socio-economic covariates that are hypothesised to play a role 
in disease (temperature, rainfall, socio-economic status, exposure to air pollution and specific indices of 
deprivation)(Grant et al., 2003).  
 
Space-time clustering approaches will be used to investigate the extent to which disease arising from 
different serotypes is clustered in space and time. In addition, the geographical pattern in the spread of 
serotypes nationally and in relation to case age is being quantified with a view to testing hypotheses that 
there is spatial variation in serotype distribution amongst empyema thoracis cases. Point process models 
will be used to investigate how the pattern of cases of each serotype depends on other covariates 
including climatic variables, socio-economic status and antibiotic use. 
 
Generalised Linear Modelling and Generalised Linear Mixed Effect Modelling is being used in 
combination with the GIS data to investigate the role of weather, climate, air pollution exposure and 
other covariates in determining cases of disease at the level of the regional centre.  
 
Descriptive statistics will be used to analyse and interpret results from the clinical and microbiological 
data. We are also documenting differences in the length of admission between different UK centres and 
the influences of different treatment regimes. Survival analysis will be used to investigate the impacts of 
  
 
socio-economic status, serotype, antibiotic treatment and other co-variates on the course of disease from 
initial diagnosis to discharge home.  
 
The influence of antibiotic prescribing in primary care will be assessed using a proxy measurement of 
generic antibiotic prescribing amounts at SHA or PCT level, based on information available from the 
PPA. This will then be used in a time-series analysis against empyema cases to look at significant trends.   
 
For the genetic component of the study, differences in the genotype distributions between empyema 
cases and healthy controls will be compared using Chi-squared testing. Logistic regression analysis will 
be performed to correct for the possible confounding effects of other genes and other recorded clinical 
variables on disease susceptibility. Correction will be made for the multiple independent comparisons 
tested as part of a genome-wide study. The majority of markers tested will not be associated with disease, 
but the large number of markers studied increases the risk of false positive associations. A P value of 
<0.000001 is generally recognised as an appropriate threshold for significance in the context of genome-
wide analysis.  
 
The total number of individuals with pneumococcal empyema who will be recruited to the genetics 
components of these studies is difficult to predict, as this will be determined largely by the success rate in 
obtaining informed consent. 2000 specimens will be required in order to obtain statistically meaningful 
results, which we estimate may take up to four years to obtain. Control genome-wide genotype results are 
already available from 2000 healthy individuals from the United Kingdom, determined by the Sanger 
Institute in Cambridge and freely available to investigators on-line. Sample size calculations for genome-
wide genetic association studies are complex, and require consideration of variable allele frequencies, 
number of genetic markers tested, and extent of linkage disequilibrium between markers, reflecting their 
independence). Stringent P values are required for declaration of true association in order to correct for 
the very large number of independent comparisons performed on the same dataset. A sample size of 
approximately 1000 cases and the same or greater number of controls is generally recommended for 
genome-wide association studies; such a sample size should allow the detection of odds ratios of 1.5 for 
allele frequencies of 10% or more, with 80% power to detect a P value of <0.000001(Wang et al., 2005). 
Some genome-wide association studies have been successfully performed on significantly fewer samples, 
however, although this limits the power of the study to detect relatively small genetic effects. Additional 
DNA sample collections from individuals with invasive pneumococcal disease are already available in 
  
 
Professor Adrian Hill’s laboratory in Oxford, and these will be studied alongside the described collection 
as additional replication groups for any positive genetic associations. 
 
 
 
 
 
 
  
 
Conclusions 
The incidence of paediatric thoracic empyema has increased dramatically over the last decade, but the 
reasons for these changes remain unclear.  
It is very likely that the serotypes of important disease causing pneumococcal serotypes will continue to 
change as a consequence of both natural variation and possibly selection pressure exerted by the 
introduction of new conjugate pneumococcal vaccines.  It is increasingly important to maintain long term 
and continuous surveillance of changes in the prevalence of disease related to different pneumococcal 
serotypes in order to plan future vaccine design and national vaccination strategies. The national UK 
programme of enhanced paediatric empyema surveillance will be an essential component of this 
surveillance (Whitney et al., 2003).  
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PIAG approval letter  
Dr David Cliff 
Sir James Spence Institute of Child Health 
Royal Victoria Infirmary 
Queen Victoria Road 
Newcastle upon Tyne 
NE1 4LP 
             
    
12 December 2007 
 
Dear Dr Cliff, 
 
RE: Application for Section 60 support 
PIAG 4-05(j)/2007:  Enhanced  surveillance of paediatric pneumococcal empyema in the UK  
 
Thank you for applying for support under Section 60 of the Health and Social Care Act 2001 to process 
patient identifiable information without consent. This application for Section 60 support was considered 
by the Advisory Group at its meeting on 4
th
 December 2007. 
 
  
 
The Advisory Group was unable to approve all of your application at the meeting but some aspects of the 
application were approved conditionally. The main grounds for seeking support under Section 60 is where 
1) anonymisation in not possible 2) obtaining consent is not practical. 
 
Your application requests access to prospective and retrospective data and we will address these issues 
separately. PIAG Members are content that there is no reasonable alternative for the collection of 
retrospective data and in this instance, have approved your application for the collection of retrospective 
data. 
 
 However, in relation to prospective data,  PIAG Members feel that a reasonable alternative to Section 60 
exists, namely consenting patients, and therefore it would be inappropriate to allow Section 60 support for 
this purpose.  
 
In summary: 
 PIAG Members agree that Section 60 approval is warranted for the collection of retrospective 
data 
 PIAG Members do not approve Section 60 support for the collection of prospective data. 
 
Approval for the collection of retrospective data is subject to the following condition: 
 
 Confirmation of appropriate security arrangements (Please note these are still to be checked by 
our security advisor, I will be back in contact with comments shortly) 
 
In addition to this, please confirm that you meet the standard conditions of approval (attached overleaf) 
 
As soon as I receive a satisfactory response, I will arrange for the Register of approved applications to be 
updated on our website www.advisorybodies.doh.gov.uk/piag to reflect this. 
 
  
 
Please note, this approval is subject to our annual review process and you will be required to submit a 
report in 12 months time. I will send out a reminder and guidance document nearer the time. 
 
Yours Sincerely 
 
 
John Sheehan 
Policy Support Manager 
PIAG Secretariat 
  
APPLICANT'S CHECKLIST
All studies except clinical trials of investigational medicinal products
REC Ref: 07/H0904/84
Short Title of Study: Enhanced surveillance of paediatric pneumococcal empyema in the UK
CI Name: Dr David/DA Spencer
Sponsor: Newcastle upon Tyne Hospitals NHS foundation trust
Please complete this checklist and send it with your application
Send ONE copy of each document (except where stated)♦ 
ALL accompanying documents must bear version numbers and dates (except where stated)♦ 
When collating please do NOT staple documents as they will need to be photocopied.♦ 
Document Enclosed? Date Version Office use
Covering letter on headed paper  Yes  No 
NHS REC Application Form, Parts A&B Mandatory 01/10/2007 5.4 
Site−Specific Information Form (for SSA)  Yes  No 
Research protocol or project proposal (6 copies) Mandatory 01/10/2007 1.0 
Summary C.V. for Chief Investigator (CI) Mandatory 01/10/2007 
Summary C.V. for supervisor (student research)   Yes  No 01/10/2007 
Research participant information sheet (PIS)  Yes  No 01/10/2007 1.0 
Research participant consent form  Yes  No 01/10/2007 1.0 
Letters of invitation to participants  Yes  No 
GP/Consultant information sheets or letters  Yes  No 
Statement of indemnity arrangements  Yes  No 
Letter from sponsor  Yes  No 01/10/2007 
Letter from statistician  Yes  No 
Letter from funder  Yes  No 01/10/2007 
Referees' or other scientific critique report  Yes  No 
Summary, synopsis or diagram (flowchart) of
protocol in non−technical language  Yes  No 
Interview schedules or topic guides for
participants  Yes  No 
Validated questionnaire  Yes  No 
Non−validated questionnaire  Yes  No 
Copies of advertisement material for research
participants, e.g. posters, newspaper adverts,
website. For video or audio cassettes, please
also provide the printed script. 
 Yes  No 
Date: 01/10/2007 Reference: 07/H0904/84 Online Form
NHS REC Application Form − Version 5.5 1 AB/105980/1
WELCOME TO THE NHS RESEARCH ETHICS COMMITTEE APPLICATION FORM
An application form specific to your project will be created from the answers you give to the following questions.
1. Is your project an audit or service evaluation?
 Yes  No
2. Select one research category from the list below:
 Clinical trials of investigational medicinal products
 Clinical investigations or other studies of medical devices
 Other clinical trial or clinical investigation
 Research administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative
     methodology
 Research involving qualitative methods only
 Research limited to working with human tissue samples and/or data
 Research tissue bank
    If your work does not fit any of these categories, select the option below:
 Other research
2a . Please answer the following questions:
a) Does the study involve the use of any ionising radiation?  Yes  No
b) Will you be taking new human tissue samples?  Yes  No
c) Will you be using existing human tissue samples?  Yes  No
3. Is your research confined to one site?
 Yes  No
4. Does your research involve work with prisoners?
 Yes  No
5. Do you plan to include in this research adults unable to consent for themselves through physical or mental
incapacity?
 Yes  No
6. Is the study, or any part of the study, being undertaken as an educational project?
 Yes  No
Date: 01/10/2007 Reference: 07/H0904/84 Online Form
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6a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?
 Yes  No
Date: 01/10/2007 Reference: 07/H0904/84 Online Form
NHS REC Application Form − Version 5.5 3 AB/105980/1
NHS Research Ethics Committee
Application form
This form should be completed by the Chief Investigator, after reading the guidance notes. See glossary for clarification
of different terms in the application form.
Short title and version number: (maximum 70 characters − this will be inserted as header on all forms)
Enhanced surveillance of paediatric pneumococcal empyema in the UK
Name of NHS Research Ethics Committee to which application for ethical review is being made:
Sunderland resesarch and ethics committee
Project reference number from above REC:  07/H0904/84
Submission date:  01/10/2007
 PART A: Introduction
A1. Title of the research
Full title: The national programme for enhanced pneumococcal surveillance of complicated pneumococcal
pneumonia and empyema in UK Children.
Key words: empyema, streptococcus pneumonia, incidence, epidemiology, immunisation
A2. Chief Investigator
Title: Dr
Forename/Initials:  David/DA
Surname: Spencer
Post: Consultant in Respiratory Paediatrics
Qualifications: MB BS(Hons) MRCP MD FRCPCH
Organisation: Newcastle Upon Tyne Hospitals NHS Foundation Trust
Work Address: Freeman Hospital
Freeman Road, High Heaton
Newcastle Upon Tyne
Post Code: NE7 7DN
E−mail: david.spencer2@nuth.nhs.uk
Telephone: 0191 244 8292
Fax: 0191 223 1099
Mobile: 07967379085
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application
A3. Proposed study dates and duration
Start date: 01/08/2007
End date: 01/08/2012
Duration: Years:  10 ;    Months:  00
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A4. Primary purpose of the research: (Tick as appropriate)
Commercial product development and/or licensing
Publicly funded trial or scientific investigation
Educational qualification
Establishing a database/data storage facility
Other
Question(s) 5 disabled.
A6. Does this research require site−specific assessment (SSA)? (Advice can be found in the guidance notes on this topic.)
 Yes  No
If No, please justify:
The only samples we require that are considered over and above those of the routine management of the
patient are saliva samples. Taking these is a low risk procedure within the professional competance of local
collaborators.
If Yes, an application for SSA should be made for each research site on the Site−Specific Information Form and submitted to
the relevant local Research Ethics Committee. Do not apply for SSA at sites other than the lead site until the main
application has been booked for review and validated by the main Research Ethics Committee.
Management approval to proceed with the research will be required from the R&D office for each NHS care organisation in
which research procedures are undertaken. This applies whether or not the research is exempt from SSA. R&D applications in
England, Wales and Scotland should be made using the Site−Specific Information Form.
Date: 01/10/2007 Reference: 07/H0904/84 Online Form
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 PART A: Section 1
A7. What is the principal research question/objective? (Must be in language comprehensible to a lay person.)
Empyema is a serious complication of pneumonia in which pus accumulates between the lung and the chest
wall. The incidence of this problem has increased dramatically in children in the UK over the last decade and
appears to be due to changes in the virulence of the pneumococcal bacteria of which there are over 90
'serotypes' (ie subgroups). In order to investigate the causes for this problem in more detail it is necessary to
introduce a robust and efficient system of data collection on children with empyema which is able to record
both laboratory and clinical data on individual patients. This will be compatible with the Data Protection Act
and fulfil the Caldicott guidelines on recording patient identifiable data. The laboratory and clinical data will
provide important epidemiological information and form the basis of a population based surveillance system
that can be used when deciding on the introduction of future vaccines against this infection.
A8. What are the secondary research questions/objectives? (If applicable, must be in language comprehensible to a lay
person.)
This data we collect will allow us to establish changes in the relative incidence of different pneumococcal
serotypes over time, document the difference in the length of admission between different UK centres and
the effect of different treatment regimes. It will also help us to identify potential risk factors for the condition.
The pneumococal bacteria itself has a number of different features that could explain the increase in the
incidence of empyema including tolerance to certain antibiotics and 'virulence' factors. These make it more
likely that there is either a poor response to treatment or an increase in severity of disease respectively. Both
of these will be investigated as a potential cause of the problem.
The prevalence of empyema thoracis varies seasonally and changes in the climate could be a contributory
factor to the rising number of cases. Investigating correlations between local changes in climate and
incidence will form part of the research.
Recent studies have suggested that there may be a genetic predisposition that leads to to the development
of complicated pneumococcal disease in adults and we will be collecting DNA samples from research
participants to investigate this in children.
A9. What is the scientific justification for the research? What is the background? Why is this an area of
importance?(Must be in language comprehensible to a lay person.)
Over the last decade there has been a significant increase in the incidence of pneumonia complicated by the
formation of pus between the chest wall and the lung (an "Empyema") in UK children. It is now known that
this phenomenon is largely due to an increase in the incidence of infection with one serotype (subgroup)of
the common bacterium Streptococcus pneumoniae. The reason/s for this change are not currently
understood. Children with this condition are often severely ill, and usually require surgical treatment. A
vaccine designed to protect against certain strains of streptococcus ("prevenar") has recently been
introduced into the routine UK vaccination schedule, but this does not cover this particular serotype. Indeed,
it has been suggested that introduction of this vaccine in the USA might possibly be associated with an
increase in the incidence of empyema thoracis due to strains not covered by the vaccine. It would therefore
be prudent to monitor any changes in the incidence of empyema in UK children following introduction of the
pneumococcal vaccine and to determine which serotypes are causing this problem each year.
Another major area of uncertainty concerns the factors that determine susceptibility to pneumococcal
empyema: although exposure to the pneumococcus is widespread in children, only a minority go on to
develop this severe infection. Recent work has demonstrated that an individual’s genetic make−up plays an
important role in determining their likelihood of developing respiratory infection. Previous research at the
University of Oxford has been successful in identifying a small number of susceptibility genes for severe
pneumococcal infection and thoracic empyema in adults, but many more genes are likely to be involved and
their identification is dependent upon the use of larger sample collections of DNA from individuals with this
disease. In particular, large DNA sample collections may allow the use of ‘genome−wide’ approaches which
study markers across all human genes – such an approach has recently proven extremely successfully in the
identification of genes responsible for common conditions such as asthma and diabetes, but has not
previously been used in the study of pneumococcal disease or thoracic empyema.
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A10−1. Give a full summary of the purpose, design and methodology of the planned research, including a brief
explanation of the theoretical framework that informs it. It should be clear exactly what will happen to the research
participant, how many times and in what order.
This section must be completed in language comprehensible to the lay person. It must also be self−standing as it will be
replicated in any applications for site−specific assessment on the Site−Specific Information Form. Do not simply reproduce or
refer to the protocol. Further guidance is available in the guidance notes.
The incidence of empyema thoracis complicating community acquired pneumonia has increased dramatically
in children in the UK over the last decade. Investigation of the cause/s for this phenomenon have previously
been complicated by the fact that the majority of cases have received antibiotics before referral to the
regional respiratory centre making most cases culture negative and no causative organism identified. Using
advanced microbiological techniques it has now been demonstrated that most cases are secondary to
infection with Streptococcus pneumonia, and that most of these are of serotype (ie subgroup) 1, whereas
until recently most cases of invasive pneumococcal infection in children were of serotype 14. The reasons for
this apparent serotype switch are currently unknown.
A new pneumococcal vaccine covering seven of the most common serotypes was introduced into routine
vaccination schedules in the USA in 2000. This vaccine does not protect against infection with serotype 1.
Introduction of this vaccine has been associated with an increase in paediatric empyema cases in at least
one region of the United States; this appears to be due to a progressive increase in serotype 1 disease along
with the emergence of disease due to serotypes not covered by the vaccine. The possibility of disease
developing from non−vaccine serotypes is a well−recognised potential problem and has been termed
"replacement disease". This new vaccine ("prevenar") was introduced into the routine vaccination schedule
for UK infants in September 2006. Given that the UK already has a problem with a rapidly increasing rate of
empyema it is recognised that there is a possibility that the introduction of this new vaccine may be
associated with further increases in the incidence of both serotype 1 and other non−vaccine pneumococcal
serotype disease. In order to monitor this problem the British Paediatric Respiratory Society (BPRS) and the
Health Protection Agency (HPA) have commenced on a collaborative programme of enhanced
pneumococcal surveillance for children with empyema thoracis for the whole of the United Kingdom.
It is recognised that the environmental, climate and social environment including temperature, rainfall,
pollution levels and socio−economic factors may influence the incidence of pneumococcal disease. In order
to study the influence of these factors on the incidence of empyema in detail it will be necessary to document
the patients' postcode, which will allow us to map each case against known data for that particular
geographical location.
Each UK paediatric respiratory centre managing this type of patient has agreed to collaborate and contribute
to this study, and a local collaborator has been established at each site. Clinical data, obtained routinely
during the hospital stay will be entered into the web−based database using the case notes once the patient
has been discharged. Data recorded on this system includes demographics, relevant past medical history,
antibiotic history, treatment, length of stay and outcome as well as postcode.
We also intend to use historical case note data from patients admitted since commencement of the national
immunisation programme September 2006. We will use these data to compare and contrast with the current
population which have been offered vaccination.
The patient's ethnic background will also be recorded − this is an essential requirement for genetic
association studies (described below), as genetic polymorphism frequencies vary naturally between different
ethnic groups irrespective of disease status.
Pleural fluid is obtained for bacterial studies as part of routine patient management. Since September 2006
UK centres have been sending this pleural fluid to the HPA in Manchester. An initial screening test (called
PCR) is performed for streptococcus pneumonia and screen positives are sent to the HPA laboratory at the
Centre for Infection, Colindale London, who perform confirmatory tests and identify the specific serotype. The
HPA also contact the general practitioner of every positive case to obtain data on vaccination history and
antibiotic therapy in the month prior to admission. Positive cultures (Blood or pleural fluid) will also be
dispatched to Newcastle and Glasgow for research work on factors responsible for causing the virulence of
this infection and how its sensitivity to antibiotics may be changing. Data analysis from the above will be
performed in collaboration with statisticians and epidemiologists working within the Sir James Spence
Institute of Child Health, University of Newcastle upon Tyne.
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We additionally propose to collect DNA samples from patients in order to try and identify gene variants
(polymorphisms) that play a role in the development of empyema in children. We will ask patients to provide
a single small sample of saliva, either by spitting into a small jar (adults and older children) or by briefly
placing a soft small sponge inside their cheek (younger children). Saliva samples will be sent to the
Wellcome Trust Centre For Human Genetics at the University of Oxford for storage, and DNA will be
extracted at 6−monthly intervals throughout the study period. DNA samples and subsequent genetic data will
be anonymised and assigned a trial number, and it will not be possible for researchers to trace genetic
polymorphism data back to individual patients.
Two different but complimentary genetic study approaches may be taken using the anonymised DNA
samples: investigation of 'candidate' genes and a 'genome−wide' screen. Study of candidate genes involves
the specific examination of a relatively small number of genes which on the basis of existing information are
strongly suspected to play a role in disease causation. Examples would include those genes that have been
previously been found to play a role in susceptibility to empyema in adults. A genome−wide screen, on the
other hand, studies a very large number of genetic markers spread across the entire genome in an attempt to
capture information about the role of the majority of human genes in susceptibility to disease. For both
approaches, polymorphism frequencies will be compared with those of healthy individuals from the United
Kingdom, which have previously been determined by the Sanger Institute in Cambridge and which are freely
available to investigators on−line. Such an approach has now been extensively used for genome−wide
studies and is well−validated.
A10−2. In which parts of the research have patients, members of the public or service users been involved?
As user−researchers
As members of a research project group
As advisor to a project
As members of a departmental or other wider research strategy group
None of the above
Please provide brief details if applicable:
A10−3. Could the research lead to the development of a new product/process or the generation of intellectual property?
 Yes  No  Not sure
A11. Will any intervention or procedure, which would normally be considered a part of routine care, be withheld from
the research participants?
 Yes  No
A12. Give details of any clinical intervention(s) or procedure(s) to be received by research participants over and above
those which would normally be considered a part of routine clinical care.(These include uses of medicinal products or
devices, other medical treatments or assessments, mental health interventions, imaging investigations and taking samples of
human biological material.)
Additional
Intervention Average number per participant
Average time
taken
(mins/hours/days)
Details of additional intervention or
procedure, who will undertake it, and
what training they have received.
Routine Care Research
Other tissue/bodily
sample 
0 1 10 seconds We will ask patients to provide a small
sample of saliva, either by spitting into a
small jar (older children) or by briefly
placing a soft small sponge inside their
cheek (younger children). This is a simple,
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low risk procedure which will be performed
by the admitting clinician/local
collaborator. This will take place when the
patient is admitted to hospital and the
diagnosis made in a private area where
the consultation takes place. 
A13. Give details of any non−clinical research−related intervention(s) or procedure(s).(These include interviews,
non−clinical observations and use of questionnaires.)
Additional Intervention
Average
number per
participant
Average time
taken
(mins/hours/days)
Details of additional intervention or procedure, who
will undertake it, and what training they have
received.
A14. Will individual or group interviews/questionnaires discuss any topics or issues that might be sensitive,
embarrassing or upsetting, or is it possible that criminal or other disclosures requiring action could take place during
the study (e.g. during interviews/group discussions, or use of screening tests for drugs)?
 Yes  No
The Information Sheet should make it clear under what circumstances action may be taken
A15. What is the expected total duration of participation in the study for each participant?
The total duration will be the time taken for the clinical and demographic details to be taken and for the saliva
sample to be provided.  
A16. What are the potential adverse effects, risks or hazards for research participants either from giving or withholding
medications, devices, ionising radiation, or from other interventions (including non−clinical)?
Taking the saliva (DNA) sample is a simple, low risk procedure not normally associated with any
complications. Apart from this, the study will not require any additional samples above or beyond those
obtained as part of the routine clinical care of a child with empyema thoracis.
A17. What is the potential for pain, discomfort, distress, inconvenience or changes to lifestyle for research
participants?
Taking the saliva (DNA) sample is a simple, low risk procedure not associated with any discomfort or
complications. Apart from this the study will not involve any additional discomfort/procedure above or beyond
those that are part of the routine clinical care of the patient. Issues to do with confidentiality of genetic
information are discussed in the answer to question 68; all samples will be anonymised and it will not be
possible to trace genetic data back to individual study participants.
A18. What is the potential for benefit to research participants?
There will be no immediate benefit for those taking part in the study.
A19. What is the potential for adverse effects, risks or hazards, pain, discomfort, distress, or inconvenience to the
researchers themselves? (if any)
A clinical lead/local collaborator established at each site has agreed to assist in collecting the sample of
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saliva (DNA) and input the clinical data into the database. Inputting data into the database takes
approximately 15 minutes per patient.  
A20. How will potential participants in the study be (i) identified, (ii) approached and (iii) recruited?
Give details for cases and controls separately if appropriate:
All paediatric patients within the UK in whom a clinical diagnosis of empyema thoracis is made should have
samples of fluid from around the lung taken as part of their routine management. All these children will be
eligible for inclusion in the study. In practice this will be limited to patients receiving some form of surgical
management as part of their care as described previously. These patients will be identified by clinicians at
each participating site and once the diagnosis is made the clinical details will be recorded. The details will
then be entered into the database.
Control data for the genetic analyses are already established in databases created from healthy volunteers in
the United Kingdom (maintained by the Sanger Institute, Cambridge).
A21. Where research participants will be recruited via advertisement, give specific details.
Not Applicable
If applicable, enclose a copy of the advertisement/radio script/website/video for television (with a version number and date).
A22. What are the principal inclusion criteria?(Please justify)
All paediatric patients with a clinical diagnosis of empyema within the UK in whom samples of fluid from
around the lung are taken as part of their routine management will be eligible for inclusion in this study. In
practice this will be limited to patients who are receiving some form of surgical management as part of their
care.
A23. What are the principal exclusion criteria?(Please justify)
As this study involves establishing a database and analysing microbiololgical samples in conjunction with
clinical data, no child presenting with empyema needs to be excluded.  
A24. Will the participants be from any of the following groups?(Tick as appropriate)
Children under 16
Adults with learning disabilities
Adults who are unconscious or very severely ill
Adults who have a terminal illness
Adults in emergency situations
Adults with mental illness (particularly if detained under Mental Health Legislation)
Adults with dementia
Prisoners
Young Offenders
Adults in Scotland who are unable to consent for themselves
Healthy Volunteers
Those who could be considered to have a particularly dependent relationship with the investigator, e.g. those in care
homes, medical students
Other vulnerable groups
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Justify their inclusion.
The study as previously described is specifically designed to investigate the increase in incidence of empyema
thoracis in children, particularly in light of the introduction of the vaccine against Streptococcus pneumoniae.  
No participants from any of the above groups
Question(s) 24 1−5 disabled.
A25. Will any research participants be recruited who are involved in existing research or have recently been involved in
any research prior to recruitment?
 Yes  No  Not Known
If Yes, give details and justify their inclusion. If Not Known, what steps will you take to find out?
The clinicians at each participating site will ask parents/carers if their child is involved in any existing research as
part of their clinical evaluation. This should not mean that patients will be excluded from particating in this study.
A26. Will informed consent be obtained from the research participants?
 Yes  No
If Yes, give details of who will take consent and how it will be done. Give details of any particular steps to provide information
(in addition to a written information sheet) e.g. videos, interactive material.
If participants are to be recruited from any of the potentially vulnerable groups listed in A24, give details of extra steps taken
to assure their protection. Describe any arrangements to be made for obtaining consent from a legal representative.
If consent is not to be obtained, please explain why not.
Consent for the sample of saliva (DNA) will be obtained by the local collaborator or his/her designated assistant
upon admission to hospital. An information sheet will be provided. If the child is deemed competent by the
admitting clinician then they will be offered the opportunity to consent or refuse to be part of the study as per
national guidelines. If they are not deemed competent then the parents/guardian alone will be asked to consent
on their behalf. Regarding consent to use patient identifiable data, please refer to A31.  
Copies of the written information and all other explanatory material should accompany this application.
A27. Will a signed record of consent be obtained?
 Yes  No
If Yes, attach a copy of the information sheet to be used, with a version number and date.
A28. How long will the participant have to decide whether to take part in the research?
The decision should be made after the patient has been assessed and the written information regarding the
study provided. There will be the opportunity for any questions and more details if required. As the research
is non interventional and purely data collection we expect that for the majority of the time decisions regarding
consent will be immediate.
A29. What arrangements have been made for participants who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs? (e.g. translation, use of interpreters etc.)
Date: 01/10/2007 Reference: 07/H0904/84 Online Form
NHS REC Application Form − Version 5.5 11 AB/105980/1
There should not be any additional communication skills or tools required in terms of providing information to
patients or parents above those that are needed as part of routine clinical management. Information leaflets
will be translated in to commonly required foreign languages, and the hospital interpreting services will be
used as deamed appropriate by the local clinician.
A30. What arrangements are in place to ensure participants receive any information that becomes available during the
course of the research that may be relevant to their continued participation?
Not applicable
A30−1. What steps would you take if a participant, who has given informed consent, loses capacity to consent during
the study?Tick one option only.
 The participant would be withdrawn from the study. Data or tissue which is not identifiable to the research team may be
retained. Any identifiable data or tissue would be anonymised or disposed of.
 The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would be
retained and used in the study.
 The participant would continue to be included in the study.
 Not applicable – informed consent will not be sought from any participants in this research.
Further details:
A31. Does this study have or require approval of the Patient Information Advisory Group (PIAG) or other bodies with a
similar remit?(see the guidance notes)
 Yes  No
If Yes, give details
We are submitting an application to the Patient Information and Advisory Group for section 60 support to use
patient identifiable data. The patient postcode will be used for purposes of analysis and DOB/surname for linking
clinical and microbiological data. Reasons for using the post code in statistical analysis are described in A53.
PIAG approval for the use of patient identifiable data is being sought for reasons described in A68
A32a. Will the research participants' General Practitioner (and/or any other health professional responsible for their
care) be informed that they are taking part in the study?
 Yes  No
If Yes, enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.
A32b. Will permission be sought from the research participants to inform their GP or other health professional before
this is done?
 Yes  No
If No to either question, explain why not
The HPA has already established up an enhanced surveillance programme that involves contacting the general
practitioner of every positive case to obtain data on vaccination history and antibiotic therapy in the month prior
to admission. GPs will therefore be aware of the diagnosis of the subject and also that additional surveillance is
being undertaken. There is therefore no need to inform the general practioners of the specifics of this research.
It should be made clear in the patient information sheet if the research participant's GP/health professional will be informed.
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A33. Will individual research participants receive any payments for taking part in this research?
 Yes  No
A34. Will individual research participants receive reimbursement of expenses or any other incentives or benefits for
taking part in this research?
 Yes  No
A35. Insurance/indemnity to meet potential legal liabilities
Note: References in this question to NHS indemnity schemes include equivalent schemes provided by Health and Personal
Social Services (HPSS) in Northern Ireland.
A35−1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) for harm to participants arising from the management of the research?
Note: Where a NHS organisation has agreed to act as the sponsor, indemnity is provided through NHS schemes. Indicate if this
applies (there is no need to provide documentary evidence). For all other sponsors, describe the arrangements and provide
evidence.
 NHS indemnity scheme will apply
 Other insurance or indemnity arrangements will apply (give details below)
Please enclose a copy of relevant documents.
A35−2. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) or employer(s) for harm to participants arising from the design of the research?
Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors
(e.g. company employees, university members), describe the arrangements and provide evidence.
 NHS indemnity scheme will apply to all protocol authors
 Other insurance or indemnity arrangements will apply (give details below)
Please enclose a copy of relevant documents.
A35−3. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of
investigators/collaborators and, where applicable, Site Management Organisations, arising from harm to participants in
the conduct of the research?
Note: Where the participants are NHS patients, indemnity is provided through NHS schemes or through professional indemnity.
Indicate if this applies to the whole of the study (there is no need to provide documentary evidence). Where non−NHS sites are
to be included in the research, including private practices, describe the arrangements which will be made at these sites and
provide evidence.
 All participants will be recruited at NHS sites and NHS indemnity scheme or professional indemnity will apply
 Research includes non−NHS sites (give details of insurance/indemnity arrangements for these sites below)
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Please enclose a copy of relevant documents.
A36. Has the sponsor(s) made arrangements for payment of compensation in the event of harm to the research
participants where no legal liability arises?
 Yes  No
If Yes, give details of the compensation policy:
Please enclose a copy of relevant documents.
A37. How is it intended the results of the study will be reported and disseminated?(Tick as appropriate)
Peer reviewed scientific journals
Internal report
Conference presentation
Other publication
Submission to regulatory authorities
Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee on
behalf of all investigators
Written feedback to research participants
Presentation to participants or relevant community groups
Other/none e.g. Cochrane Review, University Library
If other/none of the above, give details and justify:
The research will form part of an MD and the resulting thesis will be stored at Newcastle University library
A38. How will the results of research be made available to research participants and communities from which they are
drawn?
They will not be specifically informed.
A39. Will the research involve any of the following activities at any stage (including identification of potential research
participants)?(Tick as appropriate)
Examination of medical records by those outside the NHS, or within the NHS by those who would not normally have
access
Electronic transfer by magnetic or optical media, e−mail or computer networks
Sharing of data with other organisations
Export of data outside the European Union
Use of personal addresses, postcodes, faxes, e−mails or telephone numbers
Publication of direct quotations from respondents
Publication of data that might allow identification of individuals
Use of audio/visual recording devices
Storage of personal data on any of the following:
Manual files including X−rays
NHS computers
Date: 01/10/2007 Reference: 07/H0904/84 Online Form
NHS REC Application Form − Version 5.5 14 AB/105980/1
Home or other personal computers
University computers
Private company computers
Laptop computers
Further details:
In order to institute long term surveillance and research in to this problem of empyema thoracis it will be
necessary to introduce a robust and efficient system of data collection which is able to record both laboratory
and clinical data on individual patients in a manner which is compatible with the Data Protection Act and fulfils
the Caldicott guidelines on recording patient identifiable data. The British Paediatric Respiratory Society (BPRS)
has established a web−based system for recording such information administered by Dr Jimmy Paton, Reader
in Respiratory Paediatrics at the University of Glasgow. This system is secure and uses high−level encryption of
data, which has been further enhanced by incorporation of the “Soundex” system for securing patient identifiable
information. The system is already used to record data for the successful national annual paediatric acute
asthma audit, and has now been modified to record data on paediatric empyema.
Data will have to be transferred electronically from the HPA laboratories, colindale London, to The University of
Glasgow and Newcastle University for storage and interpretation (home computers will not be used to store this
data). This process will require the use of patient identifiable data for purposes of linkage (DOB/Surname). All
data transfer will be by password protected files and data entered into the database will be anonymised for
subsequent analysis with the exception of the postcode for reasons described in A53.
We also intend to collect historical case note data. The clinical research fellow will be assisting the local
collaborators in this and will obtain the appropriate authorisations (honorary contracts etc) to access patient
case notes where necessary.  
Anonymised genetic data resulting from the study will be stored on the Oxford University and personal
computers of the chief investigator and research staff in secure locations. Participants will be identified only by
trial number − no personal details such as name or date−of−birth will be stored, and it will not be possible to
trace genetic polymorphism data back to individual participants.  
A40. What measures have been put in place to ensure confidentiality of personal data? Give details of whether any
encryption or other anonymisation procedures have been used and at what stage:
Clinical data will be stored on a secure web−based computer system maintained by The University of
Glasgow that is compatible with the data protection act and fulfills the caldicott guidelines on use of patient
identifiable data. The laboratory data will be added to this database after encryption using the soundex
system to ensure patient anonymity. All data that is extracted from this database for subsequent analysis will
be anonymised with the exception of the post code as this will be required for further statistical analysis
(described in A53). Data will be stored at Newcastle University on password protected computers in secure
swipe card protected buildings.
Anonymised genetic data resulting from the study will be stored on the Oxford University and personal
computers of the chief investigator and research staff in secure locations. Participants will be identified only
by trial number − no personal details such as name or date−of−birth will be stored, and it will not be possible
to trace genetic polymorphism data back to individual participants.  
A41. Where will the analysis of the data from the study take place and by whom will it be undertaken?
Data analysis will be performed in collaboration with statisticians and epidemiologists working within the Sir
James Spence Institute of the Department of Child Health, University of Newcastle upon Tyne, and with
genetic epidemiologists based at the Wellcome Trust Centre for Human Genetics, University of Oxford.
A42. Who will have control of and act as the custodian for the data generated by the study?
Drs David Spencer and Jimmy Paton for the information generated from the database and Professor Adrian
Hill and Dr Stephen Chapman for the studies on DNA.
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A43. Who will have access to research participants' or potential research participants' health records or other personal
information? Where access is by individuals outside the normal clinical team, justify and say whether consent will be sought.
Only the clinicians treating the child will have immediate access to the personal health records. However, Dr
David Cliff, Clinical Research Fellow will be assisting the local clinical teams/collaborators to collect historical
case note data for reasons described previously. PIAG approval will be sought for this and he will also obtain
the appropriate authorisations (honorary contracts etc) within the relevant institutions. All data will be
anonymised for purposes of analysis with the exception of the post code (for reasons described in A53). Drs
David Cliff and Steve Rushton will require access to this data for purposes of analysis.
A44. For how long will data from the study be stored?
10 Years  00 Months
Give details of where they will be stored, who will have access and the custodial arrangements for the data:
The database is maintained as described above at The University of Glasgow however, for purposes of
analysis, data will be stored on secure computers at Newcastle University. The custodian will be Dr David
Spencer and the research team analysing the data includes Drs Mark Pearce, Steve Rushton and David Cliff.
A45−1. How has the scientific quality of the research been assessed? (Tick as appropriate)
Independent external review
Review within a company
Review within a multi−centre research group
Review within the Chief Investigator's institution or host organisation
Review within the research team
Review by educational supervisor
Other
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher,
give details of the body which has undertaken the review:
Study has been approved by the Joint Research Executive Scientific Committee of the Newcastle Healthcare
Charity and Newcastle Upon Tyne Hospitals Charity. It has also been reviewed by the primary funding
organisation Wyeth Vaccines.
A45−2. How have the statistical aspects of the research been reviewed? (Tick as appropriate)
Review by independent statistician commissioned by funder or sponsor
Other review by independent statistician
Review by company statistician
Review by a statistician within the Chief Investigator’s institution
Review by a statistician within the research team or multi−centre group
Review by educational supervisor
Other review by individual with relevant statistical expertise
In all cases give details below of the individual responsible for reviewing the statistical aspects. If advice has been provided
in confidence, give details of the department and institution concerned.
Title: Forename/Initials: Surname:
Dr Mark Pearce
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Department: Paediatric and Lifecourse Epidemiology Research Group
Institution: Newcastle University
Work Address: 4th Floor, Sir James Spence Institute
Royal Victoria Hospital
Newcastle Upon Tyne Hospitals NHS Trust
Postcode: NE1 4LP
Telephone: 0191 202 3082
Fax: 0191 202 3060
Mobile:
E−mail: mark.pearce@ncl.ac.uk
Please enclose a copy of any available comments or reports from a statistician.
Question(s) 46−47 disabled.
A48. What is the primary outcome measure for the study?
Changes in the incidence of empyema thoracis in UK children over time.
A49. What are the secondary outcome measures?(if any)
Changes in the relative incidence of different pneumococcal serotypes over time.
Difference in the length of admission between different UK centres and the effect of different treatment
regimes. Identification of susceptibility genes for childhood empyema.
A50. How many participants will be recruited?
If there is more than one group, state how many participants will be recruited in each group. For international studies, say how
many participants will be recruited in the UK and in total.
The incidence of empyema thoracis in UK children is approximately 800−1000 patients per year. We are
intending to obtain data on the majority of these patients which can then be entered into the database.
A51. How was the number of participants decided upon?
This is the current incidence of emypema in children in the UK; it is expected that it may change with time for the
reasons stated previously.
If a formal sample size calculation was used, indicate how this was done, giving sufficient information to justify and
reproduce the calculation.
Not Applicable.
A52. Will participants be allocated to groups at random?
 Yes  No
A53. Describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by which
the data will be evaluated to meet the study objectives.
Descriptive statistics will be used to analyse and interpret the outcome measures. Any comparisons of
categoric/continuous data will be performed using the appropriate tests based on the relevant statistical
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assumptions and data distributions (for example t−tests or Mann−Whitney, ANOVA or Kruskal−Wallis).
Various statistical packages eg Stata version 9.0 will be used to analyse the data. Space−time clustering and
generalised linear modelling approaches will be used and allow us to investigate the extent to which
incidence of the disease is clustered, to consider possible causes of clustering where it exists and investigate
the role of social and environmental predictors in determining the incidence of infection. The full post code
will be required for this analysis.
For the genetic aspect of the study, differences in the genotype distributions between empyema cases and
healthy controls will be compared using Chi−squared testing. Logistic regression analysis will be performed
to correct for the possible confounding effects of other genes and other recorded clinical variables on disease
susceptibility. Correction will be made for the multiple independent comparisons tested as part of a
genome−wide study (as the majority of markers tested will not be associated, but the large number of
markers studied increases the risk of false positive associations).
A54. Where will the research take place?(Tick as appropriate)
UK
Other states in European Union
Other countries in European Economic Area
Other
If Other, give details:
A55. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK, the European
Union or the European Economic Area?
 Yes  No
A56. In how many and what type of host organisations (NHS or other) in the UK is it intended the proposed study will
take place?
Indicate the type of organisation by ticking the box and give approximate numbers if known:
Number of
organisations
Acute teaching NHS Trusts 26
Acute NHS Trusts
NHS Primary Care Trusts or Local Health Boards in Wales
NHS Trusts providing mental healthcare
NHS Health Boards in Scotland 3
HPSS Trusts in Northern Ireland 1
GP Practices
NHS Care Trusts
Social care organisations
Prisons
Independent hospitals
Educational establishments
Independent research units
Other (give details)
Other:
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A57. What arrangements are in place for monitoring and auditing the conduct of the research?
Monitoring will take place on a monthly basis within the research team at Newcastle University. A steering
committee will be convened under the guidance of the British Paediatric Respiratory Society.
A57a. Will a data monitoring committee be convened?
 Yes  No
If Yes, details of membership of the data monitoring committee (DMC), its standard operating procedures and summaries of
reports of interim analyses to the DMC must be forwarded to the NHS Research Ethics Committee which gives a favourable
opinion of the study.
What are the criteria for electively stopping the trial or other research prematurely?
Not applicable as this is a non interventional study.
A58. Has external funding for the research been secured?
 Yes  No
If Yes, give details of funding organisation(s) and amount secured and duration:
Organisation: Wyeth Pharmaceuticals
Address: Huntercombe Lane South, Taplow, Maidenhead,
Post Code: SL6 0PH
UK contact: Dr Ros Hollingsworth
Telephone: 01628 604377
Fax: 01628 414982
Mobile:
E−mail:
Amount (£): 150,000     Duration:  36 Months
A59. Has the funder of the research agreed to act as sponsor as set out in the Research Governance Framework?
 Yes  No
Has the employer of the Chief Investigator agreed to act as sponsor of the research?
 Yes  No
Lead sponsor (must be completed in all cases)
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Name of organisation which will act as the lead sponsor for the research:
Newcastle upon Tyne Hospitals NHS foundation trust
Status:
 NHS or HPSS care organisation  Academic  Pharmaceutical industry  Medical device industry  Other
If Other, please specify:
Address:  R&D Dept
4th Floor, Leazes Wing
Royal Victoria Infirmary,Queen Victoria Road,Newcastle upon Tyne
Post Code: NE1 4LP
Telephone:  0191 2825213
Fax: 0191 282 0064
Mobile:
E−mail: Amanda.Tortice@nuth.nhs.uk
Sponsor's UK contact point for correspondence with the main REC (must be completed in all cases)
Title:  Forename/Initials:  Amanda Surname:  Tortice
Work Address:  R&D Dept
4th Floor, Leazes Wing
Royal Victoria Infirmary,Queen Victoria Road,Newcastle upon Tyne
Post Code: NE1 4LP
Telephone:  0191 2825213
Fax: 0191 282 0064
Mobile:
E−mail: Amanda.Tortice@nuth.nhs.uk
Co−sponsors
Are there any co−sponsors for this research?
 Yes  No
A60. Has any responsibility for the research been delegated to a subcontractor?
 Yes  No
A61. Will individual researchers receive any personal payment over and above normal salary for undertaking this
research?
 Yes  No
A62. Will individual researchers receive any other benefits or incentives for taking part in this research?
 Yes  No
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A63. Will the host organisation or the researcher's department(s) or institution(s) receive any payment or benefits in
excess of the costs of undertaking the research?
 Yes  No
A64. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.
financial, share−holding, personal relationship etc.) in the organisations sponsoring or funding the research that may
give rise to a possible conflict of interest?
 Yes  No
A65. Research reference numbers: (give any relevant references for your study):
Applicant's/organisation's own reference number, e.g. R&D (if available): 3927
Sponsor's/protocol number: 3927
Funder's reference number: 102358
International Standard Randomised Controlled Trial Number (ISRCTN):
Project website:  
A66. Other key investigators/collaborators (all grant co−applicants or protocol co−authors should be listed)
Title:  Dr Forename/Initials:  David Surname:  Spencer
Post: Consultant Respiratory Paediatrician
Qualifications: MB BS(Hons) MRCP MD FRCPCH
Organisation: Newcastle upon Tyne Hospitals NHS Foundation Trust
Work Address: Newcastle upon Tyne Hospitals NHS Trust
Freeman Hospital
Newcastle upon Tyne, UK
Postcode: NE7 7DN
Telephone:
Fax:
Mobile: 07967379085
E−mail: David.Spencer2@nuth.nhs.uk
Title:  Dr Forename/Initials:  David Surname:  Cliff
Post: Clinical Research Fellow
Qualifications: MB ChB MRCPCH BSc(Hons)
Organisation: Newcastle upon Tyne Hospitals NHS Foundation Trust
Work Address: Sir James Spence Institute, 4th floor
Royal Victoria Hospital
Newcastle upon Tyne Hospitals NHS Trust
Postcode: NE1 4LP
Telephone: 0191 202 3099
Fax:
Mobile: 07766052850
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E−mail: david.cliff@ncl.ac.uk
Title:  Dr Forename/Initials:  Stephen Surname:  Chapman
Post: Clinical Lecturer in Respiratory Medicine
Qualifications: BM BCh MRCP MA
Organisation: University of Oxford
Work Address: Wellcome Trust Centre for Human Genetic
Roosevelt Drive
Oxford
Postcode: OX3 7BN
Telephone: 01865 287592
Fax: 01865 287660
Mobile:
E−mail: schapman@well.ox.ac.uk
Title:  Dr Forename/Initials:  Mark Surname:  Pearce
Post: Lecturer in life course epidemiology
Qualifications: BSc, MSc, CStat, PhD
Organisation: Newcastle University
Work Address: Sir James Spence Institute, 4th floor
Royal Victoria Hospital
Newcastle upon Tyne Hospitals NHS Trust
Postcode: NE1 4LP
Telephone: 0191 202 3082
Fax: 0191 202 3060
Mobile:
E−mail: mark.pearce@ncl.ac.uk
Title:  Dr Forename/Initials:  Steve SP Surname:  Rushton
Post: Reader in Biological modelling
Qualifications: BA (Hons) Oxon, PhD
Organisation: Newcastle University
Work Address: IRES institute
Devonshire Building
Newcastle University
Postcode: NE1 7RU
Telephone: 0191 246 4836
Fax:
Mobile:
E−mail: steven.rushton@ncl.ac.uk
A67. What arrangements are being made for continued provision of the intervention for participants, if appropriate,
once the research has finished? May apply to any clinical intervention, including a drug, medical device, mental health
intervention, complementary therapy, physiotherapy, dietary manipulation, lifestyle change, etc.
Not applicable
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 PART A: Summary of Ethical Issues
A68. What are the main ethical issues with the research?
Summarise the main issues from the participant’s point of view, and say how you propose to address them.
From the participants point of view the main issue is the use of patient identifiable information for purposes of
linkage and analysis. We seek to do this   with section 60 support from PIAG. The reasons for this are as
follows:
1) As previously mentioned the pneumococcal vaccine was introduced into the national immunisation schedule
in September of 2006. At the same time the HPA commenced the national enhanced surveillance programme
(as previously described A10). We aim to obtain as much historical data on patients since this time as resources
will allow. Comparative data over time is vital to our study as the national immunisation programme begins to
have an effect and it is therefore essential we retrospectively obtain data. Considering there are 28 UK sites that
are involved and potentially over 800 children per year (increasing) then collecting consent for retrospective
analysis via pre prepared letter would be impracticable and not within our resources or those of the local
collaborators.
2) As part of the process of obtaining ethical approval for the study it is necessary to inform the local research
and development departments of all the individuals (as requested on the SSI form 14 and 23) who would be
involved in taking consent and filling in the web−based database. This is alongside their qualifications and often
with evidence of formal good clinical practice (GCP) training. We have established local collaborators
(Consultant Respiratory Paediatricians and British Paediatric Respiratory Society members) at each of the 28
sites but it would be impossible and impracticable to provide local R and D offices with further information
regarding which staff member would be the clinician available to take consent when a child presents or ensure
that all of them have had formal GCP training. This is due to the considerable number of different clinicians
admitting cases across the UK and the regular change over of staff. The work load of the individual local
collaborators at each site is too great for them to commit to be available to take consent when cases present.
3)We feel that the aforementioned issues alongside the large number of centres involved would lead to
significant under ascertainment and bias in our clinical dataset if consent were required. This is particularly
relevant when retrospectively collecting data and combining information from two sources i.e the HPA and the  
British Paedaitric Respiratory database.
We appreciate that consent is required for the DNA specimen but are prepared to accept that one individual will
be have to be responsible for this when patients are admitted and that not all children will have a specimen
taken. Retrospective data is not necessary for the genetic aspect of the study.
With regard to the genetic studies, participants may be concerned regarding the confidentiality of any
information relating to their genetic background. Others may be concerned about the potential for a
genome−wide study to identify unsuspected genetic abnormalities which have implications for their future health
− such information may be unwished for by the individual and may have implications for health insurance. In
order to address both of these issues, all genetic samples will be anonymised and it will not be possible for
researchers to trace genetic information back to individual patients. The identification of unsuspected genetic
abnormalities which are know to cause serious disease (e.g. Huntingdon's disease) is in fact exceedingly
unlikely, as these are rare mutations and will not be studied as part of a genome−wide approach. Genome−wide
approaches instead study common genetic variation (single nucleotide polymorphisms), and the genetic
variations associated with common disease typically have only small individual effects − a combination of
multiple susceptible genetic variants and exposure to particular environmental factors then results in disease.
Indicate any issues on which you would welcome advice from the ethics committee.
We would welcome advice on whether the ethics committee agree with us that site specific assessment is not
required. We feel that collecting saliva for DNA doesn't carry any appreciable risk to the patient and that those
performing the procedure have considerable clinical experience in seeking informed consent from patients. All
the local collaborators will have the support of the chief investigator and other key collaborators so named as
required.
Question(s) 69 disabled.
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 PART A: Student Page
A70. Give details of the educational course or degree for which this research is being undertaken:
Name of student:
David Cliff
Name and level of course/degree:
MD
Name of educational establishment:
University of Newcastle upon Tyne
NE1 7RU
United Kingdom
Name and contact details of educational supervisor:
Dr David Spencer
Consultant in Respiratory Paediatrics
Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Newcastle upon Tyne
U.K
NE7 7DN
Direct Dect 0191 244 8292
Hospital Switch 0191 233 6161
Fax 0191 223 1099
email: david.spencer2@nuth.nhs.
A71. Declaration of educational supervisor
I have read and approved both the research proposal and this application for the ethical review. I am satisfied that the scientific
content of the research is satisfactory for an educational qualification at this level. I undertake to fulfil the responsibilities of a
supervisor as set out in the Research Governance Framework for Health and Social Care.
Signature: ......................................
Print Name: Dr David Spencer
Date:  (dd/mm/yyyy)
A one−page summary of the supervisor's CV should be submitted with the application
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 PART B: Section 1 − Conduct of the research at local sites
From the answer given to question A6, it is assumed that:
Local Principal Investigators will not be appointed at each research site participating in this study.• 
Applications for site−specific assessment by local Research Ethics Committees will not be required.• 
There will be no requirement for individual research sites to be approved by the main REC as part of the ethical review.• 
The following general information should be provided to the main REC about the local conduct of the study.
1. What research procedures will be carried out at individual research sites?
Concerning patient contact the only research procedures to be carried out at individual centres will be the
input of clinical data into the database and the collection of saliva for DNA. All other relevant samples are
sent as part of the routine management of the patient as described previously.
Investigation of 'virulence' factors and antibiotic tolerance will be performed at laboratories at The University
of Glasgow and The Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust respectively.
These studies will use strains of the bacteria only from anonymised samples. The Health Protection Agency
are supervising the work on serotyping and have their procedures in place.  
2. Are any ethical issues likely to arise at individual sites that are not covered in the protocol for the study and if so
how will these be addressed?
For example, a need for particular facilities, or to notify local clinicians or departments about the research, or to arrange
additional local support for participants.
No
3. How will the Chief Investigator and his/her team supervise the conduct of the research at individual sites? What
responsibilities will be delegated to local collaborators?
Clear guidelines will be given to each site concerning inputting patient information into the database and
consent when collecting saliva for DNA. All the microbiological data to be analysed is already being collected
as part of a national surveillance programme as previously outlined. The research fellow will maintain regular
close contact by telephone and email with each collaborating centre and produce a monthly update email for
all centres. The Chief Investigtor and clinical fellow are based at the Freeman Hospital and will directly
supervise the studies on antibiotic tolerance. Regular monthly contact will be maintained with the team at
Glasgow who have considerable experience working in the area of pneumococcal 'virulence' factors.
Management approval to proceed with the research will be required from the R&D office for each NHS care organisation in
which research procedures are undertaken. The Site−Specific Information Form should be used to apply for R&D approval at
NHS sites in England, Wales and Scotland.
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 PART B: Section 5 − Use of newly obtained human biological materials
1. What types of human tissue or other biological material will be included in the study?
A 1−2ml sample of saliva will be taken from each participant. Saliva samples will stored frozen, and DNA will
be extracted at 6−month intervals throughout the study period.
2. Who will collect the samples?
Samples will be collected by the local collaborators (doctors) at each clinical site.
3. Will the samples be: (Tick as appropriate)
Obtained primarily for research purposes?
Surplus (i.e. left over from tissue taken in the course of normal clinical care for diagnostic or therapeutic purposes)?
4. Will informed consent be obtained from donors for use of the samples:
In this research?
 Yes  No
In future research?
 Yes  No
5. Will the samples be stored:
In fully anonymised form? (link to donor broken)
 Yes  No
In linked anonymised form? (linked to donor but donor not identifiable to researchers)
 Yes  No
If Yes, say who will have access to the code and personal information about the donor.
The only documentation which will contain both a trial number and the participant's name is the informed
consent form. These will be held securely and separately from the online enrolment form (containing patient
clinical information, identified only by trial number) and DNA sample/genetic data (identified only by trial
number), and will not be available to researchers. There will be no code which links genetic data to an individual
participant.
In a form in which the donor could be identifiable to researchers?
 Yes  No
If Yes, please justify:
6. What types of test or analysis will be carried out on the samples?
Study of variants spread across all human genes will be performed. Ethical issues relating to this are
discussed in the answer to question 68.
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7. Will the research involve the analysis of human DNA in the samples?
 Yes  No
8. Is it possible that the research could produce findings of clinical significance for individuals? (May include relatives as
well as donors)
 Yes  No
9. If so, will arrangements be made to notify the individuals concerned?
 Yes  No  Not applicable
If No, please justify. If Yes, say what arrangements will be made and give details of the support or counselling service.
It is theoretically possible but highly unlikely that the research will produce findings of clinical significance for
individuals − as discussed in question 68, the genetic polymorphisms studied are common and usually have
relatively small effects on disease causation. From an ethical perspective, however, it is important that there is
no possibility of tracing genetic information back to individual patients and therefore all samples will be
anonymised.
10. Give details of where the samples will be stored, who will have access and the custodial arrangements.
DNA samples will be stored frozen in Professor Adrian Hill’s laboratory at the Wellcome Trust Centre For
Human Genetics, University of Oxford. Only Professor Hill and Dr Stephen Chapman and their research team
will have access to the samples.
11. What will happen to the samples at the end of the research?
 Destruction
 Transfer to research tissue bank
(If the bank is in England, Wales or Northern Ireland a licence from the Human Tissue Authority will be required to store the
tissue for possible further research.)
 Storage by research team pending ethical approval for use in another project
(Unless the researcher holds a licence from the Human Tissue Authority, a further application for ethical review should be
submitted before the end of this project.)
 Storage by research team as part of a new research tissue bank
(The bank will require a licence from the Human Tissue Authority. A separate application for ethical review of the tissue bank
may also be submitted.)
 Not yet known
Please give further details of the proposed arrangements:
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 PART B: Section 7 − Declarations
Declaration by Chief Investigator
The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.1. 
I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice guidelines on
the proper conduct of research.
2. 
If the research is approved I undertake to adhere to the study protocol, the terms of the full application of which the
main REC has given a favourable opinion and any conditions set out by the main REC in giving its favourable
opinion.
3. 
I undertake to seek an ethical opinion from the main REC before implementing substantial amendments to the
protocol or to the terms of the full application of which the main REC has given a favourable opinion.
4. 
I undertake to submit annual progress reports setting out the progress of the research.5. 
I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant
guidelines relating to security and confidentiality of patient or other personal data, including the need to register
when necessary with the appropriate Data Protection Officer.
6. 
I understand that research records/data may be subject to inspection for audit purposes if required in future.7. 
I understand that personal data about me as a researcher in this application will be held by the relevant RECs and
their operational managers and that this will be managed according to the principles established in the Data
Protection Act.
8. 
I understand that the information contained in this application, any supporting documentation and all
correspondence with NHS Research Ethics Committees or their operational managers relating to the application:
9. 
− Will be held by the main REC until at least 3 years after the end of the study.
− May be disclosed to the operational managers or the appointing body for the REC in order to check that the
application has been processed correctly or to investigate any complaint.
− May be seen by auditors appointed by the National Research Ethics Service to undertake accreditation of the
REC.
− Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response to
requests made under the Acts except where statutory exemptions apply.
Optional – please tick as appropriate:
I would be content for members of other RECs to have access to the information in the application in confidence for
training purposes. All personal identifiers and references to sponsors, funders and research units would be removed.
Signature: ......................................
Print Name: David Spencer
Date:  (dd/mm/yyyy)
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Declaration by the sponsor's representative
If there is more than one sponsor, this declaration should be signed on behalf of the co−sponsors by a representative of the
sponsor nominated to take the lead for the REC application.
I confirm that: (tick as appropriate)
This research proposal has been discussed with the Chief Investigator and agreement in principle to sponsor
the research is in place.
An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and of
high scientific quality.*
Any necessary indemnity or insurance arrangements, as described in question A35, will be in place before this
research starts.
Arrangements will be in place before the study starts for the research team to access resources and support to
deliver the research as proposed.
Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will be
in place before the research starts.
The duties of sponsors set out in the NHS Research Governance Framework for Health and Social Care will be
undertaken in relation to this research.**
* Not applicable to student research (except doctoral research).
** Not applicable to research outside the scope of the Research Governance Framework.
Signature: ......................................
Print Name: 
Post:
Organisation: Newcastle Upon Tyne Hospitals NHS Foundation Trust
Date:  (dd/mm/yyyy)
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